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Abstract
Loss of p53 function is a critical event in tumour development. It has been well 
documented that p53 mutation can lead to an oncogenic gain of function (GOF) 
associated with poorer prognosis and therapeutic response. Such mutants exert their 
gain-of-function properties by modifying cells through altered transcriptional activity 
as well as novel protein-protein interactions, but the molecular details of the 
mechanisms involved are still not entirely understood. Recent reports indicate that 
mutant p53 increases TGF(3-dependent metastatic potential of cancer cells via 
inhibition of p63 function and also promotes invasion through increased integrin 
(a5pl) and EGFR recycling, which is also linked with suppression of 
transcriptionally active p63 in normal epithelial cells, lung cancer cells and invasive 
breast cancer cells.
The aim of this study was to investigate the mechanism of mutant p53 GOF in 
squamous cell carcinoma of the head and neck (SCCHN) cells. To avoid the 
potentially confounding impact of studying cells from biologically distinct anatomical 
sub-sites, the studies described here focused upon the most common sub-type of 
SCCHN - laryngeal squamous cell carcinoma (LSCC).
Two hot-spot p53 mutants representing two distinct mutational classes have been 
chosen for these studies: R175H (structural mutation) and R273H (contact mutation), 
both of which have been previously demonstrated to have GOF properties and have 
been documented to occur in laryngeal cancer. The mechanism of mutant p53 GOF 
was investigated by identifying protein interactions of mutant p53 and by studying 
gene expression changes in LSCC cells expressing these p53 mutants. In addition, the 
functional consequences of mutant p53 expression in LSCC cells were investigated in 
terms of response to radiation (a primary treatment modality for LSCC) and 
motility/invasiveness (key determinants of metastatic potential).
A number of proteins have been identified in the mutant p53 containing protein 
complexes in LSCC cells and one of these, HSP70, has been confirmed by 
immunoprecipitation to selectively interact with the p53-175H mutant.
p53-273H-expressing cells and to a smaller extent p53-175H-expressing cells 
display increased motility. A stable knock-down of the mutant p53 has been shown to 
reduce the motility of cells suggesting that p53-273H contributes to increased
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migratory potential of these cells. Interestingly, exon-array analyses revealed 
a number of differentially regulated genes in the p53-273H expressing LSCC cells 
compared to parental p53-null cells. Importantly, the most significantly affected 
pathways included cell adhesion and extracellular' matrix remodelling. Significantly, 
these cells appear’ to express predominantly the ANp63 and little (if any) TAp63 and 
thus p53 GOF mutant appears to act via an alternative pathway in LSCC cells. 
Analysis of the transcriptional networks generated on the basis of the expression data 
also suggests that this p53 mutant might modulate transcription through other 
transcription factors, such as Spl and NF-kB.
Unexpectedly, though in accordance with earlier studies from our group, mutant 
p53 expression seemed to sensitise laryngeal cancer cells to ionising radiation. The 
results presented here suggest that we have a system that can be used in further studies 
to gain insight into the mechanism of radiosensitivity of mutant p53-expressing LSCC 
cells.
In conclusion, the studies described here have identified several new lines of 
investigation connecting mutant p53 with critical pathways involved in the regulation 
of cell survival (HSP70), cell motility (FN1, TIMP2 and others) and in 
radiosensitivity. These results suggest that in LSCC cells p53 GOF mutants may act 
via different pathways than those previously identified in other cancers and moreover 
it appeal's there may be differences in the modes of action of structural and 
DNA-contact mutants. Functional analysis of these pathways should provide insights 
into the mechanisms of action of two classes of p53 GOF mutants in LSCC and may 
lead also to the identification of novel therapeutic targets.
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Chapter 1
Introduction
Introduction
1. Introduction
The aim of this thesis was the study of the mechanisms and consequences of gain of 
oncogenic function by p53 mutants in laryngeal cancer. Therefore, the purpose of this 
section is to introduce the reader to background information and concepts of 
importance to this project.
First of all, a brief introduction on the nature of cancer is given in section 1.1. 
Since the studies within this thesis focus on laryngeal cancer, an overview of the 
disease is then given in section 1.2, including epidemiology, aetiology and risk 
factors, disease diagnosis and treatment as well as the underlying molecular' 
mechanisms.
The rest of the introduction is focused upon the p53 pathway (section 1.3), which is 
the most frequently affected pathway in human cancer and the main subject of this 
thesis. p53 structure is first discussed (section 1.3.1) to allow understanding of how 
mutations in the TP53 gene result in the inactivation of the protein. This is followed 
by a detailed discussion of the most important functions of p53 (section 1.3.2) to 
allow an insight into how loss of these functions leads to tumour development. The 
importance of p53 regulation (at the level of protein stability, activity and subcellular 
localization) is also discussed (section 1.3.3).
Finally, loss of p53 function through missense mutations of the TP53 gene is 
discussed in detail (section 1.3.4). The types of p53 mutations are described 
(section 1.3.4.2) and their impact on wild-type p53 analysed (section 1.3.4.1). Further, 
the evidence for the existence of the oncogenic gain of function (GOF) of p53 mutants 
is closely examined in section 1.3.4.3. The mechanisms of the gain of oncogenic 
function are discussed in section 1.3.4.3.1. Finally, the section is concluded with an
2
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analysis of the biological consequences and manifestations of GOF p53 mutations 
(section 1.3.4.3.2) and the aims of this project are described (section 1.4).
1.1. Introduction to cancer
Cancer is a genetic disease (1). It is caused by numerous cumulative changes of the 
genome, resulting from the action of exogenous factors, such as carcinogens 
(asbestos, tobacco smoke), infection with DNA viruses, UV and ionising radiation or 
errors in the endogenous cellular processes, such as DNA replication, cell division or 
DNA repair. The accumulation of such genomic alterations transforms normal cells 
into malignant ones, which can be characterised by uncontrolled proliferation and the 
ability to invade surrounding tissues and metastasise to distant parts of the body.
The genomic alterations in cancer include mutations in certain key genes as well as 
severe chromosomal abnormalities, in which entire chromosomes are duplicated or 
lost (aneuploidy), structurally rearranged or truncated (2). These processes are 
summarised in Figure 1.1. The most commonly mutated genes in cancer belong to 
two classes: proto-oncogenes and tumour suppressors (3). Proto-oncogenes are 
involved in the regulation of proliferation and differentiation. Upon mutation of only 
one allele, they become activated (dominant gain of function) and may promote 
uncontrolled growth, which is crucial for the development of cancer (3). Most tumour 
suppressor genes, on the other hand, typically have growth-suppressing properties and 
function by inhibiting cell division, induction of apoptosis, maintaining the integrity 
of the genome and inhibition of metastasis (4). In the event of cellular' stress (such as 
DNA damage or oncogene activation) tumour suppressors induce cell cycle arrest or 
apoptosis, hence preventing the damaged cells from proliferating. It was believed for 
a long time that both tumour suppressor alleles have to be inactivated for the loss of
3
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function. More recent data, however, suggesting a possible oncogenic gain of function 
of selected mutant tumour suppressors, provide evidence that this might not always be 
the case (5, 6, 7).
In addition to the canonical tumour' suppressors, some genes exert their tumour 
suppressor function indirectly. The DNA repair genes, which are sometimes 
considered as a sub-group of tumour* suppressor genes, are another type of genes 
frequently altered in cancer (3). Their main functions are sensing DNA damage and 
inducing many different types of DNA repair programmes, including mismatch repair 
(MMR), base-excision repair (BER), nucleotide-excision repair (NER), 
recombinational repair and error-prone translesion synthesis (8). Consequently, 
mutations inactivating DNA repair genes result in the occurrence of multiple random 
mutations, which are not repaired. This allows genome instability and variability, and 
leads to the generation of cancer cells with a selective advantage (1).
Carcinogenesis is a multistage process with genomic alterations usually 
accumulating over long periods of time (9). This explains why cancer is 
predominantly a disease of old age (childhood leukaemia is an exception with the 
highest incidence rate below 20 year's of age) (10).
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Figure 1.1: The genesis of cancer. A schematic representation of the multistep process of 
carcinogenesis. Figure reproduced from reference (2).
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In the process of carcinogenesis normal cells undergo malignant transformation 
and acquire multiple capabilities, which allow for their unrestricted growth. These 
“superpowers” or “hallmarks” of cancer, described by Hanahan and Weinberg in their 
review (1), are summarised in Figure 1.2 and include: self-sufficiency in growth 
signals (autocrine signalling), insensitivity to growth-inhibitory signals, evasion of 
apoptosis (cell suicide), limitless replicative potential (immortality), sustained 
angiogenesis (formation of new blood vessels) and tissue invasion and metastasis (1). 
More recently additional hallmarks of evading immune destruction (11) and 
deregulating cellular energetics (12) have been proposed. It is believed that these traits 
are shared by most types of human cancer.
Self-sufficiency in Insensitivity to
growth signals anti-growth signals
Deregulating cellular 
energetics
Evading
apoptosis
Genome instability 
and mutation
Sustained
angiogenesis
Tissue invasion 
and metastasis
Enabling Characteristicsics^J-
Avoiding immune 
destruction
Limitless replicative 
potential
T umour-promoting 
inflammation
Figure 1.2: The hallmarks of cancer. Acquired functional capabilities of cancer cells, which 
establish their malignancy, and enabling characteristics crucial to the acquisition of these 
hallmarks. Figure adapted from reference (12).
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The acquisition of the above described hallmarks of cancer is dependent on two 
enabling characteristics: genomic instability and tumour-promoting inflammation 
(12). Genomic instability and high mutability enable the selection of rare genetic 
changes that confer selective advantage on cancer cells and can drive tumour 
progression. The response of the immune system to tumour formation can have both 
tumour-antagonizing and tumour-promoting effects. Chronic inflammation not only 
predisposes to cancer but also plays a role in tumour progression (13). The persistent 
infiltration of many tumours by cells of the immune system (macrophages, 
neutrophils and other cells involved in wound healing) makes tumours comparable to 
non-healing wounds (14). The inflammatory cells secrete many signalling molecules, 
including growth factors fostering continuous proliferation, survival factors limiting 
cell death, pro-angiogenic factors, extracellular' matrix-degrading enzymes and 
reactive oxygen species, which are highly mutagenic (15). Therefore, the 
inflammatory cells are recruited by the tumour to support many of its hallmark 
capabilities such as angiogenesis or invasiveness and metastatic potential.
In addition to the eight described hallmark capabilities, cancer cells have been 
proposed to share a number of characteristics, described collectively as the stress 
phenotypes of tumorigenesis (16). In order to form a tumour, cancer cells have to be 
able to survive and proliferate in adverse conditions (such as hypoxia) and hence must 
be capable of tolerating a number of cellular stresses, including metabolic stress, 
oxidative stress, proteotoxic stress, mitotic stress, DNA damage and replicative stress 
(16). The ability of cancer cells to tolerate these stresses through stress-support 
pathways is crucial for the acquisition of the key hallmarks of cancer.
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1.2. Head and neck cancer
“Head and neck cancer” is a collective term used to describe the malignant tumours 
arising from the mucosa of the upper aerodigestive tract. This area includes the oral 
cavity, pharynx and larynx. Cancers of the brain and melanomas, although occurring 
in the head and neck region, are excluded from this group and will not be considered 
here. Moreover, the term “head and neck cancer” will be confined to squamous cell 
carcinomas, which account for 90% of all cancers in this anatomical region (17).
1.2J. Overview
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common 
cancer worldwide with over 560,000 new cases each year (18). In spite of advances in 
treatment and surgical reconstruction, there has been no significant improvement in 
survival over the past couple of decades (Figure 1.3A). Overall five-year survival is 
still only 50% (19), mostly due to tumour resistance to treatment, recurrence and high 
frequency of second primary tumours (20). The incidence of SCCHN increases with 
age (21) with 98% of patients in Europe being over 40 years old (22). The disease is 
significantly more frequent in men (Figure 1.3B), with male:female sex ratios in 
developed countries of about 10:1 (23). The incidence and mortality of head and neck 
cancer varies between different countries of the world (21, 24), which suggests that 
there may be geographical differences in the prevalence of the risk factors or that 
environmental factors may be important in the pathogenesis of this disease.
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Figure 1.3: Laryngeal cancer statistics (adapted from the Cancer Research UK website 
(25)).
A. 5-year age-standardised survival in men between 1971 and 2001.
B. Age-specific incidence of laryngeal cancer in the UK in 2006, for men and women.
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While the overall incidence of head and neck cancer is decreasing, the incidence of 
certain types of SCCHN is increasing (26), which is related to a changing prevalence 
of different risk factors. It is important to note that incidence, mortality and response 
to treatment depend on the actual sub-sites within the head and neck where the 
tumours arose. However, there is also marked clinical and molecular heterogeneity 
among tumours arising from the same anatomical sub-sites, emphasizing the need for 
a better understanding of the disease.
1,2.2. Head and neck sub-sites
Head and neck cancers can be divided into groups of tumours arising from different 
anatomical sub-sites (Figure 1.4). About 40% of head and neck cancers arise in the 
oral cavity (which is further divided into base of tongue, tongue, floor of mouth, gum, 
palate and lip), 25% in the larynx, 15% in the pharynx (comprising nasopharynx, 
oropharynx and hypopharynx) and the remaining 20% in sites like salivary glands and 
thyroid (27). Hence, laryngeal cancer is the largest homogenous group of tumours.
The individual prognosis is strongly influenced by the actual tumour site (28). 
Tumour's arising in the larynx for instance have a significantly better prognosis than 
cancers in the oral cavity or in the hypopharynx, which have the worst prognosis of all 
SCCHN tumours (28).
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Figure 1.4: Head and neck cancer sub-sites. A diagrammatic representation of the different 
anatomical sub-sites within the head and neck. Figure adapted from the Radiation Medical 
Group, Inc. website (29).
1.2.3. Aetiology and risk factors
The pathogenesis of SCCHN is multifactorial and is linked to the use of tobacco (30) 
and alcohol (31) as well as infection with the human papillomavirus (HPV) (32). The 
importance of dietary factors (33), occupational exposures (34) and oral hygiene (35) 
has also been investigated. Multiple studies have demonstrated a link between head 
and neck cancer incidence and low socioeconomic status (36, 37). All these different 
factors are not necessarily causal agents but are associated with an increased 
probability of occurrence of head and neck cancers and are referred to as risk factors.
1.2.3.1. The use of tobacco and alcohol
The major risk factors in the development of head and neck cancer are the use of 
tobacco and alcohol (38). Distinguishing the individual effects of these agents has 
been difficult due to the fact that many tobacco users also tend to consume alcohol 
and vice versa. However, large epidemiological studies have made evaluation of the 
individual risk factors possible.
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Since tobacco was traded from North America almost 500 years ago, it has been 
extensively used through smoking cigarettes, cigars and pipes, chewing or in oral 
snuff. Smoking is the single most common cause of cancer-related deaths (39). 
Presently, there are nearly 1.3 billion active smokers worldwide (40). In Europe 
approximately 60% of oral cancers in men and 30% in women could be attributable to 
smoking alone (24). Tobacco smoking has repeatedly been reported to increase the 
risk of cancer for all sites of the head and neck with RR = 8.4 for current smokers 
(95% Cl = 5.8-12.2) (31). The use of filter cigarettes or exclusive use of blond 
tobacco is associated with lower risk (RR = 0.5; 95% Cl = 0.3-0.8) compared to 
smokers of plain cigarettes or black tobacco, respectively (41). Moreover, smoking 
history is a critical factor influencing survival of cancer patients (42). The risk of 
developing head and neck cancer decreases gradually after smoking cessation (down 
to RR =1.1; 95% Cl = 0.6-2.0 after more than 20 years from quitting) (31, 43). It has 
also been suggested that giving up smoking may be a potential way of improving 
survival of head and neck cancer patients (42). While smoking tobacco is the major 
risk factor for head and neck cancers in developed countries, many forms of 
smokeless tobacco, such as moist chewing tobacco and oral snuff, pose a significant 
problem of increased cancer risk in the developing world (RR = 1.8; 
95% Cl = 1.1-2.9) (44, 45).
Alcohol intake has been found to increase the risk of head and neck cancer, with 
the strongest relative effect for pharyngeal cancer (RR = 8.5; 95% Cl = 4.0-18.2) (31). 
Both tobacco and alcohol increase the risk of head and neck cancer in 
a dose-dependent manner (38). While each factor alone may be responsible for a 2- to 
8-fold increase in risk (depending on intensity and duration of usage) (31), combined 
exposure to tobacco and alcohol results in up to 22-fold increase
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(95% Cl = 12.9-37.8) in the relative risk (31, 38). Therefore, it can be concluded that 
alcohol and tobacco act synergistically in increasing the risk of head and neck cancer.
In spite of the fact that the incidence of head and neck cancer in general is 
decreasing (attributed mainly to a decrease in smoking prevalence) (26), the incidence 
of oropharyngeal cancer is rising (46), which likely reflects the rising prevalence of 
another risk factor - infection with high-risk types of human papillomaviruses 
(HP Vs).
1.2,3,2, HPVinfection
Oncogenic HPVs are the major cause of cervical cancer (47). Nearly 30 years ago it 
was suggested that high-risk HPVs may also be involved in the pathogenesis of head 
and neck cancer (48). Epidemiological and clinical evidence suggests that high-risk 
HPV infection may account for the development of some head and neck cancers, 
especially in patients who do not have a history of alcohol and/or tobacco use (49).
So far, more than 200 different HPV types have been identified, which include the 
oncogenic HPV types 16, 18, 31, 33, 35 and 45 (48, 50). The HPV-16 subtype is most 
commonly involved in SCCHN and accounts for 87% of all HPV-positive tumour's 
(51), including 86.7% of HPV-positive oropharyngeal and 69.2% of HPV-positive 
laryngeal cancers (52). HPV-18 is quite rare among the HPV-positive cancers of the 
oropharynx (2.8%) and larynx (17%) (52). The other most commonly detected types 
of HPV are HPV-31 and HPV-33 (51, 53). Other oncogenic HPV types are rarely 
found in cancers of the head and neck (52).
Viral DNA has been isolated from tumours arising within the upper aerodigestive 
tract with a high variation of prevalence between the individual anatomical sub-sites 
(50). In a large systematic review, 25% of SCCHN cancer specimens were found to
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be HPV-positive (52). HPV prevalence was significantly higher in cancers of the 
oropharynx (35.6%) than in those of oral cavity (23.5%) or the larynx (24%) (52, 54). 
The biological reason for these differences between sub-sites remains unclear.
Since the incidence of oropharyngeal cancer has been rising over the past couple of 
years, likely due to HPV infections, most recent studies have reported much higher 
prevalence of HPV-positive oropharyngeal cancers, ranging from 50% (55) to 74% 
(56). The prevalence of high-risk HPV in laryngeal cancer varies significantly 
between individual studies, from as low as 1% (57) up to 37% (58, 59). This 
discrepancy in the reported prevalence rates may be due to selection bias, 
geographical differences, quality of the tissue material studied and methods used to 
determine the HPV infection status. The most commonly used screening method 
relies on PCR-based detection of viral DNA. Unfortunately, such assays are generally 
too sensitive, as they can detect only a few copies of the viral DNA (possibly yielding 
false-positive results), and they do not demonstrate the role of HPV in carcinogenesis 
(60). Therefore, this method cannot distinguish between the clinically relevant and 
irrelevant HPV infections. Detection of the E6 and E7 viral oncogene transcripts, on 
the other hand, is a more reliable technique for identifying the oncogenic HPV 
infections (61). Moreover, biologically relevant high-risk HPV infections are also 
associated with pi6 expression (62) (discussed in detail in section 1.2,5.3) and hence 
immunohistochemical investigation of pi6 levels could be used as a surrogate marker 
of clinically meaningful HPV infections (63).
The majority of HPV prevalence data in SCCHN is based on PCR amplification of 
HPV DNA (52) suggesting that these studies provide little information on the causal 
role of HPV in SCCHN. Only a few studies looked at the clinically-relevant HPV 
infections in individual sub-sites of head and neck by evaluating pi6 expression
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(64, 65, 66). As defined by a molecular profile with HPV-positivity and pi6 
expression, HPV was fotmd to be causally associated with 23% of oropharyngeal 
cancers (66) and between 16% (64) and 58% (65) of laryngeal cancers. The small 
sample size of the above studies may be the source of high variability of the reported 
prevalence of clinically meaningful HPY infections in laryngeal cancer. On the other 
hand, a relatively recent systematic review looking at the association between 
HPV-16 infection and risk of head and neck cancer at individual anatomical sub-sites 
concluded that the association is strongest for tonsillar cancer (RR = 15.1; 
95% Cl = 6.8-33.7), intermediate for oropharyngeal cancer (RR = 4.3; 
95% Cl = 2.1-8.9) and weakest for oral (RR = 2.0; 95% Cl = 1.2-3.4) and laryngeal 
(RR = 2.0; 95% Cl =1.0-4.2) cancers (67). While this review clearly suggests that 
HPV infection is a risk factor for some head and neck cancers, larger series and 
case-control studies evaluating the oncogenic activity of HPV will be essential for 
reliable evaluation of the association between HPV infection and risk of head and 
neck cancer at different anatomical sub-sites.
In spite of the limited so far investigation of the clinically relevant HPV infections 
within the head and neck, HPV-positive tumours, predominantly of the oropharyngeal 
origin, seem to comprise a separate group with a distinct biological behaviour, which 
is generally associated with a better prognosis in terms of improved response to 
treatment as well as better overall and disease-specific survival in comparison with 
the HPV-negative tumours (49, 51, 68, 69). Recent reports suggest that patients with 
HPV-positive/p 16-overexpressing tumours (class III, see Figure 1.5) have 
a significantly better 5-year overall survival (79%) versus patients with class I (20%) 
or class II (18%) tumours (66). Similarly, class III tumours have an improved 5-year 
disease-free survival of 75% compared to 15% and 13% for class I and class II
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tumours, respectively (66). Class III tumours were also shown to have a lower 
recurrence rate (14%) than class I (45%) and class II (74%) tumours (66). Moreover, 
HPV infection has also been implicated in the treatment response of SCCHN (70, 71). 
HPV-positive tumours have an improved response to radiotherapy (OR = 4.07; 
95% Cl = 1.48-11.18; p = 0.006) and to concurrent chemo-radiation (OR = 2.87; 
95% Cl = 1.29-6.41; p = 0.01) compared to HPV-negative tumours (51).
p16 Status
<zo
o
>
CL
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Non-overexpressing Overexpressing
Class II Class III
Class 1
Figure 1.5: Classification of oropharyngeal tumours by pl6 expression and HPV-16 
DNA presence. Possible groups included: HPV-16-negative/p 16 non-overexpressing 
(class I), HPV-16-positive/p 16 non-overexpressing (class II) and HPV-16-positive/p 16 
overexpressing. HPV-negative/pl6 overexpressing tumours were hardly ever found. Figure 
adapted from reference (66).
In summary, biologically relevant HPV infection is a risk factor for a sub-group ot 
SCCHN, but is also associated with a favourable prognosis of HPV-positive tumours.
1.2.3.3. Dietary factors
In addition to the major risk factors for head and neck cancer discussed above, many 
epidemiological studies have implicated dietary and nutritional factors in the 
aetiology of this disease, although the effects observed could potentially be
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confounded by the socioeconomic status of the patients. Nevertheless, many studies 
have consistently shown that high intake of fruit and vegetables was associated with 
reduced risk of cancer in many sites within the head and neck with RR = 0.55 
(95% Cl = 0.47-0.65) and RR - 0.52 (95% Cl = 0.45-0.61), respectively (72). 
Carotene-rich vegetables were found to have the strongest protective effect against 
oral cancer (RR = 0.4; 95% Cl = 0.2-1.0) (73). High intake of whole grain was also 
reported to have a protective effect against upper aerodigestive tract cancers 
(RR = 0,53; 95% Cl = 0.34-0.81) (74).
While the evidence relating to other dietary components is not so strong, certain 
trends could still be observed. High consumption of some types of fish and seafood 
was suggested to have a protective effect against head and neck cancers, with most 
prominent effect observed for common carp (OR = 0.30; 95% Cl = 0.13-0.67), hairtail 
(OR = 0.48; 95% Cl = 0.25-0.91) and shrimp (OR - 0.54; 95% Cl = 0.33-0.90) (75). 
However, frequent consumption of salted meat and fish was associated with increased 
risk of oral cancer (OR “ 3.71; 95% Cl = 1.05-13.03) (76). Consumption of liver had 
a significant protective effect (RR = 0.3; 95% Cl = 0.2-0.6; p < 0.0001) (77). High 
intake of olive oil was associated with significantly lowered risk of oral and 
pharyngeal cancers (OR = 0.7; 95% Cl = 0.4-0.9) while high butter intake was found 
to increase the risk of these cancers (OR = 2.4; 95% Cl = 1.6-3.5) (78). High intake of 
milk was reported to reduce the risk of oral cancer (OR = 0.48; 95% Cl = 0.23-1.01) 
(75), while coffee and tea drinking were associated with increased risk of oral cancer 
with RR = 1.5 (95% Cl = 0.9-2.6) and RR = 1.3 (95% Cl = 0.7-2.3), respectively (73). 
Elevated consumption of stew was associated with significantly increased risk of oral 
and pharyngeal cancers (OR = 3.95; 95% Cl - 2.10-7.44, p < 0.0001) (77). Finally, 
consuming foods that have been charcoal-grilled or deep-fried was associated with
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increased risk of oral cancer (RR = 5.3; 95% Cl — 1.9-15.0 and OR - 2.15; 
95% Cl = 1.10-4.20, respectively) (73, 76).
1.2.3.4, Oral hygiene
Oral hygiene and dental status, which could be closely related to the socioeconomic 
status of the patients, have also been investigated in relation to cancers of the head 
and neck. Case-control studies suggested that poor general oral condition was 
significantly more common among oral and oropharyngeal cancer patients than in 
control subjects (OR = 4.5; 95% Cl = 1.8-10.9, p = 0.001) (79). In particular, the 
factors associated with increased risk of oral and pharyngeal cancers included: 
frequent gum bleeding (OR = 3.1; 95% Cl = 1.2-7.9), no dental check-ups (OR = 2.5; 
95% Cl = 1.3-4.8), no tooth brushing (OR = 1.3; 95% Cl = 0.4-4.5) and frequent 
mouthwash use (OR = 3.3; 95% Cl = 1.7-6.1) (80). Poor dentition (measured by the 
number of missing teeth) also proved to be a strong risk factor for oral cancer 
(OR = 5.3; 95% Cl = 2.3-11.9 in males and OR = 7.3; 95% Cl = 2.5-21.6 in females 
who lost 15-32 teeth) (35). Moreover, it has been suggested that poor oral hygiene 
may act synergistically with other risk factors like alcohol, as it increases production 
of acetaldehyde in the oral cavity (81), or on its own may be a reason of delayed 
diagnosis.
1.2.3.5. Occupational exposures
While considering the aetiology of head and neck cancer, specific occupational 
exposures should also be taken into account. It is estimated that in western countries 
approximately 4-10% of all head and neck cancers are due to occupational exposures 
(82). Firstly, exposure to asbestos was reported to increase the risk of laryngeal cancer
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in a dose-dependent manner (RR = 1.82; 95% Cl = 1.08-3.04, p — 0.02 for highest 
exposure) (34). Elevated risk of pharyngeal and laryngeal cancers was reported 
among welders, who are exposed to welding fumes (RR = 2.26; 95% Cl = 1.09-4.68, 
p = 0.04 and RR = 1.95; 95% Cl = 1.03-3.69, p = 0.04, respectively, for more than 
8-year exposure) (34). Welding fumes consist of metal dust, irritant gasses and 
polycyclic aromatic hydrocarbons (PAHs), some of which are known carcinogens 
(34). Exposure to wood dust was also associated with a strongly increased risk of 
head and neck cancer of all sites in subjects who had never smoked (RR = 2.27; 
95% Cl =1.1-3.9) (34).
In summary, head and neck cancer is a disease with a complex aetiology and 
multiple risk factors, and the increasing incidence of some types of SCCHN is of 
great concern. According to IARC estimates, reducing the prevalence of the discussed 
risk factors could prevent 60-80% of these cancers (83).
1.2.4. Diagnosis, staging and disease management 
1.2.4. L Diagnosis
Some head and neck cancers are preceded by the appearance of premalignant lesions, 
such as oral leukoplakia or erythroplakia. The rate of malignant transformation of 
these lesions varies between 5% and 15% and continued use of tobacco increases the 
risk of transformation (84). Since eaiiy-stage tumours are often asymptomatic, they 
are frequently overlooked by the patient and examiner and there is often a delay of up 
to a year between first professional visit and diagnosis (85).
Head and neck cancer patients are at a high risk of developing second primary 
tumours, which occur in 27% of cases and are often fatal (86). This suggests that these 
patients are in a cancer-prone group, which is most likely related to their continuous
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exposure to tobacco smoke and alcohol. The term “field cancerization” was 
introduced to describe repeated exposure of the squamous epithelium of the upper 
respiratory tract to carcinogenic substances, resulting in multiple primary lesions (87). 
Therefore, these second primaries arise mostly in areas such as lung, oesophagus and 
other parts of the upper aerodigestive tract (87), which have been exposed to 
carcinogens. However, the molecular’ evidence that could determine whether the 
second tumour represents a second primary cancer or a recurrence of the original 
malignancy is very limited. In fact, studies, which analysed the molecular background 
of such multiple tumours, provide evidence that some of these cancers arise from one 
preneoplastic lesion (88, 89, 90), while others may have independent clonal origins 
(91).
Up to 36% of head and neck cancers metastasise to distant sites and the risk is 
higher for advanced stage at presentation, especially with nodal involvement (92). In 
the majority of cases these head and neck cancers metastasize to the cervical lymph 
nodes before colonising distant sites such as the bones, liver or lungs (93).
The primary screening method for detection of both precancerous lesions and early 
invasive tumours is physical examination. Suspected tumours are biopsied, usually 
with the patient anaesthetised, and the biopsies are subjected to histopathological 
examination (85). In addition to an obvious epithelial primary tumour, it is common 
for patients to present with enlarged cervical lymph nodes as a result of regional 
metastatic spread. Diagnosis of regional metastasis is commonly achieved by fine 
needle aspiration (FNA) and subsequent histological evaluation (85). Computed 
tomography (CT) and magnetic resonance imaging (MRI) of the head and neck are 
used for determination of invasion of nearby structures and detection of lymph node 
involvement. In addition, it is mandatory that patients have a CT scan of their thorax
20
Introduction
and upper abdomen to exclude the presence of a second primary bronchogenic 
carcinoma or distant metastasis (94).
L2.4.2. Disease staging and management
The conventional treatment modalities for advanced SCCHN include primary surgery 
and post-operative radiotherapy (85). In an attempt to preserve function, patients are 
frequently treated with radiation therapy in combination with cisplatin-based 
chemotherapy (with salvage surgery if other treatment fails), which yields similar 
survival rates as radical surgery and radiation therapy (95). The damage associated 
with any of the above mentioned treatments affects speech, swallowing, cosmesis and 
overall quality of life (95).
In clinical practice the treatment for SCCHN is selected based on the fitness of the 
patient as well as TNM (tumour, node, metastasis) stage and histological grade (96). 
Unfortunately, these parameters have limited predictive value for therapeutic 
response. This is frequently due to the fact that SCCHN is usually considered to be 
a homogenous group of tumours even though cancers arise from the surface 
epithelium of several different anatomical sub-sites within the upper aerodigestive 
tract (85). There is a notable variability in biological behaviour and therapeutic 
response both between and within the sub-sites (97). The actual tumour site, nodal 
involvement and extracapsular spread are the strongest prognostic factors (98).
The group of HPV-positive oropharyngeal cancers forms a distinct biological 
entity with a better prognosis than HPV-negative tumours (99). Although currently 
this distinction is not made when deciding on the type of treatment, it has been 
frequently suggested that less aggressive treatment modalities should be considered in 
an attempt to reduce the treatment-related morbidities. Moreover, the fact that the
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majority of HPV-infections detected in head and neck cancer were of the HPV-16 or 
HPV-18 type suggests that the prophylactic vaccines for cervical cancer might also 
prove to be protective against SCCHN (100).
In conclusion, there is a constant need to identify novel prognostic markers that 
would enable determining how well the patient is going to respond to different 
modalities or combinations of therapy and to develop novel treatments that could be 
tailored to the individual tumours.
7.2.5. Molecular alterations
As stated above, head and neck cancers include a heterogeneous group of tumours. 
The established risk factors (described in section 1.2.3), e.g. smoking, alcohol 
consumption and infection with the HP Vs, influence many of the genetic alteration 
observed in SCCHN.
1.2.5,1. p53 tumour suppressor alterations in SCCHN
Among the various molecular alterations found in human cancer (including SCCHN), 
the inactivation of the p53 tumour suppressor pathway, especially through p53 
mutation, seems to be paramount in tumour development. Moreover, mutations in this 
tumour suppressor gene have been found to be associated with reduced survival in 
SCCHN patients (101). Most of this association was attributed to mutations disrupting 
the native structure of the p53 protein (101). The most frequent p53 mutations were 
G:C -» A:T transitions and G:C T:A transversions (102), which comes as no 
surprise given the high exposure of SCCHN patients to nitrosamines (and other 
carcinogens) contained in tobacco (103). Moreover, the prevalence of frameshift 
mutations was significantly higher in SCCHN (16%) than in other cancer types (9%) 
(104). This is also related to exposure to tobacco carcinogens (such as
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benzo[a]pyrenes or nitrosamines), which are known to preferentially induce single 
base pair deletions (105). In addition, increased incidence of p53 frameshift mutations 
in SCCHN was linked to concomitant alcohol and tobacco exposure (102), suggesting 
that the synergistic action of these two substances may contribute to such p53 
mutational spectra in SCCHN.
The timing of p53 mutation in SCCHN is still controversial. There is evidence that 
the mutations can occur prior to the conversion from the premalignant to the invasive 
state (106). However, the incidence of p53 mutation is higher in the malignant lesions 
(106) and is closely linked to the exposure of most SCCHN patients to carcinogens, 
such as tobacco and alcohol (30).
p53 has been found to be mutated in about 50% of head and neck cancers (101), so 
the mutation prevalence in SCCHN is very similar to other epithelial cancers (107). 
A lai’ge-scale p53 mutational analysis revealed that the prevalence and nature of p53 
alterations varies significantly between different anatomical sub-sites (28). The 
highest rate of alterations, including mutations, overexpression and loss of expression 
was found in tumours of the hypopharynx (28). Laryngeal cancers, on the other hand, 
exhibited the lowest frequency of p53 alterations but also had a distinct mutation 
spectrum with most mutations occurring in exon 5 (28). Interestingly, most hot-spot 
248 mutations were also found in the larynx (28). Therefore, the p53 mutation 
spectrum of the larynx resembled the one seen in lung cancer rather than those 
observed in other sites of the head and neck, such as hypopharynx (28). This 
observation is consistent with the exposure of the laryngeal surface mucosa to tobacco 
alone (similar to lungs), while in the case of other tumour sites of the head and neck 
(oral cavity, oropharynx, hypopharynx) there is frequently concomitant exposure to 
both tobacco and alcohol.
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While the presence of p53 mutations was found to have limited prognostic value in 
SCCHN (28, 108), p53 mutation was associated with reduced overall survival 
(HR = 1.48; 95% Cl = 1.03-2.11) and disease-free survival (HR = 1.47; 
95% Cl = 1.12-1.93) in oral cancer (108). Surprisingly, the presence of p53 mutation 
had a favourable effect on disease-free survival in the oropharynx (HR = 0.45; 
95% Cl = 0.27-0.73) (108). This discrepancy between two head and neck sub-sites 
may be due to sampling issues or the underlying biological differences. It is tempting 
to speculate that high prevalence of HPV-positive oropharyngeal cancers might 
account for the survival advantage observed here (HPV-positive tumours have 
a favourable prognosis, as discussed in section 1.2.3.2). However, HPV-positive 
tumours usually carry wild-type p53 (see section 1.2.5.3) so the situation observed 
here is far from clear and requires further study.
1.2.5.2. Alterations of the Rb pathway and cyclin D1 expression 
In addition to the p53 pathway, another pathway frequently altered in SCCHN is the 
retinoblastoma (Rb) pathway (109). Rb is an important tumour suppressor protein, 
which plays a role in the regulation of the cell cycle. The activity of Rb is regulated 
through its phosphorylation level by cell cycle regulators such as pi6 and cyclin D1 
(109). Underphosphorylated Rb forms a complex with E2F transcription factor, hence 
preventing it from activating S-phase genes (necessary for cell proliferation) and 
resulting in inhibition of the cell cycle at the Gl-S checkpoint (110). Cyclin Dl, in 
complexes with CDK4/6 partners, initiates Rb phosphorylation, resulting in release of 
E2F and cell proliferation (110). The tumour suppressor pi6, on the other hand, 
interferes with the binding of cyclin Dl to CDKs (see Figure 1.6), thus preventing Rb 
phosphorylation (111).
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Cyclin D1 overexpression occurs in 49-79% of SCCHN (112, 113) and is 
consistently associated with poor prognosis (highly invasive and metastatic tumours, 
reduced disease-free survival, early recurrence) (113, 114). Moreover, loss of pi6 
expression (through homozygous deletions and methylations) was reported in 52-82% 
of head and neck cancers (115, 116), which was also associated with decreased 
disease-specific survival and early recurrence (69). This further emphasizes the 
importance of the Rb pathway inactivation in head and neck carcinogenesis.
1.2,5,3. The mechanism of HPV-mediated oncogenesis
Human papillomaviruses are small DNA viruses, which infect the squamous epithelial 
cells of the skin and mucous membranes (117). While they have been known for 
a long time as the causal agents of cervical cancer (47), their role in SCCHN became 
of interest only in the 1980s. Since then it has been determined that HPV, especially 
HPV-16, is involved in 25% of head and neck cancers (52). Moreover, it has been 
observed that the majority of HPV-positive tumour's express wild-type p53 (99, 118), 
which can be easily explained by the mechanism of HPV-mediated oncogenesis (see 
Figure 1.6).
The two main viral oncoproteins are HPV E6 and E7 (50). The E6 oncoprotein is 
targeted to the nuclear matrix and by binding to p53 of the host cell, it targets it for 
ubiquitin-mediated degradation (119). Therefore, p53 mutation in HPV-positive 
tumours would simply be redundant. HPV E6 has also been suggested to mediate 
telomerase activation (120, 121), an enzyme responsible for elongating the ends of the 
eukaryotic chromosomes (telomeres), which is crucial for cellular* immortalization, 
and thus helps cells avoid replicative senescence. Active telomerase has been detected 
in about 90% of SCCHN cases analysed (122).
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HPV E7 is also a small nuclear protein, which binds to and destabilises (through 
ubiquitin-mediated proteolysis) another tumour suppressor protein - retinoblastoma 
(Rb), which is a negative regulator of cell growth (123). This results in 
overexpression of pi6^^ (a cyclin-dependent kinase inhibitor), which normally 
inhibits Rb phosphorylation and blocks cell cycle progression (as described in section 
1.2.5.2) (124). While loss of pl6 function is a frequent event in SCCHN, high level of 
pi6 could be a surrogate marker for HPV, and was found to be associated with 
increased overall and disease-free survival (99, 125).
1.2,5.4, Dysregulation of the EGF signalling pathway
An important signalling pathway dysregulated in SCCHN is the epidermal growth 
factor (EGF) signalling pathway. Epidermal growth factor receptor (EGFR) has been 
found to be overexpressed in many head and neck cancers (126, 127). EGFR belongs 
to the ErbB family of receptor tyrosine kinases and can bind multiple ligands. EGF 
and transforming growth factor a (TGF-a), which have 40% sequence similarity, are 
believed to be the most important ligands for EGFR. Upon ligand binding EGFR 
dimerises, which triggers internalisation and autophosphorylation of its cytoplasmic 
domain due to its intrinsic tyrosine kinase activity. This in turn initiates a signalling 
cascade through Ras-Raf and PI3K-AKT, resulting in a mitogenic response (128). 
Interestingly, there is some evidence that EGF-bound EGFR can be translocated into 
the nucleus, where it can function as a transcription factor (individually or in 
cooperation with other transcription factors) to induce cyclin D1 expression, 
promoting cell cycle progression (as described in section 1.2.5.2) (129). High EGFR 
expression in SCCHN has been correlated with poorer response to therapy and worse 
overall and disease-free survival (99).
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Recently, one of the first targeted therapies has been introduced into the clinic in 
the UK for treatment of locally advanced, nonresectable or metastatic SCCHN. 
Cetuximab, a monoclonal antibody against EGFR, has recently been approved for 
treatment in combination with radiotherapy in patients deemed unsuitable for 
treatment with cisplatin-based chemoradiation and resulted in a sharp improvement in 
response rate and survival of these patients compared to standard therapy (130, 131). 
Anti-angiogenic treatments and tyrosine kinase inhibitors, such as gefitinib and 
erlotinib, have proved promising in the clinical trials (132).
Figure 1.6: A schematic representation of the major molecular pathways altered in 
SCCHN. Two major tumour suppressor pathways involved in the pathogenesis of SCCHN 
are the p53 and Rb pathways. Upon DNA damage p53 is induced and stimulates p21 
expression (among many others). p21 inhibits cyclin A/B-CDK1 complexes, thus preventing 
G2-to-M transition. HPV E6 protein binds to p53 and targets it for proteasomal degradation. 
Another tumour suppressor, Rb, binds to E2F preventing it from activating the S-phase genes. 
Mitogenic signalling (including EGFR overexpression) stimulates cyclin D1 expression, 
which complexes with CDK4/6 and phosphorylates Rb, resulting in E2F dissociation and cell 
cycle entry. HPV E7 protein also inactivates Rb, preventing it from binding to E2F, which 
results in cell proliferation. Finally, pi6, an inhibitor of the CDK-cyclin D1 complexes, is 
frequently lost in SCCHN. Figure adapted from reference (133).
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The number of different molecular* alterations (some of which are described here) 
underlying the pathogenesis of head and neck cancer emphasizes the heterogeneity of 
this disease and the need for development of personalised treatments for individual 
patients. Understanding the molecular basis of SCCHN is crucial for finding 
predictive biomarkers and developing novel treatment strategies tailored to the 
individual tumour*.
1.3. The p53 tumour suppressor protein
One of the key molecular* pathways altered in cancer cells is focused upon the p53 
tumour suppressor protein (134). When it was first discovered in 1979 (135), p53 was 
identified as a cellular* oncogene due to the ability of the cloned tumour-derived p53 
cDNAs to accelerate the cell cycle, immortalize some cell types and cooperate with 
other oncogenes in cellular* transformation (136). It was not until 10 years later* when 
it was discovered that the TP53 cDNAs initially studied in different laboratories 
encoded mutant p53 proteins and wild-type p53 was found to have 
growth-suppressive properties and to inhibit cellular* transformation (137). Currently, 
p53 is one of the most intensely studied proteins in human cancer with nearly 
60,000 citations in PubMed.
1.3.1. Structural organisation of the p53 protein
p53 is encoded by the TP53 tumour suppressor gene located on the short ami of 
chromosome 17 (17pl3.1, a chromosomal locus frequently altered in human cancers) 
(138). This 20 kbp (kilobase pair) gene consists of 11 exons (2-11 coding) yielding 
a 393 amino acid protein (139), which functions as a tetramer* (140). Structurally, the
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p53 protein can be divided into three parts: the N-terminal domain, central core and 
the C-terminal domain (Figure 1.7).
Proline-rich
domain
Flexible Regulatory
linker domain
Figure 1.7: Structure of the p53 protein. Hatched boxes represent evolutionarily conserved 
regions. The protein contains the N-terminal transcriptional activation domain, central 
sequence-specific DNA binding domain and the C-terminal domain, including the 
tetramerization and regulatory domains. p53 contains three nuclear localization signals 
(NLSs) in its C-terminal domain and two nuclear export signals (NESs) - one in the 
tetramerization domain and another in the N-terminal transactivation domain.
The N-terminal domain contains the acidic transcriptional activation domain and 
encompasses residues 1-43 (141). The transactivation domain of p53 interacts with 
several general transcription factors, including the TATA box-binding protein (TBP) 
(142) and the TBP-associated factors TAFII70 and TAFII31 (143), all being part of 
the general transcription factor TFIID, and the p62 subunit of the TFIIH transcription 
factor (144). The residues FI9, L22 and W23 have been shown to be essential for 
transcriptional activation by p53 as they make direct contact with the components of 
the transcriptional machinery (145).
The central core contains the sequence-specific DNA-binding domain (DBD) of 
p53 and lies between amino acids 100-300 (146). There are four evolutionarily 
conserved regions within the core domain (region II: 117-142; III: 171-181; 
IV: 234-258; V: 270-286), which comprise a DNA-binding element, responsible for
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contacting the major and minor grooves of the bound DNA (147). The remaining 
regions of the central core make up a |3-sandwich, which forms a scaffold to support 
the a-helical DNA binding element (147). The DNA binding central core is 
a protease-resistant domain, chelating a Zn2+ ion, which is necessary for its 
sequence-specific DNA binding (148). Residues K120, S241, R273, A276 and R283 
are also responsible for the sequence-specificity of p53 as they make direct contact 
with the phosphate backbone in the major grove of DNA, while residues K120, R248, 
C277 and R280 form hydrogen bonds with DNA bases in the minor grove of DNA 
(147). The majority of p53 mutations found in human cancers are located in the 
central core domain, especially within the highly conserved regions (104), leading to 
the loss (or modification) of sequence-specific DNA binding.
The C-terminal domain (residues 300-393) is multifunctional. It can be further 
subdivided into three regions: a flexible linker (residues 300-320), a tetramerization 
domain (residues 320-360) (148) and a regulatory domain, which is rich in 
basic residues (residues 363-393). The tetramerization domain contains 
a (3-sheet-tiuii-a-helix motif, which can homodimerize (Figure 1.8) and a pair of such 
dimers forms the p53 tetramer (149, 150). The pair of dimers is held together by 
strong hydrophobic interactions between the surfaces of each helix pair (150). The 
C-terminal regulatory domain contains 9 basic residues and is capable of non-specific 
DNA binding (148). It has also been reported to bind damaged DNA (151, 152) and 
to promote reannealing of complementary DNA or RNA strands (153).
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A-B Dimer
C-D Dimer
Figure 1.8: Structure of the tetrameric DNA binding domain of p53 binding to DNA.
Subunits A (blue) and B (green) form one dimer, subunits C (purple) and D (pink) form the 
other dimer. Zn2+ ions are depicted as bright green spheres. The consensus DNA binding 
sequence is presented in red and the remaining DNA bases in grey. Figure reproduced from 
reference (154).
1.3.2. Functions of p53
The p53 protein acts as a multitarget, sequence-specific transcription factor (reviewed 
in (155)). Most of the promoters bound by p53 contain a consensus binding sequence 
with an internal symmetry. The consensus binding site consists of two copies of 
a 10 base pair motif 5,-PuPuPuC(A/T)(T/A)GPyPyPy-3’ separated by 0-13 base pairs 
(156). The symmetry of the four half-sites in the consensus sequence is striking given 
the fact that p53 binds DNA as a tetramer (140). Importantly, while the majority of 
the described and validated p53 response elements (REs) are associated with 
transcriptional activation of gene expression, many of the REs (up to 15%) are also 
linked to transcriptional repression (157). Although the mechanisms of p53-mediated 
transcriptional repression are less well understood, the following mechanisms have
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been proposed: binding of p53 to transcription factor Spl, hence inhibiting its ability 
to bind other promoters (158), direct repression of certain promoters (159) or 
competing with the TATA-box binding protein (TBP) for binding to some promoters 
(160). p53-dependent transrepression has also been suggested to be mediated by 
deacetylation of core histones at the promoter region of repressed genes (161) due to 
the interaction of p53 with a corepressor mSin3a and histone deacetylases (PIDACs) 
in response to hypoxia (162).
As a transcription factor p53 controls the expression of a large number of genes 
with various functions, involved in regulation of the cell cycle, apoptosis, senescence, 
DNA repair after genotoxic stress, oxidative stress, angiogenesis, differentiation 
(163), cell adhesion, cell migration, extracellular matrix and cytoskeleton organisation 
(164, 165). Given such a long list of p53-regulated processes, it comes as no surprise 
that TP53 mutation is found in about 50% of human cancers (107). Moreover, it is 
believed that in many other tumours p53 is inactivated indirectly via binding to viral 
proteins or through alterations of other components of the p53 pathway (interacting 
with or transmitting signals to or from p53) (134). Germline mutations of p53 have 
been found to underlie Li-Fraumeni syndrome, a rare autosomal dominant hereditary 
disorder, which greatly increases susceptibility to cancer (166).
1.3.2.1. Cell cycle regulation by p53
One of the main functions of p53 in the majority of mammalian cells is the inhibition 
of progression through the cell cycle. There are a number of pathways via which p53 
induces cell cycle arrest. First of all, p53 transcriptionally activates the expression of 
p2iWAFi/ciP^ wj1|c];1 inhibits cyclin-dependent kinases (CDK1 and CDK2) (167). 
CDKs are the key regulators of the cell cycle checkpoints (168). They become active
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only in complexes with cyclins (169) and are essential for successful progression 
through the cell cycle (G1-*“S-*,G2-*>M phase transitions) (170). By inhibiting the 
activity of the cyclin/CDK family members (cyclin E-CDK2, cyclin A-CDK1/2 and 
cyclin B-CDK1), p21 blocks cell cycle progression at G1 and G2 phases (171). p21 is 
also able to bind proliferating cell nuclear antigen (PCNA), hence blocking the 
activity of PCNA as a DNA polymerase processivity factor in DNA replication and 
causing G1 arrest (172). p21 was shown to be essential for p5 3-mediated G1 arrest 
(173).
Another p5 3-induced gene involved in cell cycle regulation is GADD45 (growth 
arrest and DNA-damage-inducible) (174). GADD45 is implicated in the induction of 
the G2 arrest as it was reported to inhibit the activity of the CDK1-cyclin B1 
complexes (175). This ensures that cell cycle progression can be halted, if necessary, 
even in the absence of p21.
p53 can also achieve cell cycle arrest via up-regulation of 14-3-3a in epithelial 
cells lining internal organs (176). 14-3-3a promotes a pre-mitotic cell cycle arrest in 
the G2 phase via sequestering cyclin B1-CDK1 complexes and preventing them from 
entering the nucleus (177). Cyclin B1 and CDK1 are cytoplasmic during interphase 
and are translocated into the nucleus at the end of G2 phase to stimulate mitosis (178). 
This DNA damage checkpoint and sequestration of cyclin B1-CDK1 complexes 
prevents the cells from entering mitosis, which could be potentially lethal if the 
cellular’ DNA is damaged (179).
Similarly to 14-3-3o, Reprimo, a newly identified candidate tumour-suppressor 
gene, is a potential mediator of the p53-dependent cell cycle arrest (180). 
Overexpression of Reprimo inhibits progression through the cell cycle, arresting cells 
at the G2 phase, likely through inhibition of CDK1 activity (180). While the
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mechanism of Reprimo-mediated cell cycle arrest is not fully understood, the 
accumulation of cyclin B1 in the cytoplasm and the presence of inactive CDK1 in 
Reprimo-overexpressing cells suggests that it may stimulate G2 arrest via inhibition 
of CDK1 activity and cytoplasmic sequestration of the CDK1-cyclin B1 complexes 
(180). Although there is no evidence for the presence of a p53 consensus binding site 
within the promoter region of Reprimo, its induction upon p53 expression suggests 
that Reprimo expression is regulated by p53 (180).
The number of p53-responsive genes involved in regulation of the cell cycle 
suggests that induction of cell cycle arrest is an important mechanism of 
p53-mediated tumour suppression.
1.3,2.2. The role ofp53 in apoptosis
The most important role of p53 is the induction of apoptosis, where it acts to 
selectively eliminate stressed or abnormal cells, hence protecting the organism from 
developing cancer. It does so predominantly by transcriptional induction or repression 
of expression of numerous genes (181) although transcriptionally-independent p53 
activities have also been well documented (182). While transcriptional activation of 
gene expression has been extensively studied, the mechanisms of p53-mediated 
transcriptional repression are less well understood.
p53 can directly activate each of the three most important apoptotic pathways in 
the cell (summarized in Figure 1.9): the intrinsic (mitochondrial) apoptotic pathway, 
the extrinsic (death receptor-mediated) apoptotic pathway and apoptosis mediated by 
reactive oxygen species (ROS) (183).
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Extrinsic
Apoptosis
Figure 1.9: A model of p53-mediated apoptosis. The diagram outlines the modes of 
p53-induced apoptosis: the intrinsic and extrinsic apoptotic pathways and induction of 
apoptosis through ROS. p53 transcriptional targets are shown in red. Figure adapted from 
reference (184).
The first two converging pathways, the extrinsic and the intrinsic apoptotic 
pathway, both lead to the activation of caspases that mediate apoptosis (185). The 
extrinsic pathway is a type of “instructive” apoptosis, which allows the organism to
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actively direct selected cells to commit suicide. It involves a type of cell surface 
receptors, the so-called death receptors, which upon binding their extracellular ligands 
transmit apoptotic signals, leading to an activation of caspase-8 and initiation of 
a caspase cascade (186). The intrinsic or mitochondrial pathway involves the 
alteration of the mitochondrial membrane potential due to the opening of the 
mitochondrial transition pores and the release of cytochrome c from the mitochondrial 
intermembrane space into the cytoplasm (187). Cytochrome c, apoptotic 
protease-activating factor 1 (Apaf-1) and procaspase-9 form a complex known as the 
apoptosome, in which procaspase-9 is cleaved and auto-activated, thence initiating 
a caspase cascade (188). The third apoptotic pathway mediated by p53 involves the 
production of ROS (189). Increased levels of ROS inflict serious damage to 
mitochondria, resulting in a leakage of calcium and mitochondrial proteins (including 
cytochrome c) into the cytoplasm and activation of a caspase cascade (182).
1.3.2.2.1, The extrinsic apoptotic pathway
p53 can initiate the death receptor apoptotic pathway by transcriptional activation of 
a number of death receptors, including Fas/Apol and DR5/KILLER (183). Ligand 
binding triggers receptor trimerization and clustering of the intracellular death 
domains (DD), which then recruit intracellular adaptor molecules to form 
a death-inducing signalling complex (DISC) (186). This leads to the activation of 
caspase-8, triggering a caspase cascade and induction of apoptosis (190).
Fas (also known as CD95 or Apol) is a cell-surface receptor belonging to the 
tumour necrosis factor receptor (TNF-R) family (191). It becomes activated by 
binding of its ligand, FasL, which is expressed predominantly in activated T cells 
(191). In response to y-irradiation, p53 can not only induce Fas expression (192), but
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also enhance trafficking of Fas from the Golgi apparatus to the cell surface (193). 
Moreover, FasL has also been observed to be up-regulated by p53 (194), providing 
yet another way, in which p53 could activate this apoptotic pathway.
DR5/KILLER is another member of the TNF-R family. Similarly to Fas, it is 
up-regulated by p53 in response to DNA damage (195) and upon binding of its ligand, 
TNF-related apoptosis-inducing ligand (TRAIL), activates the apoptotic caspase 
cascade (196).
A recently discovered gene found to play a role in this pathway is PIDD 
(p53-induced protein with a death domain), which is a transcriptional target of p53 
(197). PIDD is a cytoplasmic protein, which upon binding an adaptor protein RAIDD 
activates caspase-2, resulting in an activation of a caspase cascade and induction of 
apoptosis (198).
1.3.2.2,2. The intrinsic apoptotic pathway
In addition to apoptosis triggered by extracellular signals, apoptosis can also be 
initiated through the mitochondrial pathway. This pathway represents another type of 
apoptosis mediated by p53. It is dominated by the proteins belonging to the Bcl-2 
family, which control the release of cytochrome c from the mitochondria. The Bcl-2 
family comprises the anti-apoptotic Bcl-2 and Bc1-Xl, and the pro-apoptotic Bax, 
Bak, Bid, Noxa and PUMA.
One of the first genes identified to be an apoptotic target of p53 was Bax, encoding 
an apoptosis-inducing mediator — a member of the Bcl-2 family (199). Bax binds to 
the survival factor Bcl-2 and antagonizes its anti-apoptotic function (200). This 
suggests that the ratio of Bcl-2 to Bax could be responsible for determining the 
response (death or survival) to an apoptotic stimulus. However, Bax is not required
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for apoptosis under all circumstances and the requirement for Bax was reported to be 
cell type and context dependent (184). For example, Bax was found to be dispensable 
for the induction of p53-mediated cell death in T-lymphocytes after ionising radiation 
(201), in which apoptosis is induced through Fas (see section 1.3.2.2.1) and the death 
receptor pathway (202). This emphasizes the importance of the numerous 
p5 3-mediated apoptotic pathways discussed here.
More recently, two additional pro-apoptotic members of the Bcl-2 family, Noxa 
(203) and PUMA (204), have been identified as transcriptional targets of p53. These 
proteins, along with another p53 transcriptional target, non-Bcl-2 family member 
p53AIPl (p53-regulated Apoptosis-Inducing Protein 1) (205), localize to the 
mitochondria and through their binding to Bcl-2 stimulate the opening of the 
mitochondrial permeability transition pore, resulting in the loss of mitochondrial 
membrane potential, release of cytochrome c into the cytoplasm and stimulation of 
a caspase cascade. Moreover, p53 has also been reported to transcriptionally activate 
the expression of Apaf-1 (206) and caspase-6 (207), further contributing to the 
stimulation of the intrinsic apoptotic pathway.
As mentioned previously, determining the death or survival of a cell is dependent 
on the balance of the pro- and anti-apoptotic members of the Bcl-2 family. While p53 
can transcriptionally activate the expression of the pro-apoptotic Bcl-2 family 
proteins, Bcl-2 can specifically suppress p53-mediated apoptosis (208). Therefore, it 
can be envisaged that p53 should be able to antagonize the action of Bcl-2 for 
efficient induction of the apoptotic response. Indeed, p53 was reported to 
down-regulate Bcl-2 gene expression (209). It was further shown that this is achieved 
through transcriptional repression of the Bcl-2 gene containing a negative p53 
response element (in the 5’-untranslated region) (210). Furthermore, p53 was shown
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to bind to p2 promoter of Bcl-2 and to suppress Bcl-2 transactivation by another 
transcription factor, Brn-3a (208), hence tipping the balance towards apoptosis.
Additionally, it was reported that in response to cellular’ stress p53 can form an 
inhibitory complex with the anti-apoptotic proteins Bc1-Xl and Bcl-2, leading to 
mitochondrial membrane permeabilization and apoptosis (211).
Therefore, concomitant transcriptional repression of anti-apoptotic Bcl-2 and 
induction of pro-apoptotic Bax, Noxa and PUMA as well as physical inhibition of the 
anti-apoptotic proteins Bc1-Xl and Bcl-2 by wild-type p53 provide a plausible 
mechanism of p53-mediated apoptosis.
1.3.2.2.3. ROS-mediated apoptosis
Disturbances of mitochondrial integrity may also be influenced by the redox status of 
the cell and the levels of reactive oxygen species (ROS). The genes implicated in this 
process are the so called p53-induced genes (PIGs) (189), which encode proteins with 
activities related to the redox status of cells. So far* a number of such genes have been 
identified including: P1G1 - a member of the galectin family, stimulating superoxide 
production (212); PIGS - an NADPH-quinone oxidoreductase, a potent generator of 
ROS (213); PIG4 — a serum amyloid protein inducible by oxidative stress (214); PIG6 
- a homologue of proline oxidoreductase catalysing the first stage in the conversion of 
proline to glutamate in the mitochondria (215); PIGS - a homologue of murine Ei24 
gene induced by etoposide, which generates ROS (216) and PIG 12 — a member of the 
glutathione S-transferase family (189). The proteins encoded by the above mentioned 
genes altogether contribute to the increase of the cellular' levels of ROS, which 
damage mitochondria (189). Release of cytochrome c from the leaking mitochondria
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leads to the activation of a caspase cascade, a common event during the apoptotic 
process.
While hyper-physiological levels of p53 were reported to promote the induction of 
the pro-oxidant genes, basal p53 levels are known to play an important role in 
maintaining ROS at a non-toxic level (217). At physiological level p53 induces the 
expression of a number of antioxidant genes, including SESN1 (mammalian sestrin 
homolog), SESN2 and GPX1 (glutathione peroxidase 1), hence lowering the levels of 
ROS in cells (218, 219, 220), This dual action of p53 with respect to ROS ensures that 
in unstressed cells the levels of ROS are kept low (preventing DNA damage and 
genetic instability), while in the context of cellular' stress ROS up-regulation results in 
programmed cell death.
Although p53 is predicted to target many other genes than the ones described here, 
each of these p53-inducible proteins has been shown to be indispensable for the full 
apoptotic response, at least under certain circumstances, in vitro. These results await 
to be confirmed using in vivo models.
1.3.2.3. Choice of response to p53
The fact that p53 induces both cell cycle arrest and apoptosis has led to postulating the 
question of how the cell decides which response to choose. It appears that the key 
factor determining the cell’s response to p53 might be the cell type (221). 
Interestingly, p53 has been suggested to selectively induce apoptosis in transformed 
versions of certain cell types, compared to their normal counterparts, which might 
preferentially undergo a theoretically reversible cell cycle arrest (222). Some normal 
cell types, such as gut epithelium, clearly do undergo apoptosis in response to p53 
induction, and this is believed to be one of the main causes of the adverse side effects
40
Introduction
associated with many anti-cancer treatments (223). However, other cell types, 
including some epithelial cells and fibroblasts, become more susceptible to apoptosis 
following oncogenic transformation (224), giving rise to the exciting idea that it might 
be possible to selectively kill cancer cells while sparing the normal untransformed 
tissue.
The question of contribution of p53 to the choice of response still remains 
unanswered. The two suggested models are the ‘p53 dumb’ and ‘p53 smart’ model 
(225).
The ‘p53 dumb’ model suggests that p53 may have no influence on the cell’s 
response to it, but sends exactly identical signals upon activation in all cases, resulting 
in stimulation of both pro-apoptotic and cell cycle arrest-inducing target genes. In this 
scenario, p53 activation would always send an apoptotic signal, which could be either 
hindered by survival signals or amplified by independent apoptotic signals to reach 
a threshold necessary to kill the cells (225). This model is supported by the fact that in 
case of inhibition of p53-dependent apoptosis, p53-mediated cell cycle arrest takes 
over. However, the fact that apoptotic and cell cycle arrest target genes can be 
differentially regulated by p53 and that some p5 3-dependent apoptotic genes are 
expressed only in cells undergoing p53-mediated apoptosis (226) suggests that the 
‘p53 dumb’ model might not always be correct and needs adjusting. It has therefore 
been suggested that in the presence of identical signals sent by p53 in every situation, 
successful transcriptional activation of apoptotic target genes relies on the presence of 
other transcription factors binding to those promoters (227).
While it is clear that p5 3-independent factors play a role in determining the cellular 
response to p53, there is accumulating evidence for the existence of a direct role of 
p53 in modulating which response pathways are activated. This ‘p53 smart’ model
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suggests that p53 activities differ depending on whether the cell is destined to undergo 
apoptosis or cell cycle arrest. The type and intensity of cellular stress may influence 
p53 function by affecting the level and activity of the induced p53. The choice of 
response can be heavily affected by the abundance of p53, with increasing amounts of 
the protein turning cell cycle arrested cells into apoptotic cells (228), which could be 
explained by the lower affinity of the apoptotic target gene promoters for p53. 
Alternatively, the affinity for certain target genes might be influenced by the 
conformation of p53 (229). Moreover, post-translational modifications of p53 can also 
affect promoter binding. An example of the latter is the phosphorylation of p53 on 
serine 46, which has been correlated with the onset of apoptosis and which enables 
p53 to induce an apoptotic target p53AIPl (205). This altered action of 
phosphorylated p53 could be explained either by subtle changes in conformation 
affecting its DNA binding specificity or altered capacity to interact with coactivators 
essential for induction of apoptotic genes. Nevertheless, the retention of the cell cycle 
arrest response in apoptotic cells indicates that forms of p53 capable of inducing cell 
death may also have the capacity to drive other responses.
The selection of target genes by p53 has also been suggested to be modulated by 
p53-binding proteins. p53 forms complexes with a transcriptional coactivator 
p300/CBP, which opens up the chromatin around the p53-binding sites to make it 
accessible to both p53 and the transcriptional machinery (230). While this interaction 
allows p53 to function efficiently as a transcriptional activator in general, the 
cooperation of JMY with p300 was reported to enhance the ability of p53 to stimulate 
apoptotic target genes, such as Bax, without having a significant impact on the 
transcription of cell cycle arrest genes, such as p21 (231). A direct interaction of 
ASPP family members with p53 has also been found to enhance the ability of p53 to
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bind apoptotic target genes (232). Finally, stimulation of apoptosis by p53 has 
recently been reported to require the presence of at least one other member of the p53 
family, p63 or p73 (233). Since wild-type p53 does not directly bind either of these 
proteins, p63 or p73 may influence the binding of p53 to certain promoters indirectly.
In summary, the available evidence suggests that the consequences of p53 
activation are influenced by a number of factors, including the cell type, the nature of 
stress signals (strength, duration) and the cellular* context (presence and abundance of 
other factors) (221). The possibility to selectively induce apoptosis in cancer cells by 
modulating the above mentioned factors creates an attractive therapeutic avenue for 
development of effective anti-cancer treatments targeting p53.
1.3.2.4, The role of p53 in senescence
Apoptosis and cell cycle arrest are not the only anti-proliferative functions of p53. p53 
has also been suggested to exert its tumour suppressor properties via regulating the 
process of cellular* senescence (234).
Senescence or proliferative aging is a type of irreversible cell cycle arrest, which 
differs from quiescence (reversible cell cycle arrest) in the specific morphological 
changes and gene expression (235). Normal cells undergo a limited number of cell 
divisions (236). Every cell cycle is accompanied by shortening of telomeres 
(repetitive DNA sequences at the ends of linear* chromosomes) and telomere erosion 
results in an irreversible growth arrest known as replicative senescence (237). More 
recently, other stimuli such as DNA damage and oncogene activation have also been 
reported to cause cells to adopt a senescent phenotype (236). Since aging predisposes 
cells to accumulate mutations that could eventually lead to malignant transformation, 
senescence appears to provide a fail-safe mechanism, which prevents organisms from
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developing cancer (238). Therefore, it comes as no surprise that a number of tumour 
suppressors, including p53 and Rb, are involved in controlling cellular senescence 
(239).
p53 is induced in response to all three senescence-inducing signals (telomere 
erosion, DNA damage and oncogenic signalling). Oncogene activation and DNA 
damage lead to the induction of another tumour suppressor, pl4ARF (240). pl4ARF 
binds and sequesters MDM2, hence releasing p53 from the negative regulation by 
MDM2 (as discussed in section 1.3.3.1), leading to the stabilisation and activation of 
p53 (241). Another protein implicated in the process of senescence is the 
promyelocytic leukaemia (PML) tumour suppressor. PML is induced by telomere 
shortening and oncogene activation (242) and interacts with the p300/CBP 
acetyltransferases, which also acetylate p53 resulting in its activation (see 
section 1.3.3.2) (243). As a result p53 induces p21 transcription, which may facilitate 
the onset of senescence (244).
1.3,2.5. The role of p53 in DNA repair and maintaining genomic stability 
The ability of p53 to influence the cellular life and death decisions has implications 
also for maintaining genetic stability. First of all, p53-mediated induction of apoptosis 
in response to DNA damage directly eliminates abnormal cells harbouring mutations 
that would otherwise contribute to genomic instability. The induction of cell cycle 
arrest (a reversible pause in the cell cycle) by p53, on the other hand, allows time for 
DNA repair, which prevents the propagation of potentially deleterious mutations, 
again contributing to the maintenance of genomic stability. In addition to DNA 
damage, p53 was also reported to be activated in response to specific depletion of 
ribonucleotide pools (245). Ribonucleotide depletion was associated with prolonged
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p53 induction, resulting in p21 up-regulation and Rb dephosphorylation, leading to 
cell cycle arrest at the G1 phase (246), hence preventing DNA replication in 
conditions that could result in chromosome breakage. Chromosome breakage or 
dsDNA breaks are the most deleterious type of DNA damage, resulting in a high rate 
of chromosomal rearrangements, deletions and mutations, resulting in genomic 
instability (247). Therefore, p53-mediated cell cycle arrest in response to 
ribonucleotide depletion can stop DNA replication before damage occurs. Moreover, 
in the context of existing DNA damage, p53 was reported to induce the expression of 
a ribonucleotide reductase gene p53R2, which functions to increase the pool of free 
dNTPs when DNA repair is required (248).
In addition to the above described indirect role in DNA repair, p53, known as the 
guardian of the genome (249), is also directly involved in repair of damaged DNA. 
p53 plays a role at multiple levels of many DNA repair programmes, including MMR 
and NER.
In NER p53 is involved in DNA damage recognition by activating the transcription 
of XPC (Xeroderma pigmentosum group C) (250) and XPE/DDB2 (Xeroderma 
pigmentosum group E/damage-specific DNA binding protein 2) (251). Xeroderma 
pigmentosum (XP) is an autosomal recessive disorder caused by defects in any of at 
least 7 genes (XPA to XPG) encoding components of the NER machinery, leading to 
extreme sensitivity to UV light and high predisposition to skin cancers (8). The 
transcriptional target of p53, XPC plays an important role in the early steps of global 
genome NER, especially in damage recognition, and is essential for the recruitment of 
additional NER factors for the repair complex formation (252, 253), while XPE is 
required for binding the damaged DNA (251). Following DNA damage recognition 
and binding, a multi-protein complex is assembled to repair the damage (8).
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Following excision of the DNA lesion, DNA polymerase 5 and s are recruited along 
with their processivity factor PCNA, which is an indispensable component of 
a number of repair pathways (such as MMR, NER and BER), to fill the gap created by 
the excised lesion (254). p53 not only induces PCNA expression (255), but also 
up-regulates two other targets, p21 and GADD45, which interact with PCNA. p21 
was reported to have differential effects on PCNA - while it is able to inhibit the 
function of PCNA in DNA replication, it does not stop the PCNA-dependent NER 
(256, 257). Similarly, GADD45 was found to stimulate global genomic repair (GGR), 
which is a subtype of NER, and inhibit entry of cells into S phase (258). Therefore, 
through transcriptional activation of the above mentioned genes, p53 contributes to 
NER at multiple levels.
In addition to facilitating NER, p53 has also been implicated in mismatch repair 
(MMR). p53 induces the expression of human MutS homologue 2 (liMSH2) (259), 
whose main function is recognition of DNA mismatch, binding to it and stimulating 
a cascade of reactions leading to DNA repair (260). hMSH2 was also found to interact 
with PCNA to form an active mismatch repair complex, which facilitates hMSH2 
transfer to DNA mismatches (261). By inducing PCNA expression (as described 
above) p53 also contributes to MMR at another level.
Apart from its functions in promoting DNA repair, p53 has been implicated in the 
regulation of centrosome replication during mitosis (262). Centrosomes are major 
microtubule organising centres, which play a role in establishing the two poles of 
mitotic spindle, formation of the cleavage furrow plane and balanced segregation of 
chromosomes (263). It was reported that p53-null cells generate multiple copies of 
functional centrosomes during a single cell cycle (262), which has deleterious effects 
for mitotic fidelity and leads to unequal segregation of chromosomes between the
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daughter cells. However, p53-null mice develop normally but are highly susceptible 
to spontaneous tumours (264). While wild-type mice did not develop any tumours by 
the age of 9 months, mice with a homozygous p53 deletion developed obvious 
cancers by the age of 6 months in 74% of cases. This suggests that p53 is crucial for 
tumour suppression, as its lack might contribute to chromosomal abnormalities and 
tumour formation. Therefore, regulating centrosome duplication is yet another 
mechanism, through which p53 may contribute to maintaining genomic stability.
1.3,2.6. The role ofp53 in angiogenesis
As a part of its repertoire of tumour suppressive functions, p53 has also been 
implicated in suppressing angiogenesis. This is supported by the fact that tumours 
bearing p53 mutations are more highly vascularized (as measured by the microvessel 
density) than p53 wild-type tumours (265) and are associated with poor survival 
(266). This suggests that p53 plays a critical role in controlling tumour 
vascularization.
p53 inhibits angiogenesis via three main mechanisms: inhibition of systems 
responsible for sensing hypoxic conditions, down-regulation of pro-angiogenic factors 
and up-regulation of anti-angiogenic factors (267). By combining these mechanisms 
p53 is able to efficiently shut down the angiogenic potential of cancer cells.
Angiogenesis is stimulated in response to oxygen deprivation associated with an 
up-regulation of hypoxia inducible factor (HIT) (268). HIF functions as a heterodimer 
comprising two subunits, HIF-la and HIF-1(1, and transcriptionally activates 
expression of the vascular endothelial growth factor (VEGF) in hypoxic conditions 
resulting in enhanced angiogenesis (269). p53 can directly bind to HIF-la and
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promote its MDM2-mediated ubiquitylation and degradation, resulting in inhibition of 
angiogenesis (270).
In addition to interfering with the hypoxia-sensing systems, p53 is also able to 
repress the expression of pro-angiogenic factors, including VEGF (158), basic 
fibroblast growth factor (bFGF) (159), bFGF-binding protein (bFGF-BP) (271) and 
cyclooxygenase-2 (COX-2) (160). The mechanisms of transcriptional repression by 
p53 include: binding of p53 to transcription factor Spl, hence inhibiting its ability to 
bind other promoters (VEGF); direct repression of certain promoters (bFGF and 
bFGF-BP) or competing with the TATA-box binding protein (TBP) for binding to 
some promoters (COX-2).
Finally, p53 is also involved in transcriptional activation of anti-angiogenic factors, 
including maspin (272), a(II) collagen prolyl-4-hydroxylase [a(II)PH] (273), 
thrombospondin-1 (TSP-1) (274) and brain-specific angiogenesis inhibitor 1 (BAI1) 
(275). Maspin is a member of the serpin family, which inhibits new blood vessel 
formation, tumour invasion and metastasis (272). a(II)PH catalyses the formation and 
extracellular release of anti-angiogenic peptides derived from collagen type 4 and 18 
(273). TSP-1 inhibits angiogenesis in a number of ways, for example through negative 
regulation of growth and migration of endothelial cells (276). Finally, BAI1 is cleaved 
into an anti-angiogenic fragment called vasculostatin, which is secreted into the 
extracellular matrix (277). Collectively, the expression of the discussed proteins 
results in the inhibition of angiogenesis through many different pathways. The fact 
that p53 is involved in angiogenesis suppression at multiple levels suggests that 
inhibiting this process may be critical for effective tumour suppression.
Angiogenesis is crucial in tumours, especially in those at a late stage of 
development as they need a constant supply of oxygen and nutrients (278). This stage
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is also the time when most p53 mutations in human cancers occur (279, 280). This 
suggests that loss of p53 and the unrestrained recruitment of new blood vessels 
provide a critical growth advantage to tumours at a late stage of development.
1.3.2.7. The role of p53 in tumour invasion and metastasis
In addition to the roles of p53 in inhibiting tumour formation (through the induction 
of cell cycle arrest, apoptosis, senescence and DNA repair, and inhibition of 
angiogenesis - see sections 1.3.2.1-6), it is becoming clear that p53 also regulates 
invasiveness of tumours and the process of metastasis (see Figure 1.10).
The main cause of cancer mortality is usually not the primary tumour but distant 
metastases. In order to obtain metastatic potential cancers cells must be able to detach 
from the primary tumour, invade the stroma and basement membrane of the blood and 
lymphatic vessels and finally extravasate to seed a new tumour.
Frequently, one of the first steps of cancer cells on the road to metastasis is 
undergoing epithelial-mesenchymal transition (EMT). EMT is a process implicated in 
wound healing, in which epithelial cells at the edge of the wound, normally displaying 
cell-cell adhesions, undergo a major change in phenotype by losing cell-cell junctions 
and restructuring of the cytoskeleton to assume a motile mesenchymal-like 
appearance (110). EMT is transcriptionally regulated by Slug/Snail and Twist 
proteins, which were reported to down-regulate E-cadherin, involved in stabilising 
cell-cell jmictions, and up-regulate proteins stimulating cell migration (281, 282).
EMT is implicated in the formation of invasive and metastatic tumour cells in the 
course of tumour progression (283). Since p53 loss has been linked to activation of 
the EMT programme and high tumour grade, wild-type p53 has been suggested to 
play a role in EMT suppression through maintaining a transcriptional programme,
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which prevents EMT (284, 285). As part of this programme, p53 has been proposed to 
stimulate MDM2-mediated degradation of Slug, which was associated with 
up-regulation of E-cadherin and decreased invasiveness of cancer cells (286). 
However, these finding have been questions by other studies, which reported that 
MDM2 actually promotes cell motility and invasiveness (287, 288). While MDM2 
was suggested to promote ubiquitylation and degradation of E-cadherin (288), a more 
recent study demonstrated that the MDM2-mediated increase in motility and 
invasiveness of cells is independent of its E3 ubiquitin ligase activity, since 
a RING-finger MDM2 mutant (lacking the E3 ubiquitin ligase activity) was also able 
to promote motility and invasion (287). Altogether these data suggest that 
p5 3-dependent down-regulation of Slug likely occurs through a different mechanism 
than MDM2-mediated degradation of Slug.
An alternative pathway could involve p5 3-mediated up-regulation of miRNA-192 
and miRNA-200 family members, which suppresses EMT (284, 289). These miRNAs 
have been found to inhibit transcriptional repressors of E-cadherin (ZEB1/2), which is 
considered to be an epithelial cell marker (as discussed above) (284, 289). p53 
knock-down in MCF12A cells resulted in a conversion of the epithelial phenotype to 
an EMT phenotype, which correlated with down-regulation of E-cadherin and 
up-regulation of mesenchymal cell markers, such as Vimentin or ZEB1 (284). These 
observations provide an insight into how p53 could be involved in inhibiting the 
invasive potential of tumours.
Upon acquiring the ability to detach from the primary tumour, the cancer cells 
must gain the ability to invade and migrate through the stroma. They achieve this by 
remodelling of the actin cytoskeleton and changing their morphology. In order to be 
able to migrate, a cell needs to become polarized before forming actin-containing
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protrusions for recognition and binding to the ECM. Invasive cancer cells may 
generate cell protrusions called invadopodia, which trigger degradation of the 
surrounding ECM (290). Functionally similar structures formed by macrophages and 
oncogene-transformed fibroblasts are known as podosomes (291). p53 has recently 
been reported to suppress invadopodia formation through transcriptional activation of 
Caldesmon expression (292). Caldesmon is an actin-binding protein shown to inhibit 
the formation of podosome/invadopodium structures (293). Moreover, p53 has been 
shown to regulate a number of microRNAs (miRNAs), including miRNA-143 and 
miRNA-145 (co-expressed from a single promoter), which inhibit podosome 
formation (294). Another piece of evidence linking p53 to the invasiveness of cancer 
cells is the fact that p53-null cells display altered morphology and increased migratory 
potential (295). A number of p53-regulated genes are implicated in cell shape and 
motility, including fibronectin (296), keratin, collagens and macrophage-stimulating 
protein (Msp) (164) as well as smooth muscle a-actin (297).
Interestingly, in addition to transcriptional regulation of cytoskeletal and ECM 
components, p53 has also been suggested to influence signalling pathways regulating 
cell migration. The most important signalling pathway controlling actin 
polymerization (reorganization) and adhesion involves the Rho family of small 
GTPases, which includes Cdc42, Rac and Rho (298).
Cdc42 controls cell polarity and triggers formation of fllopodia (microspikes) 
involved in sensing the extracellular* environment and providing spatial information to 
the cell to direct movement (298). In contrast to active invasion by cancer cells 
through promotion of ECM degradation, it has been shown using intravital imaging 
that invasive squamous cell carcinoma cells may also collectively follow tracks in the 
ECM created by other motile cells (such as fibroblasts), which is known as collective
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invasion (299). Such SCC cells retain epithelial markers (such as E-cadherin), are 
unable to remodel ECM and rely on mesenchymal cells (such as stromal fibroblasts) 
to promote tumour progression (299). This also emphasizes the great influence that 
the tumour microenviromnent might have on tumour invasion and metastasis. 
Importantly, the process of collective invasion in the fibroblast-following squamous 
carcinoma cells was found to depend on Cdc42 and its effector kinases MRCK and 
knock-down of either of the molecules inhibited the invasion of cancer cells in this 
system (299).
Another member of the Rho GTPase family, Rac, promotes formation of 
lamellipodia, large membrane protrusions at the leading edge of migrating cells, 
associated with elongated cell motility (300). Finally, Rho A and RhoC, acting through 
their effector Rho kinases (ROCKs), are responsible for regulating the formation of 
focal adhesions and actin stress fibres (301), generating a mode of motility resembling 
amoeboid movement (302). Rho GTPases are active in their GTP-bound state and are 
inactivated by GTP hydrolysis (303). Their activity is regulated by GEFs (guanine 
nucleotide exchange factors), which activate them, and GAPs (GTPase activating 
proteins), which turn them off (304). p53 has been suggested to modulate the activity 
of Rac by transactivation of the PTEN gene (305). The tumour suppressor PTEN is 
a lipid phosphatase, that dephosphorylates and down-regulates the levels of 
phosphatidylinositol 3,4,5-trisphosphate (PIP3) (306), which is an important 
messenger of cell growth signalling, activating the Akt survival pathway (307). PIP3 
is also necessary for GEF-mediated Rac and Cdc42 activation (308). Therefore, by 
inducing PTEN, p53 inhibits Rac activation and contributes to suppression of 
Rac-mediated invasiveness and metastatic potential of cancer cells (309). In addition 
to its role in the regulation of Rac activity, p53 has also been suggested to influence
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the processes mediated by the other members of the Rho GTPase family. p53 was 
found to prevent actin cytoskeleton reorganization and the initiating step of filopodia 
formation, cell spreading and polarization (310), induced by active Cdc42 and 
necessary for efficient migration.
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Figure 1.10: Functional connections between p53 and regulation of EMT and cell 
migration. p53 may oppose EMT by inhibiting Slug and transcriptional activation of 
miRNA-192/200, resulting in up-regulation of E-cadherin (an epithelial marker). p53 is also 
implicated in the inhibition of invasive migration. p53 may oppose: invadopodia formation 
through Caldesmon or miRNA-143/145 up-regulation; elongated migration through 
transactivation of PTEN; collective invasion through inhibition of Cdc42 and amoeboid 
migration through Notch 1 and RhoE induction. Figure adapted from reference (311).
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Finally, p53 loss was reported to be associated with increased RlroA (and 
consequently ROCK) activity and contributed to increased invasiveness (312). RlioA 
stimulates contractility, which favours rounded amoeboid movement (302). While this 
mode of motility is difficult to reconcile with the process of EMT in tumour 
progression, it has been shown that many cancer cells migrate in this way in vivo 
(313), especially during collective migration through fibroblast-created channels 
(299). p53 may suppress ROCK activation via transcriptional activation of Notchl, 
which down-modulates Rlio effectors (314). Moreover, RlioE, which interferes with 
RhoA activation, is a transcriptional target of p53 (315). RhoE is believed to achieve 
its inhibition of RhoA through suppression of a GEF for RhoA (Syx) activating RhoA 
(316) and activation of pi 90 RhoGAP, which inactivates RhoA (317).
All these observations provide evidence for the functional connections between 
p53 and cytoskeletal and ECM components as well as signalling pathways involved in 
controlling cell morphology and migration, and suggest mechanisms through which 
p53 loss could promote invasiveness and metastatic potential of cancer cells.
1.3.3. Regulation of the p53 pathway
Since p53 regulates such a large number of cellular* processes and is a potent inhibitor 
of cell growth, its activity has to be tightly regulated during development and normal 
growth (225). This is accomplished through a number of mechanisms including 
regulation of protein stability, subcellular localization and transcriptional activity of 
p53 (318). Under normal conditions p53, which has as short half-life (approximately 
20 min.), is kept at low, often undetectable levels (mostly due to the function of its 
negative regulator MDM2) (319, 320). In response to many types of cellular stress,
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p53 is stabilised and activated through post-translational modifications (summarised 
in Figure 1.12).
1.3.3.1. Regulation of p53protein stability
Two critical proteins involved in regulation of p53 are MDM2 (murine double minute 
2) and MDMX (321). The importance of the MDM2-p53 and MDMX-p53 interaction 
is best demonstrated by in vivo studies, in which lack of MDM2 or MDMX is lethal to 
mice at early embryonic stages even before implantation (322, 323). These 
phenotypes are rescued completely by accompanying deletion of p53, indicating that 
unrestrained p53 activity is lethal to mouse embryos (324) and that MDM2 and 
MDMX play non-redundant roles in regulating p53 activity (321).
MDM2 can inhibit the transcriptional activity of p53 and promote its degradation. 
MDM2 is a RING-finger E3 ubiquitin ligase targeting p53 for ubiquitylation and 
proteasomal degradation (325, 326). MDM2 binds to p53 and monoubiquitylates it at 
multiple lysine residues (327) and other proteins, such as p300/CBP, cooperate with 
MDM2 in the polyubiquitylation and degradation of p53 (328, 329).
The function of MDMX in regulating p53 stability is less clear. MDMX, 
a homologue of MDM2, lacks the robust E3 ubiquitin ligase activity but has been 
suggested to regulate p53 stability indirectly (discussed in more detail below) (330).
p53 and MDM2 form an auto-regulatory feedback loop (Figure 1.11) (331). p53 
stimulates the expression of MDM2 by binding the MDM2 P2 promoter (332). Since 
MDM2 inhibits p53 function, a negative feedback loop is created, which tightly 
regulates p53 activity (Figure 1.11). Low p53 activity, in turn, results in decreased 
steady state levels of MDM2. To ensure that MDM2 is not present in excessive
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amounts, it can also ubiquitylate and target itself for degradation (333), which titrates 
the levels of both p53 and MDM2.
However, the E3 ubiquitin ligase activity of MDM2 towards itself and p53 also has 
to be regulated to facilitate efficient degradation of p53 without concomitant depletion 
of MDM2 in unstressed cells. This may be achieved through regulation by MDMX, 
which might facilitate ubiquitylation of p53 through stabilisation of MDM2 and 
inhibition of MDM2 autoubiquitylation by modifying substrate preference of the 
MDM2 ubiquitin ligase activity (330). Another protein implicated in the regulation of 
the MDM2 E3 ligase activity is MTBP (MDM2-binding protein), which promotes 
ubiquitylation and degradation of p53 while reducing autoubiquitylation and hence 
stabilising MDM2 (334).
In normal cells the p53 levels are kept low and p53 becomes up-regulated and 
activated in stressed or damaged cells (134). This is an inbuilt defence mechanism 
against cancer since such cells are more likely to cany mutations or have abnormal 
cell cycle control and hence be dangerous to the organism.
In order to perform its tumour suppressor functions, p53 has to be stabilised and 
this involves inhibition of p53 degradation by MDM2. The p53 network can be 
activated by a number of independent mechanisms (Figure 1.11). One of the pathways 
to be considered here is triggered by DNA damage. The activation of the p53 network 
in response to double-strand DNA breaks (induced by ionising radiation or some 
chemotherapeutic drugs) depends on two protein kinases — ATM (ataxia telangiectasia 
mutated) and checkpoint kinase Chk2. Double-strand DNA breakes activate ATM 
kinase, which in turn activates Chk2 (335). They further stabilise p53 by 
phosphorylating it on serines 15 and 20, respectively (336, 337, 338, 339). These 
modifications interfere with MDM2 binding, thus preventing p53 ubiquitylation and
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degradation (340). UV-induced DNA damage (such as pyrimidine dimers) or hypoxia, 
on the other hand, result in the activation of ATR (ataxia telangiectasia related) 
kinase, which phosphorylates p53 at serines 15, 37 and 392 (341, 342) and Chkl, 
which can also phosphorylate p53 at serine 20 (343). These modifications alleviate the 
effects of p53 inhibition by MDM2 (344).
oncogenic
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apoptosis other targets
Figure 1.11: p53-MDM2 auto-regulatory feedback loop. MDM2 is a transcriptional target 
of p53. A rise in the level of p53 results in increased MDM2 production and enhanced 
degradation of both proteins. Therefore, in normal cells the levels of both p53 and MDM2 are 
kept low. A number of cellular stresses, such as DNA damage or oncogenic signalling, 
involve inhibition of p53 degradation by MDM2, leading to the stabilisation and activation of 
p53, which can then function as a transcriptional regulator to control the expression of its 
target genes.
Another pathway is induced by aberrant growth signals, which can be the result of 
the expression of oncogenes, such as Ras or Myc (134). This leads to pl4ARF 
expression, which binds to MDM2 and prevents MDM2-mediated inhibition of p53, 
(345). The exact mechanism, through which pl4ARF inhibits MDM2 is not entirely 
clear and may be tissue-specific. pl4ARF which is mostly a nucleolar protein, was
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suggested to relocalise MDM2 to the nucleolus (241, 346, 347). In addition, pl4ARF 
was also reported to block the ubiquitin ligase activity of MDM2 (345) and interfere 
with the nucleoplasm-cytoplasm shuttling ability of MDM2 (347). Consequently, 
pl4ARF-dependent inhibition of MDM2 results in p53 stabilisation and activation.
A summary of the processes and molecules involved in the regulation of p53 
stability and activity is presented in Figure 1.12.
1.3.3.2. Regulation ofp53 activity
In addition to modulation of p53 protein stability, transcriptional activity of p53 can 
also be regulated. MDM2 for instance, apart from promoting p53 degradation, binds 
to the N-terminal transcriptional activation domain of p53 and prevents binding of the 
components of the transcription machinery, hence suppressing the activity of p53 as 
a transcriptional regulator (348). Moreover, MDM2 has also been suggested to inhibit 
p53 acetylation (see below), thus preventing its activation (349). Similarly, MDMX 
was also reported to inhibit p53 activity (350) in a manner independent of MDM2, 
since MDM2 cannot compensate for MDMX loss in vivo (351). While the 
mechanistic details of the MDMX-mediated regulation of p53 activity still remain 
unclear, it has been suggested that MDMX (similarly to MDM2) may inhibit the 
acetylation of p53 by p300/CBP (see below), thus preventing its activation (352).
On the other hand, a number of post-translational modifications of p53, such as the 
addition or removal of acetyl, phosphoryl or ribosyl chemical groups as well as 
ubiquitin or ‘SUMO’ modification, which result in a conformational change of the 
protein, have been suggested to enhance the sequence-specific DNA binding and 
transcriptional activities of p53 in response to stress (353). In the unmodified protein 
the C-terminus usually folds back inhibiting the DNA binding domain situated in the 
central core of p53. It has been suggested that acetylation or phosphorylation of p53
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near the C-terminus can interfere with this folding, hence enhancing the DNA binding 
capacity of p53 (354). Therefore, the C-terminus has been shown to allosterically 
regulate the conversion of p53 between the latent and active forms (355).
For example, casein kinase II, responsible for phosphorylating p53 at serine 389 
(356), activates sequence-specific DNA binding (357) and transcriptional activity of 
p53 (358). Histone acetyltransferases, including p300/CBP and PCAF, by acetylating 
lysines in the C-terminal domain of p53 (359) also stimulate the classical 
conformational change of p53 (seen also after other post-translational modifications 
of the C-terminus), thus enhancing its DNA binding capacity. Interestingly, 
p300/CBP are also involved in destabilisation of p53 by cooperating with MDM2 in 
its polyubiquitylation (see section 1.3.3.1). These seemingly contradictory functions 
were reported to be achieved through compartmentalisation of p300/CBP (328), with 
cytoplasmic ubiquitylation and nuclear acetylation of p53. However, the fact that 
MDM2-mediated degradation can occur both in the nucleus and in the cytoplasm 
(360) suggests that other factors (such as other interacting partners) may also be 
important in regulating the p300/CBP activity towards p53.
The efficiency of p53 acetylation by p300/CBP can also be modulated by other 
proteins. PML for instance, mentioned previously in the context of senescence (see 
section 1.3.2.4), has been reported to recruit p53 to a subset of PML nuclear bodies 
and to facilitate p300/CBP-mediated acetylation (243) and Chk-2-mediated 
phosphorylation of p53 (361) hence leading to its activation. In addition, pl4ARF, 
described previously to sequester MDM2 hence protecting p53 from degradation (see 
section 1.3.3.1), can also contribute to p53 activation by regulating its acetylation (as 
MDM2 can no longer inhibit p53 acetylation) (349).
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Figure 1.12: A summary of p53 stabilisation, activation and regulation of downstream 
target genes (adapted from reference (157)). 1) Cells are subjected to one of a number of 
cellular stresses. 2) Signal mediator proteins are up-regulated/activated and stabilise p53 by 
inhibiting its interaction with MDM2 - either through direct suppression of MDM2 or 
through p53 phosphorylation. 3) Ubiquitylation and degradation of p53 is inhibited and p53 
levels rise. 4) Additional proteins can also modify p53 (by acetylation or methylation), 
leading to further stabilization and enhanced sequence-specific DNA binding of p53. 5) DNA 
binding can also be hindered by proteins removing those modifications (like HDAC). 6) An 
active p53 tetramer binds to a p53 response element (RE) and 7) recruits cofactors (including 
TAFs) to regulate transcription of the nearby gene. 8) p53 activates transcription (as shown 
here) or represses expression of its target gene. 9) p53 up-regulates a number of transducer 
proteins, 10) which are involved in numerous pathways important in tumour suppression, 
including DNA repair, cell-cycle arrest, apoptosis, senescence and many others.
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p53 deacetylation, on the other hand, either through inhibition of histone 
acetyltransferases by MDM2 (362) or direct interaction of p53 with the histone 
deacetylase 1 (HDACl)-containing complex (363), inhibits p53 transcriptional 
activity.
p53 acts as a transcription factor and this role is crucial for its tumour suppressor 
functions. In cancer the DNA binding and transcriptional activity of p53 is frequently 
compromised due to missense mutations, which distort the folding of the core domain. 
It has been observed that conformational changes caused by posttranslational 
modifications can also be induced with the help of short peptides, antibodies or drugs 
interacting with the C-terminus of p53 (364), which might be a way of reactivating 
mutant p53 and restoring its normal function.
1.3.3,3. Regulation of subcellular localization ofp53
The transcriptional activity of p53 relies on its nuclear localization (365). Since p53 is 
a potent inhibitor of cell growth, the activity and hence nuclear import and export of 
p53 have to be tightly regulated.
The nuclear import of p53 is enabled by the three nuclear localization signals 
(NLSs) within the C-terminal domain of p53 (Figure 1.7), which target it for transport 
into the nuclear compartment and allow efficient nuclear import (366). In order to be 
transported into the nucleus by the import machinery, p53 has to be present in the 
vicinity of the nucleus. It has been reported that p53 is actively transported through 
the cytoplasm towards the nucleus along the microtubule network by dynein, 
a minus-end-directed microtubule-associated motor protein (367).
p53 also possesses a nuclear export signal (NES), located in the tetramerization 
domain (Figure 1.7) (368). Following nuclear import, p53 undergoes tetramerization
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and can perform its functions as a transcription factor (155). It has been proposed that 
p53 tetramerization conceals its NES, hence contributing to the nuclear retention of 
the fully functional protein (368). Ubiquitylation of p53 by MDM2, on the other hand, 
could expose the NES by affecting p53 tetramerization (369), resulting in export of 
p53 into the cytoplasm for ubiquitin-mediated proteolysis by the proteasome 
(Figure 1.13). While the NES of p53 was shown to be both necessary and sufficient 
for nuclear export (368), more recent studies have suggested that the ubiquitylation of 
p53 within its C-terminal domain by MDM2 is critical for nuclear export of p53 
(370,371).
In a number of tumour types harbouring wild-type p53, including some 
neuroblastomas and breast cancers, loss of p53 function is suggested to be due to 
cytoplasmic sequestration of the protein (372, 373). The mechanisms involved in the 
cytoplasmic accumulation of p53 are far from clear. It has been suggested that 
wild-type p53 might be shuttled into the cytoplasm due to hyperactive nuclear export 
(374). It has also been reported that wild-type p53 might accumulate in the cytoplasm 
due to the cytoplasmic anchorage mediated by interaction of p53 with parkin-like 
ubiquitin ligase (PARC) or with the glucocorticoid receptor (GR) (375). Treatment of 
neuroblastoma cells with GR inhibitors resulted in the dissociation of the p53-GR 
complex, redistribution of both proteins into the nucleus and restoration of p53 
functions (375). Therefore, the use of drugs disrupting the GR-p53 interaction might 
have a significant therapeutic potential in certain types of cancer displaying 
cytoplasmic p53 sequestration.
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Figure 1.13: Intracellular transport of p53. p53 associates with microtubules and is 
actively transported towards the nucleus with the help of a motor protein, dynein. Import 
receptors located in the nuclear envelope recognise the NLS of p53. Export of p53 into the 
cytoplasm occurs most likely upon p53 ubiquitylation by MDM2, which reveals the NES of 
p53. Figure reproduced from reference (365).
1.3.4. Loss of p53 function in cancer
The most common alteration found in human cancers is inactivation of the p53 
tumour suppressor pathway, which can happen via a number of mechanisms, 
including altered subcellular localization of the p53 protein, defects preventing p53 
activation, mutations or deletions of the TP53 gene itself or lesions in the signalling 
pathways downstream of p53 (376).
Loss of p53 function increases cancer risk. Li-Fraumeni syndrome patients, 
carrying germline p53 mutations, have increased susceptibility to various types of 
cancer (166) and p53-null mice are highly tumour-prone (264). Somatic TP53
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mutations are found in ~50% of human cancers (107). The vast majority of p53 
alterations are missense mutations resulting in the production of a full-length protein 
with single amino acid substitutions, which accumulates in the nucleus of cancer cell 
(377). Theoretically, based on the frequency of STOP codons in the codon table (3 out 
of 64), missense mutations are more likely to occur' than nonsense mutations. This 
hypothesis is confirmed by a large-scale mutational analysis of genomes of colorectal 
and breast cancers (sequencing of 13,000 genes in a total of 22 tumours, without 
a preference for oncogenes or tumour' suppressors) (378). The overall frequency of 
missense mutations was 81%, while nonsense, splice mutations and 
deletions/insertions (fi’ame-shift mutations) comprised 7%, 4% and 8% of all 
mutations, respectively (378). This spectrum is strikingly similar’ to the mutational 
spectrum of p53 in human cancer with missense mutations representing 74%, 
nonsense mutations 8% and frame-shift mutations 9% of all p53 mutations (139). This 
also suggests that the mutational spectrum of p53 reflects a general mutagenesis 
mechanism.
In contrast, the mutational spectra of other tumour' suppressors like Rb or APC are 
significantly different and comprise primarily deletions, nonsense or frameshift 
mutations (Figure 1.14), resulting in the production of a truncated protein or no 
protein expression at all (107). This suggests that loss of protein expression is the 
most efficient mechanism to inactivate the functions of these tumour' suppressors in 
a developing tumour. However, most of the tumour' suppressor genes are believed to 
be recessive and inactivation of one allele is not sufficient for tumour development. 
According to Knudson’s two-hit hypothesis both functional copies of a tumour' 
suppressor gene need to be lost to initiate a cancer (379). This loss of the second 
allele, known as the loss of heterozygosity (LOH), may occur through deletion of part
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or the entire chromosome carrying the tumour suppressor gene, gene conversion, 
mitotic recombination or a second inactivating mutation (110).
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Figure 1.14: Mutation types in tumour suppressor genes (data adapted from reference 
(380)). While the predominant mutation types in many other tumour suppressor genes are 
nonsense or frameshift, the majority of p53 mutations are missense. This suggests that there is 
a selective advantage of the mutant p53 protein over the truncation.
The fact that mutation in only one copy of p53 results in tumour development (as 
demonstrated by mice heterozygous for mutant p53 (6)) suggests that the p53 tumour 
suppressor gene does not strictly follow the Knudsoms model (see section 1.3.4.1). 
The majority of tumour-derived p53 mutations (more than 95%) cluster in the central 
DNA binding domain of the protein (see section 1.3.4.2) and most of them result in 
the loss of wild-type p53 transcriptional activity (381), suggesting that it is the loss of 
p53 function that leads to cancer development. Moreover, the fact that missense 
mutations are significantly more common than nonsense mutations suggests that there 
is a selective advantage of the mutant protein over the truncation. This apparent 
selection bias might be explained by the fact that p53 functions as a tetramer. The 
presence of nonsense mutation in one of TP53 alleles would potentially result in no 
protein expression or expression of a truncated protein, most likely lacking the
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C-terminal tetramerization domain. However, wild-type p53 expressed from the 
second allele could retain its transcriptional activity and suppress tumour formation. 
On the other hand, DNA binding domain missense p53 mutants, lacking wild-type 
p53 transcriptional activity, might oligomerize with the remaining wild-type p53 and 
abrogate its function (as discussed below in section 1.3.4.1).
L3.4.1. Dominant negativity of p53 mutants
Due to the fact that p53 functions as a tetramer, hetero-oligomerisation between 
mutant and wild-type forms of p53 may have a dominant-negative effect, which 
neutralises the wild-type protein (382). Specifically, p53 mutants were reported to 
inhibit the sequence-specific DNA binding of wild-type p53 and transactivation of its 
target genes (383), explaining why such mutations could be preferentially selected in 
a developing tumour. Indeed, mice heterozygous for a dominant-negative p53 mutant 
develop tumours (382) indicating that the inhibition of the wild-type p53 by the 
mutant might give some selective advantage in tumour progression.
Since this hetero-oligomerisation underlies the mutant p53 transdominant 
suppression, it is not surprising that the DBD mutants have the tetramerization 
domain fully functional (384). It has also been suggested that in these complexes 
mutant p53 is capable of shifting the wild-type p53 into a mutant conformation (385).
However, frequent loss of heterozygosity (LOH) in cancers harbouring TP53 
mutations (eliminating the wild-type allele) (386) suggests that the dominant-negative 
effects of the mutants might not lead to complete loss of p53 function. In this respect 
p53 also partly complies with the Knudson’s two-hit model of tumorigenesis (see 
section 1.3.4).
66
Introduction
1.3.4.2. Types of p53 mutations
Some TP53 codons have a high frequency of mutation, with more than 40% of all 
mutations found at only six p53 residues - 175, 245, 248, 249, 273 and 282 (139), the 
so-called mutational hot-spots (Figure 1.15). These residues are located in the 
conserved regions within the DNA-binding domain of p53 and are critical for the 
structural integrity and sequence-specific DNA binding of the protein (147).
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Figure 1.15: Mutational hot-spots in the p53 tumour suppressor gene (data adapted from 
reference (139)). The majority of p53 mutations are found in the DNA binding domain of the 
protein with six mutational hot-spots at residues 175, 245, 248, 249, 273 and 282.
It is now commonly recognised that different DBD mutants of p53 display varying 
oncogenic potency (387). Determination of the crystal structure of the core domain of 
p53 revealed that p53 mutations can be divided into two main classes: contact and 
structural (147).
The contact mutations affect residues that make direct contact with DNA. Hence, 
they occur on the L3 loop or the nearby loop-sheet-helix (LI loop-S2-S2’ sheet-H2 
helix) motif of p53 (Figure 1.16) (147). The two most common contact mutations are 
found at residues R248 and R273, with frequencies of 8% and 7.5%, respectively 
(139).
The structural mutations, on the other hand, disrupt the folding of the p53 protein. 
They occur at residues R175 (5.5%), G245 (3.5%), R249 (3%) and R282 (3%) (139).
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The R175 residue is located on the L2 loop near the Zn2+ binding site (Figure 1.16), 
which is buried away from the surface of the protein (147). The R249 residue is 
located on the L3 loop and makes multiple contacts via van der Waals forces, 
hydrogen bonds and salt bridges with the surrounding residues on the L2 and L3 loops 
(147). The residue R282 located on the H2 helix is crucial for maintaining the 
structure of the loop-sheet-helix motif as it is involved in the packing of the H2 helix 
against the S2-S2’ hairpin and the LI loop (147). It is important to note that all these 
three mutations occur at arginine residues. These residues are structurally important 
because arginines fully utilize the potential of their guanidinium groups to form 
hydrogen bonds with the carbonyl groups of the polypeptide backbone and hence are 
critical for stabilizing the structure of the DNA binding core domain. Finally, the 
G245 residue located on the L3 loop is the only non-arginine residue being 
a mutational hot-spot (147). This residue appeal's to be critical because of its small 
size, which allows the L3 loop to adopt a conformation not favoured by residues with 
a side chain (147). Moreover, due to the tight packing, any residue with a side chain 
would lead to the disruption of the L2 loop, which is located in close proximity to 
G245 (147). Therefore, mutations at any of the above mentioned residues disrupt the 
stable folding of the core domain of p53 and such mutants are generally unfolded. 
This is supported by several lines of evidence. First of all, the structural mutants 
associate with the heat shock protein HSC70 (388), suggesting that they are denatured 
or misfolded. Secondly, they are recognised by the PAb240 monoclonal antibody, 
which is specific for unfolded p53, but not the PAbl620 antibody specific for the 
native p53 conformation (389). Finally, the structural mutants, unlike wild-type p53, 
are highly sensitive to proteases, suggesting that their core domains are unfolded and 
exposed (146).
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Figure 1.16: Structure of the core domain of p53 (reproduced from reference (147)).
A. Schematic representation of the core domain-DNA complex. The p-strands (S), a-helices 
(H), loops (L) and the zinc atom (Zn) are shown. The conserved regions are shown in yellow, 
blue, red and fuchsia. The loop L3 and the loop-sheet-helix (consisting of loop LI, P-sheet 
comprising the S2-S2’ hairpin and the terminus of P-strand S10, and a-helix H2) are 
responsible for contacting DNA in the minor and major groove, respectively.
B. Ribbon representation of the core domain-DNA complex showing the six most frequently 
mutated residues of p53 (yellow). The core domain is coloured green, the DNA - blue and the 
zinc atom is depicted as a red sphere.
C. Topological diagram of the secondary structures of the core domain. The residue numbers 
at the beginning and end of each structure are shown. The conserved regions are coloured as 
in A. The shaded areas correspond to the two P-sheets that make up the P-sandwich.
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In contrast, contact mutants of p53 display none of the above properties. They do 
not bind HSC70 (388), they yield a stable core domain (similarly to wild-type p53) 
upon proteolytic cleavage (146) and are usually recognised by the native 
conformation specific antibody PAbl620 (389).
In spite of these differences, both the structural and contact mutations of p53 result 
in the loss of sequence-specific DNA binding of this protein (390, 391). However, 
they have been suggested to have different oncogenic potency with the structural 
mutations being more tumorigenic (387). It can be speculated that this is due to the 
fact that structural mutants can shift the remaining wild-type p53 into a mutant 
conformation upon hetero-oligomerisation (392), resulting in complete loss of p53 
function while the contact mutants might retain native conformation and therefore 
when incorporated into tetramers with wild-type p53, they may retain some residual 
wild-type activity (393). It might therefore be expected that in a developing tumour 
the structural mutations would be preferentially selected compared to the contact 
mutations. Clearly, this is not the case as residues R273 and R248 are the two most 
common mutational hot-spots of p53 (139). This seemingly unexpected observation 
can probably be explained by the fact that in carcinogenesis, which is a multistep 
process, the lower oncogenicity of the contact mutants will result in a number of 
subsequent tumorigenic steps. For example, it was reported that In SCCHN 
expression of the contact p53 mutants (in 13 patients) was associated with 
100% LOH, while expression of the structural mutants (in 24 patients) was associated 
with LOH in only 50% of cases (p = 0.0034) (394). This finding is in line with the 
structural mutants exerting a stronger dominant-negative effect on wild-type p53 
(392), hence decreasing the selective pressure for losing the wild-type allele. 
Nevertheless, SCCHN carrying the contact mutations were associated with higher
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tumour stages, increase in lymph node metastasis and shorter recurrence-free and 
overall survival, than tumours expressing the structural mutations (394), This suggests 
that dominant-negative inhibition of the wild-type allele by the mutant is not complete 
and LOH remains an important event during tumorigenesis. This conclusion is 
consistent with studies of mouse models of Li-Fraumeni syndrome, where mice 
hemizygous for the mutant p53 allele (p53R270H/" or p53R172H/’) had a much shorter 
overall survival (8 vs. 24 months) than mutant p53-heterozygous mice (p53R270H/+ or 
p53R172H/+) (6). Note that the structural R172H mutation in mice corresponds to the 
R175H mutation in human p53, while the contact R270H mutation in mice is 
equivalent to the R273H mutation in humans.
1.3.4.3. Oncogenic gain of function of mutant p53
Apart from the dominant-negative effects on the wild-type protein, some p53 mutants 
have been suggested to acquire oncogenic properties contributing to accelerated cell 
growth and tumorigenic potential (395). The fact that the majority of p53 mutations 
are missense indicates that there is a selective advantage of a mutated protein over the 
truncation in cancer cells. The first idea that mutant p53 might not be just an 
inactivated tumour suppressor came from a study showing that point mutations in 
wild-type TP53 activate it for cellular transformation in cooperation with the RAS 
oncogene (320). The term ‘oncogenic gain of function’ (GOF) of p53 mutants was 
first suggested in 1990 when different mutant forms of p53 were reported to gain 
transforming potential (396). Moreover, p53 mutants were also suggested to enhance 
metastatic potential and tissue invasiveness (397), hinder differentiation (398) and 
induce gene amplification (399). However, convincing evidence for the gain of 
function of mutant p53 was only provided by more recent studies of two mouse
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models of Li-Fraumeni syndrome (5, 6). These studies focused on two p53 mutants 
containing mis sense mutations, which result in single amino acid (arginine to 
histidine) substitutions at positions 172 and 270. These mutations in the murine Tp53 
correspond to R175H and R273H mutations in the human gene, respectively. These 
mutants represent two mutational classes: the R175H mutation is a structural mutation 
causing a significant conformational shift of p53, while the R273H mutation belongs 
to the class of contact mutations affecting the p53 residues that make direct contact 
with DNA (discussed in detail in section 1.3.4.2) and leading to a loss of p53-specific 
DNA binding (147). Although the two p53 mutations did not affect overall survival 
(Figure 1.17A), mice heterozygous for the mutant p53 (p53M/+) developed different 
tumour spectra than mice hemizygous for wild-type p53 (p53+/"). Moreover, mice 
hemizygous for the mutant p53 allele (p53M/‘) developed novel tumours compared to 
p53-null (p53_/") mice suggesting that these two p53 mutants play a role in stimulating 
tumorigenesis (Figure 1.17B).
In human cancer, mutations in the conserved regions of p53 have been associated 
with high tumour grade, worse prognosis (400) and tumour resistance to treatment 
(401, 402). Various p53 mutants have been suggested to confer resistance to apoptosis 
in response to a number of agents used in cancer therapy including etoposide and 
cisplatin (393), 5-fluorouracil (403), UV and ionising radiation (404). Moreover, the 
strength of these effects has been found to vary between different p53 mutants (393).
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Figure 1.17: Overall survival and tumour spectra of mice carrying one mutant p53 allele
(reproduced from reference (6)).
A. Kaplan-Meyer plot demonstrating similar overall survival of p53 p53R270H' and p53RI7'H'
mice.
B. Histograms representing the spectrum of tumours developed by p53 ' (blue), p53R~ 0H" 
(red) and p53RI72H' (green) mice.
Note: The R270H and R172H mutations in murine Tp53 correspond to R273H and R175H 
mutations in the human gene, respectively.
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1.3.4.3.1. Mechanisms of mutant p53 gain offunction
The mechanism of action of the GOF mutants is not well understood but it has been 
suggested that the mutant proteins may exert their oncogenic effects via inhibition of 
other members of the p53 family, transactivation of a distinct set of target genes 
(involved in cellular proliferation, cell survival or angiogenesis) or participation in 
novel protein-protein interactions (405).
1.3.4.3.1.1. Dominant-negative effects on other p53 family members
Unlike wild-type p53, many GOF mutants have been reported to bind to and inhibit 
function of other members of the p53 family - p73 and/or p63 (406), which share 
some functions with p53. For p73 and mutant p53, interaction occurs between the 
DNA binding domains of the two proteins (407), and not through the tetramerization 
domains (408) as in the case of wild-type and mutant p53, hence preventing 
transactivation and p53-independent apoptosis induced by p73 in response to DNA 
damage (409). Recently, increased chemoresistance of tumour's overexpressing some 
of the GOF mutants has been mechanistically linked to hetero-oligomerisation 
between mutant p53 and p73 (410).
The binding affinity of different p53 mutants for p73 varies and is also influenced 
by the status of the p53 polymorphism at amino acid 72 (411). An arginine at position 
72 has been correlated with a stronger interaction between mutant p53 and p73 as well 
as stronger inhibition of p73-mediated apoptosis (412). It has been further shown that 
p53-72R mutants are capable of inhibiting chemotherapy-induced apoptosis more 
efficiently than p53-72P mutants and in a group of SCCHN patients those with 
tumour-specific expression of the 72R allele had both a decreased response to 
cisplatin chemotherapy and an overall worse survival than those with p53-72P
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expression (413). Consequently, it can be concluded that tumour chemosensitivity is 
influenced by the type of p53 mutation and its efficiency of binding p73 as well as the 
status of the p53 polymorphism at position 72.
1.3.4.3.1.2. Transactivation-dependent mechanism
p53 mutants may function as oncogenic transcription factors. The genomic sequences 
bound by mutant p53 are notoriously heterogeneous and so far there has been no 
success in establishing a linear consensus sequence for mutant p53 binding sites. The 
mutant proteins associate with DNA either due to their intrinsic DNA binding ability 
(direct binding) or by interacting with other DNA binding proteins (passive binding) 
to activate transcription of genes that do not contain the canonical p53 DNA binding 
sites (414).
The remarkable heterogeneity of the mutant p53 response elements may be partly 
due to passive binding of p53 mutants to DNA. In such cases the specificity of mutant 
p53 association with certain DNA sequences may be dependent on the DNA binding 
specificity of mutant p53 interacting partners. In support of this notion, mutant p53 
was found to associate with a number of sequence-specific transcription factors, 
including Spl (415), Ets-1 (416) and NF-Y (417). Interestingly, such tethering to 
non-mutant p53 specific binding sites is not unique to p53 mutants. Interactions 
between wild-type p53 and other sequence-specific DNA binding proteins play an 
important role in p53-mediated transcriptional repression. By interacting with other 
transcription factors wild-type p53 can inhibit their DNA binding and transcriptional 
activity. Importantly, the association of wild-type and mutant p53 with non-canonical 
binding sites can have functionally opposite outcomes (418). For example, association 
of wild-type p53 with Ets-1 results in transcriptional repression of Ets-1-regulated
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genes (419) while p53 mutants were found to cooperate with Ets-1 to enhance the 
transcription of cancer-related genes (416). One of the genes regulated in this manner 
is MDR1 (multi-drug resistance-1 gene) (418), encoding an ATP-dependent efflux 
pump responsible for pumping various hydrophobic cytotoxic drugs out of the cell. 
MDR1 plays an important role in the response of tumour's to chemotherapeutic agents, 
such as taxanes. Analogously to Ets-1, transcriptional activation by NF-Y is repressed 
by wild-type p53 but augmented by p53 mutants (417). The presence of mutant 
p53/NF-Y complexes results in increased DNA synthesis and up-regulation of cyclin 
A, cyclin Bl, cyclin B2, CDK1 and CDC25 expression (all of which are involved in 
cell cycle control) in response to DNA damage (417).
The inverse effects of wild-type and mutant p53 interactions with other 
transcription factors with respect to transcriptional regulation of target genes may 
stem from the different chromatin modifying activities recruited by wild-type and 
mutant p53 proteins to the regulated gene promoters. Mutant p53 was found to recruit 
p300 to NF-Y target promoters (417), resulting in histone acetylation and hence 
increased accessibility of chromatin to transcription machinery. Interestingly, 
differences between gene regulation by mutant and wild-type p53 become apparent 
only under stress conditions, suggesting that association of p53 proteins with DNA is 
a prerequisite rather than an initiating event for control of NF-Y-mediated 
transcription.
Remarkably, the interaction between mutant p53 and DNA binding proteins, 
including Spl, Ets-1 and NF-Y, is dependent on the presence of an intact C-terminal 
domain of p53, where the binding sites for these proteins are located (420).
Other genes transactivated by p53 mutants include: BAG-1 (421), PCNA 
(proliferating cell nuclear antigen) (422), c-MYC (423), IL-6 (424), HSP70 (heat
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shock protein 70) (425), EGFR (426), IGF-II (insulin-like growth factor receptor II) 
(427), EGR1 (428) and dUTPase (403).
It is believed that mutant p53 requires an intact N-terminal acidic transactivation 
domain to exert its gain of function (429). While the tumour-derived GOF p53-281G 
mutant acts as a transcriptional activator of MDR1 and c~MYC and enhances the 
tumorigenic potential of cells, additional mutations at residues 22 and 23, which 
prevent interaction with TAF and C-terminal modifications, completely abolish these 
functions (429).
Independently of binding to other factors, p53 mutants exhibit DNA 
structure-selective binding, associating with divergent sequences of DNA, containing 
numerous repetitive DNA elements and capable of adopting a non-B-DNA 
conformation (430). Among such sequences mutant but not wild-type p53 was found 
to bind with high affinity to the MAR/SAR (nuclear matrix/scaffold attachment 
region) DNA elements (431), which are important in a number of nuclear processes, 
such as maintaining genomic organisation and controlling transcription and DNA 
replication. It is suggested that association of p53 mutants with MAR/SAR elements 
may interfere with these processes, resulting in multiple oncogenic effects (431). 
Moreover, p53 mutants were found to interact with the trinucleotide CTG*CAG 
repeats, which act as nucleosome positioning elements (432) and promote the 
maintenance of an inactive state of chromatin (heterochromatin) (433). Therefore, 
mutant p53 binding to such CTG*CAG tracts was suggested to play a role in 
formation and maintenance of a repressive state of chromatin (414).
All of this evidence suggests that mutant p53 may be a key molecule in the 
oncogenic signalling pathways. Its ability to interact with DNA and coordinate 
chromatin remodelling and gene transcription is remarkable and indicates that altering
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the transcriptome of cancer cells may be one way through which mutant p53 proteins 
exert their gain-of-function properties.
1.3.4.3.1.3. Novel protein-protein interactions
Last but not least, the GOF p53 mutants have been suggested to have 
transcription-independent functions and act through novel protein-protein interactions. 
Specific binding to mutant but not wild-type p53 might be due to the differences in 
structure and conformation between the two proteins. For example, p42 and p38 
MAPKs have been found to interact with mutant p53 rather than the wild-type in 
a cell cycle specific manner, with increased interactions during S phase, suggesting 
a cell growth promoting role of these proteins (434). More recently, MBP1 (Mutant 
p53-Binding Protein 1) has been identified as a mutant p53-175H interacting protein 
(435). Since overexpression of MBP1 accelerates malignant transformation and has 
tumour cell growth enhancing properties, it has been suggested to be an oncogene 
(435). Therefore, interaction of mutant p53 with MBP1 could serve as an example of 
cooperation of two oncogenes.
The GOF properties of mutant p53 can also be mediated by its prolonged half-life 
(405). Both the wild-type and mutant proteins interact with MDM2. However, mutant 
p53 seems to accumulate in cancer cells and remain stable (436). Since p53 mutants 
have been shown to associate with MDM2 and to be inherently unstable (437, 438), 
there must be additional mechanisms that stabilize the mutant protein. The most 
plausible mechanism for the absence of the MDM2-p53 negative-feedback loop is 
one, in which p53 mutants fail to transactivate the MDM2 promoter. This leads to 
insufficient MDM2 levels for efficient targeting of p53 for degradation (437). 
Interestingly though, mutant p53 also stabilises MDM2, which normally has a very
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short half-life (5-15 min) (439). Therefore, an alternative theory suggests that mutant 
p53 could be protected from MDM2-mediated degradation by associating with heat 
shock proteins (440), including HSP90 (441). Mutant p53 enables HSP90 to bind to 
MDM2, hence blocking the ARF binding site (442). Since MDM2 can stimulate 
hyperproliferation and aneuploidy in p53-null mice (443), MDM2 stabilisation 
provides yet another mechanism how mutant p53 can contribute to tumorigenesis.
1.3.4.3.2. Biological manifestations of mutant p53 gain of function 
GOF mutations in p53 are frequently associated with poor prognosis (444) and 
tumour resistance to treatment (401, 402). These could result from the acquired 
capabilities of mutant p53 such as enhancement of cell proliferation, promotion of 
genetic instability, migration and invasion, and interference with apoptosis. In order to 
tailor specific therapies for individual cancer patients it is important to understand the 
biological mechanisms employed by mutant p53 to achieve its oncogenic potential.
1,3.4.3,2,1, GOF p53 mutants promote genomic instability
Genomic instability is one of the key characteristics driving tumour progression. 
Mutant p53 can enhance genetic instability by affecting overall chromosome number 
and structure, and by influencing DNA repair and thus affecting mutation rates.
Abnormal centrosome numbers were observed with high frequency in tumour cells 
from mice expressing the p53-175H GOF mutant as opposed to p53-null mice (445) 
although another study showed that p53-null cells in vitro also exhibit centrosomal 
abnormalities (262), suggesting that this effect could be a result of mere loss of 
function by mutant p53. Because centrosomes are duplicated once per cell cycle, an
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increased number of centrosomes would result in unequal segregation of 
chromosomes between the daughter cells.
Moreover, GOF p53 mutants have been reported to disrupt spindle checkpoint 
control, resulting in S-phase re-entry (instead of arrest) of cells with a 4n DNA 
content in the presence of spindle depolymerising agents and generation of polyploid 
cells (446). This activity was also found to be independent of the N-terminal domain 
of p53, as expression of mutant p53 with additional mutations at residues 22 and 23 
resulted in similar degrees of polyploidy (446). This suggests that GOF p53 mutants 
promote aneuploidy via a transcription-independent mechanism. As discussed 
previously, GOF p53 mutants inhibit the activity of the other p53 family members, 
p63 and p73 (406). In the absence of p53, p73 can suppress aneuploidy and 
polyploidy (447). Therefore, inhibition of p73 by p53 mutants could provide 
a potential mechanism, through which mutant p53 might promote genomic instability.
1,3.4,3.2.2. GOF of p53 mutants through inhibition of apoptosis 
In addition to genomic instability, many GOF p53 mutants have been shown to confer 
resistance to various pro-apoptotic signals in cancer cells, hence contributing to 
tumour’ promotion and tumour resistance to treatment.
First of all, it was observed that p53 mutants are able to suppress apoptosis induced 
by oncogenic signalling, such as deregulated c-Myc expression (448), which is 
a frequent event in many cancer cells. c-Myc expression results in the induction of 
p5 3-mediated apoptosis through pl4ARF up-regulation and inhibition of 
MDM2-mediated degradation of p53 (345) and the resistance to c-Myc-induced 
apoptosis may be a result of neutralising wild-type p53 activity by the GOF p53 
mutants. In this way, cancer cells can fully benefit from the pro-proliferative potency
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of c-Myc, without the danger of undergoing c-Myc-mediated apoptosis. Mutant p53 
has also been suggested to protect cells from undergoing apoptosis in response to 
growth factor deprivation (449). Growth factor deprivation down-regulates c-Myc 
expression but may also up-regulate pl4ARF, triggering the same p5 3-dependent 
apoptotic pathway (450). Moreover, p53 mutants have also been implicated in 
suppression of p53-independent apoptosis, which might be a result of inhibition of 
p73 functions by GOF p53 mutants (as described in section 1.3.4.3.1.1).
Importantly, many GOF p53 mutants are associated with increased resistance of 
tumours to various anti-cancer treatments, including y-irradiation, doxorubicin, 
cisplatin (451), etoposide (393), 5-FU (403), UV and methotrexate (404). Moreover, 
knock-down of endogenous mutant p53 expression was observed to sensitise cancer 
cells to apoptosis induced by such agents and other pro-apoptotic signals (452), 
providing further links between apoptosis resistance and mutant p53.
Mechanistically, there are a number of ways to explain the increased resistance of 
tumours to anti-cancer treatment. As mentioned previously, p53 mutants are known to 
inhibit p73 function (see section 1.3.4.3.1.1), which is responsible for induction of 
p53-independent apoptosis in response to DNA damage (409). Hence, it is 
conceivable that p73 inhibition by mutant p53 could render cells expressing GOF p53 
mutants resistant to many types of anti-cancer treatments (410).
Another possible mechanism of increased resistance to apoptosis could be the 
transcriptional activation of expression of EGR1 by mutant p53 (428). EGR1 (early 
growth response 1) is a transcription factor implicated in regulating proliferation, 
apoptosis and angiogenesis (453). Its induction by mutant p53 enhances transforming 
properties and has an anti-apoptotic effect on cancer cells (428). It was further shown 
that this apoptosis resistance may be also due to down-regulation of procaspase-3,
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a key component of the apoptotic caspase cascade (see Figure 1.9), by some p53 
mutants (452).
All this evidence suggests that mutant p53 might promote resistance to apoptosis 
via a number of mechanisms, which may vary depending on the cellular context. By 
doing so it may not only promote tumour progression but also enhance tumour 
resistance to anti-cancer therapy.
1.3.4.3.2.3. The role of GOF p53 mutants in cell migration, invasion and metastasis 
Although p53 mutations are known to occur at many different stages of 
tumorigenesis, in some cancers they are significantly more frequent at later stages and 
are associated with advanced, metastatic tumours (9). As discussed previously tumour 
progression is associated with acquisition of invasiveness and metastatic potential by 
cancer cells. In addition to losing the wild-type p53-mediated suppression of these 
characteristics, p53 mutants have been implicated in active promotion of cell 
migration, invasiveness and metastasis (454).
Firstly, wild-type p53 was suggested to suppress migration and invasiveness 
through MDM2-mediated degradation of an invasion promoter Slug, resulting in 
up-regulation of E-cadherin (286). On the other hand, the presence of mutant p53 was 
associated with low MDM2 expression, stabilisation of Slug, down-regulation of 
E-cadherin and short metastasis-free survival of non-small cell lung cancer patients 
(286). Importantly, these effects seemed to go beyond the simple loss of wild-type 
p53 function. It was suggested that mutant p53 might promote Slug up-regulation by 
repressing MDM2 expression since knockdown of mutant p53 resulted in increased 
MDM2 levels (286), providing the first potential mechanism for mutant p53-mediated 
invasiveness of cancer cells. However, more recent studies demonstrated that MDM2
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actually promotes invasiveness of cells in a RING-fmger-independent manner (287) 
and since MDM2 is usually maintained at a low level in the presence of mutant p53 
(which is unable to transactivate MDM2), mutant p53 is likely to promote motility 
and invasiveness via an alternative mechanism.
Interestingly, induction of cell migration by mutant p53 is strongly dependent on 
the cellular context. It was suggested that cooperation between mutant p53 and 
oncogenic Ras may be critical for some of the malignant phenotypes displayed by 
mutant p53 expressing tumours (455) explaining why some studies reported 
dominant-negative rather than GOF effects of mutant p53 in promoting cell migration
(456) . Moreover, oncogenic Ras and mutant p53 were found to be essential for 
TGF-p-induced invasiveness and metastatic spread (457).
Transforming growth factor (3 (TGF-P) plays a dual role in cancer progression. At 
early stages of tumour' development it functions as a tumour suppressor putting 
a break on proliferation of epithelial cells, while in advanced cancers it is 
paradoxically diverted into a potent enhancer of invasion and metastasis (458). Smad2 
and Smad3 are the key mediators of TGF-p signalling, which are phosphorylated 
upon TGF-p receptor activation and accumulate in the nucleus, eliciting gene 
responses to TGF-P (459). The molecular basis of the switch of TGF-P from tumour 
suppressor to oncogene is not fully understood. Recently, mutant p53 has been 
reported to be crucial for TGF-p-mediated invasiveness (457). Mutant p53 inhibits the 
activities of p63, which was shown to suppress TGF-p-induced malignant responses
(457) . p63 inhibits invasiveness and metastatic potential of cancer cells by induction 
of its transcriptional targets, Sharp-1 and cyclin G2, suggested to function as 
metastasis suppressors (457). Indeed, knockdown of either of these targets mimics the 
ability of mutant p53 to drive migration and invasiveness (457).
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However, most stratified epithelia express predominantly ANp63, an isoform of 
p63 unable to bind to mutant p53 (406). In this context, Smads were found to be 
essential for complex formation between mutant p53 and p63 (457). Moreover, 
oncogenic Ras was required for phosphorylation of mutant p53 at the N-terminus, 
which was a prerequisite of the TGF-p-induced mutant p53/Smad/p63 ternary 
complex formation (457). Hence, TGF-(3 signalling induces phosphorylation of 
Smads, which serve as a platform for a ternary complex formation by Ras-activated 
mutant p53 and p63, resulting in the acquisition of invasiveness and metastatic 
proclivity. These findings demonstrate yet another role for the GOF p53 mutants in 
promoting cancer invasion and metastasis.
However, TGF-[3 signalling is not always indispensable for mutant p53 to exhibit 
its function in promoting migration and invasiveness (460). In addition to suppression 
of Sharp-1 and cyclin G2 expression, p63 inhibition by mutant p53 was reported to 
result in increased a5pl integrin and EGFR recycling, driving cancer cell migration 
and invasion (454). Integrin recycling is driven by Rab-coupling protein (RCP), 
which by associating with a5[31 integrin directs it from the recycling endosomes back 
to the plasma membrane, where it can bind its substrate, fibronectin, and promote cell 
migration (461). Moreover, RCP was suggested to function as a scaffold for 
coordinated trafficking of a5[31 integrin and EGFR, resulting in enhanced EGFR 
autophosphorylation and signalling via Akt (461). Importantly, Akt in addition to its 
pro-survival activities has recently been reported to promote cell migration and 
invasiveness (462). Transcriptionally active TAp63 was found to inhibit activation of 
RCP hence inhibiting integrin and EGFR recycling and consequently blocking cell 
migration (454). However, direct transcriptional targets of p63 regulating the 
association of RCP with a5[31 integrin are currently unknown. The anti-migratory
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effect of p63 was relieved by mutant p53 expression, promoting tumour cell migration 
and invasion (454). Altogether, these observations suggest that through increased 
integrin and EGFR recycling, mutant p53 drives migration and invasion via the Akt 
signalling pathway.
While mutant p53 is likely to be involved in numerous other pathways, which are 
dysregulated in human cancer, the findings discussed above shed light onto how the 
oncogenic gain of function of mutant p53 could contribute to tumour invasiveness, 
metastatic potential and resistance to treatment. However, many of the mechanisms 
through which mutant p53 promotes tumour progression are still not well understood 
and there are areas, which require further investigation. Poor prognosis associated 
with expression of mutant p53 underlies the need for screening, developing novel 
therapies and better prediction of treatment response. Elucidating the mechanism of 
action of individual GOF p53 mutants will be crucial for developing targeted 
therapies tailored to individual patients and perhaps improving survival of cancer 
patients with mutant p53 expressing tumours.
1.4. Aim of this project
p53 is an important tumour suppressor protein, whose function is lost through TP53 
mutations in about 50% of human tumour's (107), making it arguably the most 
frequently altered gene in human cancer. The majority of p53 mutations are missense, 
resulting in the expression of full-length protein with single amino acid substitutions, 
which tends to accumulate in tumour cells (436). These missense p53 mutants not 
only lack wild-type p53 tumour-suppressor activity but in addition evidence suggests 
that some of these also gain new functions that can promote tumorigenesis (see
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section 1.3.4.3). This oncogenic ‘gain of function’ of p53 mutants is proposed to be 
achieved via modulating the transcriptome of a cancer cell or through novel 
protein-protein interactions (as discussed in section 1.3.4.3.1) but the molecular 
details of the mechanisms involved are still not entirely understood.
Therefore, the aim of this project was to investigate the mechanisms and functional 
consequences of mutant p53 GOF in LSCC cells, which are important preclinical 
models in the search for new therapies for treatment of laryngeal cancer (463). The 
mutants chosen for these studies represent two different mutational classes:
• R175H - a structural mutation causing a significant conformational shift of p53,
• R273H — a contact mutation affecting a p53 residue that makes direct contact with 
DNA and hence leading to a loss of wild-type p53-specific DNA binding; note 
that mutants of this class may retain altered ability to transactivate p53-responsive 
genes.
Both of these mutants have been shown to display GOF properties using in vivo 
models (5, 6) and have been documented to occur in laryngeal cancer (139). The 
mechanism of action of the GOF p53 mutants mentioned above was investigated by 
identifying mutant p53 interacting proteins and studying the gene expression changes 
in cells expressing those p53 mutants. Since mutant p53 expression is frequently 
linked to poor prognosis (101), the functional consequences of GOF p53 mutations in 
laryngeal cancer were studied with respect to cellular motility and invasiveness, 
which may be used as surrogate indicators of metastatic potential. In addition, GOF 
p53 mutants are frequently associated with resistance to treatment (401, 402) and 
hence the response of mutant p53 expressing LSCC cells to ionising radiation 
(a common treatment modality for laryngeal cancer) was also studied.
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Since many biological functions involve interactions of proteins with other proteins 
and with DNA, identifying the interacting partners of mutant p53 and studying the 
gene expression changes in mutant p53 expressing cells may elucidate, which 
molecular- networks and pathways mutant p53 proteins are involved in, and the 
components of these networks (including the identified mutant p53 interacting 
proteins) may represent important new therapeutic tar-gets. Moreover, better 
understanding of the impact of mutant p53 expression on response to treatment may 
make the choice of treatment suitable for particular patients easier as well as facilitate 
development of novel therapies tailored to the individual tumour’s.
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Materials and Methods
Materials and Methods
2. Materials and Methods
2.1. List of reagents 
2J.1. General reagents
Reagent or product
Acetic acid (glacial) 100% anhydrous
Acetone
Acetonitrile
Acrylogel 2.6 (40%) solution
Adenosine 5’-triphosphate, disodiurn salt hydrate
Agar
Amaxa® Nucleofector® Kit V 
Ammonium bicarbonate 
Ammonium persulfate (APS)
Ampicillin sodium salt 
Aprotinin
Albumin from bovine serum (BSA), minimum 96% 
electrophoresis
Blotting Grade Blocker Non Fat Dry Milk 
Bromophenol Blue 
Crystal Violet 
d-Biotin
Dimethyl sulfoxide (DMSO)
Dimethylformamide (DMF)
DL-Dithiothreitol, for molecular biology, minimum 
99% titration
DPX Mountant for histology
Manufacturer
Merck
Prolabo
Fisher
BDH
Sigma
ForMedium
Lonza
Sigma
Sigma
Sigma
Roche
Sigma
Bio-Rad
Sigma
Sigma
SUPELCO Analytical
Sigma
BDH
Sigma
Sigma
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Reasent or oroduct Manufacturer
Dual-Luciferase® Reporter 1000 Assay System Promega
EndoFree Plasmid Mega Kit (5) Qiagen
Ethanol, absolute, 200 proof, for molecular biology Sigma
Ethanol (Abs), reagent grade
Department of Chemistry 
University of Liverpool
Ethidium Bromide solution Sigma
Ethylenediaminetetra-acetic acid (EDTA) disodium salt BDH
Ethylene glycol-bis(|3-aminoethyl ether)-N,N,N’,N’- 
tetracetic acid (EGTA)
Sigma
Gelatin from porcine skin Sigma
Geneclean Turbo Kit Qbiogene
GenSieve LE agarose Flowgen Bioscience
25% Gluteraldehyde solution BDH
Glycerol, > 99.5%, A.C.S. reagent Sigma
Glycine Fisher Scientific
HEPES, Free Acid, Molecular Biology Grade Calbiochem
Hybond™ ECL™ Nitrocellulose Membrane GE Healthcare
lodoacetamide (IAA) Sigma
InterPlay™ Mammalian TAP System Stratagene
Kanamycin sulphate, from Streptomyces kanamyceticus Sigma
Leupeptin Roche
Luria Broth Sigma
Magnesium acetate tetra-hydrate, Minimum 99% Sigma
Magnesium chloride Sigma
|3-mercaptoethanol Sigma
Methanol, analytical reagent grade Fisher Scientific
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Reasent or oroduct Manufacturer
Pepstatin Roche
Phenol red BDH
Phenylmethanesulfonyl fluoride (PMSF) Fluka
Ponceau S, practical grade Sigma
Potassium hexacyanoerrate(II) 3-hydrate (potassium
ferro cyanide)
BDH
Potassium hexacyanoerrate(III) (potassimn ferricyanide) BDH
Prestained Protein Marker, Broad Range (7-175 kDa) NEB
Protein Assay Dye Reagent Concentrate Bio-Rad
Protein G Sepharose® Sigma
QIAprep Spin Miniprep Kit (50) Qiagen
Qiashredder™ (50) Qiagen
REASTAIN Quick-Diff Kit Reagena
Rely+On™ Virkon® Tablets DuPont
RNase-Free DNase Set (50) Qiagen
RNeasy® Mini Kit (50) Qiagen
SeaKem® GTG® Agarose Lonza
Sequencing Grade Modified Trypsin Promega
Silver Stain Plus Kit Bio-Rad
Sodium chloride (NaCl) VWR
Sodium dodecyl sulphate (SDS) BDH Prolabo
Sodium dihydrogen phosphate dihydrate 
(NaH2P04 • 2H20)
Fluka BioChemika
Sodium fluoride Fluka BioChemika
Sodium phosophate dibasic dihydrate 
(Na2HP04 • 2H20)
Sigma
Soybean Trypsin Inhibitor (STI) Roche
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Reagent or product Manufacturer
TA Cloning kit Invitrogen
NjNjN’ ,N’ -tetramethylenediamine (TEMED) BDH
Trichloroacetic acid (TCA) BDH Prolabo
Trifluoroacetic acid Applied Biosystems
Tris Base, ULTROL® Grade Calbiochem
Triton X-100 Amersham Biosciences
Tween 20 Sigma
Western Lightning Phis-ECL chemiluminescence
reagent
PerkinElmer
Whatman 3 mm Chromatography Paper VWR
X-Gal
(5-Bromo-4-chloro-3-indoiyl-B-D-galactopyranoside)
BDH
Xylene cyanole FF Sigma
All H2O used was ultra-pure H2O (> 18 MQ • cm) produced by PURELAB Ultra-pure 
Water Purification System (ELGA Process Water).
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2*1.2* Tissue culture reagents
Reagent Manufacturer
Dulbecco’s Modified Eagle’s Medium, HEPES Modification Sigma
Dulbecco’s Phosphate Buffered Saline Sigma
Fetal Bovine Serum Sigma
FuGENE® HD Transfection Reagent Promega
G418 Sulfate, Cell Culture Tested Calbiochem
Gene Juice® Transfection Reagent Novagen
L-Glutamine 200 mM Sigma
Lipofectamine™ 2000 Transfection Reagent Invitrogen
MEM Non-essential amino acid solution 100x Sigma
Opti-MEM® I Reduced Serum Medium Invitrogen
Penicillin-Streptomycin, BioReagent Sigma
Phosphate Buffered Saline (Dulbecco A), non-sterile Oxoid
Puromycin InvivoGen
RPMI-1640 Medium Sigma
Trypsin-EDTA solution (lx) Sigma
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2.1.3. Enzymes and cloning reagents
Reagent Manufacturer
Adenosine 5'-Triphosphate (ATP) NEB
Anatarctic Phosphatase NEB
10x Antarctic Phosphatase Reaction Buffer NEB
BaniHI NEB
DNA Polymerase I, Large (Klenow) Fragment NEB
dNTP Mix NEB
EcoRI NEB
EcoRY NEB
Hexamminecobalt(III) chloride (HCC) Sigma
Ndel NEB
Notl NEB
pCR2.1 vector (25ng/|ol) Invitrogen
Phusion® High-Fidelity DNA polymerase Finnzymes
5x Phusion® HF Buffer Finnzymes
Quick-Load 1 kb DNA Ladder NEB
Smal NEB
10x Standard Taq Reaction Buffer NEB
StuI NEB
T4 DNA ligase Ambion
10x T4 DNA Ligase Reaction Buffer Ambion
Taq DNA polymerase NEB
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2.2. Cloning
IQx DNA/RNA native loading buffer
Concentration
0.1% (w/v) 
0,1% (w/v)
1 mM 
50% (v/v)
Reagent
bromophenol blue 
xylene cyanol 
EDTA 
glycerol
1.2% /w/v-) agarose gel 
Reagent Amount
agarose 0.6 g
ethidium bromide (lOgg/jil) 2.5 fil 
TAE buffer 50 ml
TAE (Tris-acetate-EDTA) buffer (50x
Concentration
2 M
5.71% (v/v)
50 mM
Reagent
Tris
glacial acetic acid 
EDTA
For restriction digests, 3 gg of the plasmid containing the insert of interest and 1 jig of 
the vector “backbone” DNA were digested routinely with 10-fold excess of enzyme 
(restriction endonuclease of interest), e.g. 10 U of enzyme were used to digest 1 pg of 
DNA. The digests were carried out under conditions indicated for the respective 
enzymes by the manufacturer. The backbone DNA was further dephosphorylated (to 
minimise the rate of religation) by adding 0.5 pi Antarctic phosphatase and
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10x Antarctic Phosphatase Reaction Buffer (to a final concentration of lx) and 
incubating at 37°C for 15 min.
The digested DNA was then resolved by gel electrophoresis on a 1.2% (w/v) 
agarose gel (prepared using SeaKem GTG Agarose, which contains low levels of 
poly anionic contaminants that could inhibit DNA modifying enzymes) containing 
0.5 (ig/ml ethidium bromide, in a horizontal electrophoresis unit (Scie-Plas) 
comiected to a PowerPac power supply (Bio-Rad). The insert and backbone of interest 
were then cut out of the gel using a sterile scalpel and purified using a Geneclean 
Turbo Kit according to the manufacturer’s instructions. The ligation was set up as
follows.
Component Volume
insert DNA 6.5 pi
backbone DNA 1 pi
T4 DNA ligase 1 pi
10x T4 DNA ligase reaction buffer 1 pi 
ATP 0.5 pi
Total volume: 10 pi
“No insert” and “no ligase” controls were also set up. The ligations were incubated at 
14°C overnight. For blunt-end ligations 0.2 pi of 100 pM HCC was also added.
2.3. Bacterial strains, transformation and plasmid purification
One Shot TOP-10 Chemically Competent E. coli (Invitrogen) were used as a cloning 
strain and chemically competent E. coli strain XL-1 Blue (Stratagene) were used for 
large-scale plasmid preparation.
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Luria-Bertani (XB') liquid medium
Reagent Amount
powdered LB 12.5 g
H20 500 ml
Sterilised by autoclaving (121°C for 15 min.).
Luria-Bertani (LB ) medium with agar
Reagent Amount
powdered LB 12.5 g
agar 7.5 g
H2O 500 ml
Sterilised by autoclaving (121°C for 15 min.). After the medium partially cooled 
down, antibiotics were added as required, the medium was then poured into 10 cm 
Petri dishes and allowed to set.
For transformation, competent cells were thawed on ice. 5 pi of the ligation mix 
was added to the TOP-10 competent cells and incubated on ice for 30 min. to allow 
even distribution of the plasmid. Next, the cells were incubated at 42°C for 30 sec. 
and then placed back on ice immediately for 2 min. 200 pi of SOC medium was then 
added to the cells and they were incubated in a shaker at 37°C, 220 rpm for 1 hour. 
Following incubation, the transformations were plated on LB/Agar plates containing 
the appropriate antibiotic (10% and 90% of the entire volume per plate). The plates 
were incubated at 37°C overnight.
Usually, between 5 and 10 colonies were inoculated into 4 ml liquid LB containing 
the appropriate antibiotic. The cultures were incubated at 37°C with shaking at 
220 rpm, overnight. The cultures were then centrifuged at 16,000xg for 5 min. and 
DNA was extracted using the QIAprep Spin Miniprep Kit according to the
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instructions. This procedure is based on the original alkaline extraction method by 
Birnboim and Doly (464). The method relies on the fact that under carefully selected 
alkaline pH (12-12.5) linear genomic DNA is denatured while plasmid DNA remains 
in its native state. Lysis was achieved with lysozyme (to weaken the cell wall), SDS 
and NaOH. The lysate was then neutralised by acidic NaAc solution, resulting in 
renaturation and aggregation of the chromosomal DNA and high molecular weight 
RNA and precipitation along with protein while plasmid DNA remained in solution. 
Genomic DNA, some RNA and protein was then removed in a single centrifugation 
step.
The QIAprep Miniprep is a modification of this method. Briefly, the bacterial 
pellets were resuspended in 250 pi of Buffer PI (containing LyseBlue reagent). The 
cells were lysed by alkaline lysis by adding 250 pi of Buffer P2 and inverting the tube 
a few times. The presence of LyseBlue in the resuspension buffer helped to ensure 
thorough mixing of the solutions mitil a homogenously coloured blue suspension was 
obtained. 350 pi of neutralization Buffer N3 was then added and the tubes were 
inverted a few times imtil all trace of blue disappeared. The tubes were centrifuged at 
16,000 xg for 10 min. and the supernatants were applied to the QIAprep spin columns 
(containing a silica membrane). Due to the specifically optimised high-salt conditions 
dining the lysis procedure only DNA binds to the silica membrane, while RNA and 
proteins are found in the flow-through. The columns were centrifuged at 16000xg for 
1 min. The flow-through was discarded. The columns were washed by adding 500 pi 
of Buffer PB (to remove endonucleases) and centrifuged at 16000xg for 1 min. The 
flow-through was discarded. A second wash to remove salts was performed by adding 
750 pi of Buffer PE and centrifugation at 16000xg for 1 min. The flow-through was 
discarded. The columns were centrifuged at 16000xg for an additional 1 min. to
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remove residual ethanol from wash buffer. The columns were then placed in fresh 
1.5 ml microcentrifuge tubes and DNA was eluted with a low-salt solution - usually 
30-50 pi of H20 was added to the centre of each column, which were then incubated 
for 1 min. at room temperature and centrifuged at 16,000xg for 1 min.
The colonies were screened by restriction digestion and agarose gel electrophoresis 
(using GenSieve LE agarose) for the presence and orientation of the insert.
XL-1 Blue competent cells were then transformed with the plasmid DNA from 
a positive clone as described previously. A single colony was inoculated into 4 ml 
liquid LB containing the appropriate antibiotic and the culture was incubated at 37°C 
with shaking at 220 rpm, overnight. 50 pi of this culture was then used to set up 
a 500 ml culture. The culture was then incubated at 37°C with shaking at 220 rpm, 
overnight. The bacterial cells were pelleted by centrifugation at 6,000xg for 15 min. at 
4°C and DNA was extracted using the EndoFree Plasmid Mega Kit according to the 
manufacturer’s instructions. Similarly to the miniprep procedure, the Megaprep 
plasmid purification is also based on a modified alkaline lysis procedure. The plasmid 
DNA is then bound to a QIAGEN Anion-Exchange Resin under optimized low-salt 
and pH conditions. RNA, protein and other impurities are removed by a medium-salt 
wash and plasmid DNA is eluted using a high-salt buffer. It is then concentrated and 
desalted by isopropanol precipitation. The EndoFree kit used includes also an 
endotoxin removal step. Bacteria shed small amounts of endotoxins into their 
surroundings during active growth and large amounts when they are dying. Bacterial 
endotoxins are lipopolysaccharides (LPSs), which are toxic to eukaryotic cells. Due to 
their chemical properties and tendency to form micellar' structures they tend to 
co-purify with plasmid DNA. For example, they can interact with the anion-exchange 
resins due to the negatively charges phosphate groups present on the endotoxins. The
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endotoxin removal buffer prevents the LPS molecules from binding to the 
anion-exchange resin, yielding a high quality plasmid DNA preparation, which is 
suitable for transfections.
Briefly, the bacterial pellet was resuspended in 50 ml of Buffer PI (containing 
LyseBlue). The cells were lysed by adding 50 ml of Buffer P2 and inverting the tube 
a few times until a homogenously coloured blue suspension was obtained. The lysate 
was incubated for 5 min. at room temperature. 50 ml of pre-chilled Buffer P3 was 
then added and the tube was inverted a few times until all trace of blue disappeared. 
The lysate was then poured into the QIAfilter Mega-Giga Cartridge (attached to 
a vacuum source) and incubated for 10 min. at room temperature. The vacuum source 
was then switched on and the liquid pulled through. The vacuum source was switched 
off. 50 ml of Buffer FWB2 was added to the QIAfilter Cartridge and the precipitate 
was stirred gently using a clean pipette tip. The vacuum source was switched on until 
all the liquid was pulled through. The QIAfilter Cartridge was then detached and 
disposed. 12.5 ml of Buffer ER was added to the filtered lysate, mixed by inverting 
the bottle a few times and incubated on ice for 30 min. During this time, 
a QIAGEN-tip 2500 was equilibrated with 35 ml of Buffer QBT and the column was 
emptied by gravity flow. Following the incubation the lysate was applied onto the 
column. The flow-through was discarded. The column was washed with 200 ml of 
Buffer QC. The DNA was eluted with 35 ml of Buffer QN and collected into a 50 ml 
Falcon tube. The DNA was then precipitated by adding 24.5 ml of room-temperature 
isopropanol, mixed and centrifuged immediately at 5,000xg for 1 hour at 4°C. The 
supernatant was carefully decanted and the pellet was transferred into a fresh 
microcentrifuge tube in 1 ml of endotoxin-free room-temperature 70% ethanol. The 
tube was centrifuged at 16,000xg for 10 min. at 4°C. The supernatant was carefully
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decanted and the wash with ethanol to remove salts was repeated twice. The DNA 
pellet was then air-dried until the pellet became translucent. It was then redissolved in 
a suitable volume (based on the size of the pellet) of O.lx Buffer TE. DNA was 
quantified with a BioPhotometer (Eppendorf) using the dsDNA program.
2.4. DNA constructs and plasmids
Vector maps were generated using Vector NTI Advance M 11 (Invitrogen). Wherever 
indicated, 2 pg of DNA was vacuum dried and sent for sequencing to Eurofins MWG 
Operon. The obtained sequence was compared to the reference sequence from the 
NCBI (National Center for Biotechnology Information) database using NCBI BLAST 
(Basic Local Alignment Search Tool) (465), which allows for alignment of two 
sequences.
In order to investigate protein interactions of mutant and wild-type p53 proteins 
using TAP-tag purification, the p53 cDNAs (wt and two mutants) were cloned into 
pNTAP vector, which resulted in N-terminally TAP-tagged forms of p53. The cDNAs 
were also subcloned into pCMV-Script vector for validation studies without the 
TAP-tag.
2.4.1. pCMV-Script.p53
pCMV-Script.p53, containing human p53 cDNA, was a kind gift from Dr Carlos 
Rubbi (University of Liverpool). The p53 cDNA was sequenced.
2.4.2. pNTAP-B.p53
p53 cDNA was excised from pCMV-Script,p53 and inserted into pNTAP-B vector 
(Stratagene) using BamHI and EcoRI restriction sites. The B version of the pNTAP
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vector (containing one extra nucleotide in front of the multiple cloning site) was used 
to ensure that p53 is in frame with the TAP-tag (consisting of the CBP- and 
SBP-tags). The generated pNTAP-B.p53 was sequenced.
2.4.3. pCB6+.p53-l 75H
pCB6+.p53-175H vector, containing cDNA of human p53 with a mutation at position 
175 (arginine to histidine) was a kind gift from Dr Karen Yousden (Beatson Institute 
of Cancer Research). Since no vector map or sequence was available, the regions 
upstream and downstream of p53, as well as the entire p53 cDNA itself, were 
sequenced.
2.4.4. pCR2.Lp53-175H
Due to the lack of appropriate restriction sites to excise p53-175H cDNA from 
pCB6+.p53-175H that would allow insertion into the pNTAP vector, the cDNA of the 
mutant p53 was amplified by PCR from the pCB6+.p53-175H vector using primers 
introducing a BamHI site at the 5’-end (forward: 5’-GAG AGG ATC CAT GGA 
GGA GCC GCA GTC AGA TC-3’) and an EcoRI site at the 3’-end (reverse: 5’-GAG 
AGA ATT CTC AGT CTG AGT CAG GCC CTT CG’). Phusion High-Fidelity DNA 
Polymerase was used for amplification. The following reaction was set up.
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Component Volume
template DNA (l 00 ng) 3.84 pi
primer-F (O.lpg/pl) 1 pi
primer-R (O.lpg/pl) 1 pi
Phusion DNA polymerase (2 U/pl) 0.2 pi
5 x Phusion HF Buffer 4 pi
dNTPs (lOmM) 0.4 pi
H20 9.56 pi
Total: 20 pi
The following thermal cycling reaction conditions were used, 
denaturation; 98°C, 30 sec. 
denaturation: 98°C, lOsec.
annealing: 60°C, 30 sec. [>• 15 cycles 
extension: 72°C) 1 min. 
final extension: 72°C, 5 min. 
inactivation: 940C, 20 min.
2 pi of Taq DNA Polymerase (5 U/pl) and 2 pi of lOmM dATP were then added to 
the reaction to add 35-A-overhangs to the PCR product and incubated at 72°C for 
20 min. The reaction was resolved on a 1% (w/v) agarose gel. The PCR product was 
excised from the gel, purified using Geneclean and ligated into pCR2.1 vector 
from the TA Cloning kit. pCR2.1 is a linearized vector containing single 
3’-deoxythymidine (dT) overhangs, allowing for efficient ligation of PCR products.
TOP-10 competent cells were transformed with the overnight ligations. The 
transformants were plated on LB/Agar plates containing 50pg/ml Amp and 
50 pg/ml X-Gal and screened using the blue-white selection. White colonies were 
inoculated into 4 ml of LB with 50 pg/ml Amp. The culture was incubated at 37°C
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with shaking at 220 rpm, overnight. Following a miniprep DNA extraction, the p53 
cDNA was sequenced to confirm that no additional mutations had been introduced 
during PCR.
2.4.5. pNTAP-B.p53-l 75H
p53-175H cDNA was then subcloned from pCR2.1.p53-175H into pNTAP-B using 
BamHI and EcoRI sites so that p53 is in frame with the TAP-tag.
2.4.6. pCMV-Script.p53-l 75H
p53-175H cDNA was also subcloned from pCR2.1.p53-175H into pCMV-Script 
(Stratagene) using BamHI and EcoRI sites.
2.4.7. pET24a(+).p53-273H
pET24a(+) .p5 3 -273H vector, containing cDNA of human p53 with a mutation at 
position 273 (arginine to histidine), was a kind gift from Prof. Sir Alan Fersht 
(University of Cambridge). The p53 cDNA was sequenced.
2.4.8. pNTAP-B.p53-2 73H
p53-273H cDNA was excised from pET24a(+).p53-273H using Ndel and EcoRI sites 
and inserted into BamHI and EcoRI sites of pNTAP-B so that p53 is in frame with the 
TAP-tag. This involved blunting of the ends cut with Ndel and BamHI using 2 pi of 
DNA Polymerase I, Large (Klenow) Fragment (5U/pl) and 10x NEBuffer 2 (added 
to a final concentration of lx) at 25°C for 15 min. and a subsequent digestion with 
EcoRI.
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2.4.9. pCMV-Script.p53-2 73H
p53-273H cDNA was also subcloned from pET24a(+).p53-273H into pCMV-Script 
using Smal and EcoRV sites (both produce blunt ends). Digestion with StuI was 
performed on 5 of the clones to confirm that p53 cDNA was inserted into 
pCMV-Script in the correct orientation.
2.4.10. Other constructs
pP-gal is an expression vector encoding fhgalactosidase (p-gal) under the regulation 
of an SV40 promoter.
pp53-TA-luc is a p53 luciferase reporter construct. It drives firefly luciferase 
expression from a minimal herpes simplex virus (HSV) thymidine kinase promoter, 
located downstream of a p53 response element comprising a fragment of the putative 
replication origin of the human ribosomal gene cluster (RGC) p53 binding element 
and a p53 consensus binding sequence (466). The construct was obtained from BD 
Clontech.
pRL-TK is a luciferase reporter construct. It drives constitutive Renilla luciferase 
expression from an HSV thymidine kinase promoter. The construct was a kind gift 
from Prof. Mike White (University of Liverpool).
pSUPER.GFP is an expression vector encoding GFP under the regulation of the PGK 
promoter. The vector was obtained from Oligoengine.
pSUPER*puro.shp53 is an expression vector encoding a short hairpin specific for 
p53 and a fluorescent protein mCherry. The vector was generated by Dr Radoslaw 
Polanski (University of Liveipool).
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pSUPER.puro.shScr is an expression vector encoding a control (scrambled) short 
hairpin and a fluorescent protein mCherry. The vector was generated by Dr Radoslaw 
Polanski (University of Liverpool).
2.5. Cell culture
HI299 cells (non-small cell lung carcinoma) were obtained from the American Type 
Culture Collection (Manassas, YA). They were maintained in RPMI-1640 medium 
supplemented with 10% FBS. HI299 cells are p53-null They were used in this study 
because they are well known, grow quickly and are relatively easy to transfect.
UM-SCC-12 cells (laryngeal squamous cell carcinoma) were a kind gift from 
Prof. Thomas Carey (University of Michigan). They were maintained in Dulbecco’s 
Modified Eagle’s Medium (HEPES Modification) supplemented with 10% FBS, 
1% penicillin/streptomycin, 1% L-glutamine and 1% Non-Essential Amino Acids. 
These cells are functionally p53-null, as they cany a homozygous p53 truncation 
(Q104X).
All cells were grown at 37°C in a humidified atmosphere of 5% CO2.
In order to prepare cryostocks, cells were harvested by trypsinization and pelleted 
by centrifugation at 300xg for 5 min. The media was aspirated and the pellets were 
resuspended in 1 ml of freezing medium (10% DMSO in FBS). The cell suspensions 
were transferred into cryovials (Nunc). To ensure slow freezing, the vials were placed 
in a cryogenic freezing container (Nalgene) filled with 100% isopropanol and stored 
at -80°C overnight. The following day the vials were transferred to liquid nitrogen.
When recovering cells from liquid nitrogen, the stocks were thawed as quickly as 
possible in a 37°C water bath. Since DMSO is toxic to cells at concentrations above 
0.5%, the cells were resuspended in at least 20 ml of complete growth media and
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transferred to an appropriate tissue culture flask. As soon as the cells adhered to the 
surface (usually the following day), the media was changed.
2.6. Transfections
HI 299 cells were routinely transfected with Gene Juice (Novagen) at 3 pi per jig of 
DNA (ratio 3:1) with empty vectors added to ensure equal DNA content of 
transfections.
For transfection efficiency testing HI299 and UM-SCC-12 cells were seeded into 
6-well plates and transfected with 1 pg of p(3-gal per well using GeneJuice at ratios 
2:1, 3:1 and 4:1; Lipofectamine 2000 (Invitrogen) at ratios 2:1, 2.5:1 and 3:1; and 
FuGENE HD (Roche) at ratios 2:1, 2.5:1 and 3:1. UM-SCC-12 cells were also 
transfected by electroporation using the Amaxa® Nucleofector® Kit, in an attempt to 
achieve higher transfection efficiency.
Small interfering RNAs were delivered to cells using Lipofectamine 2000.
2.6.1, GeneJuice transfection
The day before transfection cells were plated at such a density (20% confluent for 
HI299) so that they were approximately 50-80% confluent before transfection.
Before transfection, serum-free (SF) medium, GeneJuice and DNA were 
equilibrated to room temperature. For one well of a 6-well plate 100 pi of SF medium 
was placed in a sterile tube. 3 pi of GeneJuice was added directly to the serum-free 
medium (making sure that GeneJuice does not come in contact with the walls of the 
tube) and mixed thoroughly by vortexing. The GeneJuice/SF medium mixture was 
incubated at room temperature for 5 min. 1 pg of DNA was then added and the 
mixture was mixed by flicking the tube with a finger. The reaction mix was incubated
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at room temperature for 15 min. The GeneJuice/DNA mixture was then added 
drop-wise to cells in complete growth media, distributing the drops over the entire 
dish surface. The dish was then rocked gently to ensure even distribution of the 
transfection mixture and the cells were incubated at 37°C5 5% CO2. The cells were 
analysed 24 hours post transfection.
The GeneJuice:DNA ratio used in the above example was 3:1. The volumes used 
were adjusted based on the amount of DNA and GeneJuice:DNA ratio used.
2.6.2. Lipofectamine transfection
The day before transfection cells were plated at such a density (35-40% confluent for 
HI299) so that they were approximately 90% confluent before transfection.
Before transfection, SF Opti-MEM medium, Lipofectamine and DNA were 
equilibrated to room temperature. For one well of a 6-well plate 1 pg of DNA was 
diluted in 250 pi of SF Opti-MEM medium and 2.5 pi of Lipofectamine was diluted in 
250 pi of SF Opti-MEM medium. The mixtures were incubated for 5 min. at room 
temperature. Following incubation the diluted DNA was added to the diluted 
Lipofectamine. The transfection mixture was mixed by flicking the tube with a finger 
and incubated for 20 min. at room temperature. The entire transfection mixture was 
then added drop-wise to cells in complete growth media, distributing the drops over 
the entire dish surface. The dish was then rocked gently to ensure even distribution of 
the liposome complexes and the cells were incubated at 37°C, 5% CO2. The cells were 
analysed 24 hours post transfection.
The Lipofectamine:DNA ratio used in the above example was 2,5:1. The volumes 
used were adjusted based on the amount of DNA and Lipofectamine:DNA ratio used.
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2.6.3. FuGENE transfection
The day before transfection cells were plated at such a density (30-35% confluent for 
HI299) so that they were approximately 85% confluent before transfection.
Before transfection, SF medium, FuGENE and DNA were equilibrated to room 
temperature. For one well of a 6-well plate 1 jig of DNA was diluted in 100 pi of 
SF medium. 3 pi of FuGENE was then added to the diluted DNA (making sure that 
FuGENE does not come in contact with the walls of the tube). The transfection 
mixture was mixed by flicking the tube with a finger and incubated for 15 min. at 
room temperature. The entire transfection mixture was then added drop-wise to cells 
in complete growth media, distributing the drops over the entire dish surface. The dish 
was then rocked gently to ensure even distribution of the liposome complexes and the 
cells were incubated at 37°C, 5% COa. The cells were analysed 24 hours post 
transfection.
The FuGENE:DNA ratio used in the above example was 3:1. The volumes used 
were adjusted based on the amount of DNA and FuGENE:DNA ratio used.
2.6.4. Nucleofection
The day before nucleofection UM-SCC-12 cells were sub-cultured so that they were 
approximately 70-85% confluent before nucleofection. A protocol for nucleofection 
of UM-SCC-14A cells (a cell type similar to UM-SCC-12) was found in Lonza’s cell 
line database and tested on UM-SCC-12.
On the day of nucleofection a 6-well plate with 1.5 ml of complete growth media 
per well was placed in the incubator to prewarm the media. The Nucleofector 
Solution, supplement and DNA were equilibrated to room temperature.
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The cells were harvested by trypsinization and counted using the Z2 Coulter 
Particle Count and Size Analyzer (Beckman Coulter). IxlO6 cells were then 
aliquoted in separate 15 ml polypropylene centrifuge tubes (Corning) and pelleted by 
centrifugation at 90xg for 10 min. at room temperature. The media was then aspirated 
and one pellet was resuspended in complete growth media and transferred directly 
into one well of the prewarmed 6-well plate (untreated control). The remaining pellets 
were resuspended in 100 pi of Nucleofector mix (prepared freshly by combining 82 pi 
Nucleofector Solution V with 18 pi of supplement) each. 3 pg of DNA was then 
added to the cell suspensions and the mixtures were transferred to individual 
nucleofection cuvettes, making sure that the sample covered the bottom of the cuvette 
and no air bubbles were present. One sample was kept without DNA (untransfected 
control). The cuvettes were then inserted into the Cuvette Holder of the 
Nucleofector™ II Device (Lonza) and the U-031 program was applied by pressing the 
X-button. Extra care was taken to ensure that the cells did not stay in the Nucleofector 
mix for more than 15 min., as this can reduce cell viability and transfection efficiency. 
Approximately 500 pi of the prewarmed culture medium was added to each of the 
cuvettes using a supplied sterile Pasteur pipette and the samples were gently 
transferred into the prepared 6-well plate avoiding repeated aspiration of the samples. 
The cells were then incubated at 37°C, 5% CO2 and analysed 18 hours post 
nucleofection.
2.6.5. siRNA delivery
The day before transfection with siRNA, cells were plated into 10 cm dishes at such 
a density (30% confluent for UM-SCC-12) so that they were approximately 
40% confluent before transfection.
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On the day of transfection, the media on the 10 cm dishes was aspirated and 
replaced with 6.4 ml of complete growth media (to obtain a final volume of 8 ml after 
adding the transfection mixture). Before transfection, SF Opti-MEM medium and 
Lipofectamine were equilibrated to room temperature, siRNA was thawed just before 
transfection. Cells were transfected with siRNA at a final concentration of 40 nM. For 
one 10 cm dish 320 pmoles of siRNA was diluted in 800 pi of SF Opti-MEM medium 
and 16 pi of Lipofectamine was diluted in 800 pi of SF Opti-MEM medium. The 
mixtures were incubated for 5 min. at room temperature. Following the incubation the 
diluted siRNA and Lipofectamine were combined. The transfection mixture was 
mixed by flicking the tube with a finger and incubated for 20 min. at room 
temperature. The entire transfection mixture (1.6 ml) was then added drop-wise to 
cells in 6.4 ml of complete growth media, distributing the drops over the entire dish 
surface, resulting in a final volume of 8 ml and a 40 nM final concentration of siRNA. 
The dish was then rocked gently to ensure even distribution of the liposome 
complexes and the cells were incubated at 37°C, 5% COi- The media was changed 
and replaced with 10 ml of complete growth media 6 hour's post transfection. The 
cells were analysed 48 hours post transfection.
The following siRNAs were used:
p53 (S’-GGA CAU ACC AGC UUA GAU U-3’) - as described in reference (467), 
MDM2 (5’-GCC AC A AAU CUG AUA GUA U-3’) - synthesized by Dharmacon, 
scrambled (5’-GGA CGC AUC CUU CUU AAU U-3’) - synthesized by Dharmacon.
2.7. Bradford assay
Cells were harvested by trypsinization and pelleted by centrifugation at 300xg for 
5 min. The pellets were washed with 1 ml of PBS and the cells were pelleted by
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centrifugation as previously. The pellets were frozen at -80°C prior to further 
processing.
SLIP fStuart Linn Immunonrecipitation) buffer
Concentration Reagent
50 mM HEPES, pH 7.5
150 mM NaCl
10% (v/v) glycerol
0.1% (v/v) Triton X-100
Protein sample loading buffer 04 x)
Concentration Reagent
250 mM Tris, pH 6.8
8% (w/v) SDS
40% (v/v) glycerol
4 mg/ml bromophenol blue
1% (v/v) p-mercaptoethanol
2* 7,1, Preparation of protein standards
SLIP buffer was supplemented with protease inhibitors: aprotinin (2 pg/ml), leupeptin 
(0.5ng/ml), pepstatin A (ipg/ml), soybean trypsin inhibitor (lOOpg/ml) and 
phenylmethylsulfonyl fluoride (1 mM). 20 mg of BSA was dissolved in 1 ml of SLIP 
buffer. A serial dilution was then made to obtain the following BSA concentrations: 
lOmg/ml, 5mg/ml, 2.5mg/ml, 1.25mg/ml, 0.6mg/ml and 0.3mg/ml. 2 pi of 
the standards were then added to 1 ml of protein assay dye reagent (diluted 1:5 with 
H20). 2 pi of the SLIP buffer was also added to 1 ml of protein assay dye reagent and 
used as a blank. A standard curve was prepared on the BioPhotometer (Eppendorf)
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using the Bradford program, which measures absorbance at 595 mn. The calibration 
was considered acceptable if the obtained CV was below 5.
2.7.2. Protein extraction and quantification
Cell pellets were lysed on ice in SLIP buffer supplemented with protease inhibitors 
(as above). After incubation on ice for 10 minutes, the lysates were centrifuged at 
16,000xg for 10 min. at 4°C and the supernatants were transferred to fresh tubes. 2 pi 
of the lysates were then added to 1 ml of protein assay dye reagent and the protein 
concentrations were determined based on the prepared standard curve.
Typically, 50 pg of total protein was then made up in sample loading buffer (final 
concentration of the buffer lx) to a total volume of 20 pi.
2.8. SDS-PAGE (polyacrylamide gel electrophoresis) 
Tris-Glvcine electrophoresis buffer (running buffer)
Concentration Reagent
25 mM Tris
250 mM glycine
0.1% (w/v) SDS
Table 2.1: Composition of SDS-PAGE gels (volumes needed for 2 gels).
Reagent
Resolving gel
Stacking gel
10% 12%
40% acrylamide mix 2 ml 2.4 ml 510 pi
1.5 M Tris, pH 8.8 2 ml 2 ml —
1 M Tris, pH 6.8 — — 500 pi
10% SDS 80 pi 80 pi 40 pi
h2o 3.83 ml 3.43 ml 2.9 ml
TEMED 6.4 pi 6.4 pi 4 pi
10% APS 80 pi 80 pi 40 pi
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The percentage of acrylamide in the resolving gel was chosen based on the size of 
proteins to be analysed. The glass slides for making 0.75 mm thick gels were 
assembled and the resolving gel was poured into the sandwich, overlaid with water 
and allowed to polymerize. After the gel had set, the water was poured off and the 
stacking gel was poured, a comb inserted and the gel allowed to polymerize. 
Following polymerization, the comb was removed and the glass sandwich was placed 
in an electrophoresis tank filled with running buffer.
The protein samples were denatured by boiling for 5 min, vortexed, spun down and 
placed on ice. Typically 50 pg of total protein in lx sample loading buffer was loaded 
on the gel alongside a pre-stained protein marker. SDS-PAGE was performed using 
a two-gel Mini-PROTEAN® Tetra cell (Bio-Rad) at 200 V for 1 hour.
2.9. Silver Staining
After resolving proteins on SDS-PAGE, it is possible to visualize them by staining 
with silver. Silver staining is very sensitive and can detect as little as nanogram 
quantities of protein (468). Silver Stain Plus Kit (Bio-Rad) was used for this purpose.
Fixative Enhancer Solution
Reagent
Reagent Grade Methanol 
Reagent Grade Acetic Acid 
Fixative Enhancer Concentrate 
H20
Volume (1 gel) 
10 ml 
2 ml 
2 ml 
6 ml
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Staining Solution
Reagent
H20
Silver Complex Solution 
Reduction Moderator Solution
Volume (1 gel) 
3.5 ml
0.5 ml
0.5 ml
Image Development Reagent 0.5 ml
Development Accelerator Solution 5 ml
The components were added in the indicated order.
All the reagents were prepared freshly immediately before use. Development 
Accelerator Solution was prepared by dissolving 0.5 g of Development Accelerator 
Reagent in 10 ml of H2O.
Following SDS-PAGE the gel was transferred to a clean tray and incubated in the 
Fixative Enhancer Solution with gentle agitation for 20 min. The solution was then 
decanted and the gel was rinsed in 20 ml of H2O for 10 min. with gentle agitation. 
The water was decanted and the rinse step was repeated. The gel was then placed in 
the Staining Solution and incubated with gentle agitation until the desired staining 
intensity was reached. The staining was stopped by placing the gel in 5% (v/v) acetic 
acid solution and incubating for 15 min. with gentle agitation. Afterwards, the gel was 
rinsed in H2O for 5 min., scanned and dried using a Model 543 Gel Dryer (Bio-Rad) 
attached to a LABOPORT® Vacuum Pump (KNF Neuberger).
2.10. Western blotting
Western blotting is a technique, which allows for detection of specific proteins in the 
studied sample. Proteins are first separated by size using SDS-PAGE and then
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transferred to a membrane, which is probed with antibodies specific to the proteins of 
interest.
Transfer Buffer
Concentration 
25 mM 
192 mM 
20% (v/v)
PBS/Tween 
Concentration
65 mM 
15 mM 
75 mM 
0.1 % (v/v)
Ponceau S solution
Concentration Reagent
0.2% (w/v) Ponceau S
5% (v/v) acetic acid
Following SDS-PAGE proteins were transferred onto a Hybond ECL nitrocellulose 
membrane using the Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad). The 
gel was removed from between the glass slides onto pre-wetted Whatman paper. The 
nitrocellulose membrane was placed gently over the gel making sure that no air 
bubbles were trapped in between. It was then covered with another piece of Whatman 
paper, placed between a pair of sponges and inserted into the blotting cassette. The 
cassette was placed in the tank along with an ice pack (to prevent overheating during
Reagent
Tris
glycine
methanol
Reagent
Na2HP04-2H20 
NaH2P04 *2H20 
NaCl 
Tween 20
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the transfer) and the tank was filled with transfer buffer. The transfer was performed 
at 100 V for 1 hour. Following the transfer, the membrane was stained briefly with 
Ponceau S and rinsed with H2O to check whether the transfer of proteins was 
successful. The membrane was destained briefly in PBS/Tween and blocked in 
5% (w/v) non-fat dry milk in PBS/Tween solution at 4°C overnight (to prevent 
non-specific binding of antibodies to the membrane).
The membrane was sliced into strips based on the size of studied proteins as 
required and incubated with primary antibodies (in 5% milk-PBS/Tween solution) for 
1 hour at room temperature. The membranes were then washed thrice for 15 min. in 
PBS/Tween. The horseradish peroxidase (HRP)-conjugated secondary antibodies (in 
5% milk-PBS/Tween solution) were then applied and the membranes were incubated 
for 1 hour at room temperature. The membranes were washed 3 times as previously. 
All the incubation and washing steps were performed on a shaker with gentle 
agitation. Following the final wash, the membranes were transferred to dry trays and 
the Western Lightning Plus-ECL chemiluminescence reagent was applied for 1 min. 
The signal was detected by chemiluminescence and recorded using a Kodak IM4000 
image station.
The primary antibodies used included:
• anti-actin antibody C-2 (sc-8432, Santa Cruz Biotechnology) - 3pg/ml; a mouse 
monoclonal antibody, which recognizes an epitope within amino acids 350-375 of 
human actin,
• anti-Bcl-2 antibody 124 (M0887, DakoCytomation) - 1:100 dilution, a mouse 
monoclonal antibody raised against a synthetic peptide comprising amino acids 
41-54 of human Bcl-2,
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• anti-GFP antibody (Roche) - 0.4(.ig/ml; a mixture of two mouse monoclonal 
antibodies (from clone 7.1 and 13.1) raised against partially purified GFP from 
Aequorea victoria,
• anti-MDM2 antibody IF2/Ab-1 (OP46T, Calbiochem) - 3 pg/ml; a mouse 
monoclonal antibody, which recognizes an epitope within amino acids 26-169 of 
human MDM2,
• anti-MDMX goat polyclonal antibody D-19 (sc-14738, Santa Cruz) - 3 jig/ml; 
a goat polyclonal antibody, which recognizes an epitope within an internal region 
of human MDMX,
• anti-MTBP antibody T-14 (ProMab Biotechnologies) - 3pg/ml; a mouse 
monoclonal antibody raised against recombinant MTBP by ProMab 
Biotechnologies using their standard protocol for monoclonal antibody production 
(469),
• anti-p21 antibody F-5 (sc-6246, Santa Cruz Biotechnology) - 3 (ig/ml; a mouse 
monoclonal antibody raised against amino acids 1-159 representing full-length 
p21 of mouse origin, cross-reacts with human p21,
• anti-p53 antibody DO-l/Ab-6 (OP43, Calbiochem) - 3 pg/ml; a pantropic mouse 
monoclonal antibody, which recognizes an epitope within amino acids 21-25 of 
human p53,
• anti-p53 antibody (ab2433, Abeam) — 3 pg/ml; a rabbit polyclonal antibody raised 
against a synthetic peptide comprising amino acids 277-296 of human p53,
• anti-Tmod3 antibody (R5168) - 3 (.ig/ml; a rabbit polyclonal antibody raised 
against recombinant human Tmod3; the antibody was a kind gift from Prof. Velia 
Fowler (The Scripps Research Institute).
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The secondary antibodies used were HRP-conjugated and included:
• sheep anti-mouse antibody (RPN4201, GE Healthcare) - used at a 1:2500 
dilution,
• donkey anti-rabbit antibody (NA934, GE Healthcare) — used at 1:5000 dilution,
• rabbit anti-goat antibody (305-036-003, Jackson ImmunoReseai'ch Laboratories) - 
used at a 1:20,000 dilution.
2.10.1, Densitometry
Wherever indicated signal intensity was estimated by performing densitometry. 
Kodak Molecular Imaging Software v. 4.0.3K1 was used for this purpose. When 
collecting data, the software records intensity value for each pixel. The areas for 
analysis were defined by creating manual regions of interest (ROIs) on the image 
using the ROI Rectangle tool. Volume measurement was then performed by the 
software using the recorded pixel information. One of the ROIs was selected on 
a blank paid of blot (without any samples) and used as background. The signal 
intensity for each sample was calculated by subtracting the sum intensity of the blank 
ROI from the sum intensity (the sum of all the pixel intensities within the ROI, 
including the background) of each of the sample ROIs.
2.11. Dual-luciferase reporter assays
Luciferase reporter assays are a commonly used technique to study eukaryotic gene 
expression. In dual-reporter assays the simultaneous expression of two individual 
reporter enzymes is measured within a single system. Typically, one reporter enzyme 
reflects the specific experimental conditions and the other serves as a baseline control
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and can indicate whether the transfection efficiency between different conditions was 
equal.
The Dual-Luciferase® Reporter 1000 Assay System (Promega) was used for 
performing dual-reporter assays (as descriebd previously (470)). In this assay, the 
activities of firefly luciferase (from Photinus pyralis) and Renilla luciferase (from 
Renilla reniformis also known as sea pansy) are measured sequentially from a single 
sample. It is possible to distinguish between the respective bioluminescent reactions 
of firefly and Renilla luciferases due to different structures and substrate requirements 
of these two enzymes. None of these enzymes requires post-translational 
modifications for its enzymatic activity and hence they can function as genetic 
reporters immediately following translation. Firefly luciferase catalyzes a luminescent 
reaction, in which photon emission is achieved through oxidation of beetle luciferm to 
oxyluciferin. Renilla luciferase catalyzes a luminescent reaction, in which light is 
generated as a result of oxidation of coelenterazine (coelenterate-luciferin) to 
coelenteramide. In this assay, the firefly and Renilla luciferase reactions produce 
stabilized luminescence signals, which decay slowly over time. Both reporters yield 
lineai’ assays, which are extremely sensitive (ranging from sub-attomole amounts of 
enzyme per reaction over seven orders of magnitude).
For reporter assays, cells were seeded into 6-well plates and co-transfected with 
1.2 pg of pp53-TA-luc (firefly luciferase), 0.12 pg of pRL-TK {Renilla luciferase) and 
0.3 pg of pSUPER.GFP per well (constructs described in detail in section 2.4.10). 
24 hours post transfection the cells were lysed on plates by adding 500 pi of Passive 
Lysis Buffer (diluted 1:5 in FLO) per well and incubating the plates for 10 min. at 
room temperature with gentle agitation. Passive Lysis Buffer promotes rapid lysis of 
cultured mammalian cells, provides optimum stability of the firefly and Renilla
120
Materials and Methods
luciferases as well as minimum background luminescence. The lysates were 
transferred into microcentrifuge tubes and centrifuged for 1 min. at 16,000xg at 4°C. 
The supernatants were then transferred into fresh microcentrifuge tubes. The firefly 
luciferase signal was measured first. 100 pi of LAR II (Luciferase Assay Reagent II) 
was placed in a fresh tube. 20 pi of the sample was added, the tube was vortexed for 
1 sec. and luminescence was measured at 560 nm in a Glomax 20/20 luminometer 
(Turner BioSystems). The reaction was then quenched and the Renilla luciferase 
reaction was initiated by adding 100 pi of Stop & Glo® Buffer (supplemented with 
50x Stop & Glo® Substrate). The tube was vortexed for 5 sec. and the Renilla 
luciferase activity was measured with an integration period of 10 sec. The results were 
normalised to protein concentrations in the samples, which were measured using 
a microBradford assay. A microBradford assay was performed analogically to 
Bradford assay (described in section 2.7) with the following BSA concentrations 
prepared by serial dilution and used for calibration: 5mg/ml, 2.5mg/ml, 
1.25mg/ml, 0.625mg/ml, 0.313mg/ml, 0.156mg/ml and 0.078mg/ml.
2.12. In situ p-galactosidase assay
In situ P-galactosidase staining was used for determination of transfection efficiency. 
Cells were transfected with pp-gal containing the lacZ gene, which encodes 
p-galactosidase. p-galactosidase cleaves X-Gal into galactose and 
5-bromo-4-chloro-3-hydroxyindole, which upon oxidation forms an insoluble blue 
product. Therefore, the cells, which were transfected with pp-gal and express 
p-galactosidase will turn blue.
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Substrate Buffer
Concentration
3mM 
3 mM 
1 mM 
2% (w/v)
Reagent
potassium ferrocyanide 
potassium ferricyanide 
magnesium chloride 
X-Gal
24 hours post transfection the cells were washed in PBS and fixed using Fixing 
Buffer (0.5% (v/v) glutaraldehyde in PBS) for 15 minutes at room temperature. 
Following the incubation the Fixing Buffer was removed, the cells were washed twice 
with PBS and incubated in Substrate Buffer overnight at 37°C, 5% CO2. The 
following day the Substrate Buffer was removed, the cells were washed twice in H2O 
and the plates were dried.
2.13. Establishing stable cell lines
2.13.1. Stable cell lines expressing TAP-tagged forms ofpS3
In order to study protein interactions of the two mutant forms of p53 in laryngeal 
cancer, large numbers of UM-SCC-12 cells expressing TAP-tagged p53-175H and 
p53-273H were required. Given the low transfection efficiency of UM-SCC-12, 
establishing lines with a stable expression of the p53 mutants was attempted.
To determine the optimal concentration of G418 antibiotic to be used for selection, 
UM-SCC-12 cells were grown in the presence of G418 at the following 
concentrations: lOOpg/ml, 200pg/ml, 400pg/ml, SOOpg/ml, 1000qg/ml. The 
concentration of the selective marker that killed all the cells in approximately 12 days 
was chosen.
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For establishing stable cell lines, UM-SCC-12 cells were transfected with 
pNTAP-B.p53, pNTAP-B.p53~175H or pNTAP-B.p53-273H using FuGENE at 
a ratio 3:1. Stable clones were selected by growing the transfected cells in full growth 
medium containing 400 pg/ml G418. After individual colonies were formed, they 
were picked using a sterile pipette tip containing 5 pi of trypsin, transferred to 24-well 
plates and expanded. Following selection, the G418 concentration was reduced to 
200pg/ml for maintenance of the stable clones. The clones were screened by western 
blotting for the expression of the TAP-tagged p53 proteins.
2.13.2. Stablep53-knock-down cell lines
Following the generation of UM-SCC-12 clones expressing the TAP-tagged 
p53-175H or TAP-tagged p53-273H, a stable knock-down of p53 expression in these 
clones was attempted to determine whether the results observed in the generated 
mutant p53-expressing clones are due to mutant p53 and to exclude the possibility of 
clonal variation.
To determine the optimal concentration of selective marker to be used for 
selection, UM-SCC-12 cells were grown in the presence of Puromycin at the 
following concentrations: 0.2pg/ml, 0.4pg/ml, 0.6pg/ml, O.Spg/ml, lpg/ml. The 
concentration of the selective marker that killed all the cells in approximately 5 days 
was chosen.
For establishing stable cell lines, UM-SCC-12 clones were transfected with 
pSUPER.puro.shp53 or pSUPER.puro.shScr using FuGENE at a ratio 3:1. Stable 
clones were selected by growing the transfected cells in full growth medium 
containing 0.5 pg/ml Puromycin. Following the selection, the Puromycin 
concentration was reduced to 0.25 pg/ml for maintenance of the stable clones. The
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clones were screened by western blotting for the expression of the TAP-tagged p53 
proteins.
2.14. Live imaging of cell migration
Live cell imaging is a technique that allows for long-term observation of living cells 
and analysis of cell migration. Over the course of an experiment the cell culture vessel 
is kept in a microscope chamber, which is heated to 37°C and the cells are supplied 
with a humidified C02-containing atmosphere (see Figure 2.1 for an illustration of the 
microscope chamber setup).
plexiglass 
environmental 
chamber \
stage with 
clamp "
access door
inverted
microscope
humidifying
container
heating unit
C02 supplying 
tube
C02 flow 
controller
Figure 2.1. Microscope configuration for live-cell imaging. The culture plate (typically 
a 6-well plate) with cells was inserted into the plexiglass environmental chamber through the 
access door and fitted on the stage with a clamp. The temperature probe was inserted into the 
water-filled space of the plate in-between the wells. C02 was passed through ajar with water 
placed over the heating unit to facilitate evaporation and this humidified C02 was delivered to 
the plate through two inlets in the lid.
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Typically, between 150,000 and 200,000 cells were seeded per well of a 6-well 
plate one day before the start of the experiment. On the day of the experiment the 
microscope chamber was pre-heated to 37°C. The media was replaced with 6 ml of 
fresh full growth media per well and 2 ml of H2O was placed in the spaces between 
the wells to minimise evaporation. The cell culture plate was placed inside the 
microscope chamber and the temperature probe was placed in the water-containing 
space between the wells. The CO2 supply was switched on and imaging was started.
A few positions (2-3) were selected per well and these were imaged with 
a time-lapse of 3 min. for 12 to 24 horn's using Simple PCI software (Hamatsu 
Corporation). The recorded images were then combined to create movies.
The motility of cells was analysed using ImageJ software (National Institutes of 
Health). Plugins enabling tracking of individual cells were written by Dr Carlos Rubbi 
(University of Liverpool). Between 20 and 50 cells per condition were selected and 
tracked. The following parameters were determined and compared:
• total distance travelled - the length of the entire track of each cell,
• net distance travelled - distance in straight line between the first and last position 
of each cell,
• speed — total distance travelled divided by the duration of experiment in minutes,
• directionality - net distance travelled divided by total distance travelled.
2.14.1. Live imaging of migration in cells manipulated by RNAi 
Transfection with siRNA was performed as described in section 2.6.5. 6 hour's post 
transfection the media was changed and replaced with full growth media. 8 hours post 
transfection the cells were trypsinized and counted. Two 6-well plates were prepared 
for live imaging to ensure that the cells did not become overconfluent during the
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imaging, which could affect motility. One plate was seeded with 200,000 ceils per 
well (one well per condition) to be imaged 24-36 hours post transfection and 
175,000 cells per well (one well per condition) were seeded into another plate to be 
imaged 36-48 hours post transfection. Imaging was performed as described in 
section 2.14.
The remaining cells from each condition were seeded into 6-well plates (one plate 
per condition) distributing the cells evenly between all wells. 3 wells per condition 
were harvested for a western blot in the middle of each of the imaging intervals (at 
30 hour's and 42 hours post transfection, respectively) to determine the knock-down 
efficiency.
2.15. Boyden chamber migration assays
The Boyden chamber migration assay measures the migratory potential of cells as 
determined by their ability to migrate from one medium-filled compartment to another 
through a microporous membrane.
BD Falcon™ Cell Culture Inserts for 24-well plates with a membrane containing 
8.0 pm pores at a density of 6 + 2-104 per cm2 (BD Biosciences) were used for 
migration assays. The cell culture inserts were placed in a 24-well Companion Plate 
(BD Biosciences) containing 600 pi of full growth media. Typically, 15,000 cells in 
300 pi of full growth media were seeded into the insert and the plate was incubated at 
37°C, 5% CO2 for 18 hours. Following incubation the inner side of the insert was 
scraped rigorously with a cotton bud to remove all the cells that did not migrate 
through the porous membrane. The inside of the insert was further washed with 
a cotton bud soaked in PBS. The cells that migrated through the membrane were fixed 
and stained using the REASTAIN Quick-Diff Kit. The cells were first fixed by
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placing the cell culture insert in a well with 500 pi of REASTAIN Quick-Diff Fix 
solution for 10 min. The insert was then stained with 500 pi of REASTAIN 
Quick-Diff Red solution for 2 min., followed by a 2 min. staining with 500 pi of 
REASTAIN Quick-Diff Blue solution. The inserts were then rinsed in a large volume 
of H2O and left upside down on a piece of towel to dry.
Once the cell culture inserts were completely dry, the membranes were excised 
from the inserts using a sharp scalpel blade and mounted on a microscope glass slide 
under a cover slip using DPX Mountant. The slides were allowed to dry and the cells 
that migrated through the membrane were counted using a phase contrast microscope.
2.16. Boyden chamber invasion assays
The Boyden chamber invasion assay enables to study invasiveness of cells in vitro as 
determined by their ability to penetrate through a reconstituted basement membrane 
and migrate from one medium-filled compartment to another (containing 
chemoattractant) through a microporous membrane.
BD BioCoat™ Matrigel™ Invasion Chambers for 24-well plates with a membrane 
containing 8.0 pm pores (BD Biosciences) were used for invasion assays. The 
membrane of the invasion inserts is coated with a thin layer of Matrigel Matrix, 
serving as a reconstituted basement membrane, which completely occludes the pores 
of the membrane. Therefore, only the cells, which are capable of invading through the 
Matrigel Matrix can migrate through the membrane pores.
The invasion inserts were removed from -20°C storage and allowed to warm to 
room temperature. They were then placed in a 24-well Companion Plate and 500 pi of 
pre-warmed SF bicarbonate-based media was added to the interior of the inserts and 
the wells. The chambers were allowed to rehydrate for 2 hour's in a humidified tissue 
culture incubator (37°C, 5% CO2).
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Towards the end of the incubation period the cells were harvested by trypsinization 
and pelleted by centrifugation at 90xg for 10 min. at room temperature. The media 
was aspirated and the cells were resuspended in DMEM supplemented with 
0.1% FBS, 1% L-glutamine and 1% Non-Essential Amino Acids.
The Companion Plate was removed from the incubator. The media from the inside 
of the inserts was aspirated gently without disturbing the layer of Matrigel. The inserts 
were then transferred to fresh wells containing 750 pi of full growth media (with 
10% FBS serving as a chemoattractant). 50,000 cells in 500 pi of media containing 
0.1% FBS (thus generating a serum gradient) were then seeded into the inserts and the 
plate was incubated at 37°C, 5% CO2 for 30 hours. Following the incubation the inner 
side of the inserts was scraped rigorously with a cotton bud to remove all the cells that 
did not migrate through the porous membrane. The inside of the inserts was further 
washed with a cotton bud soaked in PBS. The inserts were then placed in a well with 
500 pi of REASTAIN Quick-Diff Fix solution (methanol) for 10 minutes to fix the 
cells that migrated through the membrane. The inserts were then stained with 500 pi 
of 0.5% Crystal Violet solution for 30 min. The inserts were rinsed in a large volume 
of H2O and left upside down on a piece of towel to dry.
Once the cell culture inserts were completely dry, the membranes were excised 
from the inserts using a sharp scalpel blade and mounted on a microscope glass slide 
under a cover slip using DPX Mountant. The slides were allowed to dry and the cells 
that migrated through the membrane were counted using a phase contrast microscope.
2.17. RNA isolation and quality testing
In order to study gene expression in UM-SCC-12 cells (p53-null) and UM-SCC-12 
derivatives expressing high levels of the GOF p53 mutants (p53-175H or p53-273H)
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total cellular RNA was extracted using the RNeasy Mini Kit. Briefly, cells are lysed 
in a buffer containing guanidine thiocyanate, which inactivates RNases and prevents 
RNA degradation. The total RNA is then bound to the silica membrane of the RNeasy 
column under high-salt conditions. The on-column DNase treatment allows for 
removal of the contaminating DNA, which is washed away along with other 
contaminants during the washes. High-quality RNA is then eluted in RNase-free H2O. 
This procedure provides an enrichment for mRNA since RNA molecules smaller than 
200 nucleotides (15-20% of total RNA) are selectively excluded. RNA purified using 
this method is suitable for downstream applications such as microarrays or qRT-PCR.
Typically, 3xl06 cells were seeded into a tissue culture flask and incubated 
overnight. The following day the cells were harvested by trypsinization and pelleted 
by centrifugation at 300xg for 5 min. at room temperature. The media was aspirated 
and the cells were washed in 1 ml of PBS. The cells were centrifuged again at 300xg 
for 5 min. at room temperature and the supernatant was removed completely. The 
cells were lysed in 350 pi of Buffer RLT (for processing up to 5xl06 cells) by 
pipetting up and down. The lysate was then pipetted directly into a QIAshredder spin 
column (to ensure complete homogenization) and the column was centrifuged for 
2 min. at 16,000xg. 350 pi of 70% ethanol were then added to the homogenized lysate 
and mixed by pipetting. The sample was then transferred into an RNeasy spin column 
and centrifuged for 15 sec. at 8,000xg. The flow-through was discarded. The column 
was washed with 350 pi of Buffer RW1 and centrifuged for 15 sec. at 8,000xg. The 
flow-through was discarded, 80 pi of DNase I incubation mix, prepared directly 
before use by adding 10 pi of DNase I to 70 pi of Buffer RDD, was then pipetted into 
the centre of the column membrane and incubated for 15 min. at room temperature. 
Following the incubation 350 pi of Buffer RW1 was added to the column, which was
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then centrifuged for 15 sec. at 8,000xg. The flow-through was discarded. The column 
was then washed with 500 jil of Buffer RPE and centrifuged for 15 sec. at 8,000xg. 
The flow-through was discarded. The column was washed again with 500 gl of Buffer 
RPE and centrifuged for 2 min. at 8,000xg. The column was then placed in a fresh 
collection tube and centrifuged for 1 min. at 16,000xg. The column was then 
transferred to a 1.5 ml RNase-free microcentrifuge tube, 30-50 pi of RNase-ffee H2O 
was pipetted directly onto the column membrane and the RNA was eluted by 
centrifugation for 1 min. at 8,000xg.
RNA was quantified by spectrometry at 260 mn with a BioPhotometer using the 
RNA program. The integrity was tested by running 500 ng of total RNA on 
a 1% (w/v) agarose gel (prepared using GenSieve LE agarose).
2.18. Expression microarrays
Microarray technology enables monitoring of genome-wide expression levels of genes 
in a given organism. Thousands of DNA molecules (of known identity, called probes) 
are immobilised on a glass slide in a highly organised manner at specific positions 
known as features. A microarray may contain thousands of features, each containing 
a few million copies of identical probes that are unique to specific genes. Determining 
the gene expression levels is based on complementary binding between the unknown 
sequences and the probes.
First, RNA is extracted from cells or tissue. It is then reverse-transcribed and 
subjected to linear amplification to create sense strand cDNA. The sense strand cDNA 
is fragmented (to aid exon array hybridisation), providing a template for the synthesis 
of either reverse strand cDNA or cRNA, which is fluorescently labelled either 
directly, by incorporation of fluorescently labelled nucleotides, or in the case of single
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colour microarrays, indirectly by the incorporation of biotinylated nucleotide residues. 
cRNA may be used because RNA-DNA hybridization is more stable (stronger) than 
DNA-DNA hybridization. The sample (cDNA or cRNA) is hybridized onto 
a microarray glass slide (chip). Immediately following hybridization, the array is 
washed and, if using biotinylated cDNA, the array is stained with streptavidin 
phycoerythrin conjugate. Phycoerythrin is derived from cyanobacteria and eukaryotic 
algae and exhibits extremely bright fluorescence. The labelled cDNA is then excited 
by a laser and the chip with the fluorescing features is scanned to quantify the emitted 
fluorescence, which corresponds to the amount of nucleic acid bound to the probes 
(and the initial mRNA present).
Expression profiles of mutant p53-expressing (p53-273H) laryngeal cancer cells 
(12-273H-39) were compared with parental UM-SCC-12 cells (p53-null). The RNA 
samples for each cell line were prepared in triplicate on three separate occasions. The 
microarray hybridization of biotinylated cDNA was performed using an Affymetrix 
GeneChip® Human Exon 1.0 ST Array (as described previously (471)) within the 
Cancer Research UK Affymetrix GeneChip Microarray Service hosted by the 
Molecular* Biology Core Facility (Paterson Institute for Cancer Research). The array 
consisted of 5,362,207 features, used to investigate 1,084,639 exon clusters 
(collections of overlapping exons) with over 1.4 million probe sets (472). A probe set 
contains typically between 11 and 20 probe pairs, which interrogate the same 
sequence (e.g. a transcript). The probes were 25 bp long. Most of the exon-based 
probe sets contained 4 probes for each exon and there were approximately 40 probes 
per gene.
Following hybridisation, the microarray chip was scanned using a GeneChip® 
Scanner 3000 (Affymetrix). Affymetrix GeneChip Command Console software
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(AGCC) was used to extract pixel intensities from the generated image and to 
calculate single intensity values for each gene. Data analysis was performed by Dr 
Bryony Lloyd (University of Liverpool). Quality control analysis was performed on 
the raw array data using Expression Console software (Affymetrix). Normalisation 
was performed to minimise systematic errors and ensure that the majority of observed 
differences are due to biological variation. The data was then analysed to identify 
differentially expressed genes and clustered to identify groups of co-regulated genes 
and the pathways involved.
The generated microarray data was MIAME compliant (Minimum Information 
About a Microarray Experiment) and was logged in a secure database known as 
MIAME VICE (measuring Variations In Cellular' Expression) (473), which was 
written by the Bioinformatics Department at the Paterson Institute for Cancer 
Research.
2.19. Quantitative real-time PCR
The results obtained from the expression array analysis were validated using two-step 
quantitative real-time PCR (qRT-PCR). qRT-PCR was performed by members of the 
Applied Biology team (led by Prof. D. Ross Sibson and Dr Bryony Lloyd, University 
of Liverpool). Data analysis was performed by Dr Bryony Lloyd.
2.19d. Reverse transcription
1.5 pg of total RNA was reverse transcribed using a Superscript™ First-Strand 
Synthesis System for RT-PCR (Invitrogen) according to manufacturer’s instructions. 
The following mixture was prepared.
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Component
total RNA (1.5 jag) 
50 (xM oligo(dT)2o 
10 mM dNTP mix 
DEPC-treated water
Volume
n jal (depending on the RNA concentration) 
1 pi 
1 pi
up to a total volume of 10 pi
The mixture was incubated at 65°C for 5 min. and then placed on ice for at least 
1 min. The cDNA Synthesis Mix was prepared by combining the following 
components in the indicated order.
Component
10x RT buffer 
25 mM MgCl2 
0.1 MDTT 
RNaseOUT (40 U/jd) 
Superscript™ III RT (200 U/pl)
Volume (1 reaction) 
2 pi 
4 pi 
2 pi 
1 pi 
1 pi
10 pi of the cDNA Synthesis Mix was added to each RNA/primer mixture and 
incubated at 50°C for 50 min. The reaction was terminated by heating to 85°C for 
5 min. and then chilled on ice. 1 pi of RNase H was added to each reaction and 
incubated at 37°C for 20 min.
Each RNA sample was reverse transcribed in duplicate and the no RT control was 
performed once per sample. A 1:20 dilution of the resulting cDNA and no RT control 
was prepared and stored at -20°C. 5 pi of the respective cDNA/no RT control was 
used for each qRT-PCR reaction.
2.19.2. Standard preparation
Genes of interest selected from the expression microarray data analysis were 
amplified by PCR from the cDNA using the primers and thermal cycling reaction
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conditions listed in Appendix 1. The PCR products were cloned into pCR2.1 vector 
from the Topo TA cloning kit (Invitrogen). The identity of the PCR products was 
confirmed by direct sequencing using DYEnamicET Dye Terminator Cycle 
Sequencing Kit for MegaBACE (Amersham Biosciences) and analysed on 
a MegaBACE1000 (Amersham Biosciences). Once confirmed, plasmid purification 
was performed using the QIAPrep SpinMiniprep Kit (Qiagen). The DNA was 
quantified using NanoDrop ND-1000 (Thermo Scientific) and the following 
7 standard amounts of each plasmid were prepared: 2xl03, 2xl02, 2X101, 2, 
2 x 1 O'1, 2 x 1 O'2 and 2 x 1 O'3 attomoles per reaction.
2J9.3. qRT-PCR
iQ™ SYBR® Green Supermix (Bio-Rad) was used for qRT- PCR (performed as 
described previously (474)). iQ SYBR Green Supermix is a 2x mix for real-time PCR 
application containing a 2x proprietary reaction buffer with dNTPs, iTaq DNA 
polymerase, 6 mM MgCfr, SYBR Green I, fluorescein and stabilizers. The reactions 
were set up in 96-well PCR microplates by combining the following components.
Component Volume (1 reaction)
2x iQ SYBR Green Supermix 10 pi
primer 1 (10 pM) 1 pi
primer 2 (10 pM) 1 pi
sterile water 3 pi
cDNA 5 pi
Final reaction volume: 20 pi
The final concentration of the primers was 500 nM. The qRT-PCR was carried out 
in triplicate for each reverse transcription (see Figure 2.2) and in duplicate for each no
134
Materials and Methods
RT control. The 7 concentrations of the standards (plasmid DNA containing the PCR 
product of interest) were also present in triplicate on each plate. The thermal cycling 
reaction conditions and primers used for each gene are included in Appendix 1. The 
qRT-PCR was performed using an iQ5 Multicolour Real-Time PCR Detection System 
(Bio-Rad).
2.19.4. Data analysis
The cycle number (CT) at which the fluorescence passes a certain threshold was 
determined. Ct determined for the 7 standards was plotted against the log of the 
standard amounts to create a standard curve, from which the amount of product in the 
unknown samples could be determined. This was performed using the CFX 
Manager™ Software (Bio-Rad).
RNA sample
reverse transcription
cDNA cDNA
qRT-PCR
PCR product PCR product PCR product PCR product PCR product PCR product 
amount amount amount amount amount amount
Figure 2.2: A schematic representation of the qRT-PCR experimental setup. Additionally, 
each RNA sample was present in triplicate.
Average values for each gene (for each transcription reaction separately) were 
determined. The results were normalised by dividing the average gene expression 
value by the average expression value of the reference gene (histone H3) for the 
corresponding reverse transcription reaction. This normalised relative value was then
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averaged between the two reverse transcription reactions. Since the RNA samples 
were also present in triplicates, the normalised relative values for each gene were 
averaged between the triplicates and the standard deviation was calculated. The 
relative gene expression was obtained by dividing the gene expression level in the test 
sample (e.g. expressing mutant p53) by the gene expression level in the control 
sample (e.g. p53-null).
2.20. TAP-tag purification
Tandem affinity purification (TAP) is a technique, which enables purification of 
a protein complex of interest using two different affinity purification tags: 
streptavidin-binding peptide (SBP) and calmodulin-binding peptide (CBP). SBP is 
a synthetic sequence isolated from a random peptide library, which has a high affinity 
for streptavidin (~ 2xl0“9 m) and can be specifically eluted with biotin (475). CBP 
is a peptide derived from a C-terminal fragment of skeletal muscle myosin light-chain 
kinase, which has a high affinity for calmodulin (~lxl0-9 m) in the presence of 
calcium (476) and can be specifically eluted by removing calcium with a chelating 
agent (477). The lysate containing the tagged protein of interest is passed through two 
consecutive columns with streptavidin and calmodulin resins, respectively (Figure 
2.3). The gentle washing and elution conditions allow for isolation of whole protein 
complexes without disrupting them. TAP-tag purification is a method of isolating 
highly purified protein complexes thanks to two rounds of specific binding and 
specific elution.
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Cell lysate is applied 
to Streptavidin resin
The eluate is applied 
to Calmodulin resin
1
Unbound proteins and contaminants 
are washed away
TAP-tagged protein and interacting 
partners are eluted
Unbound proteins and contaminants 
are washed away
TAP-tagged protein and interacting 
partners are eluted
Protein of interest (red) with 
interacting partner (green)
Streptavidin-binding 
^ peptide (SBP)
Calmodulin-binding 
peptide (CBP)
Contaminants £ Streptavidin resin Calmodulin resin
Figure 2.3: A schematic representation of the tandem affinity purification procedure.
The InterPlay Mammalian TAP System was used to isolate TAP-tagged p53-175H 
and p53-273H binding proteins according to the manufacturer’s instructions. The 
reagents necessary for the purification were prepared directly before use and kept on 
ice. Lysis buffer was supplemented with protease inhibitors: aprotinin (2pg/ml), 
leupeptin (0.5pg/ml), pepstatin A (ipg/ml), soybean trypsine inhibitor (lOOpg/ml) 
and phenylmethylsulfonyl fluoride (1 mM). Streptavidin binding buffer (SBB),
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streptavidin elution buffer (SEB) and calmodulin binding buffer (CBB) were 
supplemented with protease inhibitors (as described above) and (3-mercaptoethano 1 
(10 mM). Calmodulin elution buffer was supplemented only with (3-mercaptoethanol 
(10 mM). All centrifugation steps were performed at 4°C and the samples were kept 
on ice at all times. Samples from each step of the purification were kept for analysis.
lOxlO6 cells were lysed in 1 ml of the supplemented lysis buffer by three rounds 
of freeze-thawing. The lysate was centrifuged at 16,000xg for 10 min. at 4°C. The 
pre-cleared lysate was transferred to a fresh tube and supplemented with 4 pi of 
0.5 M EDTA and 0.7 pi of 14.4 M p-mercaptoethanol.
50 pi of 50% streptavidin resin slurry was centrifuged for 5 min. at l,500xg. The 
supernatant was discarded and the resin was washed twice with 1 ml of SBB followed 
by centrifugation for 5 min. at l,500xg to collect the resin. The supernatant was 
discarded and the resin was resuspended in 25 pi of SBB.
The pre-cleared lysate was then incubated with the streptavidin resin for 2 h at 4°C 
on a Clay Adams Brand Nutator (Becton Dickinson). Following the incubation the 
resin was collected by centrifugation for 5 min. at l,500xg and the supernatant was 
removed. The resin was washed twice with 1 ml of SBB and collected by 
centrifugation for 5 min. at l,500xg. The bound proteins were eluted in 100 pi of SEB 
by rotating the tube for 30 min. at 4°C on a nutator. Following the incubation the resin 
was collected by centrifugation for 5 min. at l,500xg. The eluate was transferred to 
a fresh tube and supplemented with 2 pi of streptavidin supernatant supplement and 
400 pi of CBB.
25 pi of 50% calmodulin resin slurry was centrifuged for 5 min. at l,500xg. The 
supernatant was discarded and the resin was washed twice with 1 ml of CBB followed
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by centrifugation for 5 min. at l,500xg to collect the resin. The supernatant was 
discarded and the resin was resuspended in 12.5 pi of CBB.
The supplemented streptavidin eluate was then incubated with calmodulin resin for 
2 h at 4°C on a nutator. Following the incubation the resin was collected by 
centrifugation for 5 min, at l5500xg and the supernatant was removed. The resin was 
washed twice with 1 ml of CBB and collected by centrifugation for 5 min. at l,500xg. 
The bound proteins were eluted in 50 pi of CEB by rotating the tube for 30 min. at 
4°C on a nutator. Following the incubation the resin was collected by centrifugation 
for 5 min. at l,500xg. The eluate was transferred to a fresh tube.
The streptavidin and calmodulin resins used for purification were resuspended in 
a volume of 1x sample loading buffer (see section 2.7) equal to the volume of packed 
resin used (25 pi and 12.5 pi, respectively).
The eluted proteins were resolved by SDS-PAGE and analysed using Silver 
Staining and western blotting. The purified proteins were identified using nanospray 
mass spectrometry.
2.20.1. Optimisation of the TAP-tag purification procedure
Due to the very low efficiency of the original TAP-tag purification procedure (see 
section 3.6), optimisation was necessary. Since the composition of the buffers 
provided with the kit was proprietary, a different protocol (including buffer 
composition) was obtained from reference (478) and used as a starting point for 
optimisation. All the buffers prepared in the course of optimisation will be referred to 
as custom buffers.
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Lvsis buffer
Concentration Reagent
10% (v/v) glycerol
50 mM HEPES
150 mM NaCl
2 mM EDTA
0.1% (v/v) Triton X-100
2 mM DTT
10 mM NaF
Supplemented with protease inhibitors (as described previously).
Streptavidin elution buffer fSEB)
Concentration Reagent
10 mM p-mercaptoethanol
50 mM HEPES
150 mM NaCl
1 mM MgAc
1 mM imidazole
0.1% (v/v) Triton X-100
2 mM CaCl2 2 mM CaCl2
10 mM D-biotin
Calmodulin binding buffer fCBEL
Concentration Reagent
10 mM P-mercaptoethanol
50 mM HEPES
150 mM NaCl
1 mM MgAc
1 mM imidazole
0.1% (v/v) Triton X-100
2 mM CaCl2
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Calmodulin rinsing buffer fCRB)
Concentration Reagent
50 mM ammonium bicarbonate
75 mM NaCl
1 mM MgAc
1 mM imidazole
2 mM CaCl2
Calmodulin elution buffer fCEB)
Concentration Reagent
50 mM Ammonium bicarbonate
25 mM EGTA
The reagents necessary for the purification were prepared directly before use and 
kept on ice. The streptavidin and calmodulin resins provided with the InterPlay 
Mammalian TAP System were used also for the optimisation experiments. All 
centrifugation steps were performed at 4°C and the samples were kept on ice at all 
times. Samples from each step of the purification were kept for analysis.
lOxlO6 cells were lysed in 1 ml of custom lysis buffer by rotating the tube for 
15 min. at 4°C on a nutator and performing two rounds of freeze-thawing. The lysate 
was centrifuged at 16,000xg for 15 min. at 4°C. The pre-cleared lysate was transferred 
to a fresh tube.
20 pi of 50% streptavidin resin slurry was centrifuged for 1 min. at 800 xg. The 
supernatant was discarded and the resin was washed twice with 800 pi of custom lysis 
buffer followed by centrifugation for 1 min. at 800xg to collect the resin. The 
supernatant was discarded leaving between 20 pi and 50 pi of buffer on the beads to 
prevent them from drying.
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The pre-cleared lysate was then incubated with the streptavidin resin at 4°C 
overnight on a nutator. After the incubation the resin was collected by centrifugation 
for 1 min. at 800 xg and the supernatant was removed. The resin was washed twice 
with 800 pi of custom lysis buffer, followed by three washes with 800 pi of custom 
CBB. The resin was then collected by centrifugation for 1 min. at 800xg5 the 
supernatant was removed leaving some liquid on the beads. The bound proteins were 
eluted in 20 pi of custom SEB by rotating the tube for 30 min. at 4°C on a nutator. 
The resin was collected by centrifugation for 1 min. at 800xgs the eluate was 
transferred to a fresh tube and the elution was repeated with another volume of 
custom SEB. The eluates were pooled together and supplemented with 40 pi of 
custom CBB and 5 pi of 0.1 M CaCl2.
20 pi of 50% calmodulin resin slurry was centrifuged for 1 min. at 800 xg. The 
supernatant was discarded and the resin was washed twice with 800 pi of custom 
CBB followed by centrifugation for 1 min. at 800xg to collect the resin. The 
supernatant was discarded leaving some liquid on the beads to prevent them from 
drying.
The supplemented streptavidin eluate was then incubated with calmodulin resin for 
2 h at 4°C on a nutator. The resin was washed twice with 800 pi of custom CBB, 
followed by three washes with 800 pi of custom CRB. The resin was then collected 
by centrifugation for 1 min. at 800xg, the supernatant was removed leaving some 
liquid on the beads. The bound proteins were eluted in 10 pi of custom CEB by 
rotating the tube for 30 min. at 4°C on a nutator. The resin was collected by 
centrifugation for 1 min. at 800xg, the eluate was transferred to a fresh tube and the 
elution was repeated with another volume of custom CEB. The eluates were pooled 
together.
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The streptavidin and calmodulin resins used for purification were resuspended in 
a volume of 1 x sample loading buffer (see section 2.7) equal to the volume of packed 
resin used (10 pi each).
The eluted proteins were analysed as described previously. The details of 
optimisation of the above procedures are described in section 3.6.
2.21. Mass spectrometry
Mass spectrometry (MS) is an analytical technique, which enables determination of 
the composition of a sample by measuring the mass-to-charge ratio (m/z) of charged 
particles. In this procedure a sample is loaded onto the MS instrument and undergoes 
vaporization. The sample then passes through an ionisation source, where it is 
bombarded with a beam of electrons (electrospray ionisation, ESI), which displace 
electrons from organic molecules to form radical cations (also called molecular ions). 
The collection of ions is accelerated into the magnetic field and deflected according to 
their mass-to-charge ratio within the mass analyzer. The separated ions are then 
detected along with their relative abundance by the detector and recorded. The ion 
signal is processed into mass spectra.
MS is also frequently combined with liquid chromatography (LC), which may be 
used to physically separate the compounds before they are introduced into the 
ionisation source. LC-MS is a highly sensitive technique oriented at specific detection 
and identification of components in a complex mixture.
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Detector
Figure 2.4: A diagrammatic representation of the operating principle of mass spectroscopy 
(adapted from reference (479)).
LC-ESI-MS/MS (as described previously (480)) was used to identify the binding 
partners of p53-175H and p53-273H in the protein complexes isolated using TAP-tag 
purification. The eluted proteins were precipitated by mixing one volume of 
100% (w/v) TCA with four volumes of the sample (final TCA concentration 20%) 
and incubating on ice for 1 hour. The samples were centrifuged at 16,000xg for 
10 min. at 4°C. The supernatant was discarded and the pellet was washed twice with 
ice-cold acetone. Following a centrifugation at 16,000xg for 5 min. at 4°C, the 
supernatant was discarded and the pellet was air-dried briefly. The pellets were 
resuspended in 20 pi of 50 mM ammonium bicarbonate and treated with 0.1 mM DTT 
for 15 min. at room temperature. They were then treated with 55 mM iodoacetamide 
for 15 min. at room temperature. Finally, the samples were treated with 250 ng of 
trypsin overnight at 37°C, to digest the purified proteins into peptides.
Following the trypsin digest, the samples were cleaned up using Zip-Tips 
(Millipore). A Zip-Tip is a 10 pi pipette tip with a small bed of chromatography
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media fixed at its end, which is used for purifying protein, peptide and 
oligonucleotide samples to remove salts, buffers or detergents that could interfere 
with mass spectrometry. Briefly, 10 pi of a sample was transferred to a fresh tube and 
acidified by adding 1 pi of 1% (v/v) TFA. The Zip-Tip was wetted by pipetting 10 pi 
of 100% (v/v) ACN through it twice. It was then washed 3 times with 0.1% (v/v) 
TFA. The sample was bound to the Zip-Tip by pipetting it up and down 
approximately 10 times. The Zip-Tip was washed 3-5 times with 0.1% (v/v) TFA and 
the sample was eluted with 10 pi of 75% (v/v) ACN by pipetting it up and down 
5-6 times.
Following clean-up using Zip-Tips the samples were delivered into an API 
QSTAR Pulsar i system (Applied Biosystems) by automated in-line chromatographys 
using an integrated LC Packings System and a PepMap™ 100 C18 column of 75 pm 
internal diameter x 15 cm long (Dionex), via a nanoelectrospray source head and 
a 10 pm internal diameter PicoTip (New Objective). The LC conditions were the 
following: 5% (v/v) ACN, 0.05% (v/v) TFA for 15 min; 5-45% (v/v) ACN, 
0.05% (v/v) TFA for 60 min; 99% (v/v) ACN, 0.05 % (v/v) TFA for 10 min; 5% (v/v) 
ACN, 0.05% (v/v) TFA for 10 min; with a flow rate of 0.35pl/min throughout. 
MS and MS/MS spectra were acquired using the Analyst QS software (Applied 
Biosystems). The proteins present in the purified complexes were identified with 
Protein Pilot software (Applied Biosystems) using the Paragon™ algorithm (481) and 
the most recent version of SwissProt database. The identified proteins were accepted 
if they fell within the 1% local false discover rate (FDR) and if at least two peptides 
were identified with a confidence >95%. The mass accuracy of each peptide ion was 
determined at 5-30 ppm (parts per million).
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Mass spectroscopy and data analysis was performed by Dr Rosalind Jenkins 
(University of Liveipool).
2.22. Immunoprecipitation
Immunoprecipitation is a technique used to isolate protein complexes containing 
a protein of interest using an antibody specific for that protein. Immunoprecipitation 
coupled with SDS-PAGE and western blotting is frequently used to study 
protein-protein interactions.
Immunoprecipitation was performed to determine whether the mutant p53 
interacting proteins identified by mass spectrometry in the complexes isolated by 
TAP-tag purification were present in protein complexes in cells.
HI299 cells were seeded into 15 cm dishes and transfected with 15 jig of p53, 
p53-175H, p53-273H or empty vector per dish. The cells were co-transfected with 
15 pg of (3-gal per well to estimate transfection efficiency. One day post transfection 
the cells were trypsinized and split into two 15 cm dishes per transfection with a small 
aliquot placed in a 6-well plate for in situ P-galactosidase assay.
SLIP buffer (with BSA3
Concentration Reagent
50 mM HEPES, pH 7.5
150 mM NaCl
10% (v/v) glycerol
0.1% (v/v) Triton X-100 
0.5 mg/ml BSA
Supplemented with protease inhibitors (as described in section 2.7.1).
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The following day the cells were harvested, lysed in SLIP buffer for 10 min. on ice 
and the lysates were clarified by centrifugation at 16,000xg for 10 min. at 4°C. The 
supernatants were transferred to fresh tubes and protein concentration in the samples 
was determined using Bradford assay. 4 mg of total protein was used for 
immunoprecipitation. The volume of the lysate was made up to 500 pi with SLIP 
buffer. All centrifugation steps were performed at 4°C and the samples were kept on 
ice at all times.
Protein G Sepharose beads (100 pi of 50% slurry per sample) were washed 3 times 
with 1 ml of SLIP buffer and collected by centrifugation at 16,000xg for 30 sec. After 
the last wash the beads were resuspended in SLIP buffer to obtain 50% slurry.
50 pi of the 50% slurry of Protein G Sepharose beads was then added to each 
protein sample. The tubes were incubated for 1 hour at 4°C on a nutator to remove the 
proteins that bind non-specifically to the beads. Following the incubation the beads 
were collected by centrifugation at 16,000xg for 30 sec. and the supernatants were 
transferred to fresh tubes.
2 pg of anti-p53 antibody Ab-1 (PAb421, Calbiochem) was added to each of the 
samples and incubated for 1 hour at 4°C on a nutator to allow the antibody to bind to 
p53. Following the incubation 50 pi of the 50% slurry of Protein G Sepharose beads 
was added to each of the samples and incubated for 2 hours at 4°C on a nutator to 
capture the immune complexes on the beads. The beads were then collected by 
centrifugation at 16,000xg for 30 sec. The supernatant was discarded and the beads 
were washed 3 times with 500 pi of SLIP. After the last wash the supernatant was 
removed completely, draining the beads of any residual SLIP buffer. The beads were 
then resuspended in 60 pi of 1 x sample loading buffer (see section 2.7) and boiled for
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5 min. at 99°C. 20 |il of the immunoprecipitated complexes were analysed by 
SDS-PAGE and western blotting.
2.23. Clonogenic assay
Clonogenic assay (colony formation assay) is an in vitro cell survival assay, which 
measures the ability of single cells to proliferate and form colonies. Since radiation 
therapy is one of the treatment modalities for laryngeal cancer, clonogenic assays (as 
described previously (482)) were used to investigate the response to y-radiation of the 
mutant p53 expressing laryngeal cancer cell lines.
Immediately before the experiment the required number of 6-well plates was 
coated with gelatin. 0.1% (w/v) gelatin solution was prepared in H2O. A few drops of 
phenol red were added until a bright yellow colour was achieved. The solution was 
sterilised by autoclaving (121°C for 15 min.). 2 ml of the gelatin solution were added 
per well of a 6-well plate and incubated for 2 hour's. Following the incubation, the 
gelatin solution was aspirated and the plates were ready to use.
The day before irradiation, 1.1 xlO6 cells were seeded into 25 cm2 flasks (2 flasks 
per condition) such that they were subconfluent on the day of the treatment. The 
following day the cells (in flasks) were treated with 0 Gy (untreated), 2 Gy, 4 Gy or
6 Gy at room temperature using a 137Cs source delivering -6.25 Gy/min of 
y-radiation. Subsequently, the cells were trypsinized and counted using the Coulter 
Counter. The cells were seeded in triplicates into gelatin-coated 6-well plates at the 
following concentrations (number of cells per well): 800, 1,600, 3,200, 6,400, 12,800, 
25,600, 51,200, 102,400. Pre-gassed (kept in tissue culture flasks inside a humidified 
tissue culture incubator for 48 hours prior to the experiment) full growth media was 
used for plating. The plates were then placed in the incubator (37°C, 5% CO2) and
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incubated for 14 days until sufficiently large colonies have been formed. A colony 
was defined as a group of > 50 cells corresponding to more than 5 cell divisions
(482).
Fixing/staining solution
Concentration Reagent
6% (v/v) glutaraldehyde
0.5% (w/v) crystal violet
in PBS
Following incubation, the media was aspirated and the cells were washed with 
PBS. The cells were then incubated with the fixing/staining solution for 30 min. at 
room temperature. The plates were washed by immersing them gently in a sink filled 
with tap water. The plates were then left upside down on a piece of towel to dry.
The colonies were counted under the light microscope for at least 2 different 
seeding concentrations (in triplicate) for each treatment. The plating efficiency (PE) 
was calculated for the untreated cells by dividing the number of colonies formed by 
the number of cells seeded.
no. of colonies formed 
no. of cells seeded
The number of colonies formed after treatment was then used to calculate the 
surviving fraction (SF) taking the plating efficiency into account:
no. of colonies formed 
no. of cells seeded x PE
The results were plotted on a logarithmic scale and fitted to the linear-quadratic
equation where y is the surviving fraction and x is the
treatment dose (483).
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3. Results
p53 is an important tumour' suppressor protein, whose function is lost through TP53 
mutations in about 50% of human tumours, making it arguably the most frequently 
altered gene in human cancer. The majority of p53 mutations are missense, resulting 
in the expression of full-length protein with single amino acid substitutions, which 
tends to accumulate in tumour cells. These missense p53 mutants not only lack 
wild-type p53 tumour-suppressor activity but in addition evidence suggests that some 
of these also gain new functions that can promote tumorigenesis. This oncogenic 
‘gain of function’ of p53 mutants is proposed to be achieved via modulating the 
transcriptome of a cancer cell or through novel protein-protein interactions (as 
discussed in section 1.3.4.3.1).
To investigate the mechanism of action of a GOT p53 mutant, two defined GOT 
mutants, which represent distinct mutational classes, were chosen for these studies:
• R175H - single amino acid substitution (arginine to histidine) at position 175 is an 
example of a structural mutation, causing a significant conformational shift of 
p53,
• R273H - single amino acid substitution (arginine to histidine) at position 273 is 
a contact mutation, affecting a residue that makes direct contact with DNA and 
hence leading to a loss of wild-type p5 3-specific DNA binding; note that mutants 
of this class may retain altered ability to transactivate p53-responsive genes.
In order to study the mechanisms of gain of function of p53 mutants, protein 
interactions of the two defined GOT mutants (R175H and R273H) were identified as 
well as gene expression of the R273H mutant of p53 was studied.
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To enable purification of p53-containing complexes, cDNAs encoding wt and two 
mutant forms of p53 were cloned into TAP-tag vectors (section 3.1). The vectors were 
tested for expression and p53 transcriptional activity in a p53-null cell line (HI299) 
using western blotting and luciferase p53 transcriptional activity assays (section 3.2).
In order to study protein interactions of the GOF p53 mutants in laryngeal cancer, 
a p53-null laryngeal cancer cell line was required. A functionally p53-null LSCC cell 
line (UM-SCC-12) has been identified in the panel of available cell lines and tested 
for p53 expression (section 3.3). To engineer these cells to express the GOF p53 
mutants of interest, the cells had to be transfected with the generated TAP-tag vectors. 
Therefore, the transfection efficiency of UM-SCC-12 cells was tested and optimised 
(section 3.4). Since the transfection efficiency of UM-SCC-12 cells remained 
extremely low in spite of optimisation, in order to obtain a sufficient amount of 
protein for TAP-tag purification, stable laryngeal cancer cell lines expressing either of 
the two GOF p53 mutants have been established (section 3.5).
TAP-tag purification of mutant p53-containing complexes has been performed and 
the purified proteins have been identified using mass spectroscopy (section 3.7). 
Validation of some of the identified binding partners was performed using 
immunoprecipitation and western blotting (section 3.8).
The migratory potential (a surrogate indicator of metastatic potential) of the 
established LSCC cell lines expressing the GOF p53 mutants was investigated using 
live cell imaging and Boyden chamber motility assays (section 3.9). Down-regulation 
of mutant p53 by RNAi in the generated cell lines was performed to investigate 
whether the observed increase in motility was due to mutant p53 expression (section 
3.10). The invasiveness of the highly motile mutant p53 expressing cells was also 
studied using Boyden chamber invasion assays (section 3.11).
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To study gene expression changes in the highly motile cells expressing one of the 
GOF p53 mutants, exon array analysis was performed and the obtained results were 
validated by qRT-PCR (section 3.12).
Finally, the response to ionising radiation (one of the main treatment modalities for 
head and neck cancer) of the mutant p53 expressing cells was investigated using 
clonogenic assays (section 3.13).
3.1. DNA construct maps and sequencing
Table 3.1: List of all the constructs generated or used in the current study and their 
application.
Construct Purpose/Use
pCMV-Script.p53 validation studies using untagged forms of p53; source of p53 cDNA for subloning into other vectors
pNTAP-B.p53 purification of p53 containing complexes using the TAP-tag purification system
pCB6+.p53-175H source of p53-175H cDNA for subcloning into other vectors
pCR2.1.p53-175H
temporary vector, into which p53-175H cDNA amplified by 
PCR was ligated; used for subcloning p53-175H cDNA into 
other vectors
pNTAP-B.p53-175H purification of p53-175H containing complexes using the TAP-tag purification system
pCMV-Script.p53-175H validation studies using untagged forms of p53
pET24a(+).p53-273H source of p53-273H cDNA for subcloning into other vectors
pNTAP-B.p53-273H purification of p53-273H containing complexes using the TAP-tag purification system
pCMV-Script.p53-273H validation studies using untagged forms of p53
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3.1.1, pCMV-Script.p53
pCMV-Script.p53 vector was used for subcloning of the human p53 cDNA into 
a TAP-tag vector (pNTAP) and was utilised for validation studies using untagged 
forms of p53. The p53 cDNA was sequenced to confirm its identity. The obtained 
sequence was compared with the reference sequence of p53 (accession number: 
NM_000546) and no mutations were foimd. Based on the sequencing results 
(Appendix 2) and the pCMV-Script sequence found in the Addgene Vector Database 
(484) a vector map was generated (Figure 3.1).
3.1.2. pNTAP-B.p53
p53 cDNA was subcloned from pCMV-Script.p53 into pNTAP-B (as described in 
section 2.4.2) to enable protein purification using the TAP-tag purification system. 
Based on the sequencing results (Appendix 3) and the vector sequence provided by 
Stratagene a vector map was generated (Figure 3.2).
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Figure 3.1: Map of the pCMV-Script.p53 vector. The size of the vector is 5448 bp. 
Features: P CMV - CMV promoter; BamHI, EcoRI - restriction sites for the indicated 
endonucleases; 72R SNP - single nucleotide polymorphism at amino acid 72 (arginine); 
p53 - human p53 cDNA; SV40 pA - SV40 polyadenylation signal; P bla - bla promoter; 
P SV40 - SV40 promoter; neo/kan - neomycin/kanamycin resistance cassette.
neotun
P CMV
pNTAP-B.p53
5701 bp
PSV40
PhU
EcoRI (2111) 
SV40 |»A
Figure 3.2: Map of the pNTAP-B.p53 vector. The size of the vector is 5701 bp. Features: 
P CMV - CMV promoter; CBP - calmodulin binding peptide; SBP - streptavidin binding 
peptide; BamHI, EcoRI - restriction sites for the indicated endonucleases; 72R SNP - single 
nucleotide polymorphism at amino acid 72 (arginine); p53 - human p53 cDNA; SV40 pA - 
SV40 polyadenylation signal; P bla - bla promoter; P SV40 - SV40 promoter; neo/kan - 
neomycin/kanamycin resistance cassette.
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3.1.3. pCB6+.p53-l 75H
pCB6+.p53-175H vector was used for subcloning of the cDNA encoding human p53 
with in a single amino acid substitution at position 175 (arginine to histidine) into 
a TAP-tag vector (pNTAP). The entire sequence of the pCB6+ vector was not 
available. To determine the strategy for cloning p53-175H into pNTAP vector, the 
regions upstream and downstream as well as the entire coding sequence of p53 were 
sequenced (Appendix 4). Based on these sequencing results, an approximate map of 
pCB6+.p53-175H was generated (Figure 3.3). The features known to be present in the 
pCB6+ vector (such as the pCMV promoter or the antibiotic resistance cassettes) are 
also outlined.
3.1.4. pCR2.1.p53-l 75H
The p53 cDNA was amplified by PCR from pCB6+.p53-175H and subcloned into 
pCR2.1 vector (as described in section 2.4.4) for further subcloning into a TAP-tag 
vector (pNTAP). Sequencing results (Appendix 5) confirmed that p53 cDNA 
contained only the desired mutation at codon 175 (R to H). Based on the sequencing 
results and pCR2.1 sequence found in the Addgene Vector Database (484) a vector 
map was generated (Figure 3.4).
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Figure 3.3: An approximate map of the pCB6+.p53-175H vector. Features: P CMV - 
CMV promoter; BamHI, EcoRI - restriction sites for the indicated endonucleases; 72P SNP - 
single nucleotide polymorphism at amino acid 72 (proline); R175H - single amino acid 
substitution at position 175 (arginine to histidine); p53 - human p53 cDNA; neo/kan - 
neomycin/kanamycin resistance cassette; amp - ampicillin resistance cassette. Note that the 
features are not drawn to scale.
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EcoRI(6)
Figure 3.4: Map of the pCR2.1.p53-175H vector. The size of the vector is 5131 bp. 
Features: M13 (-20) for - M13 (-20) forward priming site; P T7 - T7 promoter; fl ori - fl 
origin; Ran - kanamycin resistance cassette; amp - ampicillin resistance cassette; pUC ori - 
pUC origin; M13 rev - M13 reverse priming site; BamHI, EcoRI - restriction sites for the 
indicated endonucleases; p53 - human p53 cDNA; R175H - single amino acid substitution at 
position 175 (arginine to histidine); 72P SNP - single nucleotide polymorphism at amino acid 
72 (proline).
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3.L5. pNTAP-B.p53-l 75H
The p53-175H cDNA was then subcloned from pCR2.1.p53-175H into pNTAP-B 
vector (as described in section 2.4.5) to enable protein purification using the TAP-tag 
purification system. The p53/pNTAP-B junctions were sequenced to confirm that the 
cDNA was cloned correctly and that it is in frame with the TAP-tag (Appendix 6). 
A vector map was generated based on the sequencing results and the vector sequence 
provided by Stratagene (Figure 3.5).
3.1.6. pCMV-Script.p53-l 75H
The p53-175H cDNA was also subcloned from pCR2.1.p53-175H into pCMV-Script 
vector (as described in section 2.4.6). The vector was utilised for validation studies 
using untagged forms of p53. Based on the pCMV-Script sequence found in the 
Addgene Vector Database (484) a vector map was generated (Figure 3.6).
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Figure 3.5: Map of the pNTAP-B.p53-175H vector. The size of the vector is 5701 bp. 
Features: P CMV - CMV promoter; CBP - calmodulin binding peptide; SBP - streptavidin 
binding peptide; BamHI, EcoRI - restriction sites for the indicated endonucleases; 72P SNP - 
single nucleotide polymorphism at amino acid 72 (proline); R175H - single amino acid 
substitution at position 175 (arginine to histidine); p53 - human p53 cDNA; SV40 pA - SV40 
polyadenylation signal; P bla - bla promoter; P SV40 - SV40 promoter; neo/kan - 
neomycin/kanamycin resistance cassette.
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Figure 3.6: Map of the pCMV-Script.p53-175H vector. The size of the vector is 5448 bp. 
Features: P CMV - CMV promoter; BamHI, EcoRI - restriction sites for the indicated 
endonucleases; 72P SNP - single nucleotide polymorphism at amino acid 72 (proline); 
R175H - single amino acid substitution at position 175 (arginine to histidine); p53 - human 
p53 cDNA; SV40 pA - SV40 polyadenylation signal; P bla - bla promoter; P SV40 - SV40 
promoter; neo/kan - neomycin/kanamycin resistance cassette.
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3.1.7. pET24a(+).p53-273H
The pET24a(+).p53-273H vector was used for subcloning of the cDNA encoding 
human p53 with a single amino acid substitution at position 273 (arginine to histidine) 
into a TAP-tag vector (pNTAP). The p53 cDNA was sequenced to confirm its 
identity. Based on the sequencing results (Appendix 7) and the pET24a(+) sequence 
found in the Addgene Vector Database (484) a vector map was generated (Figure 3.7).
3.1.8. pNTAP-B.p53-273H
The p53-273H cDNA was subcloned from pET24a(+).p53-273H into pNTAP-B 
vector (as described in section 2.4.8) to enable protein purification using the TAP-tag 
purification system. The p53/pNTAP-B junctions were sequenced to confirm that the 
cDNA was cloned correctly and that it is in frame with the TAP-tag (Appendix 8). 
A vector map was generated based on the sequencing results and the vector sequence 
provided by Stratagene (Figure 3.8).
3.1.9. pCMV-Script.p53-273H
The p53-273H cDNA was also subcloned from pET24a(+).p53-273H into 
pCMV-Script vector (as described in section 2.4.9). The vector was utilised for 
validation studies using untagged forms of p53. Based on the pCMV-Script sequence 
found in the Addgene Vector Database (484) a vector map was generated (Figure 3.9).
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Figure 3.7: Map of the pET24a(+).p53-273H vector. The size of the vector is 6448 bp. 
Features: T7 term - T7 terminator; EcoRI, Ndel - restriction sites for the indicated 
endonucleases; R273H - single amino acid substitution at position 273 (arginine to histidine); 
p53 - human p53 cDNA; 72P SNP - single nucleotide polymorphism at amino acid 72 
(proline); P T7 - T7 promoter; lad - lactose repressor coding sequence; pBR322 ori - 
pBR322 origin; kan - kanamycin resistance cassette; fl ori - fl origin.
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Figure 3.8: Map of the pNTAP-B.p53-273H vector. The size of the vector is 5699 bp. 
Features: P CMV - CMV promoter; CBP - calmodulin binding peptide; SBP - streptavidin 
binding peptide; Smal, EcoRI, EcoRV - restriction sites for the indicated endonucleases; 
72P SNP - single nucleotide polymorphism at amino acid 72 (proline); p53 - human p53 
cDNA; R273H - single amino acid substitution at position 273 (arginine to histidine); 
SV40 pA - SV40 polyadenylation signal; P bla - bla promoter; P SV40 - SV40 promoter; 
neo/kan - neomycin/kanamycin resistance cassette.
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Figure 3.9: Map of the pCMV-Script.p53-273H vector. The size of the vector is 5446 bp. 
Features: P CMV - CMV promoter; Smal, EcoRV - restriction sites for the indicated 
endonucleases; 72P SNP - single nucleotide polymorphism at amino acid 72 (proline); p53 - 
human p53 cDNA; R273H - single amino acid substitution at position 273 (arginine to 
histidine); SV40 pA - SV40 polyadenylation signal; P bla - bla promoter; P SV40 - SV40 
promoter; neo/kan - neomycin/kanamycin resistance cassette.
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3.2. R175H and R273H p53 mutants display dominant-negative effects on 
wild-type p53
Wt and two mutant forms of p53 (R175H and R273H) cloned into TAP-tag vectors 
were tested for expression and transcriptional activity in a p53-null NSCLC cell line 
(HI299). HI299 cells were chosen for these studies because they grow quickly and 
are relatively easy to transfect with transfection efficiencies of approximately 30-50% 
being obtained routinely.
HI299 cells were transfected with a constant amount (20 ng) of untagged wt p53 
and co-transfected with increasing amounts of the TAP-tagged p53 mutants (Figure 
3.10 and 3.11). With increasing amount of the mutant p53 there is a fall in p53 
activity, which demonstrates that both p53 mutants display a dominant-negative effect 
on wt p53, which is dose-dependent (Figures 3.10A and 3.11A). 100 ng of 
TAP-tagged p53-175H reduces the activity of 20 ng of untagged wt p53 12.4-fold, 
while 100 ng of TAP-tagged p53-273H reduces the activity of 20 ng of untagged wt 
p53 9-fold. This suggests that the structural p53 mutant (R175H) is more effective in 
inhibiting wt p53 activity than the contact mutant (R273H). A possible explanation 
could be the fact that upon hetero-oligomerization the structural mutant may shift wt 
p53 into mutant conformation (as discussed in section 1.3.4.2) while the contact 
mutants might retain native conformation and in tetramers with wt p53 they may have 
some residual wild-type transcriptional activity. Note, however, that the TAP-tagged 
p53 mutants discussed above display no wild-type transcriptional activity.
164
Results
900000
800000
p53
P53-175H
Transfected DNA
B p53 -
P53-175H -
p53
actin
actin
GFP
Figure 3.10: Expression and dominant-negative activity of TAP-tagged p53-175H 
mutant. HI299 cells were transfected with 20 ng of pCMV-Script.p53 encoding untagged wt 
p53 (as indicated with “+”) and increasing amounts of pNTAP-B.p53-175H encoding 
TAP-tagged p53-175H (3 ng, 10 ng, 30 ng, 100 ng). The experiment was performed once.
A. Luciferase reporter p53 transcriptional activity assay. The histograms represent the mean 
of three replicates, the error bars represent standard error of mean.
B. Western blot analysis with the indicated antibodies (DO-1 for p53) showing the expression 
of TAP-tagged p53-175H. Actin is a loading control and GFP is a transfection efficiency 
control.
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Figure 3.11: Expression and dominant-negative activity of TAP-tagged p53-273H 
mutant. HI299 cells were transfected with 20 ng of pCMV-Script.p53 encoding untagged wt 
p53 (as indicated with “+”) and increasing amounts of pNTAP-B.p53-273H encoding 
TAP-tagged p53-273H (10 ng, 30 ng, 100 ng). The experiment was performed once.
A. Luciferase reporter p53 transcriptional activity assay. The histograms represent the mean 
of three replicates, the error bars represent standard error of mean.
B. Western blot analysis with the indicated antibodies (DO-1 for p53) showing the expression 
of TAP-tagged p53-273H. Actin is a loading control and GFP is a transfection efficiency 
control.
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As shown in Figures 3.1 OB, 3.1 IB, 3.12 B and 3.13B expression of wt p53 from 
pCMV-Script vector resulted in a double band on western blots at approximately 
52 kDa. The expected mobility of wt p53 corresponds to the lower band. Careful 
analysis of the sequence upstream of p53 cDNA in pCMV-Script revealed the 
presence of an alternative translation initiation codon CTG (485, 486), which was in 
frame with p53 cDNA and was not followed by an in-frame STOP codon. If 
translation was initiated from this codon, the resulting p53 would be 15 amino acids 
longer and hence its predicted molecular weight would be approximately 1.7 kDa 
greater than that of wt p53 translated from its original ATG. This could explain the 
presence of two bands recognised by a p53 specific antibody on a western blot.
Expression of TAP-tagged p53 forms from pNTAP-B vector resulted in multiple 
bands at approximately 58 kDa and 52 kDa, recognised by a p53-specific antibody on 
a western blot. The presence of these multiple bands can also be explained by 
alternative initiation of translation. It is important to note that CBP, SBP and p53 
cDNA each have their own ATG so translation could be initiated from any of these 
START codons. Moreover, since the pNTAP-B vector differs from the pCMV-Script 
vector only by the presence of the TAP-tag coding sequence, alternative initiation of 
translation from codon CTG could also occur, explaining the number of different 
bands observed in Fiugres 3.10B, 3.1 IB, 3.12 B and 3.13B.
TAP-tagged wt p53 displays wt p53 transcriptional activity, which is lower than 
the activity of the untagged protein and this becomes more apparent with increasing 
p53 dose (Figure 3.12A). Moreover, the efficiency of transfecting TAP-tagged wt p53 
was higher than that of untagged wt p53 as judged by the levels of co-transfected GFP 
(Figure 3.12B), resulting in a higher level of expression of TAP-tagged wt p53 
compared to untagged wt p53. This means that a higher level of TAP-tagged wt p53
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results in a comparable transcriptional activity when 10 ng of each vector are 
transfected and the transcriptional activity of the TAP-tagged wt p53 does not 
increase proportionately with the increasing amounts of the vector transfected 
(although the level of expressed protein increases proportionately). This suggests that 
the TAP-tagged wt p53 might have some auto-inhibitory effect when higher levels of 
the protein are present.
It was also observed that TAP-tagged wt p53 reduces the activity of the untagged 
protein when co-transfected (Figures 3.13 A). 100 ng of TAP-tagged wt p53 reduced 
the activity of 100 ng of untagged wt p53 1.5-fold. One interpretation of this 
observation is that TAP-tagged p53 is acting as a partial dominant-negative in this 
system. However, the inhibitory effect of the TAP-tagged wt p53 on untagged wt p53 
is much weaker than that of the dominant-negative p53 mutants, p53-175H or 
p53-273H (1.5-fold reduction compared to 12.4-fold and 9-fold, respectively). 
Moreover, increasing amounts of TAP-tagged wt p53 co-transfected with a constant 
amount (100 ng) of untagged wt p53 did not result in a dose-dependent inhibition but 
actually in gradual increase of wt p53 transcriptional activity. This also suggests that 
TAP-tagged wt p53 has intrinsic wt p53 transcriptional activity.
Ultimately, derivatives of a p53-null LSCC cell line were to be engineered to 
express these TAP-tagged constructs to permit purification of protein complexes 
containing the wt and mutant forms of p53. Since TAP-tagged wt p53 has wt p53 
transcriptional activity and since it was not intended to be transfected in combination 
with untagged wt p53, this partial dominant-negative effect described above would 
not take place. Moreover, since wt p53 has strong growth-inhibitory properties, if 
cells expressing TAP-tagged wt p53 were established, they would most likely express 
it at a low level, at which TAP-tagged wt p53 was shown to behave similarly to its
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untagged counterpart. Finally, any results obtained using the TAP-tagged wt p53 can 
be further validated in studies using cDNAs that lack the TAP-tag.
The activity of the Renilla luciferase, which is expressed constitutively in this 
system, serves as an internal control of the transfection efficiency. Similar activity 
indicates comparable transfection efficiencies between the conditions (Figure 3.10A 
and 3.11 A). These results, however, have to be analysed with caution as wild-type 
p53 was reported to modulate the activity of some promoters (487), including 
HSV-TK used here for Renilla expression. In experiments shown in Figures 3.12A 
and 3.13A it appeal's that as the amount of wt p53 expressing plasmid increases, the 
Renilla activity also seems to increase and this is particularly clear for the 
combination of TAP-tagged and untagged wt p53 (Figure 3.13A). Therefore, the 
firefly luciferase activity was not normalized to the Renilla activity as recommended 
by the kit manufacturer, but the two luciferase activities were presented side by side. 
Such approach helps to avoid artefacts, which could occur due to normalization to 
another reporter construct, which may be influenced by many variables (in addition to 
wild-type p53 expression) including oncogene activity or DNA damage (488).
Since Renilla activity is not an ideal internal control for transfection efficiency for 
the reasons described above, GFP levels were also monitored by western blotting as 
an additional indicator of the efficiency of transfection between the conditions.
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Figure 3.12: Expression and transcriptional activity of TAP-tagged p53 compared to 
untagged p53. HI299 cells were transfected with the indicated amounts of pCMV-Script.p53 
encoding untagged wt p53 or pNTAP-B.p53 encoding TAP-tagged wt p53. The experiment 
was performed thrice.
A. Luciferase reporter p53 transcriptional activity assay. The histograms represent the mean 
of three replicates, the error bars represent standard error of mean.
B. Western blot analysis with the indicated antibodies (DO-1 for p53) showing the expression 
of TAP-tagged and untagged p53 forms. Actin is a loading control and GFP is a transfection 
efficiency control.
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Figure 3.13: Expression and transcriptional activity of TAP-tagged p53. HI299 cells 
were transfected with the indicated amounts of pCMV-Script.p53 encoding untagged wt p53 
or pNTAP-B.p53 encoding TAP-tagged wt p53. The experiment was performed once.
A. Luciferase reporter p53 transcriptional activity assay. The histograms represent the mean 
of three replicates, the error bars represent standard error of mean.
B. Western blot analysis with the indicated antibodies (DO-1 for p53) showing the expression 
of TAP-tagged and untagged p53 forms. Actin is a loading control and GFP is a transfection 
efficiency control.
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3.3. UM-SCC-12 is functionally p53-null
As presented above, mutant p53 exerts dominant-negative effects on wild-type p53. 
Therefore, in order to investigate the true gain of function of p53 mutants, studies 
have to be performed in cells that are p53-null, which is now a common practice in 
the field. Clearly, a functionally p53-null cell line is desirable for both studying the 
gene expression changes mediated by mutant p53 and to avoid potential interference 
from endogenous p53 in the purification of mutant p53 protein complexes.
A laryngeal cancer cell line with a nonsense mutation of the glutamine residue at 
amino acid 104 (Q104X), leading to a homozygous p53 truncation (UM-SCC-12) has 
been identified in the panel of available cell lines and tested for p53 expression. If the 
truncated protein was expressed it would be expected to be approximately 11 kDa. As 
shown in Figure 3.14A UM-SCC-12 cells have no detectable p53 expression. The 
faint band observed at approximately 23 kDa is most likely non-specific as it is not 
affected by transfection with siRNA for p53 (Figure 3.14A). A control experiment 
using siRNA for MDM2 confirmed knock-down efficacy in this cell line (Figure 
3.14B).
While no p53 was detected in UM-SCC-12, there is always a possibility of 
alternative p53 isoforms being expressed in these cells. Such isoforms could 
theoretically be a result of alternative initiation of translation or alternative splicing. 
The p53 sequence contains two alternative in-frame start codons - at residues 40 and 
44, respectively. These alternative translational start sites both fall in exon 4 of p53, 
which is the largest exon of p53 and encompasses base pairs 97-375 of the coding 
sequence. These alternative start codons are located upstream of and within the same 
exon as the nonsense mutation in UM-SCC-12 cells, resulting in a stop codon at 
residue 104. Therefore, alternative initiation of p53 translation seems rather unlikely
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as the ribosome would have to read through the stop codon at residue 104. Alternative 
splicing, however, still remains possible. The alternative splice isoforms could be 
composed of any combination of exons 2-11 with the exception of exon 4, as this 
would result in polypeptide chain termination.
The expression of alternative splice variants is usually lower than the expression of 
the main transcript (in this case truncated). It could be expected that some of the 
produced splice variants should contain exon 2 and hence be detected using the 
anti-p53 antibody DO-1 (recognising epitope within residues 20-25). Since no 
truncated p53 or other p53 isoforms containing exon 2 were detected, it is likely that 
the expression of the other splice variants is also very low or absent. Therefore, it can 
be concluded that there is little or no p53 protein being expressed in the UM-SCC-12 
cell line.
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Figure 3.14: UM-SCC-12 is a p53-null laryngeal cell line with no detectable p53.
UM-SCC-12 cells were transfected with control (scrambled) siRNA, siRNA for p53 or 
MDM2. The cells were analysed 48 hours post transfection. The experiment was performed 
once.
A. Western blot for p53 with DO-1. UM-SCC-12 cells were tested for p53 expression 
following transfection with siRNA for p53. A lysate from untransfected HI299 cells and 
HI299 cells transfected with 20 ng of p53 were used as a negative and positive antibody 
control, respectively.
B. Western blot analysis with the indicated antibodies. The level of MDM2 in UM-SCC-12 
was tested following transfection with siRNA for MDM2. A lysate from p53 /MDM2 MEF 
(p53-null/MDM2-null) cells and HEK293 cells were used as a negative and positive antibody 
control, respectively.
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3.4. Transfection optimisation of UM-SCC-12
In order to study the mechanisms of mutant p53 GOF in laryngeal cancer, the 
p53-null UM-SCC-12 cells had to be engineered to express wt and the two mutant 
forms of p53. This could be achieved through either transient or stable transfection of 
UM-SCC-12 cells with the generated TAP-tag constructs (described in section 3.1). 
Since very little information was available on UM-SCC-12 prior to this study, the 
transfection efficiency had to be tested and if required, the conditions optimised.
UM-SCC-12 and H1299 cells (as a positive control) were transfected with 1 jig of 
p(3-gal per well of a 6-well plate using different transfection reagents at different 
ratios to find the conditions yielding the highest transfection efficiency of 
UM-SCC-12 cells. Following transfection, the transfection efficiency was estimated 
based on in situ |3-gal staining.
The highest transfection efficiency (—40%) of HI299 cells was obtained using 
Lipofectamine at a 2:1 ratio (Figure 3.15G) while UM-SCC-12 cells were transfected 
most efficiently (1-2%) using FuGENE at a 3:1 ratio (Figure 3.15R). In further 
optimisation experiments it was determined that the highest transfection efficiency of 
UM-SCC-12 cells was obtained when they were seeded at a 50% confluence (data not 
shown).
In spite of extensive optimisation studies, the best transfection efficiency achieved 
on UM-SCC-12 was still low (1-2%). Therefore, in order to obtain a population of 
cells with a moderate to high level expression of the TAP-tagged proteins, stable cell 
lines had to be generated. High level of expression would clearly reduce the number 
of cells needed to perform TAP-tag purification of p53 containing complexes. On the 
other hand, high level of expression could disturb the cellular’ balance and force 
protein interactions that would not normally occur due to the abundance of the
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transfected p53. Therefore, generating cell lines with a moderate (physiological) level 
of expression of the TAP-tagged p53 forms would be most desirable in an attempt to 
reproduce physiologically relevant conditions and interactions.
Towards the end of the studies described in this thesis, a new transfection system 
became available to our laboratory - transfection by electroporation (nucleofection). 
This system was tested on UM-SCC-12 cells using condition recommended by the 
manufacturer for a similar SCC cell line (UM-SCC-14A). The transfection efficiency 
achieved using this system without optimisation was significantly better than any 
other transfection method used so far and reached 50% (Figure 3.16A).
This technique is, however, much more toxic to the cells than lipofection 
(~60% viable cells after the nucleofection). Because it was expected that more cells 
(than the recommended 1 x 106 per reaction) would be needed for further experiments, 
the technique was tested for use with a larger number of cells (3 x 106). While the cell
viability was higher for 1 x 106 cells used, the transfection efficiency was very similar' 
between the two conditions. The apparent difference in confluence between the two 
conditions (Figure 3.16) was due to difference in seeding density (different sizes of 
dishes used). Based on this test it was decided that 3xl06 cells would be used for 
future nucleofection experiments.
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Figure 3.15: p-galactosidase transfection efficiency testing of H1299 and UM-SCC-12 
cells. UM-SCC-12 cells were transfected with 1 jxg of pP-gal per well of a 6-well plate and 
analysed by in situ P-galactosidase staining 24 hours post transfection (as described in section
177
Results
2.12). Transfection efficiency was estimated by judging the number of blue cells compared to 
the total number of cells in the dish. The experiment was performed at least thrice.
A, B, C. HI299 cells transfected using GeneJuice at 2:1, 3:1 and 4:1 ratios, respectively.
D, E, F. UM-SCC-12 cells transfected using GeneJuice at 2:1, 3:1 and 4:1 ratios, 
respectively.
G, H, I. HI299 cells transfected using Lipofectamine at 2:1, 2.5:1 and 3:1 ratios, respectively. 
J, K, L. UM-SCC-12 cells transfected using Lipofectamine at 2:1, 2.5:1 and 3:1 ratios, 
respectively.
M, N, O. H1299 cells transfected using FuGENE at 2:1, 2.5:1 and 3:1 ratios, respectively.
P, Q, R. UM-SCC-12 cells transfected using FuGENE at 2:1, 2.5:1 and 3:1 ratios, 
respectively.
Figure 3.16: P-galactosidase testing of nucleofection efficiency of UM-SCC-12 cells.
UM-SCC-12 cells were transfected by nucleofection as described in section 2.6.4. The 
experiment was performed once.
A. 1 x KU cells were transfected with 3 pg of pP-gal and seeded into a well of a 6-well plate.
B. 3x10° cells were transfected with 3 pg of pP-gal and seeded into a 10 cm dish.
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3.5. Establishing stable UM-SCC-12 cell lines expressing mutant p53
Due to extremely low transfection efficiency of UM-SCC-12 cells using lipofection, 
establishing stable cells lines expressing the TAP-tagged forms of wt and mutant p53 
was attempted. Stable UM-SCC-12 derived cell lines expressing TAP-tagged 
p53-175H (12-175H-20) and TAP-tagged p53-273H (12-273H-39 and 12-273H-41) 
have been established. The level of the mutant p53 expression in the generated clones 
has been compared to tumour-derived UM-SCC cell lines expressing wt 
(UM-SCC-17AS) or mutant p53 (UM-SCC-81B) (Figure 3.17). While two of the 
generated clones (12-175H-20 and 12-273H-39) show moderate overexpression of the 
TAP-tagged p53, 12-273H-41 seems to express the mutant p53 closer to physiological 
level.
Attempts to produce similar clones expressing TAP-tagged wt p53 were 
unsuccessful in spite of performing the process of cloning and selection twice. More 
than 100 colonies, both fast and slowly growing ones, were selected for further 
expansion but many of them were lost during the expansion process because they 
failed to grow exhibiting signs of senescence - the cells were flat, enlarged (often 
more than two times larger than normal dividing cells) and had irregular, 
heterogeneous shapes. The clones that survived and proliferated were screened by 
western blotting but showed no detectable p53 expression. Given the potent growth 
inhibitory effects of wt p53 it could be expected that the cells would not tolerate p53 
expression and therefore the failure of these attempts is not surprising.
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Figure 3.17: Expression levels of the TAP-tagged p53 mutants in the established 
clones of UM-SCC-12. Western blot analysis with the indicated antibodies (DO-1 for 
p53) of cell lysates of H1299 transfected with 10 ng of pNTAP-B.p53, UM-SCC-17AS 
(wt p53), UM-SCC-81B (mutant p53) compared to the stable clones of UM-SCC-12 
expressing TAP-tagged p53-175H or p53-273H. The stable clones were tested for p53 
expression multiple times.
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3.6. Optimisation of the TAP-tag purification of mutant p53 complexes
In order to identify the binding partners of mutant p53, TAP-tag purification of 
protein complexes was performed using 12-175H-20 cells according to the 
manufacturer’s protocol. 16xl06 cells were used for this purification and the 
amounts of the resins and buffers used were scaled-up proportionately to the volumes 
described in section 2.20. This purification was performed once.
As shown in Figure 3.18A p53 is purified using this method. MDM2, the main 
negative regulator known to bind p53, was also identified in the purified protein 
complexes by western blotting (inset of Figure 3.18B), validating the technique as 
a means to purify p53-interacting proteins. Note however that other known wt 
p53-interacting partners, such as Bcl-2 and MDMX (discussed in sections 1.3.2.2.2 
and 1.3.3.1-2, respectively), were not detected. This suggests that these proteins might 
specifically interact with wt p53 but not mutant p53 or that the interaction with p53 
mutants is much weaker and not detectable using this system (TAP-tag purification 
and western blotting). Indeed, Bcl-2 was reported to be bound specifically by wt but 
not the tumour-derived mutants of p53 (211).
The discrete bands on the silver-stained gel suggest that there are numerous 
proteins in the purified complexes (indicated with arrows in Figure 3.18B) and that 
the sample is not degraded.
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Figure 3.18: TAP-tag purification of protein complexes containing p53-175H.
A. Western blot for p53 (using DO-1) of equivalent amounts (1%) of the fractions of 
a TAP-tag purification from 12-175H-20 cells, resolved on a 10% polyacrylamide gel.
B. Silver staining of the proteins in 12.5% of the calmodulin eluate fraction resolved on 
a 10% polyacrylamide gel (representative of two replicate gels). Inset shows western blot for 
MDM2 in 10% of the calmodulin eluate fraction resolved on a 10% polyacrylamide gel. 
There is no evidence for the presence of Bcl-2 or MDMX in this fraction.
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While the TAP-tag purification clearly works in principle since p53 is 
demonstrably purified, it is also very inefficient. The major problem seems to be the 
first step of the purification — binding the TAP-tagged p53 to the streptavidin resin. 
Densitometry was performed on western blots from samples representing the 
equivalent amounts (1%) of the purification fractions (Figure 3.18A) and it appeared 
that -90% of p53 present in the lysate did not bind to the streptavidin resin and 
remained in the supernatant. The elution from streptavidin resin was fairly efficient. 
However, a significant proportion of the eluted p53 did not bind to calmodulin resin 
and remained in the calmodulin supernatant. Finally, the elution of the purified 
complexes from calmodulin resin was also very difficult with more protein staying on 
the beads than was present in the final eluate.
3.6.1. Optimisation 1 - scaling-up the amount of starting material 
The first attempt to obtain a sufficient amount of protein for mass 
spectrometry identification involved scaling up the amount of starting material. 
47xl06 12-175H-20 cells were used for this purification but the volumes of resins 
and buffers used were kept the same as previously. This was based on the assumption 
that the streptavidin resin was not saturated (not all of the binding sites were occupied 
by the TAP-tagged p53) and perhaps only part of the total p53 pool was in the 
conformation allowing it to bind to the resin. In such a situation increasing the amount 
of starting material should increase the amount of protein binding to the resin. This 
optimisation attempt was performed once.
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Figure 3.19: TAP-tag purification of protein complexes containing p53-175H.
Western blot for p53 (using DO-1) of equivalent amounts (0.3%) of the fractions of 
a TAP-tag purification from the 12-175H-20 cells, resolved on a 10% polyacrylamide gel.
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Based on the strength of the signal of the streptavidin eluate fraction (Figure 3.19) 
and bearing in mind that three times less of each fraction was resolved on the gel this 
time (due to a larger volume of the lysate and to keep the amount of each fraction on 
the gel equal) compared to the previous experiment (Figure 3.18A), it can be 
concluded that the amount of TAP-tagged p53, which bound and was eluted from 
streptavidin resin increased to some extent although not as much as expected. 
Moreover, it appeal's that the vast majority of the TAP-tagged p53 never bound to 
streptavidin resin remaining in the streptavidin supernatant, suggesting that increasing 
the amount of stalling material does not improve binding significantly. The majority 
of the eluted protein bound to calmodulin resin. However, most of it was not eluted 
and remained on calmodulin beads. Although it is a common practice in the field to 
boil the proteins off the calmodulin resin, this approach would increase contamination 
with proteins bound non-specifically to the beads and therefore on this occasion this 
approach was not used.
90% of the calmodulin eluate was subjected to nanospray mass spectrometry. Only 
two proteins were identified in the purified sample: calmodulin (99.3% coverage) and 
p53 (11.5% coverage). Any p53-interacting proteins that might have been purified 
were most likely below the threshold of detection of the mass spectrometer.
3,6,2. Optimisation 2 - extending binding and elution times
57xl06 12-175H-20 cells were used for this purification keeping the volumes of 
resins and buffers used the same as previously. Since the composition of the buffers 
provided with the InterPlay TAP-tag kit is proprietary, manipulation of concentrations 
of individual components was not possible. Therefore, a composition of a custom 
calmodulin elution buffer was obtained from reference (489).
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Calmodulin elution buffer (CEB)
Concentration Reagent
10 mM Tris, pH 7.9
10 mM (3-mercapto ethanol
0.1% (v/v) Triton X-100
200 mM KAc
20 mM EGTA
The time of binding to streptavidin resin was extended and the lysate was 
incubated on the beads overnight. The elution time was extended to 90 min. The 
calmodulin binding conditions remained the same. Following binding the calmodulin 
resin was divided into two equal aliquots and the proteins were eluted with either the 
proprietary CEB or the freshly prepared CEB by rotating the tubes on a nutator at 4°C 
overnight. The supernatants were then transferred to fresh tubes and another elution 
step was performed by placing the tubes on a vortexer for 1 h at room temperature. 
This optimisation attempt was perfonned once.
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Figure 3.20: TAP-tag purification of protein complexes containing p53-175H.
Western blot for p53 (using DO-1) of equivalent amounts (0.3%) of the fractions of 
a TAP-tag purification from the 12-175H-20 cells, resolved on a 10% polyacrylamide gel.
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The extended binding time seems to have increased the amount of p53 bound to 
streptavidin resin (Figure 3.20). The extended elution time did not have much 
influence on the amount of protein recovered and in this purification more protein 
stayed on streptavidin beads than was eluted in streptavidin eluate. It is possible that 
the extended binding time allowed for more non-specific interactions of p53 with the 
resin and only the specifically-bound p53 could then be eluted from the streptavidin 
resin. This could mean that the resin was actually saturated and the hence increasing 
the amount of protein was not the correct approach. The assumption that the resin is 
unlikely to be saturated was initially made because TAP-tag purification (performed 
according to manufacturer’s instructions) was previously successfully used in our 
laboratory to purify MDM2-interacting proteins. Moreover, the amount of proteins 
purified this way was sufficient for mass spectroscopy identification. However, in this 
case it appeal’s that all the binding sites on the streptavidin resin might actually be 
occupied.
The vast majority of the eluted protein did not bind to calmodulin resin, which 
could suggest that the resin might be saturated. Elution from calmodulin resin was 
improved slightly by an additional incubation of the beads for 1 h at room temperature 
in the elution buffer. By comparing the amount of the protein that remained on the 
calmodulin beads after the elution, it can be concluded that the freshly prepared CEB 
was slightly better than the proprietary CEB in eluting the proteins.
3.6.3. Optimisation 3 — extending binding and elution times further 
Since increasing the amount of starting material did not have much influence on the 
amount of protein recovered from the purification, the approach of overloading the 
resins was abandoned and 10xl06 12-175H-20 cells were used for this purification.
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In addition to EDTA and [3-mercaptoethanol the lysate was supplemented with EGTA 
to a final concentration of 10 mM. EDTA and EGTA are added to the lysate to chelate 
any Ca2+ and hence prevent binding of the cellular calmodulin to the 
calmodulin-binding peptide (CBP) of the TAP-tagged protein, which could potentially 
conceal the streptavidin-binding peptide and interfere with binding to streptavidin 
resin. Moreover, binding of intracellular calmodulin to the CBP could also hinder- 
later binding of the tagged protein to calmodulin (discussed in reference (490)).
Binding and elution from streptavidin resin and binding to calmodulin resin were 
performed overnight at 4°C. The prepared CEB (section 3.6.2) was used and two 
consecutive elutions from calmodulin resin were performed for 1 h at room 
temperature on a vortexer. The amounts of resins and buffers used were as indicated 
in section 2.20 for processing lOxlO6 cells. This optimisation attempt was performe 
once.
While binding to streptavidin resin was significantly better compared to the first 
purification (Figure 3.18A), the overnight elution from streptavidin resin does not 
seem to have improved the elution efficiency suggesting that the proteins remaining 
on streptavidin resin might be bound to it non-specifically. Most of the eluted protein 
bound to calmodulin resin supporting the hypothesis that the calmodulin resin may 
have been overloaded in the previous optimisation attempt (section 3.6.2). Although 
the two consecutive elution steps with prepared CEB (see section 3.6.2) at room 
temperature resulted in nearly complete elution of the bound proteins from calmodulin 
resin, the amount of TAP-tagged p53 in the calmodulin eluate (as judged by the 
western blot signal in Figure 3.21) was still insufficient for mass spectrometry 
identification.
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Figure 3.21: TAP-tag purification of protein complexes containing p53-175H.
Western blot for p53 (using DO-1) of equivalent amounts (0.75%) of the fractions of 
a TAP-tag purification from the 12-175H-20 cells, resolved on a 10% polyacrylamide gel.
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3.6.4. Optimisation 4 - custom buffers and increasing the amount of streptavidin 
resin
No significant improvement in the efficiency of purification was achieved in the 
previous optimisation attempts. Since the composition of the buffers provided with 
the kit was proprietary, the buffers were replaced with custom buffers and the 
purification was performed as described in section 2.20.1. Two purifications were 
performed in this optimisation attempt - both using 10xl06 12-175H-20 cells. For 
one purification the amounts of resins used were as described in section 2.20.1 
(Figure 3.22A) and for the other - 10 times greater amount of streptavidin resin and 
the respective elution buffer were used while the amount of calmodulin resin used was 
kept the same (Figure 3.22B). Densitometry was performed on the western blots to 
obtain an estimation of signal intensity of the purification fractions. This optimisation 
attempt was performed once.
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Figure 3.22: TAP-tag purification of protein complexes containing p53-175H.
Western blot for p53 (using DO-1) of equivalent amounts (0.75%) of the fractions of 
a TAP-tag purification from the 12-175H-20 cells, resolved on a 10% polyacrylamide gel. 
The purification was performed using the recommended amount of streptavidin resin (A) or 
10 times the recommended amount of streptavidin resin (B).
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In this purification custom buffers were used. In order to check whether the lysis of 
the cells is complete using the custom lysis buffer, the pellet of the cell debris was 
resuspended in lx sample loading buffer, boiled at 99°C and loaded onto the 
polyacrylamide gel alongside all the other purification fractions. As shown in Figure 
3.22, although some TAP-tagged p53 remains in the cell debris, the majority of the 
protein is in the lysate. Using 10-fold more than the recommended amount of 
streptavidin resin significantly increases binding efficiency with only 40% remaining 
in the unbound fraction (streptavidin supernatant, Figure 3.22B) compared to 74% 
when the recommended amount of resin was used (Figure 3.22A). Elution from the 
streptavidin resin was successful in both cases with more protein being eluted than 
staying on streptavidin resin.
When binding to calmodulin resin is considered approximately 22% of total 
TAP-tagged p53 available bound to calmodulin in the first purification (Figure 3.22A) 
compared to 28% when 10 times more streptavidin resin was used (Figure 3.22B). 
Clearly, although over twice as much (62% vs. 27%) of the TAP-tagged p53 was 
applied to calmodulin resin, the amount of protein bound increased marginally (by 
only 6%). This suggests that the calmodulin resin was satumted and hence no more 
protein could bind to it. Elution from calmodulin resin was highly inefficient in both 
cases as more protein remained on the beads than was eluted in the final eluate.
3.6.5. Optimisation 5 - increasing the amount of calmodulin resin 
The results from the previous optimisation attempt suggested that the calmodulin 
resin might be saturated so the next step was to increase the amount of calmodulin 
resin used. 10xl06 12-175H-20 cells were used for this purification and in addition 
to using 10-fold more streptavidin resin, the amount of calmodulin resin and the
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respective elution buffer were increased 10-fold. Moreover, since the elution from 
calmodulin was quite inefficient in the previous optimisation attempt (section 3.6.4), 
two consecutive elutions were performed for 30 min. at room temperature on 
a vortexer. The calmodulin elution buffer was prepared based on the recipe used 
before (section 3.6.2) increasing the concentrations of KAc and EGTA. All the other 
buffers used were the same as in the previous optimisation attempt (section 3.6.4). 
This optimisation attempt was performed once.
Calmodulin elution buffer (CEB)
Concentration Reagent
10 mM Tris, pH 7.9
10 mM p-mercapto ethano 1
0.1% (v/v) Triton X-100
1 M KAc
25 mM EGTA
Similarly to the previous purification (section 3.6.4), approximately 40% of the 
total TAP-tagged protein did not bind to streptavidin resin and approximately 60% 
was eluted from the resin, suggesting that the purification efficiency is very 
consistent. Increasing the amount of calmodulin resin used, however, did not improve 
the binding significantly as only 32% seemed to bind to calmodulin resin 
(Figure 3.23) compared to 28% in the previous optimisation attempt (Figure 3.22B).
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Figure 3.23: TAP-tag purification of protein complexes containing p53-175H.
Western blot for p53 (using DO-1) of equivalent amounts (0.75%) of the fractions of 
a TAP-tag purification from the 12-175H-20 cells, resolved on a 10% polyacrylamide gel.
195
Results
3.6,6. Optimisation 6 - adding EGTA to the lysate
Binding to streptavidin was improved significantly by increasing the amount of 
streptavidin resin used but binding to calmodulin remained highly inefficient. In an 
attempt to improve binding to calmodulin, the lysate was supplemented with EGTA to 
a final concentration of 10 mM, as described in section 3.6.3. All the remaining 
buffers used were the same as in the previous optimisation attempt (section 3.6.5). 
10xl06 12-175H-20 cells were used for this purification. This optimisation attempt 
was performed once.
While addition of EGTA did not influence binding to streptavidin resin, the 
elution seemed to be less efficient with 49% of protein recovered from streptavidin 
resin (Figure 3.24) compared to 58% in the previous optimisation attempt 
(Figure 3,23). Importantly, binding to calmodulin resin was also not improved with 
only about 25% binding to the resin.
196
Results
■5? & $
MW (kDa)
100%
Figure 3.24: TAP-tag purification of protein complexes containing p53-175H.
Western blot for p53 (using DO-1) of equivalent amounts (0.75%) of the fractions of 
a TAP-tag purification from the 12-175H-20 cells, resolved on a 10% polyacrylamide gel.
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3.6.7. Optimisation 7 - lysis in the absence of EDTA
Since addition of EGTA to the lysate seemed to reduce the recovery of TAP-tagged 
p53 from the streptavidin resin, in this optimisation attempt neither EDTA nor EGTA 
were added to the lysis buffer or lysate, respectively. All the remaining buffers 
used were the same as in the previous optimisation attempt (section 3,6.6). 
10xl06 12-175H-20 cells were used for this purification. Additionally, the
purification through streptavidin resin only was also performed using 
10xl06 UM-SCC-12 cells (as a negative control for the purification specificity) in 
order to check whether the p53-175H complexes purified only using streptavidin resin 
contained a lot of proteins that were bound to the resin non-specifically. This 
experiment was performed once.
Removing EDTA from the lysis buffer significantly improved binding to 
streptavidin, with approximately 90% binding and 69% of the protein recovered from 
streptavidin resin (Figure 3.25A). Binding to calmodulin remained unaffected with 
28% binding to the resin. Since no improvement in the second purification stage 
(calmodulin purification) was achieved in spite of multiple optimisation attempts, it 
was investigated whether purification of the mutant p53-containing complexes could 
be performed using streptavidin resin alone. For this purpose, a lysate from 
UM-SCC-12 cells, which do not express TAP-tagged p53, was used for the first 
purification stage (streptavidin purification) and equivalent fractions of streptavidin 
eluates from purifications performed using both cell lines (UM-SCC-12 and 
12-175H-20) were compared on a silver-stained polyacrylamide gel (Figure 3.25B). 
The purification through streptavidin resin alone appeared to be quite specific with 
only a few proteins (indicated with arrows in Figure 3.25B) being present in both 
samples. Therefore, it was decided that the mutant p53-containing complexes would 
be purified using streptavidin resin only.
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Figure 3.25: TAP-tag purification of protein complexes containing p53-175H.
A. Western blot for p53 (using DO-1) of equivalent amounts (0.75%) of the fractions of 
a TAP-tag purification from the 12-175H-20 cells, resolved on a 10% polyacrylamide gel.
B. Silver staining of the proteins in 1.75% of the streptavidin eluate fraction from a TAP-tag 
purification performed using lysates from UM-SCC-12 and 12-175H-20 cells, resolved on 
a 10% polyacrylamide gel.
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3.7. Purification and identification of mutant p53 interacting partners 
3.7.1. Purification of mutant p53-containing complexes
Due to the poor efficiency of binding and elution of TAP-tagged p53 from the 
calmodulin resin, the TAP-tag purification was reduced to purification through 
streptavidin resin only. 10xl06 UM-SCC-12 cells, 12-175H-20 cells and 12-273H-39 
cells were used for this purification. The buffers used were the same as in the previous 
optimisation attempt (section 3.6.7) and for clarity the compositions are listed below. 
To maximise the purification efficiency, three consecutive elutions from streptavidin 
resin were performed.
Lysis buffer
Concentration Reagent
10%(v/v) glycerol
50 mM 
150 mM 
0.1% (v/v) 
2 mM 
10 mM
HEPES
NaCl
Triton X-100
DTT
NaF
Supplemented with protease inhibitors (as described previously).
Calmodulin binding buffer fCBB) - used for washes before the elution
Concentration Reagent
10 mM [3-mercaptoethanol
50 mM HEPES
150 mM NaCl
1 mM MgAc
1 mM imidazole
0.1% (v/v) Triton X-100
2 mM CaCl2
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Streptavidin elution buffer (SEE)
Concentration Reagent
10 mM p-mercaptoethanol
50 mM HEPES
150 mM NaCl
1 mM MgAc
imidazole1 mM
0.1% (v/v) Triton X-100
2 mM CaCl2 2 mM CaCl2
10 mM D-biotin
Purification using 12-175H-20 cells was perfomed twice, while the other two 
purifications (using UM-SCC-12 cells and 12-273H-39 cells) were performed once.
An additional, third consecutive elution step significantly increased the recovery of 
proteins from streptavidin resin with 91% of total TAP-tagged p53-175H being 
present in the final streptavidin eluate (Figure 3.26A). The streptavidin eluate from 
the p53-273H purification seems to contain more protein than was present in the 
lysate (Figure 3.26B), an impression which may be due to pipetting error (unequal 
loading).
Silver staining of the streptavidin eluates (Figure 3.27) revealed a different pattern 
of bands in the samples containing the two p53 mutants (p53-175H and p53-273H) 
suggesting that they have different interacting partners. Performing the purification 
using the parental UM-SCC-12 cells (p53-null) allowed for exclusion of any proteins 
binding to the streptavidin resin non-specifically from analysis.
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Figure 3.26: Purification of the mutant p53-containing complexes.
Western blot for p53 (using DO-1) of equivalent amounts (0.75%) of the fractions of 
a TAP-tag purification from the 12-175H-20 cells (A) or 12-273H-39 cells (B), resolved on 
a 10% polyacrylamide gel.
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Figure 3.27: Purification of the mutant p53-containing complexes.
Silver staining of the proteins in 2% of the streptavidin eluate fractions from TAP-tag 
purifications performed using lysates from UM-SCC-12, 12-175H-20 and 12-273H-39 cells, 
resolved on a 10% polyacrylamide gel.
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3.7.2. Identification of mutant p53-interacting proteins
95% of the final streptavidin eluates from section 3.7.1 were subjected to mass 
spectrometry. A full list of identified proteins is presented in Appendix 9. The 
proteins present only in the test samples (containing the mutant TAP-tagged p53) and 
not in the control sample (purified from UM-SCC-12) are shown in Table 3.2.
p53 was detected in both of the test samples (Table 3.2). Another protein identified 
in both mutant p53-containing complexes was myosin light chain kinase 2 
(skeletal/cardiac muscle). Given that the calmodulin-binding peptide was derived 
from skeletal muscle myosin light-chain kinase, the identified peptides were most 
likely those comprising the CBP.
HSP70 was identified only in the p53-175H-containing complexes. HSP70 is an 
inducible chaperone stabilising existing proteins against aggregation and mediating 
the folding of newly translated proteins (491). p53-175H is a structural mutant and it 
may be bound by HSP70 because it is most likely misfolded.
Although 3 peptides of heat shock cognate 71 kDa protein (HSP7C, also known as 
HSC70) were identified in the control sample (from UM-SCC-12), 43 peptides of this 
protein were found in the test sample from p53-175H purification. The significant 
enrichment of this heat shock cognate in the p53-175H-containing sample suggests 
that the interaction of these two proteins is specific, likely because p53-175H is 
recognised by HSC70 as a misfolded protein. Most likely both HSP70 and HSC70 
contribute to the thick band observed on the silver-stained gel slightly above the 
58 kDa marker band in p53-175H-containg sample but not in the other two samples 
(Figure 3.27).
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Table 3.2: The list of proteins identified in the mutant p53-contaiiiing complexes, 
purified from 12-175H-20 and 12-273H-39 cells, respectively. The number next to each 
protein indicates the number of peptides identified. Due to high sequence similarity of some 
proteins, some of the identified peptides could not be unequivocally assigned to one protein. 
These ambiguous cases are shaded with the same colour.
12-175H-20 cells 12-273H-39 cells
Cellular tumour antigen p53 21 Cellular tumour antigen p53 37
Heat shock 70 kDa protein 1 (HSP70) 38 Serum albumin 3
Heat shock cognate 71 kDa protein 
(HSP7C)
43 CDS9 glycoprotein 2
BAG family molecular chaperone 
regulator 2 (BAG2)
7 Histone HI.2 1
Tropomodulin-3 (Tmod3) 2 Tropomodulin-3 (Tmod3) 2
Myosin light chain kinase 2, 
skeletal/cardiac muscle
1 Myosin light chain kinase 2, 
skeletal/cardiac muscle
2
Myosin-VI 1 Myosin-VI 2
Keratin, type II cytoskeletal 1 4
Keratin, type I cytoskeletal 10 2
Keratin, type II cytoskeletal 2 
epidermal
3
Keratin, type II cytoskeletal 6A 2
Keratin, type II cytoskeletal 75 1
Keratin, type II cytoskeletal 5 2
Keratin, type II cytoskeletal 6C 2
Keratin, type II cytoskeletal 6B 2
Keratin, type II cytoskeletal 79 1
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BAG2 (BCL2-associated athanogene 2) was also identified only in the 
p53-175H-containing sample. BAG2 binds with high affinity to the ATPase domain 
of HSC70/HSP70 and promotes substrate release (492), resulting in reduced 
degradation of misfolded proteins (493). It is possible that BAG2 co-purified with 
p53-175H due to its interaction with HSP70.
Tropomodulin-3 was identified in both of the mutant p53-containing samples. 
Tropomodulin-3 regulates actin polymerization by capping pointed ends of actin 
filaments and sequestering actin monomers, and hence acts as a negative regulator of 
cell migration. The fact that only 2 peptides of tropomodulin-3 were identified in each 
of the samples may suggest that the interaction with mutant p53 is relatively weak.
Myosin-VI was identified in both of the mutant p53-containing samples. 
Myosin-VI is an actin-based motor protein, involved in intracellular vesicle transport 
and cell migration. However, the small number of peptides actually identified 
suggests that the interaction with the two p53 mutants is relatively weak.
The proteins identified only in the p53-273H complexes included: serum albumin, 
CD59 glycoprotein, histone HI.2 and a number of cytoskeletal keratins (Table 3.2). 
Skeletal keratins have a high sequence similarity and based on the few peptides 
identified it was impossible to distinguish, which type was actually present 
(Table 3.2). Generally, only between 1 and 3 peptides were identified in the 
p53-273H-containing sample for the above proteins suggesting that these interactions 
are relatively weak.
Interestingly, MDM2 was not identified in the mutant p53 containing complexes 
by mass spectroscopy although it was detected previously by western blotting in the 
calmodulin eluate from the first purification of p53-175H-containing complexes 
(Figure 3.18B). It is important to note that a large proportion (10%) of the final
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calmodulin eluate was probed with an anti-MDM2 antibody, which is very sensitive. 
This likely suggests that the interaction of mutant p53 with MDM2 is relatively weak 
and the amount of MDM2 present in the purified complexes was below the threshold 
of detection by the mass spectrometer.
3.8. HSP70 interacts specifically with the R175H mutant of p53
Following purification of the mutant p53 containing complexes using a simplified 
TAP-tag purification method coupled with identification of the isolated proteins by 
mass spectroscopy (section 3.7), immunoprecipitation was performed to further 
determine whether the identified mutant p53 interacting proteins were present in 
protein complexes in cells. Since this entailed using a different approach, such data 
would provide additional evidence supporting the validity of the identified protein 
interactions and of the TAP-tag/mass spectrometry method for identifying mutant p53 
binding proteins.
H1299 cells were transfected with wt p53, p53-175H, p53-273H or the 
corresponding empty vector. The p53-containing complexes were immunoprecipitated 
using a p53-specific antibody (as described in section 2.22) and analysed by 
SDS-PAGE and western blotting (Figure 3.28). This experiment was performed once.
Transfection of wt and two mutant forms of p53 into HI299 cells (p53-null) 
resulted in uneven expression of the p53 forms, with the highest level of expression of 
wt p53, slightly lower of p53-273H and even lower of p53-175H. Nevertheless, the 
efficiency of immunoprecipitation of these p53 forms was comparable with perhaps 
a slightly stronger signal for wt p53 (Figure 3.28). The observed difference in the 
mobility of the three p53 forms (with wt p53 migrating faster than the p53 mutants) is 
most likely due to differences in the SNP at amino acid 72. The p53 mutants used in
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this project cany a proline at residue 72, while the used wt p53 has an arginine at this 
position. Difference in mobility of p53 forms differing in the status of the SNP at 
amino acid 72 was reported previously, with p53-72R exhibiting faster mobility than 
p53-72P (494).
As expected, wt p53 caused induction of MDM2 (as observed in the lysate of 
H1299 transfected with wt p53). MDM2 also immunoprecipitated preferentially with 
wt p53, suggesting that not only is MDM2 induced by wt p53 but also the interaction 
of MDM2 with wt p53 is probably stronger than with either of the mutant p53s.
HSP70 was found to immunoprecipitate specifically with p53-175H, providing 
further support that it is a p53“175H-interacting protein. Moreover, the absence of 
HSP70 in the other immunoprecipitated samples suggests that the interaction of 
HSP70 with p53-175H is preferential, likely due to misfolded or altered structure of 
this p53 mutant (as discussed previously).
Tmod3, on the other hand, although identified in the mutant p5 3-containing 
complexes, does not seem to immunoprecipitate with p53 in this assay (Figure 3.28). 
As discussed previously, the interaction of Tmod3 with mutant p53 may be either 
non-specific or too weak to be identified by western blotting.
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Figure 3.28: Immunoprecipitation of wt and mutant p53-containing complexes. Western 
blot analysis with the indicated antibodies (ab2433 for p53) of lysates and 
immunoprecipitated fractions from HI299 cells transfected with 15 pg of p53, p53-175H, 
p53-273H in pCMV-Script or the corresponding empty vector. Cells were harvested 48 hours 
post transfection. Immunoprecipitation with a p53-specific antibody (Ab-1) was performed 
using 4 mg of total protein per condition. This experiment was performed once.
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3.9. Cells expressing mutant p53 exhibit increased motility
GOF p53 mutants are associated with highly aggressive and metastatic tumours, 
which are the main cause of cancer mortality. Therefore, cell migration and 
invasiveness (surrogate indicators of metastatic potential) of mutant p53-expressing 
cells were studied in this project.
The motility of the previously generated cell clones expressing TAP-tagged 
p53-175H and p53-273H (see section 3.5) was studied using Boyden chamber 
motility assays and live cell imaging. These two assays measure different properties. 
The Boyden chamber motility assay measures the ability of cells to migrate through 
pores in a membrane, whilst live cell imaging measures the motility of cells in two 
dimensions on plastic.
3*9.1. Boyden chamber motility assays
Boyden chamber motility assays were performed as described in section 2.15. The 
motility of the following cell lines was studied in this experiment:
• UM-SCC-12 - p53-null,
• 12-175H-20 - expressing high level of TAP-tagged p53-175H,
• 12-273H-39 - expressing high level of TAP-tagged p53-273H,
• 12-273H-41 - expressing low level of TAP-tagged p53-273H,
• 12-273H-null - a cell line established as a result of the cloning process but with no 
detectable p53-273H expression.
This entire experiment was performed once, however the motility of UM-SCC-12 
cells in this assay was tested twice.
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Figure 3.29: Motility of mutant p53-expressing cell lines determined using Boyden 
chamber motility assays. 15,000 cells were seeded into Boyden chambers and incubated for 
18 hours. The number of cells that migrated through the membrane was counted. The values 
shown above the histograms represent the mean of three replicates, the error bars represent 
standard error of mean. Statistical analysis was performed using Student’s t-Test. The 
differences were considered significant if p < 0.05.
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As shown in Figure 3.29, 12-175H-20 cells have a slightly reduced motility in this 
assay as compared to the parental UM-SCC-12 cells but this difference is not 
statistically significant (p = 0.053). The motility of 12-273H-41 cells was similar to 
UM-SCC-12 cells (p = 0.48). 12-273H-39 cells were over 8-fold more motile than 
UM-SCC-12 cells and this difference was statistically significant (p < 0.05). 
Interestingly, 12-273H-null cells turned out to be over 50-fold more motile than the 
parental UM-SCC-12 cells (p < 0.05). It was observed that these cells display an 
elongated, spindle-like morphology and form numerous filopodia. The morphology of 
these cells is compatible with an EMT. Whilst this has not been investigated 
specifically, such an EMT could provide an explanation for how the cells are able to 
migrate more efficiently through the Boyden chamber membrane.
Generally, it can be observed that the laryngeal cancer cell lines studied are not 
very motile in this system since out of 15,000 cells seeded into the Boyden chambers, 
only between 11 and 1274 cells (less than 8.5%) migrated through the membrane. 
These data suggest that this might not be the most appropriate system to study the 
migratory potential of these cells. This might be partially due to the fact that the cells 
studied in this project require a considerable time to adhere to the surface of the dish 
and their plating efficiency is very low. It was observed as part of a different 
experiment (clonogenic assays, section 3.13) that the plating efficiency (see section 
2.23) of UM-SCC-12 cells is very low (~9.5%) and even lower for p53-175H and 
p53-273H-expressing cells (—5.9% and —3.8%, respectively). Hence, the number of 
cells that actually adhered to the surface of the membrane might have influenced the 
number of migrating cells. Moreover, with an increased time required for the cells to 
adhere to the membranes, the time during which the cells could have migrated 
through the pores was considerably shorter. Extending the duration of the experiment,
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however, proved to be impractical since most of the cells were able to divide during 
the experiment making the data impossible to interpret.
3.9.2. Live imaging of cell migration
Live cell imaging was performed as described in section 2.14 using the same cell lines 
that were used for Boyden chamber motility assays (section 3.9.1). The motility of 
UM-SCC-12 cells and 12-273H-39 cells was tested in this system of two different 
occasions. In this experiment the cells were imaged for 14.4 hours with a time-lapse 
of 3 min. (288 passes). Two fields were selected per cell line and 10 cells from each 
field were tracked, resulting in a total of 20 cells tracked per cell line. Representative 
movies are available on the attached CD (see Appendix 10). The tracks of 10 cells on 
a 2D plane are presented below (Figure 3.30).
Based on the recorded cell tracks (Figure 3.30), UM-SCC-12 cells seem to have 
travelled the smallest net distance out of all the cell lines. The total distance travelled, 
net distance travelled, speed and directionality (as defined in section 2.14) were then 
determined using a plugin for ImageJ based on the coordinates of each of the cells 
recorded for each frame.
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Figure 3.30: Tracks of cells selected for tracking represented on a 2D plane.
The cells were imaged for 14.4 hours with a time-lapse of 3 min. 10 cells per field were 
tracked. The plane, on which the tracks are shown, represents the actual area, on which the 
cells were moving. The axes represent the coordinates assigned to the image by ImageJ.
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12-273H-39 cells and 12-273H-41 cells display increased motility (approximately 
2-fold higher) compared to the parental UM-SCC-12 cells, as judged by the total 
distance travelled and speed, which are directly proportional (Figure 3.31 A and D). 
The net distance travelled by the cells expressing the 273H mutant of p53 is also 
significantly larger than that of the parental UM-SCC-12 (p < 0.05). The directionality 
of 12-273H-39 cells and 12-273H-41 cells seems slightly higher than that of 
UM-SCC-12 cells but this difference is not statistically significant (Figure 3.3IB and 
C). Directionality provides information about whether the movement of cells is 
random. Directionality is always < 1, as it is defined by the ratio of net distance 
travelled and total distance travelled (the first cannot exceed the latter). The larger the 
directionality (closer to 1), the less random the movement is. In this case, the 
directionality of all three cell lines is below 0.3, suggesting that 12-273H-39 cells and 
12-273H-41 cells display an increase in random movement.
12-175H-20 cells also display increased motility compared to the parental 
UM-SCC-12 cells but the difference in total distance travelled and speed, although 
significant (p = 0.02), was much smaller than in the case of p53-273H-expressing 
cells (Figure 3.31 A and D). 12-175H-20 cells displayed also a significant increase 
(p < 0.05) in net distance travelled and directionality compared to the parental 
UM-SCC-12 cells (Figure 3.3IB and C) suggesting that these p53-175H-expressing 
cells display an increase in organised, directional movement.
In this assay 12-273H-null cells behaved almost identically to UM-SCC-12 cells, 
with no significant difference between the two cell lines (p > 0.05) in any of the four 
parameters studied (Figure 3.31).
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Figure 3.31: Live cell imaging of the mutant p53-expressing cell lines.
A. Total distance travelled by the cells over the course of experiment.
B. Net distance travelled by the cells over the course of experiment.
The histograms represent the mean of 20 cells tracked, the error bars represent standard error 
of mean. Statistical analysis was performed using Student’s t-Test.
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Figure 3.31 (cont.): Live cell imaging of the mutant p53-expressing cell lines.
C. Directionality of the cells over the course of experiment.
D. Average speed of the cells over the course of experiment.
The histograms represent the mean of 20 cells tracked, the error bars represent standard error 
of mean. Statistical analysis was performed using Student’s t-Test.
217
Results
The live imaging system seems to be suitable for monitoring the migratory 
potential of the laryngeal cancer cell lines under study, as there are clear differences in 
motility between the mutant p53-expressing cells and the parental p53-null cells. 
Moreover, 12-273H-null cells, which serve as a negative control for the process of 
establishing stable clones, behave as expected in this system with all four parameters 
studied (total distance travelled, net distance travelled, directionality and speed) 
comparable to those of UM-SCC-12 cells.
It is important to remember that the cells studied in this project are squamous cell 
carcinoma cells, which are derived from epithelial cells lining the skin and internal 
cavities (110). Due to the fact that squamous cells often exhibit flattened morphology 
and their main function is to line surfaces, it is possible that these cells are more 
potent in migrating on 2D surfaces (such as laboratory dish surfaces) rather than in 
3D space (the Boyden chamber motility assay measures the ability of cells to migrate 
through pores in a membrane, which might represent three-dimensional migration). 
These observations suggest a possible explanation why live cell imaging could be 
a more appropriate assay than Boyden chambers for monitoring the migratory 
potential of the LSCC under study.
However, it is also important to note that the mutant p53-expressing cells studied 
are clones of UM-SCC-12 cells and, therefore, the results presented above have to be 
interpreted with a note of caution. During the process of establishing stable clones, the 
cells are treated with an antibiotic to select the colonies expressing the resistance 
marker (present in the same vector as the gene of interest — mutant p53 in this case). 
This process may result in the selection of rare clonal valiants harbouring mutations 
in genes that affect the phenotype under study. Therefore, when studying stable clones 
the possibility of clonal variation cannot be underestimated.
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3.10. Increased motility of mutant p53-expressing cells is likely due to mutant 
p53 expression
In order to test whether the observed differences in motility of the established mutant 
p53-expressing clones are due to mutant p53 expression or whether they can be 
attributed to clonal valuation, down-regulation of mutant p53 expression by RNAi was 
attempted in the highly motile 12-273H-39 cells.
3.10.1. The impact of transient down-regulation of mutant pS3 by RNAi on motility 
of12-273H-39 cells
12-273H-39 cells were transfected with siRNAs as described in section 2.6.5. Since 
the cells were to be used for live imaging and transfection reagents frequently have 
high toxicity, four different conditions were studied in this experiment:
• untreated cells,
• cells treated with Lipofectamine alone (to estimate the influence of Lipofectamine 
treatment on cell motility)
• cells transfected with scrambled siRNA (as a control for siRNA specificity),
• cells transfected with siRNA for p53.
Live imaging of cell migration following RNAi manipulation was performed as 
described in section 2.14.1. Total distance travelled by the cells was studied, as this 
was one of the most prominently changed parameters when compared to the parental 
UM-SCC-12 cells (Figure 3.31). This experiment was perfonned once. Representative 
movies are available on the attached CD (see Appendix 11).
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Figure 3.32: Transient knock-down of mutant p53 and motility. 12-273H-39 cells were 
transfected with control (scrambled) siRNA, siRNA for p53 or an equal volume of 
Lipofectamine alone. The cells were imaged 24-48 hours post treatment with a time-lapse of 
3 min. This experiment was performed once.
A and C. Total distance travelled by the cells 24-36 hours (A) or 36-48 hours (C) post 
transfection. The histograms represent the mean of 20 cells tracked, the error bars represent 
standard error of mean. Statistical analysis was performed using Student’s t-Test.
B and D. Western blot analysis with the indicated antibodies (DO-1 for p53) showing the 
expression of p53 at 30 hours (B) or 42 hours (D) post transfection (in the middle of the 
imaging periods shown in panels A and C, respectively).
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As shown in Figure 3.32A in the period 24-36 hours post transfection, treatment 
with Lipofectamine alone did not have a significant impact on motility of 12-273H-39 
cells (p - 0.66). Treatment of cells with scrambled siRNA as compared to treatment 
with Lipofectamine alone resulted in a slight reduction in motility but this difference 
was not statistically significant (p = 0.34). Finally, transfection with siRNA for p53 
resulted in a reduction in motility, which was significant when compared to treatment 
with Lipofectamine alone (p = 0.014), but not statistically significant when compared 
to transfection with scrambled siRNA (p = 0.15). However, the small differences 
observed could be due to poor knock-down efficiency. As shown in Figure 3.32B, 
there is no visible reduction in the level of p53 in the cells transfected with siRNA for 
p53 at 30 hours post treatment, which is likely due to poor transfection efficiency of 
12-273H-39 cells.
In the following 12 horn's of the experiment (36-48 hour's post transfection) the 
toxicity of Lipofectamine became more apparent as treatment of 12-273H-39 cells 
with Lipofectamine alone resulted in a significant reduction in the total distance 
travelled by the cells (p = 0.002) when compared to untreated cells (Figure 3.32C). 
Treatment of cells with scrambled siRNA compared to treatment with Lipofectamine 
alone did not have a significant impact on motility (p = 0.2). Transfection with siRNA 
for p53, on the other hand, resulted in a significant reduction in motility when 
compared to transfection with scrambled siRNA (p < 0.0001). Western blotting 
confirmed that there was a slight reduction in the p53 level at 42 hours after- 
transfection of cells with siRNA for p53 (Figure 3.32D). Although it seems like the 
p53 siRNA lane might have been slightly underloaded (as judged by the level of 
actin), it is unlikely that the difference in p53 level observed would be solely due to 
a loading difference. In Figure 3.32B the scr. siRNA and p53 siRNA lanes also appear
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slightly underloaded (as judged by the level of actin), yet the p53 level is relatively 
even in all lanes. This is likely because the level of p53-273H in 12-273H-39 cells is 
high and small loading differences are difficult to spot in terms of p53 level in these 
cells. This suggests that the reduction in p53 level observed in Figure 3.32D is due to 
p53 siRNA transfection rather than a small loading difference.
If knock-down of mutant p53 really results in the reduction of motility, then it can 
be concluded that the increased motility of mutant p5 3-expressing clones is a result of 
mutant p53 expression.
3.10.2. Stable knock-down of mutant p53 in the generated clones 
Due to persistently low transfection efficiency and knock-down efficiency of the 
mutant p53-expressing laryngeal cancer cell lines, establishing cell lines with a stable 
knock-down of mutant p53 has been attempted (as described in section 2.13.2). 
A number of clones with a significant reduction of mutant p53 expression have been 
established. Stable clones expressing scrambled short hairpins have also been 
generated as a negative control for the cloning process.
A number of clones with a reduced level of p53 have been established from 
12-273H-39 cells (Figure 3.33A) and 12-273H-41 cells (Figure 3.33C). Cell lines 
with a comparable level of p53 following transfection with scrambled siRNA have 
also been generated from these cells (Figure 3.33B and D, respectively). Knock-down 
of mutant p53-175H in 12-175H-20 cells appeared more difficult and the two clones 
with the lowest level of p53 out of all the ones screened showed only a partial 
reduction of the p53 level (Figure 3.33E). A number of control (scrambled siRNA) 
clones with a comparable p53 level to the parental 12-175H-20 cells have also been 
generated (Figure 3.33F).
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Figure 3.33: Expression levels of the TAP-tagged p53 mutants in the established 
knock-down clones. The previously established mutant p53-expressing cell lines were 
transfected with pSUPER.puro.shp53 or pSUPER.puro.shScr and stable clones were 
established. All the clones presented here were tested for p53 expression at least twice.
A-F. Western blot analysis with the indicated antibodies (DO-1 for p53) of cell lysates of the 
generated clones as compared to the parental cell line: 12-273H-39 (A and B), 12-273H-41 
(C and D) or 12-175H-20 (E and F).
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The motility of some of the generated clones was studied using the live cell 
imaging system. Representative movies are available on the attached CD (see 
Appendix 12).
12-273H-39 cells were more motile in this experiment than the parental 
UM-SCC-12 cells (p < 0.0001), showing that the data collected using the live cell 
imaging system are reproducible. The two generated clones of 12-273H-39 cells 
tested in this experiment, 12-273H-39-lowi and 12-273H-39-low3 (expressing 
a reduced level of p53-273H), displayed reduced motility compared to the parental 
cell line (Figure 3.34) and these differences were statistically significant (p < 0.05). 
Moreover, the reduction in motility of 12-273H-39-lowi cells was so large that they 
became comparably motile to UM-SCC-12 cells, with there being no significant 
difference in motility between the two (p = 0.17). While 12-273H-39-low3 cells were 
clearly less motile than their parental cells (12-273H-39), there was still a significant 
difference in motility (p = 0.012) between these cells and UM-SCC-12 cells, which 
could be explained by incomplete p53-knockdown in 12-273H-39-low3. This also 
suggests that a very low level of mutant p53 is sufficient for the cells to display 
increased motility.
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p = 0.02
Cell line
Figure 3.34: Stable knock-down of mutant p53 and motility. 150,000 cells were seeded 
per well of a 6-well plate. The cells were imaged for 12 hours with a time-lapse of 3 min. The 
histograms represent the mean of the total distance travelled by 50 tracked cells, the error bars 
represent standard error of mean. Statistical analysis was perfonned using Student’s t-Test. 
This experiment was performed once.
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In summary, mutant p53 expressing clones display increased motility 
(section 3.9.2). Transient knock-down of mutant p53 in 12-273H-39 cells results in 
a statistically significant reduction in motility 36-48 hours post transfection 
(Figure 3.32C), however, due to poor knock-down efficiency in 12-273H-39 cells 
(Figure 3.32D), analysis of this result was problematic. Generation of cell clones of 
12-273H-39 cells with a stable reduction of p53-273H expression (Figure 3.33A) 
allowed to address the question of mutant p53 contribution to the observed increased 
motility of 12-273H-39 cells once again. Both of the tested clones exhibited 
significantly reduced motility (Figure 3.34). All of these data collectively suggest that 
the increased motility of the mutant p53-expressing cells is indeed due to mutant p53 
expression.
3.11. Mutant p53-expressing LSCC cells do not display increased invasiveness
Since mutant p53 was shown to increase motility of laryngeal cancer cells 
(section 3.10), it was investigated whether the mutant p53-expressing cells display 
increased invasiveness in vitro, which is another indicator of metastatic potential. 
Boyden chamber invasion assays were performed on UM-SCC-12 cells, 12-273H-39 
cells (highly motile) and 12-273H-39-lowi cells (displaying reduced motility 
compared to the parental cells) as described in section 2.16.
As previously discussed, Boyden chambers are not an ideal system for studying the 
LSCC cells used in this project. However, it was expected that the thin layer of 
Matrigel that the invasion chambers are coated with would facilitate cell adhesion. 
Indeed the cells appeared to adhere to the Matrigel within an hour from the time of 
seeding. To encourage cell migration a serum gradient was also used. Moreover, this 
was the only invasion assay performed routinely and readily available in our
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laboratory and therefore, despite the problems observed previously, invasion was 
investigated using this assay. The experiment was performed twice.
As shown in Figure 3.35, 12-273H-39 cells do not display increased invasiveness 
compared to the parental UM-SCC-12 cells, as measured by their ability to degrade 
matrigel and migrate through the pores of a Boyden chamber membrane. In fact, 
12-273H-39 cells appear to be slightly less invasive than UM-SCC-12 cells but this 
difference is not statistically significant (p = 0.08). Similarly, the invasiveness of 
12-273H-39-lowi cells (reduced expression of p53-273H) does not differ significantly 
from their parental cells (12-273H-39).
It is important to note that these three cell lines are generally not invasive in this 
system as out of 50,000 cells seeded only 15 cells (in case of UM-SCC-12) managed 
to degrade the matrigel and migrate through the membrane, which is less than 
0.05% of the entire population. As shown previously, the laryngeal cancer cell lines 
studied here are generally not very efficient in migrating through the Boyden chamber 
membranes (see section 3.9.1) and this could partially be a reason why such a small 
number of cells migrated through the membranes in this assay. Perhaps, as in the case 
of motility, live imaging of invasion would be a more suitable way to study the 
invasive potential of these cells (as discussed in section 3.9.2).
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Cell line
Figure 3.35: Mutant p53-expressing cells do not seem to display increased invasiveness.
50,000 cells were seeded into invasion chambers and allowed to migrate through the 
membrane towards a serum gradient for 30 hours. The number of cells that passed through the 
membrane was counted. The histograms represent the mean of three replicates, the error bars 
represent standard error of mean. Statistical analysis was performed using Student’s t-Test.
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3.12. Expression of p53-273H alters gene expression
Following the finding that mutant p5 3-expressing cells display increased motility, 
gene expression profiles of the highly motile 12-273H-39 cells and parental 
UM-SCC-12 cells were studied using exon array analysis to investigate the gene 
expression changes of cells expressing the GOF contact mutant of p53 compared to 
the parental p53-null cells. Only 12-273H-39 cells (and not 12-175H-20 cells) were 
included in this analysis due to limited resources and because these cells displayed the 
most distinct increased motility phenotype.
RNA was extracted from UM-SCC-12 cells and 12-273H-39 cells in triplicate. 
Following RNA extraction, it is important to assess the quality of the RNA before 
proceeding to evaluate gene expression. Since mRNA comprises only 1-3% of total 
RNA it is not easily detectable. Ribosomal RNA, on the other hand, comprises 
>80% of total RNA, with the majority being 28S and IBS ribosomal RNA (rRNA). 
These rRNA species appear as two clear bands on agarose gels stained with ethidium 
bromide (EtBr). Since 28S and 18S rRNA species are derived from the same 
precursor rRNA, the number of copies of both molecules is the same and the ratio of 
28S:18S rRNA relies solely on their size, which is approximately 5 kb and 1.9 kb (in 
mammals), respectively. The theoretical ratio of 28S:18S is approximately 2.7:1 but 
a ratio of 2:1 is considered to be indicative of good quality, intact RNA. The ratio of 
the intensity of these bands can be used for determining the integrity of the extracted 
RNA due to the fact that these two rRNA species degrade at different rates (495). 
28S rRNA is more susceptible to degradation than 18S rRNA, partly due to the 
presence of ‘hidden breaks’ in the 28S rRNA molecules, ‘Hidden breaks’ are actually 
true breaks in the middle of the 28S rRNA molecules and are called ‘hidden’ because
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under non-denaturing conditions the rRNA molecule is held together by hydrogen 
bonds between its secondary structure elements.
The ratio of the 28S:18S rRNA in the analysed samples is approximately 2:1 
(Figure 3.36) suggesting that the RNA is not degraded. An OD 260/280 ratio is an 
indication of nucleic acid purity and an ideal value for RNA is 2.0. The ratios 
obtained for the extracted samples (Table 3.3) are slightly lower (above 1.79), which 
could be caused by protein or phenol contamination. The OD 260/230 ratio is 
a secondary indicator of nucleic acid purity. The ratio should be greater than 2.0 and 
lower ratios may suggest the presence of inorganic contaminants that absorb at 
230 nm (guanidine thiocyanate, phenol, EDTA). As shown in Table 3.3, all obtained 
OD 260/230 ratios were above 2.0, suggesting that the samples are essentially free of 
inorganic contaminants.
The extracted RNA was deemed suitable for expression analysis, which was 
performed as described in section 2.18. Cluster analysis of the differentially expressed 
genes is represented graphically in the form of a heat map (Figure 3.37).
193 genes were found to be differentially regulated in 12-273H-39 cells compared 
to UM-SCC-12 cells, with 154 genes up-regulated and 39 genes down-regulated more 
than 2.25-fold (FDR < 0.05; p < 0.05). A complete list of differentially regulated 
genes is presented in Appendix 13. The genes were grouped according to the 
processes they are involved in and the 10 most significantly affected processes are 
listed in Figure 3.38.
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Table 3.3: Spectrophotometrical quantification of the RNA used for exon arrays. RNA
was extracted from the indicated cell lines on three separate occasions (I-III).
Concentration [pg/pl] OD 260/280 OD 260/230
UM-SCC-12 I 2.66 1.88 2.23
UM-SCC-12 II 1.45 1.86 2.12
UM-SCC-12 III 1.49 1.79 2.38
12-273H-39 I 2.38 1.84 2.36
12-273H-39 II 1.59 1.82 2.42
12-273H-39 III 1.79 1.88 2.25
1.0
18S
0.5
Figure 3.36: RNA used for exon array analysis. RNA was extracted from the indicated cell 
lines on three separate occasions (I-III). The RNA integrity was tested by running 500 ng of 
total RNA on a 1% (w/v) agarose gel (with EtBr) and visualised using ultraviolet light. The 
28S and 18S RNA bands are indicated.
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Figure 3.37: Heat map representing the cluster analysis of differentially expressed genes 
(more than 2.25-fold change) identified using exon microarrays. The heat map was 
generated by hierarchical clustering of individual genes (each column corresponds to one 
gene) and samples/cell lines (each row represents a different sample), the cluster relationships 
are indicated by the tree-like structures adjacent to the map. The genes represented in blue are 
down-regulated, while the ones represented in red are up-regulated. (Data analysis performed 
by Dr Bryony Lloyd.)
log(pValue)
1. Cell adhesion - ECM remodelling
2. Cell adhesion - Chemokines and adhesion
3. Development - WNT signalling pathway, Part 2
4. Development - TGF-p-dependent induction of EMT via SMADs
5. Immune response - MIF in innate immunity response
6. Immune response - TLR signalling pathways
7. Immune response - IL-17 signalling pathways
8. Development - Regulation of EMT
9. Cytoskeleton remodelling - TGF, WNT and cytoskeletal remodelling
10. PGE2 pathways in cancer
Figure 3.38: The list of 10 processes most significantly affected by the genes 
differentially expressed in 12-273H-39 cells compared to UM-SCC-12 cells. Pathway 
analysis was performed using the MetaCore software v. 6.5 (GeneGo, Inc.) based on 
a proprietary manually created and maintained database of human protein-protein, 
protein-DNA and protein compound interactions, metabolic and signalling pathways. (Data 
analysis performed by Dr Bryony Lloyd.)
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Interestingly, given the increased migratory potential of 12-273H-39 cells, the most 
significantly affected pathways are involved in cell adhesion and extracellular matrix 
(ECM) remodelling, which suggests that the p53-273H mutant may confer the motile 
phenotype on UM-SCC-12 cells by altering their transcriptome with an emphasis on 
inducing ECM remodelling programmes. For example, fibronectin, a component of 
the ECM implicated in cell migration driven by enhanced integrin recycling (see 
section 1.3.4.3.2.3), was found to be up-regulated 8.4-fold in 12-273H-39 cells.
A number of the identified genes are known to be transcriptional targets of 
wild-type p53 (including SPRR2A, MFAP5, PTGES, CCND2, OGN, FN1 as well as 
many others). Based on the transcriptional networks generated from the microarray 
analysis (Appendix 14) it appears that a number of genes, which were found to be 
differentially expressed in this study, could be transcriptionally regulated by mutant 
p53 via other transcription factors, such as Spl and NF-kB.
It is noteworthy that Spl activates VEGF transcription, hence stimulating 
angiogenesis (as discussed in section 1.3.2.6). While wild-type p53 is known to 
repress angiogenesis via binding of p53 to the transcription factor Spl (hence 
inhibiting its ability to bind other promoters such as VEGF), VEGF-A was found to 
be up-regulated 2.48-fold in the mutant p53 expressing cells compared to p53-null 
cells, suggesting that the interaction of mutant and wild-type p53 with Spl may have 
opposite outcomes (see section 1.3.4.3.1.2).
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3.12.1. Validation of the expression microarray data by qRT-PCR 
Following the identification of 193 differentially regulated genes in 12-273H-39 cells, 
it was important to validate the expression differences obtained from microarray 
analysis. For this purpose 12 genes were selected from Tables 6.5 and 6.6 
(Appendix 13) based on the relative mRNA expression level (normalised to the 
expression level in the parental UM-SCC-12 cells, further referred to as control 
expression level) and an analysis (based upon the literature) of their known roles in 
regulating motility/invasion/metastasis, suggesting that they could be relevant to the 
observed migratory phenotype of 12-273H-39 cells. A brief summary of the functions 
of the selected genes is presented in Table 3.4.
qRT-PCR for the selected targets listed in Table 3.4 was performed by members of 
the Applied Biology team (led by Prof. D. Ross Sibson and Dr Bryony Lloyd, 
University of Liverpool) using the RNA samples used for microarray analysis to 
validate the observed differences in gene expression. RNA extracted from 
12-175H-20 cells was also included in this analysis to compare the expression levels 
of the selected genes in cells expressing two different GOF p53 mutants. The 
experimental setup is described in section 2.19. The relative expression of the 
12 selected targets in 12-273H-39 and 12-175H-20 cells compared to UM-SCC-12 
cells is presented in Table 3.5, while the normalised expression levels (normalised to 
histone H3 expression) are presented in Figure 3.39.
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Table 3.4: The list of genes selected for validation (by qRT-PCR) of the expression 
differences obtained from the expression array analysis. The relative expression level 
(normalised to control expression level) of genes found to be up-regulated are indicated in 
red, while those of down-regulated genes - in blue.
Gene
symbol Full name
Relative
expression Relevant functions
SPRR2A Small proline- rich protein 2A 23.13
SPRR2A enhances migration and EMT in wound 
healing (496)
TLR4 Toll-like receptor4 14.63
S100A8-SAA3-TLR4 pathway enhances
metastasis to the lungs by promoting the 
accumulation of macrophages and
haematopoietic progenitors (497)
S100A8
SI00 calcium 
binding protein
A8
10.31
Co-expression of S100A8 and S100A9 is 
associated with poor tumour differentiation, 
vessel invasion and node metastasis (498)
C8orf4 / 
TCI
Chromosome 8 
open reading 
frame 4
10.22
TCI up-regulates Wht/p-catenin target genes 
(MMP7, MMP14, cyclin Dl), which are 
implicated in the aggressive biological behaviour 
of cancers; enhances Matrigel invasiveness (499)
FN1 Fibronectin 1 8.40
Fibronectin is involved in cell adhesion and 
migration processes during embryogenesis, 
wound healing, angiogenesis and metastasis; it 
promotes cell invasion through increased 
association with integrins and expression of 
MMPs (500)
PTGES/ 
PIG 12
Prostaglandin E 
synthase 8.12
PTGES is implicated in cancer metastasis by 
increasing proliferation, migration and
invasiveness of cancer cells (501)
TIMP2
TIMP
metallopeptidase 
inhibitor 2
7.92
Tissue inhibitor of MMP2, prevents protease 
activity in tissues undergoing ECM remodelling; 
implicated in tissue invasion and metastasis (502)
TSPAN1 Tetraspanin 1 5.82
Tetraspanin-integrin interaction contributes to 
increased migration and invasiveness of SCCHN 
cells (503)
MMP2
Matrix
metalloproteinase
2
2.94
MMP2 degrades type IV collagen, the major 
structural component of basement membranes; it 
is implicated in migration and invasiveness (504)
CCND2 Cyclin D2 -10.94
Cyclin D2 forms a complex with CDK4 or 
CDK6, necessary for Gl-S transition; it is 
up-regulated in senescent cells and may 
contribute to the induction/maintenance of the 
non-proliferative state (505)
OGN Osteoglycin -8.51
High osteoglycin expression contributes to 
decreased potential for both migration and 
invasion and decreased metastatic potential (506)
NPNT / 
POEM Nephronectin -6.90
Nephronectin is an ECM protein, the expression 
of which increases cell adhesion and decreases 
cell migration and invasion; loss of nephronectin 
is associated with tumour progression (507)
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As shown in Table 3.5 and Figure 3.39 the obtained microarray data have been 
validated for all the selected genes by qRT-PCR. All of the selected genes found to be 
up-regulated in 12-273H-39 cells relative to UM-SCC-12 cells in the microarray 
study have also been found up-regulated by qRT-PCR. Similarly, the genes found to 
be down-regulated in the microarray analysis were also down-regulated in the 
qRT-PCR validation study. This suggests that the microarray data is reliable and 
confirms the observed differences in gene expression.
Note, however, that there is a difference in the scale of the relative expression data 
obtained from microarray analysis (Table 3.4) and qRT-PCR validation (Table 3.5). 
The observed differences are due to a difference in the dynamic range of the 
microarray and qRT-PCR. Dynamic range defines the range of the initial mRNA 
concentrations, over which accurate expression levels can be determined. Most 
commercially available microarray platforms have a dynamic range of 3-4 orders of 
magnitude while real-time PCR can achieve a dynamic range of up to 8 orders of 
magnitude (508). Consequently, the larger dynamic range of real-time PCR assays 
provides them with a superior detection sensitivity while the gene expression changes 
determined using microarray technology are underestimated in the extreme parts of 
the range (changes > 10 or < -5) (509).
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Table 3.5: The relative expression levels (determined by qRT-PCR) of the selected genes 
in 12-273H-39 and 12-175H-20 cells (normalised to the control expression levels). The
relative expression of genes found to be up-regulated is indicated in red, while those of 
down-regulated genes - in blue. (Data provided by Dr Bryony Lloyd.)
Gene
symbol
Relative expression
12-273H-39 12-175H-20
SPRR2A 30.6 219.3
TLR4 54.1 1.1
S100A8 83.2 450.4
C8orf4 157.7 15.5
FN1 38.3 3.0
PTGES 428.8 23.4
TIMP2 21.1 2.0
TSPAN1 37.8 21.8
MMP2 8.8 1.8
CCND2 -4.5 -4.6
OGN -1.6 -1.7
NPNT -2.3 -4.7
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Figure 3.39: Expression levels of the indicated genes in UM-SCC-12, 12-273H-39 and 
12-175H-20 cells. qRT-PCR was performed on RNA extracted from the indicated cells lines. 
The histograms show mean of the average expression levels (normalised to histone H3 
expression) in three replicate RNA samples (see section 2.19.4 for details), the error bars 
represent standard error of mean. (Data provided by Dr Bryony Lloyd.)
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Figure 3.39 (cont.): Expression levels of the indicated genes in UM-SCC-12, 12-273H-39 
and 12-175H-20 cells. qRT-PCR was perfonned on RNA extracted from the indicated cells 
lines. The histograms show mean of the average expression levels (normalised to histone H3 
expression) in three replicate RNA samples (see section 2.19.4 for details), the error bars 
represent standard error of mean. (Data provided by Dr Bryony Lloyd.)
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The qRT-PCR analysis of the selected genes also allowed for comparison of the 
expression levels of the cell lines expressing two different GOF p53 mutants - 
p53-273H and p53-175H. Some genes (including TLR4, C8orf4, FN1, PTGES, 
TIMP2 and MMP2) have been found to be up-regulated only, or much more 
significantly, in 12-273H-39 cells. Given the fact that these cells display much higher 
motility than 12-175H-20 cells, these genes might be functionally important in 
mediating the motile phenotype. TSPAN1 was up-regulated in both cell lines but 
up-regulation in 12-273H-39 cells was higher. Two of the analysed genes (SPRR2A 
and S100A8) were up-regulated much more significantly in 12-175H-20 cells than in 
12-273H-39 cells. Down-regulation of CCND2, OGN and NPMT was similar in both 
cell lines.
A number of the validated genes will be selected for functional examination to 
determine their possible contribution to the observed migratory phenotype of 
12-273H-39 cells. The best candidates for functional studies include genes, which are 
more highly up-regulated in 12-273H-39 cells (displaying dramatically increased 
migratory potential) compared to 12-175H-20 cells (displaying slightly increased 
migratory potential).
While the microarray analysis revealed up-regulation of many genes involved in 
regulation of cell adhesion and ECM remodelling, which could explain the increased 
migratory potential of 12-273H-39 cells, it is important to remember that the cell lines 
analysed in this study are clones of UM-SCC-12 cells and, therefore, the possibility of 
the observed differences being a result of clonal variation cannot be underestimated. 
Moreover, it should also be mentioned that 12-273H-39 cells and 12-175H-20 cells 
express TAP-tagged p53 mutants and hence any observed difference could also 
potentially be due to the presence of this tag. To address these issues, UM-SCC-12
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cells were transiently transfected with untagged wt p53, p53-175H, p53-273H or the 
con-esponding empty vector and the expression of the 12 selected genes (Table 3.4) 
was studied by qRT-PCR.
3,12.2. Validation of the observed gene expression changes in UM-SCC-12 cells 
In order to address the issue of clonal variation and to exclude the possibility of the 
TAP-tag at the N-terminus of p53 mutants affecting the gene expression differences 
observed in 12-273H-39 cells and 12-175H-20 cells, UM-SCC-12 cells were 
transfected with untagged wt p53, p53-175H, p53-273H or the corresponding empty 
vector in triplicate using recently optimised nucleofection (Amaxa Nucleofector 
Technology). RNA was extracted from each individual transfection and the 
12 selected genes (Table 3.4) were analysed by qRT-PCR. A small aliquot of cells 
from each condition was kept for western blot analysis. The experiment was 
performed once.
Nucleofection of UM-SCC-12 cells with the untagged p53 forms resulted in 
a comparable level of expression of p53, p53-175H and p53-273H, respectively 
(Figure 3.40). MDM2 was clearly induced in cells transfected with wt p53. It seems 
that the MDM2 level was also marginally higher in cells transfected with p53-175H 
or p53-273H than in those transfected with empty vector, suggesting that these p53 
mutants may retain some residual wt p53 transcriptional activity. Similarly, p21 was 
induced strongly in cells expressing wt p53 and only slightly in those expressing the 
p53 mutants.
The observed difference in the mobility of the mutant p53 forms compared to wt 
p53 is most likely due to differences in the SNP at amino acid 72, with wt p53 having 
72R and the p53 mutants - 72P (as discussed in section 3.8).
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p53
actin
p21
Figure 3.40: Expression levels of the untagged p53 forms in transiently transfected 
UM-SCC-12 cells. 3x10*' UM-SCC-12 cells were transfected with 3 fig of wt p53, 
p53-175H, p53-273H in pCMV-Script or the corresponding empty vector and analysed 
24 hours post transfection. The panel shows western blot analysis with the indicated 
antibodies (DO-1 for p53) from UM-SCC-12 cells transfected with the indicated constructs.
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Following RNA extraction from the triplicate transfections, the RNA quality was 
tested as described previously (section 3.12). Based on the 28S:18S rRNA, 
OD 260/280 and OD 260/230 ratios of the analysed samples (Table 3.6 and Figure 
3.41), the extracted RNA was deemed suitable for qRT-PCR analysis. qRT-PCR was 
performed by members of the Applied Biology team (led by Prof. D. Ross Sibson and 
Dr Bryony Lloyd, University of Liverpool) as described previously (section 2.19). 
The relative expression of the 12 selected targets in UM-SCC-12 cells transfected 
with wt p53, p53-175H or p53-273H, respectively, compared to UM-SCC-12 cells 
transfected with the corresponding empty vector is presented in Table 3.7, while the 
normalised expression levels (normalised to histone H3 expression) are presented in 
Figure 3.42.
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Table 3.6: Spectrophotometrical quantification of the RNA extracted from transiently 
transfected UM-SCC-12 cells. 3xl0(' UM-SCC-12 cells were transfected with 3 jig of 
wt p53, p53-175H, p53-273H in pCMV-Script or the corresponding empty vector in triplicate 
(I-II1). RNA was extracted from the transiently transfected cells 24 hours post transfection.
UM-SCC-12 + Concentration [pg/pl] OD 260/280 OD 260/230
empty vector I 1.21 1.94 2.36
empty vector II 1.29 2.07 0.97
empty vector III 1.08 1.91 2.39
p53 I 1.30 1.94 2.36
p53 II 1.18 1.93 2.01
p53 III 1.59 1.96 2.23
p53-175H I 1.39 1.67 2.57
p53-175H II 2.01 1.71 2.53
p53-175H III 1.88 1.69 2.47
p53-273H I 1.18 1.65 2.33
p53-273H II 1.57 2.01 2.17
p53-273H III 1.25 1.97 2.69
A empty
0.5
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Figure 3.41: RNA extracted from transiently transfected UM-SCC-12 cells.
SxlO6 UM-SCC-12 cells were transfected with 3 jig of wt p53, p53-175H, p53-273H in 
pCMV-Script or the corresponding empty vector in triplicate. RNA was extracted from the 
transiently transfected cells 24 hours post transfection. The RNA integrity was tested by 
running 500 ng of total RNA on a 1% agarose gel (with EtBr) and visualised using ultraviolet 
light. The 28S and 18S RNA bands are indicated.
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As shown in Table 3.7, most of the determined relative gene expression levels of 
the 12 selected genes in UM-SCC-12 cells transfected with wt p53, p53-175H or 
p53-273H (normalised to the control expression levels in UM-SCC-12 cells 
transfected with the corresponding empty vector) were not statistically significantly. 
The variability of the generated data is well illustrated by the relative expression 
levels of MMP2 in UM-SCC-12 cells following transfection with wt p53 and 
p53-175H (Table 3.7). The relative expression levels are equal 1.20 in both cases, yet 
only the relative expression level in wt p53-expressing UM-SCC-12 cells is 
statistically significant. This is clearly due to the fact that the variability of the relative 
expression levels of MMP2 from the triplicate transfections of UM-SCC-12 cells with 
wt p53 was much lower than that of triplicate transfections of UM-SCC-12 cells with 
p53-175H, making only the first value statistically significant.
When looking at the average expression levels of each of the 12 selected genes 
following transfections (Figure 3.42), it is clear that the variation was very high. To 
determine the source of variation it was necessary to analyse the normalised 
expression levels (and their variations) for each transfection separately (Appendix 15). 
In many cases it can be observed that variation for individual transfections was very 
large (for example for TLR4 expression following p53-273H transfection or FN1 
expression following p53 transfection). These variations are derived from the 
differences between the average expression values determined for the two reverse 
transcriptions (see Figure 2.2), suggesting that the source of variation lies in the 
qRT-PCR assays rather than in the actual biological differences.
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Table 3.7: The relative expression levels (determined by qRT-PCR) of the selected genes 
following transfection of UM-SCC-12 cells with wt p53, p53-175H and p53-273H, 
respectively (normalised to the control expression levels in UM-SCC-12 cells transfected 
with the corresponding empty vector). The relative expression levels reflecting differences, 
which were statistically significant (p < 0.05 as determined by a Student’s t-Test), are shown 
in red (if up-regulated) or blue (if down-regulated). (Data provided by Dr Bryony Lloyd.)
Gene
symbol
Relative expression
p53 p53-175H p53-273H
SPRR2A -1.12 -1.60 -1.29
TLR4 1.15 1.32 -1.11
S100A8 -1.23 -4.04 -2.69
C8orf4 -3.41 -1.51 1.67
FN1 1.04 -1.38 -1.01
PTGES 1.04 -1.47 -1.30
TIMP2 1.08 -1.40 -1.26
TSPAN1 -1.17 -1.06 1.39
MMP2 1.20 1.20 -1.15
CCND2 1.05 1.14 -1.04
OGN 1.67 1.12 1.59
NPNT 1.10 -1.04 -1.13
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Figure 3.42: Expression levels of the indicated genes in UM-SCC-12 cells following 
transfection with wt p53, p53-175H, p53-273H or the corresponding empty vector.
qRT-PCR was performed on RNA extracted from UM-SCC-12 cells transiently transfected 
with the indicated vectors. The histograms show mean of the average expression levels 
(normalised to histone H3 expression) in three replicate RNA samples (see section 2.19.4 for 
details), the error bars represent standard error of mean. (Data provided by Dr Bryony Lloyd.)
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Figure 3.42 (cont.): Expression levels of the indicated genes in UM-SCC-12 cells 
following transfection with wt p53, p53-175H, p53-273H or the corresponding empty 
vector. qRT-PCR was performed on RNA extracted from UM-SCC-12 cells transiently 
transfected with the indicated vectors. The histograms show mean of the average expression 
levels (normalised to histone H3 expression) in three replicate RNA samples (see 
section 2.19.4 for details), the error bars represent standard error of mean. (Data provided by 
Dr Bryony Lloyd.)
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There were also some cases, in which the variation for individual transfections was 
small (such as S100A8 expression following p53-175H transfection or C8orf4 
expression following p53-175H transfection). In those instances, any variations 
observed in Figure 3.42 would most likely be due to biological variation. A possible 
reason for such variation between the transfection replicates could be operator-based 
errors.
In the performed nucleofection-based transfections, high toxicity of the 
procedure was observed (approximately 50% viable cells). Nucleofection is an 
electroporation-based method, in which specific combinations of electrical pulses 
permeabilize both the plasma membrane and the nuclear* envelope, resulting in DNA 
transfer directly into the nucleus. The inability of many cells to seal the generated 
microholes in the plasma membrane is likely the main reason for the high cellular 
mortality after nucleofection. While nucleofection is a highly cytotoxic transfection 
technique, it is the only method of the ones tested, with which UM-SCC-12 cells 
could be successfully transfected (approximately 50% transfection efficiency 
compared to 1-2% transfection efficiency with other techniques used). It should be 
possible to increase cell viability through optimisation of this technique, including the 
nucleofection program and number of cells used.
In conclusion, it will be important to try to eliminate the sources of variation 
(mostly in the qRT-PCR assays) in future experiments in order to obtain statistically 
significant differences in gene expression that are a consequence of the expression of 
the various forms of p53 under study.
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3.12.3. Validation of the observed gene expression changes in H1299 cells 
In addition to an attempt to validate the gene expression changes obtained from the 
microarray study in UM-SCC-12 cells to exclude the possibility of clonal variation, 
a parallel validation was attempted in HI299 cells to determine whether the observed 
differences are specific to laryngeal squamous cell carcinoma or if they can also be 
observed in other cells, HI299 cells were transfected with mitagged wt p53, 
p53-175H, p53-273H or the corresponding empty vector (pCMV-Script) in triplicate. 
RNA was extracted from each individual transfection and the 12 selected genes 
(Table 3.4) were analysed by qRT-PCR. A small aliquot of cells from each condition 
was kept for western blot analysis. The experiment was performed once.
Transfection of HI299 cells with the untagged p53 forms resulted in a comparable 
level of expression of p53, p53-175H and p53-273H, respectively (Figure 3.43). 
MDM2 was clearly induced in cells transfected with wt p53, A slight increase in 
MDM2 level was also observed in cells transfected with p53-175H or p53-273H 
compared to those transfected with empty vector, suggesting that these p53 mutants 
may retain some residual wt p53 transcriptional activity. p21 induction was observed 
only in cells expressing wt p53.
The observed difference in the mobility of the mutant p53 forms compared to 
wt p53 is most likely due to differences in the SNP at amino acid 72, with wt p53 
having 72R and the p53 mutants — 72P (as discussed in section 3.8).
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Figure 3.43: Expression levels of the untagged p53 forms in transiently transfected 
H1299 cells. HI299 cells were transfected with 5 pg of wt p53, p53-175H, p53-273H in 
pCMV-Script or the corresponding empty vector per 10 cm dish and analysed 24 hours post 
transfection. The panel shows western blot analysis with the indicated antibodies (DO-1 for 
p53) from HI299 cells transfected with the indicated constructs.
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Following RNA extraction from the triplicate transfections, the RNA quality was 
tested as described previously (section 3.12). Based on the 28S:18S rRNA, 
OD 260/280 and OD 260/230 ratios of the analysed samples (Table 3.8 and Figure 
3.44), the extracted RNA was deemed suitable for qRT-PCR analysis. qRT-PCR was 
performed by members of the Applied Biology team (led by Prof. D. Ross Sibson and 
Dr Bryony Lloyd, University of Liverpool) as described previously (section 2.19). 
The relative expression of the 12 selected targets in HI299 cells transfected with 
wt p53, p53-175H or p53-273H, respectively compared to H1299 cells transfected 
with the corresponding empty vector is presented in Table 3.9, while the normalised 
expression levels (normalised to histone H3 expression) are presented in Figure 3.45.
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Table 3.8: Spectrophotometrical quantification of the RNA extracted from transiently 
transfected H1299 cells. HI299 cells were transfected with 5 pg of wt p53, p53-175H, 
p53-273H in pCMV-Script or the corresponding empty vector per 10 cm dish, in triplicate 
(I-III). RNA was extracted from the transiently transfected cells 24 hours post transfection.
H1299 + Concentration [pg/pl] OD 260/280 OD 260/230
empty vector I 2.43 1.73 2.48
empty vector II 1.91 1.75 1.57
empty vector III 2.27 1.70 2.35
p53 I 2.38 1.74 2.21
p53 II 2.20 1.69 2.27
p53 III 2.00 1.69 2.49
p53-175H I 1.95 1.78 1.53
p53-175H II 1.07 1.59 2.45
p53-175H III 2.70 1.74 2.40
p53-273H I 2.22 1.66 2.47
p53-273H II 1.59 1.70 1.69
p53-273H III 2.53 1.72 2.42
empty
vector p53 p53-175H p53-273H
Size (kb) -------------------------- -------------------------- -------------------------- --------------------------
Figure 3.44: RNA extracted from transiently transfected H1299 cells. HI299 cells were 
transfected with 5 pg of wt p53, p53-175H, p53-273H in pCMV-Script or the corresponding 
empty vector per 10 cm dish, in triplicate. RNA was extracted from the transiently transfected 
cells 24 hours post transfection. The RNA integrity was tested by running 500 ng of total 
RNA on a 1% agarose gel (with EtBr) and visualised using ultraviolet light. The 28S and 18S 
RNA bands are indicated.
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As shown in Table 3.9, most of the determined relative gene expression levels of 
the 12 selected genes in H1299 cells transfected with wt p53, p53-175H or p53-273H 
(normalised to the control expression levels in HI299 cells transfected with the 
corresponding empty vector) were not statistically significantly. When looking at the 
average expression levels of each of the 12 selected genes following transfections 
(Figure 3.45), it is clear that the variation was very large, perhaps even larger than in 
the parallel experiment performed on UM-SCC-12 cells (section 3.12.2). To 
determine the source of variation it was necessary to analyse the normalised 
expression levels (and their variations) for each transfection separately (Appendix 16). 
As observed previously (section 3.12.2), there are cases, in which the variation for 
individual transfections is very large (for example for FN1 expression following p53 
transfection or CCND2 expression following p53-273H transfection). These 
variations are derived from the differences between the average expression values 
determined for the two reverse transcriptions (see Figure 2.2), suggesting that the 
source of variation in these cases lies in the qRT-PCR assays rather than in the actual 
biological differences.
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Table 3.9: The relative expression levels (determined by qRT-PCR) of the selected genes 
following transfection of H1299 cells with wt p53, p53-175H and p53-273H, respectively 
(normalised to the control expression levels in UM-SCC-12 cells transfected with the 
corresponding empty vector). The relative expression levels reflecting differences, which 
were statistically significant (p < 0.05 as determined by a Student’s t-Test), are shown in red 
(if up-regulated) or blue (if down-regulated). (Data provided by Dr Bryony Lloyd.)
Gene
Fold change
p53 p53-175H p53-273H
SPRR2A 1.97 -1.21 2.65
TLR4 2.88 1.10 4.04
S100A8 1.93 -1.10 2.53
C8orf4 1.73 -1.27 1.44
FN1 3.00 1.16 1.14
PTGES 2.11 1.05 1.62
TIMP2 1.11 -1.02 1.03
TSPAN1 1.40 1.04 1.30
MMP2 2.09 -1.25 2.14
CCND2 -1.30 -1.45 -1.63
OGN 1.35 -1.12 1.93
NPNT 2.28 -1.17 -1.03
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Figure 3.45: Expression levels of the indicated genes in H1299 cells following 
transfection with wt p53, p53-175H, p53-273H or the corresponding empty vector.
qRT-PCR was performed on RNA extracted from HI299 cells transiently transfected with the 
indicated vectors. The histograms show mean of the average expression levels (normalised to 
histone H3 expression) in three replicate RNA samples (see section 2.19.4 for details), the 
error bars represent standard error of mean. (Data provided by Dr Bryony Lloyd.)
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Figure 3.45 (cont.): Expression levels of the indicated genes in H1299 cells following 
transfection with wt p53, p53-175H, p53-273H or the corresponding empty vector.
qRT-PCR was performed on RNA extracted from HI299 cells transiently transfected with the 
indicated vectors. The histograms show mean of the average expression levels (normalised to 
histone H3 expression) in three replicate RNA samples (see section 2.19.4 for details), the 
error bars represent standard error of mean. (Data provided by Dr Bryony Lloyd.)
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However, in this experiment the variation for individual transfections was 
relatively small for most target genes (such as NPNT, PTGES or S100A8 expression 
in all four transfections). It is therefore most likely that any variations observed in 
Figure 3.45 are due to biological differences. A possible reason for such variation 
between the transfection replicates could be operator-based errors.
Compared to nucleofection used in the parallel experiment to transfect 
UM-SCC-12 cells (see section 3.12.2), GeneJuice transfection was relative non-toxic. 
Gene Juice, used to transfect HI 299 cells, is described by the manufacturer as 
a proprietary formulation of a non-toxic cellular* protein and a small amount of a novel 
polyamine. Polyamine-DNA complexes (polyplexes) are taken up by the cell through 
endocytosis. Polyamine-mediated transfection is one of the least toxic transfection 
methods available. Moreover, GeneJuice transfection can be performed in the 
presence of serum, which further reduces cytotoxicity and GeneJuice was shown to 
have the lowest cytotoxicity out of the transfection reagents tested on HI299 cells. 
Nevertheless, polyamines have been reported to cause membrane permeability (510), 
which could be the reason for the minimal toxicity observed.
Therefore, in future experiments it will be important to minimise the experimental 
variability (likely due to operator-based errors), which seems to be the main source of 
variation in this experiment, in order to more accurately determine the levels of gene 
expression in response to expression of the various forms of p53 under study.
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3.13. Mutant p53 expression sensitises laryngeal cancer cells to ionising radiation
Since radiation therapy is one of the treatment modalities for laryngeal cancer, it was 
important to determine the impact of mutant p53 expression on the response of cells 
to ionising radiation.
Clonogenic assays were performed (as described in section 2.23) to investigate the 
response to y-radiation of UM-SCC-12 cells, 12-175H-20 cells and 12-273H-39 cells. 
This experiment was performed once.
UM-SCC-12 (p53-null) cells are relatively radioresistant (Figure 3.46). 
12-175H-20 cells are more sensitive to y-radiation than UM-SCC-12 and 12-273H-39 
cells are the most sensitive of all three. Since the studied cell lines are isogenic, the 
obtained results suggest that mutant p53 expression renders cells sensitive to 
radiation, with the contact mutation (R273H) having a stronger effect than the 
structural mutation (R175H). These data are rather unexpected since it is well 
documented that GOF mutant p53 expression is associated with tumour’ resistance to 
ionising radiation (511). On the other hand, a similar- effect of p53 mutation has been 
previously observed in our laboratory, when LSCC cells expressing endogenous 
homozygous p53 mutations were found to be more sensitive to radiation than cells 
carrying any other p53 genotype (wt p53, heterozygous mutant p53 or p53-null) 
(512).
While the mechanistic details of this radiosensitisation remain unclear, the panel of 
generated isogenic cell lines provides an ideal experimental system for studying the 
response of LSCC cells to radiation.
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Figure 3.46: Expression of mutant p53 sensitises LSCC cells to ionising radiation.
UM-SCC-12 cells, 12-175H-20 cells and 12-273H-39 cells were treated with the indicated 
doses of y-irradiation and then seeded at a range of concentrations into 6-well plates and 
allowed to form colonies for a period of 2 weeks. Clonogenic assays were performed and 
survival data were fitted to the linear-quadratic equation y = exp(- (a • x + b • x2)), where y is 
the surviving fraction and x is the treatment dose; all R2 values were > 0.81. This experiment 
was performed once.
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4. Discussion
Inactivation of the p53 tumour suppressor pathway, frequently due to missense 
mutations in the TP53 gene, is one of the most common genetic alterations in human 
cancer (134, 139). p53 mutation is consistently associated with poor prognosis and 
therapeutic response in head and neck cancer (101, 513). It has been suggested that 
this may be due to an oncogenic gain of function of p53 mutants (reviewed in (514)).
Therefore, the main objective of this project was investigation of the mechanisms 
and functional consequences of the oncogenic gain of function of mutant p53 in 
laryngeal cancer cells, which are important preclinical models in the search for new 
therapies for treatment of laryngeal cancer (463). The two hot-spot mutants chosen for 
the studies described in this thesis were R175H (a structural mutation affecting 
p53 folding) and R273H (a contact mutation affecting one of the p53 residues, which 
make direct contact with DNA) (147). Both of these mutants have been shown to 
display GOT properties using in vivo models (5, 6) and have been documented to 
occur in laryngeal cancer (139).
Such p53 mutants exert their GOF properties by modifying cells through altered 
transcriptional activity or novel protein-protein interactions (411, 515). Therefore, the 
mechanism of action of the GOF p53 mutants discussed above was investigated by 
identifying the mutant p53 interacting proteins and studying the gene expression 
changes in cells expressing those p53 mutants. Since many biological functions 
involve interactions between proteins, identifying the interacting partners of mutant 
p53 may elucidate, which molecular networks and pathways mutant p53 proteins are 
involved in, and the identified mutant p53 interacting proteins may represent 
important new therapeutic targets. The functional consequences of GOF p53
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mutations in laryngeal cancer were studied with respect to cellular motility, 
invasiveness and response to ionising radiation (a common treatment modality for 
laryngeal cancer).
To permit purification of p53 containing protein complexes for future identification 
of mutant p53 interacting proteins, cDNAs of wt and the two GOF mutants (R175H 
and R273H) were cloned into TAP-tag vectors. The constructs were then tested for 
expression and transcriptional activity in a p53-null background (HI299, a non-small 
cell lung carcinoma cell line). H1299 cells were chosen for these studies because they 
lack p53 expression, grow relatively rapidly (doubling in less than 24 hours) and are 
readily transfectable.
Expression of different p53 forms (wt, R175H or R273H) from a TAP-tag vector 
resulted in the expression of proteins of apparent molecular' weight of 57 kDa, which 
is in accordance with the predicted size of TAP-tagged p53 - the apparent molecular 
weight of untagged p53 is 50 kDa and the theoretical molecular weight of the 
TAP-tag is 8 kDa. Both p53 mutants lack wt transcriptional activity as tested in 
a luciferase p53 transcriptional activity assay (using a RGC p53 binding element 
upstream of ap53 consensus binding sequence; see section 3.2). Furthermore, the two 
p53 mutants studied inhibited the wt p53 transcriptional activity in a dose-dependent 
manner (Figures 3.10 and 3.11), likely through hetero-oligomerisation of the wt and 
mutant forms of the protein (a dominant-negative effect) (411). Dominant-negative 
effects of the p53 mutants on wt p53-activated transcription from the RGC were also 
reported by others (516). The dominant-negative effect of the structural p53-175H 
mutant on wt p53 transcriptional activity was found to be stronger than that of the 
contact p53-273H mutant (Figures 3.10A and 3.11 A). This phenomenon was also 
reported by others (392). It can be explained by the fact that the structural mutants
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upon hetero-oligomerization with wt p53 are capable of shifting wt p53 into a mutant 
conformation while hetero-oligomers of contact mutants with wt p53 may retain some 
wt transcriptional activity. This is also supported by the fact that in a group of 
37 patients with SCCHN the presence of the contact mutation (in 13 patients) is 
associated with LOH in 100% of cases while the structural mutation (in 24 patients) is 
associated with LOH in only in 50% of cases (p = 0.0034) (394).
Expression of wt p53 from a TAP-tag vector resulted in p53 that activates 
transcription from RGC, but which produces slightly lower levels of activity 
compared to the untagged wt p53 (Figure 3.12). It was observed that TAP-tagged wt 
p53 also reduces the activity of the untagged protein, thus acting as a partial 
dominant-negative in this system (Figure 3.13). This is likely due to 
hetero-oligomerisation of the tagged and untagged proteins. Therefore, TAP-tagged 
wt p53 retains reduced transcriptional activity and can reduce the activity of untagged 
wt p53 when the two proteins are co-expressed. Since all of the TAP-tagged proteins 
were to be introduced into p53-null cells, the partial inhibition the untagged wt p53 by 
the TAP-tagged protein would not be observed. Finally, this dominant-negative effect 
should not be of major concern unless the TAP-tag fusion prevents functionally 
critical proteins from associating with p53. Ultimately, the obtained results can be 
validated by using cDNAs that lack the fusions.
In order to study the interacting partners of the chosen GOF p53 mutants in 
laryngeal cancer cells, stable cell lines of a functionally p53-null LSCC cell line 
(UM-SCC-12) have been generated to express the TAP-tagged mutant forms of p53 
(Figure 3.17). The approach of generating cell clones with a stable expression of the 
TAP-tagged p53 forms was taken because a transient expression system was not
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feasible due to extremely low transfection efficiency of UM-SCC-12 (typically 1-2%, 
see Figure 3.15).
One cell clone that stably expresses a TAP-tagged R175H mutant of p53 
(12-175H-20) and two cell clones with stable expression of the R273H mutant of p53 
(12-273H-39 and 12-273H-41) were generated. It is important to note that in the first 
attempt to generate mutant p53 expressing LSCC cells, 12-175H-20 was the only 
positive clone obtained displaying mutant p53 expression and it was one of the most 
slowly growing ones, which may suggest that the expression of TAP-tagged 
p53-175H has some inhibitory effects on cell growth. In the second attempt to 
establish cell clones expressing p53-273H, a clone 12-273H-39 (expressing a high 
level of p53-273H) was also one of the slower growing cell clones, while another 
clone 12-273H-41 (expressing a low level of p53-273H comparable to the level of 
mutant p53 expression in tumour-derived laryngeal cancer cell lines) was established 
earlier during the selection process because it was growing faster. This further 
supports the conclusion that these p53 mutants may exhibit some growth inhibitory 
properties.
Attempts to produce similar clones expressing TAP-tagged wt p53 were 
unsuccessful in spite of performing the process of cloning and selection twice and 
selecting a large number of colonies for expansion. Many cell clones were lost during 
the expansion because they failed to grow (exhibiting signs of senescence or cell cycle 
arrest) and eventually died. The fast growing clones, on the other hand, showed no 
p53 expression. Given the potent growth inhibitory effects of wt p53 it could be 
expected that the cells would not tolerate p53 expression and therefore the failure of 
these attempts is not surprising. A similar’ situation was reported in a recent study of 
the GOF p53 mutants (454). The authors clearly stated that wt p53 was not used in the
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analysis because its expression resulted in cell-cycle arrest or apoptosis. Moreover, 
the authors speculated that obtaining wt p53-expressing cells would likely suggest 
that these cells had undergone additional alterations allowing them to tolerate wt p53 
expression.
Although isogenic cell lines expressing mutant and wt p53 forms would certainly 
be a valuable system for studying the novel functions of p53 mutants, which are 
distinct from those of the wt protein, the lack of a wt p53-expressing cell line can be 
dealt with in validation studies on transiently transfected cells.
Using a simplified TAP-tag purification system (streptavidin affinity purification) 
in combination with mass spectroscopy, a number of mutant p53 interacting proteins 
have been identified in lysates from p53-175H and p53-273H mutant expressing 
LSCC clones (Table 3.2). The identified proteins are discussed in the following 
section.
Comparing lysates prepared from p53-175H and p53-273H mutant expressing 
LSCC clones, HSP70 was identified only in the p53-175H-containing complexes. The 
interaction of HSP70 and p53-175H was also confirmed by immunoprecipitation to be 
specific and selective for this p53 mutant. Since p53-175H is a structural mutant it 
seems likely that p53-175H is bound by HSP70 (an inducible chaperone stabilising 
existing proteins against aggregation and mediating the folding of newly translated 
proteins) because it is misfolded. Importantly, HSP70 was reported to bind 
preferentially to conformational p53 mutants (517). The binding sites in p53 for 
HSP70 have been mapped to hydrophobic secondary structures (especially (3-strands) 
in the central DNA binding domain (518). It has been suggested that these high 
affinity binding sites are cryptic in wt p53 and become exposed upon p53 mutation, 
which alters the tertiary structure of the protein causing it to adopt a ‘mutant’
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conformation. The functional consequences of this interaction are not fully understood 
but it has been proposed that HSP70 forms a complex with HSP90 and Hdj in an 
attempt to restore its native conformation (519). However, the inherent instability of 
conformational p53 mutants is suggested to result in the formation of stalled 
chaperone-mutant p53 complexes and stabilisation of mutant p53 by molecular 
chaperones (519).
HSC70, identified by mass spectroscopy in p53-175H-containing complexes, is 
a constitutive chaperone belonging to the heat shock protein 70 family. HSC70 also 
assists in appropriate folding of proteins and has 85% sequence identity to HSP70. In 
the context of conformational p53 mutants, the molecular basis and functional 
consequences of the interaction between HSC70 and p53-175H are likely to be similar 
to those described above for HSP70.
BAG2, identified also in p53-175H-containing complexes, is a co-chaperone with 
high affinity for the ATPase domain of HSC70/HSP70 (492). BAG2 was reported to 
inhibit the activity of CHIP, a chaperone-associated ubiquitin ligase, which marks 
misfolded proteins presented by HSC70/HSP70 for proteasomal degradation 
(493, 520). The presence of BAG2 in the isolated complexes containing p53-175H 
suggests that BAG2 may contribute to stabilisation of this p53 mutant by inhibiting its 
proteasomal degradation. The interaction of BAG2 and p53-175H has not been 
reported previously. It is possible that BAG2 was purified with p53-175H because of 
its interaction with HSC70/HSP70. The specificity of the BAG2/p53-175H interaction 
remains to be validated. In the present study it was not possible to accomplish this due 
to the lack in our laboratory of an anti-BAG2 antibody, which could be used for 
western blotting to determine whether BAG2 was present in protein complexes 
isolated from p53-175H expressing cell clone by immunoprecipitation.
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Tmod3 was identified in both p53-175H and p53-273H-containing complexes. 
Tmod3 functions as a negative regulator of cell migration (521). It regulates actin 
polymerisation by capping the ends of actin filaments and sequestering monomeric 
actin (522). The interaction of Tmod3 with any p53 forms has not been reported 
previously. Tmod3 was also not detected by western blotting in the 
immunoprecipitated complexes containing wt and the two mutant forms of p53, 
respectively. There are a few possible explanations for this finding. First of all, 
a possibility exists that Tmod3 bound to the streptavidin sepharose rather than to p53 
mutants and was eluted non-specifically from the beads. Secondly, Tmod3 might have 
been purified with TAP-tagged mutant p5 3-containing complexes because it might 
bind to the TAP-tag itself. This would explain why it was not identified in the 
immunoprecipitated complexes purified using untagged p53 versions as bait. 
Moreover, it is possible that the antibody used for immunoprecipitation blocks the 
interaction site of mutant p53 and Tmod3. Finally, the interaction might be weak and 
the antibody used for western blotting might be not strong enough to detect a possibly 
small amount of Tmod3 in the purified complexes.
In the first purification of p53-175H-containing complexes MDM2 was identified 
in the calmodulin eluate containing p53-175H by western blotting (Figure 3.18B). It is 
important to note, however, that a large proportion (10%) of the final calmodulin 
eluate was probed with an anti-MDM2 antibody, which can detect very small amounts 
of MDM2. Interestingly, MDM2 was not identified in the mutant p5 3-containing 
complexes by mass spectroscopy. This likely suggests that the interaction of mutant 
p53 with MDM2 is relatively weak and the amount of MDM2 present in the purified 
complexes was below the threshold of detection by the mass spectrometer. The fact 
that both of the studied p53 mutants are bound by MDM2 to some extent is also
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supported by the presence of MDM2 in the immunoprecipitated complexes containing 
P53-175H and p53-273H> which was detected by western blotting.
None of the remaining proteins identified in the mutant p53-containing complexes 
(but not present in the control sample) was previously reported to interact with wt or 
mutant p53. It will be important to determine whether these selectively or specifically 
interact with mutant p53 and also if they do, what the functional consequences of 
these interactions are. p53 GOF mutants have been linked with poor prognosis and 
thus novel GOF mutant interacting proteins may represent important new therapeutic 
targets.
Mutant p53 has been linked with reduced survival and highly metastatic tumours 
(513). GOF p53 mutants have also been shown to stimulate metastasis in mouse 
models (395, 523). Since cell motility and invasiveness in vitro are often used as 
surrogate indicators of metastatic potential, the migratory potential and invasiveness 
of GOF mutant p53 expressing cells were studied.
Boyden chamber motility assays were used initially to investigate the migratory 
potential of the studied cells. Although one of the GOF mutant p53-expressing cell 
lines (12-273H-39) displayed 8-fold increased motility compared to the parental 
UM-SCC-12 cells, 12-273H-nuIl cells exhibited the highest migratory potential in this 
system with 50-fold higher motility compared to the parental UM-SCC-12 cells 
(Figure 3.29). 12-273H-null cells went through the cloning and selection process but 
showed no detectable p53-273H expression. These cells displayed a morphology 
typical of EMT with elongated, spindle-shaped cells and numerous philopodia (see 
Appendix 10), which could explain why they were able to migrate through the 
membrane pores. 12-273H-null cells survived the selection process, which means they 
express the G418-resistance gene, but show no detectable mutant p53 expression
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suggesting that the observed phenotype is likely due to clonal selection from 
a heterogeneous population of cells. The increased motility of these cells in the 
Boyden chamber motility assay is a good example why the possibility of clonal 
variation should never be underestimated.
Overall the studied cell lines were not very motile as determined using the Boyden 
chamber motility assay when compared to other lines that have been examined in our 
research laboratory (287). Out of 15,000 cells seeded into the chambers only between 
11 and 1,274 cells (less than 8.5%) migrated through the membranes. In contrast with 
H1299 cells out of 15,000 cells seeded typically 1,500 cells were found to migrate 
through the membrane (287). These data suggest that this might not be an ideal 
system to study the migratory potential of these cells. The cells studied in this project 
are squamous cell carcinoma cells. These cancers arise from epithelial cells forming 
protective cell layers that line the skin and internal cavities (110). Squamous cells are 
often flattened and scale-like (from Latin squama meaning ‘scale’). Due to the 
flattened morphology of squamous cells and the fact that they usually line surfaces it 
is possible that these cells have a greater potential to move on flat surfaces (such as 
the surfaces of a tissue culture dish) rather than in 3D space. The Boyden chamber 
motility assay measures the ability of cells to migrate through pores in a membrane, 
which might represent three-dimensional migration. Additionally, it was observed as 
part of a different experiment (clonogenic assays, section 3.13) that the plating 
efficiency (see section 2.23) of UM-SCC-12 cells is very low (~9.5%) and even lower 
for p53-175H and p53-273H-expressing cells (-5.9% and -3.8%, respectively) and 
that the cell lines require a considerable time to adhere to the surface of the dish. All 
of these factors could also contribute to the low numbers of cells migrating through 
the Boyden chamber membranes.
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Therefore, another approach was used to study the motility of these cells - live 
imaging of cell migration. Interestingly, in this assay 12-273H-null cells behaved 
almost identically to UM-SC012 cells
All the mutant p53-expressing cells (12-175H-20, 12-273H-39 and 12-273H-41 
cells) displayed increased motility (as determined by total distance travelled or speed) 
compared to the parental UM-SCC-12 cells (Figure 3.31 A and D). The increase in 
motility of p53-273H-expressing cells was more significant than that of 12-175H-20 
cells. The movement of 12-273H-39 and 12-273H-41 cells was similarly disorganised 
(as determined by directionality) as that of the parental UM-SCC-12 cells while the 
migration of 12-175H-20 cells was more organised (higher directionality). 
Interestingly, a recently published study has also investigated the motility of cells 
(H1299) expressing the same p53 mutations studied in this project (p53-175H and 
p53-273H) using similar' techniques to the ones described here (live cell imaging and 
tracking of individual cells) (454). These mutants were reported to promote random 
cell migration (in terms of decrease in directionality) and disorganised lamellipodia. 
However, no difference in speed of the mutant p53-expressing cells was observed 
compared to their parental p53-null cells (HI299), which is in contrast to the results 
presented here. The authors of the study further propose that the random migration of 
the mutant p53-expressing cells may be associated with their inability to correctly 
establish an axis of polarity. The reasons for the differences in the reported results 
may stem from different cell lines used for studying the effects of the GOF mutants 
and the differences in their intrinsic motility and directionality of movement. HI299, 
used in the published article, are non-small cell lung carcinoma cells, which are 
intrinsically less motile on 2D surfaces (data not shown) than the UM-SCC-12 cells 
used in this project. The movement of HI 299 cells also appeal’s to be more organised
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(directionality of ~0.7) compai'ed to the movement of UM-SCC-12 cells, which is 
intrinsically more random (directionality ~0.2). Moreover, the p53 polymorphism at 
amino acid 72 could have also contributed to the differences in the obtained results 
(the mutants used in the published study expressed the codon 72R polymorphism 
while the mutants used in this project are all codon 72P). p53 polymorphism at codon 
72 was reported to be an intragenic modifier of mutant p53 behaviour (412). One of 
the mechanisms, through which p53 mutants might exert their GOF properties, is 
binding to and inhibition of the functions of p53-family proteins, p73 and/or p63 (as 
discussed in section 1.3,4.3.1.1). It was further shown that p53 polymorphism at 
codon 72R strongly influences the ability of mutant p53 to interact with and inhibit 
p73 function, but has no influence on the binding of mutant p53 to wt p53 (412). 
Consequently, 72R conformational p53 mutants were found to be more effective in 
suppressing p73 -dependent apoptosis in cultured cells (412). Additionally, it was 
observed that in squamous cell carcinomas of the head and neck heterozygous for the 
p53 polymorphism at codon 72 and displaying p73 expression, it is the 72R allele that 
is preferentially mutated (in 26 cancers heterozygous for p53 polymorphism at codon 
72, the mutated allele was R in 21 cases and P in 5 cases) (412). Furthermore, it was 
shown that p53-72R mutants are capable of inhibiting chemotherapy-induced 
apoptosis more efficiently than p53-72P mutants and in a group of SCCHN patients 
those with tumour-specific expression of the mutant 72R allele had both a decreased 
response to cisplatin chemotherapy and reduced overall survival compared to those 
with p53-72P expression (413). Altogether these data suggest that codon 72 
polymorphism influences the biological behaviour' of p53 mutants, at least in certain 
types of cancer.
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In order to test whether the observed differences in motility of the established 
mutant p53-expressing clones are due to mutant p53 expression or whether they can 
be attributed to clonal variation, down-regulation of mutant p53 expression by RNAi 
was attempted in the highly motile 12-273H-39 cells. However, due to poor 
transfection efficiency of 12-273H-39 cells, down-regulation of mutant p53 
expression (based on western blot analysis) was questionable and therefore the 
corresponding motility results (although difference in motility was statistically 
significant 36-48 hours post transfection with siRNA) could not be analysed with 
confidence (Figure 3.32).
In order to achieve satisfactory down-regulation of mutant p53 expression in 
12-273H-39 cells, cell lines with stably reduced mutant p53 levels have been 
generated (Figure 3.33). The motility of two clones with significantly reduced 
p53-273H level was analysed and both cell lines displayed significantly reduced 
motility compared to parental 12-273H-39 cells (Figure 3.34). The data presented here 
suggest that the increased motility of 12-273H-39 cells is due to mutant p53 
expression. However, the motility of the remaining clones expressing reduced levels 
of p53-273H as well as the motility of the control clones still need to be analysed 
before the possibility of clonal variation can be excluded and the observed increase in 
migratory potential of cells contributed unequivocally to mutant p53 expression.
Since mutant p53-expressing laryngeal cancer cells exhibited increased motility 
(section 3.9 and 3.10), further studies were performed to determine whether the 
mutant p53-expressing cells displayed increased invasiveness in vitro, another 
surrogate indicator of metastatic potential. Boyden chamber invasion assays were 
used for this purpose. As previously discussed, Boyden chambers are not an ideal 
system for studying the LSCC cells used in this project. However, it was expected that
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the thin layer of Matrigel that the invasion chambers are coated with should facilitate 
cell adhesion. Indeed, it appeared as if the cells had adhered to the Matrigel within an 
hour from the time of seeding as determined microscopically (data not shown). 
Migration of cells through the Matrigel-coated membranes was also encouraged by 
the presence of a serum gradient. Moreover, this was the only invasion assay 
performed routinely and readily available in our laboratory and thus it was decided to 
attempt analysis of invasion using this system in the first instance despite the 
anticipated limitations.
Although the variation of the obtained results was very high and none of the 
resulting differences was statistically significant, 12-273H-39 cells seemed to be less 
invasive than the parental UM-SCC-12 cells. While this difference is not statistically 
significant, such reduction of the ability of 12-273H-39 cells to degrade Matrigel 
could theoretically be explained by a significant up-regulation of fibronectin in these 
cells (Table 6.5). Fibronectin is a component of ECM and hence the increased 
production of ECM by 12-273H-39 cells might hinder Matrigel degradation and 
contribute to the observed reduction in the invasive potential of these cells. However, 
the increased production of fibronectin may at the same time contribute to the 
increased motility of these mutant p53-expressing cells on 2D surfaces since 
fibronectin was significantly up-regulated in the highly motile 12-273H-39 cells and 
relatively unchanged in the much less motile 12-175H-20 cells (Figure 3.39E). 
Clearly, the importance of other contributing factors should also not be 
underestimated.
A recent study reported that fibronectin expression induces autocrine up-regulation 
of MMP-9, resulting in increased invasiveness of A431 cells (500). While 
12-273H-39 cells display increased fibronectin expression, MMP-9 expression was
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not up-regulated, which could potentially explain the lack of increased invasiveness of 
these cells. However, it is more likely that the Boyden chamber invasion assay is 
simply inappropriate for studying migration or invasiveness of these cells.
The reduced invasiveness of 12-273H-39 cells also seems to be in conflict with the 
previously mentioned study of GOF p53 mutants (454). Polyclonal populations of 
mutant p53-expressing HI299 and RPE (retinal pigment epithelial) cells displayed 
increased invasiveness as determined by their ability to migrate into a Matrigel plug 
towards a serum and EGF gradient. The first reason for this discrepancy may be the 
clear differences in the experimental procedures used to study invasiveness of cells. In 
the study described above cells migrated towards EGF (and serum) gradient. The use 
of EGF as chemoattractant is clearly biased towards cells displaying increased EGFR 
expression. Moreover, EGF binding to EGFR triggers receptor internalisation and 
initiates a signalling cascade through Ras-Raf and PI3K-AKT, resulting in 
a mitogenic response (128). Therefore, inclusion of EGF in this assay is a clear 
limitation since EGF might stimulate proliferation of cells, which could be an 
unnecessary confounding variable.
Another possible reason for the discrepancy in the reported results may lie in the 
low efficiency with which UM-SCC-12 cells (and any derivatives thereof) migrate 
through the Boyden chamber membranes and this factor may conceal the actual 
potential of these cells to degrade Matrigel. It will be important to use a different 
experimental system, such as invasion into Matrigel plugs, to reliably determine the 
invasive potential of these mutant p53-expressing cells.
The mechanisms through which GOF p53 mutants promote invasiveness and 
metastatic potential of tumours are still not entirely understood. Recent reports 
indicate that mutant p53 increases TGF(3-dependent metastatic potential of cancer
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cells via inhibition of p63 function (457) and also promotes invasion through 
increased integrin (a5[31) and EGFR recycling, which is also linked with suppression 
of transcriptionally active p63 (454).
p63 is a p53 homologue. Structurally, it contains three functional domains: 
transactivation, DNA binding and oligomerisation domain. There are many different 
isoforms of p63, which can be divided into two main groups, which are a result of 
transcription from two alternative promoters: the TAp63 isoforms, containing a fully 
function N-terminal TA domain, and the ANp63 isoforms, which lack the N-terminal 
TA domain (524, 525). While the functions of p63 are not entirely understood (partly 
due to the large number of different isoforms), TAp63 is known to play a critical role 
in epithelial development and was also suggested to have some functions similar to 
p53 such as regulation of apoptosis or senescence (526). More recently, p63 (TAp63 
and ANp63) was suggested to play a role in regulation of cell adhesion and cell 
survival, with p63 down-regulation resulting in cell detachment and apoptosis (527). 
Importantly, TAp63 was also suggested to suppress metastasis (528). The short 
ANp63 isoform is a dominant-negative inhibitor of TAp63 and other p53 family 
members (due to hetero-oligomerization) (526). ANp63 was reported to suppress both 
the extrinsic and the intrinsic apoptotic pathways (see section 1.3.2.2) (529). 
Moreover, overexpression of the ANp63a isoform resulted in sustained proliferation 
and suppression of oncogene-induced senescence in vivo, suggesting that ANp63 
might function as an oncogene (530).
Importantly, the laryngeal cancer cells studied in this project appear to express 
predominantly the ANp63 isoform (lacking the N-terminal transactivation domain) 
and little (if any) TAp63, which is a common situation in head and cancer (531). 
Therefore, suppression of TAp63 function is unlikely to underlie the increased
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motility of 12-273H-39 cells and the p53-273H GOF mutant appears to act via an 
alternative pathway in LSCC cells.
Following the motility and invasion analysis of the mutant p5 3-expressing cells, 
gene expression profiles of the highly motile 12-273H-39 cells and parental 
UM-SCC-12 cells were studied using exon array analysis to investigate the gene 
expression changes of cells expressing the GOF contact mutant of p53. The 
expression analysis revealed 154 genes up-regulated and 39 genes down-regulated in 
the p53-273H-expressing cells. The pathways most significantly affected by the 
differentially expressed genes are involved in cell adhesion and ECM remodelling 
(Figure 3.38). Considering the increased migratory potential of 12-273H-39 cells this 
suggests that p53-273H mutant may confer a motile phenotype on UM-SCC-12 cells 
by altering their transcriptome with an emphasis on inducing ECM remodelling 
programmes.
A number of the identified genes are known to be transcriptional targets of wt p53 
(including SPRR2A, MFAP5, PTGES, CCND2, OGN and FN1). Based on the 
transcriptional networks generated from the microarray analysis (Appendix 14) it 
appeal's that a number of genes, which were found to be differentially expressed in 
this study, could be transcriptionally regulated by mutant p53 via other transcription 
factors, such as Spl and NF-kB.
Wild-type p53 is known to bind to transcription factor Spl, resulting in the 
inhibition of the ability of Spl to bind other promoters (such as VEGF) and this is one 
of the mechanisms of p53-mediated transcriptional repression (532). However, 
VEGF-A was found to be up-regulated 2.48-fold in the mutant p53 expressing cells 
compared to p53-null cells, suggesting that p53-273H might cooperate with Spl in 
induction of Spl-regulated genes. This would mean that the interaction of mutant and
277
Discussion
wild-type p53 with Spl may have opposite outcomes. Indeed, mutant p53 has been 
reported to interact with Spl and increase transcription from Spl-responsive 
promoters (415).
Based on the generated transcriptional networks p53-273H also seems to affect the 
expression of a number of NF-kB-responsive genes. This finding is supported by 
a number of studies, which have reported induction of NF-kB gene expression by 
tumour-derived p53 mutants (533, 534). Similarly to Spl, the regulation of NF-kB 
responsive genes by wt and mutant p53 proteins seems to yield opposite outcomes 
with wt p53 antagonizing the transactivating effect of NF-kB (535) and mutant p53 
stimulating it (534). NF-kB activation results in increased expression of downstream 
targets, such as MMP9 (535) or BCRP (536), which are associated with increased 
invasiveness and multi-drug resistance, respectively. Given that the processes 
controlled by NF-kB are known to include inflammation, transformation, 
proliferation, angiogenesis, invasion, metastasis, chemoresistance and radioresistance, 
activation of NF-KB-responsive genes by mutant p53 could provide a plausible 
mechanistic basis for some or all of its oncogenic gain-of-function effects.
While the results obtained from the microarray analysis of gene expression in 
p53-null and p53-273H-expressing LSCC cells have been validated by qRT-PCR, it is 
important to remember that the studied cells (12-273H-39) are a clonal derivative of 
UM-SCC-12 and hence there is a chance that the observed gene expression changes 
are due to clonal variation. To address the issue of clonal variation as well as discount 
any of the observed results being due to the presence of TAP-tag at the N-terminus of 
p53 mutants, HI299 and UM-SCC-12 cells were transiently transfected with either 
untagged wt or the two GOF p53 mutants. qRT-PCR of the selected targets was, 
however, inconclusive due to high experimental variation. Therefore, it will be
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important to minimise the experimental variability in order to determine whether the 
observed differences in gene expression are a consequence of the expression of the 
various forms of p53 under study.
Moreover, in future experiments a number of the genes validated by qRT-PCR will 
be selected for functional examination to determine their possible contribution to the 
observed migratory phenotype of 12-273H-39 cells. The best candidates for functional 
studies include genes, which are more highly up-regulated in 12-273H-39 cells 
(displaying dramatically increased migratory potential) compared to 12-175H-20 cells 
(displaying slightly increased migratory potential), although threshold effects might 
also complicate this simplistic interpretation.
GOF p53 mutants are widely known to be associated with tumour resistance to 
treatment (401, 402). Therefore, the response of mutant p53-expressing cells to 
ionising radiation (IR) has also been studied. Radiotherapy is the basis of treatment 
for LSCC and p53 is vital for activating the responses to a number of cellular stresses 
including DNA damage. Therefore, it comes as no surprise that tumour response to 
radiation therapy relies on the p53 pathway (537). It has been reported that 
p53-mediated apoptosis is crucial in the sensitivity of tumours to radiation therapy, as 
wt p53 suppression or p53 inactivation through mutation results in radioresistance 
(538). However, more recent studies suggest that other p53-regulated processes (such 
as cell-cycle arrest or senescence) may also contribute to radiation sensitivity 
mediated by wt p53 (512).
Interestingly, the expression of mutant p53 was shown to sensitise p53-null LSCC 
cells to IR with p53-273H having a stronger effect than p53-175H (Figure 3,46). It 
can be speculated that these p53 mutants retain some residual wt p53 activity and are 
able to induce p53-mediated apoptosis to some extent. p53-273H is a contact mutant
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retaining native p53 folding, which may make it more capable of binding and 
transactivating p53-responsive apoptotic genes than p53-175H, a structural mutant 
with its DNA binding domain significantly distorted. A similar effect of p53 mutation 
has been previously observed in our laboratory, when LSCC cells expressing 
endogenous homozygous p53 mutations were found to be more sensitive to radiation 
than cells carrying any other p53 genotype (wt p53, heterozygous mutant p53 or 
p53-null) (512).
However, these results are in contrast to other studies reporting increased 
radioresistance of mutant p53-expressing tumours and cells in vitro (539, 540). It has 
been suggested that this radioresistance is mediated via stimulation of Gal-3 (an 
anti-apoptotic molecule transcriptionally repressed by wt p53) expression by GOF 
p53 mutants in thyroid cancer (540). Gal-3 overexpression was reported in most 
thyroid cancer cell lines studied, particularly those expressing the R273H mutant of 
p53 (540). Since Gal-3 up-regulation was not observed in p53-273H-expressing cells 
in the current study, it seems likely that the malignancies of the head and neck 
constitute a completely separate group of tumour's and the GOF p53 mutants exert 
their oncogenic properties via alternative mechanisms in this cancer type. These 
results warrant further study of the mechanisms of radiosensitivity mediated by these 
two GOF p53 mutants in LSCC cells.
4.1. Future work
The work presented in this thesis identified several new lines of investigation relating 
to mutant p53 gain-of-function. First of all, HSP70/HSC70 were shown to 
preferentially interact with the structural mutant p53-175H. In future studies it will be 
important to determine the functional consequences of these interactions, which can
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be studied with the help of HSP70/HSC70 inhibitors. It will also be interesting to 
study the role of BAG2 in mutant p53-HSP70 complexes. Moreover, it will be 
important to determine whether the remaining proteins identified in the mutant 
p5 3-containing complexes (none of which was reported to interact with wt or mutant 
p53 previously) selectively or specifically interact with mutant p53. Since p53 GOF 
mutants are frequently associated with poor prognosis, novel mutant p53 binding 
partners may represent important new therapeutic targets.
Since mutant p53 has been linked with reduced survival and highly metastatic 
tumours (513), cell motility and invasiveness (surrogate indicators of metastatic 
potential) of the mutant p53 expressing cells were studied in vitro. While the stable 
clones expressing p53-175H or p53-273H displayed increased motility, the possibility 
of the observed phenotype being due to clonal variation could not be excluded. Stable 
knock-down of p53-273H resulted in reduced motility in two clones tested so far. In 
order to imequivocally determine whether the increased motility of mutant p53 
expressing cells is due to mutant p53 expression, it will be important to test the 
motility of the remaining knock-down clones and the established control clones.
Exon array analysis revealed a number of differentially expressed genes in the 
highly motile 12-273H-39 cells compared to the parental p53-null cells. Importantly, 
the pathways most significantly affected by the differentially expressed genes are 
involved in cell adhesion and ECM remodelling. The results of the microarray 
analysis were successfully validated by qRT-PCR. However, it is important to 
remember that the mutant p53 expressing cells under study are a cell clone and, 
therefore, the possibility of the obtained results being due to clonal variation also 
needs to be considered. To address this issue, validation of selected targets was 
attempted by qRT-PCR in cells (HI299 and UM-SCC-12) following a transient
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transfection with wt or mutant p53 forms. While the internal experimental variation 
was too high to obtain statistically significant data (Figure 3.39 and 3.42), it is also 
clear* that generally there were no significant differences in expression of the studied 
targets. This may be due to high toxicity of transfection, resulting in highly stressed 
cells. Therefore, transient transfection of cells with p53 forms does not seem 
a feasible approach to studying differences in gene expression. Instead, polyclonal 
populations of cells expressing mutant p53 forms may be established to enable the 
investigation of gene expression changes in mutant p53 expressing cells. In this way, 
clonal variation would not be a problem and cells would be allowed sufficient time to 
recover from the stress of transfection.
Finally, some of the targets identified to be differentially expressed in the mutant 
p53 expressing polyclonal populations can then be selected for further study. So far, 
fibronectin, reported to stimulate invasiveness and metastatic potential of cancer cells, 
seems to be an ideal candidate for future functional studies. The contribution of 
fibronectin to the increased migratory potential of 12-273H-39 cells could be studied 
by RNAi and live cell imaging. Identifying targets, through which mutant p53 
promotes motility and invasiveness, will be crucial for developing novel targeted 
therapies. Moreover, it will be important to determine whether any of the 
differentially expressed genes are direct transcriptional targets of p53 mutants. This 
could be achieved using chromatin immunoprecipitation (ChIP), which may be 
performed using TAP-tagged p53 forms and the optimised (highly efficient) TAP-tag 
purification procedure.
Although the current study failed to demonstrate a role for mutant p53 in 
stimulating invasiveness (perhaps due to a lack of appropriate experimental system), 
there is convincing evidence that p53 mutants are involved in the process of invasion
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(311). To address this issue, invasion of the mutant p53 expressing laryngeal cancer 
cells into extracellular* matrices (Matrigel or Collagen I) could be investigated 
(without the use of Boyden chambers). This could be achieved in a number of ways, 
for example by overlaying seeded cells with Matrigel/Collagen I and applying 
a chemoattractant above the matrix to stimulate invasion. The cells, which invaded 
into the matrix, can then be stained with a fluorescent dye (such as Fluorescein or 
Calcein AM) and the number of invading cells quantified using confocal microscopy.
Finally, the most biologically relevant assay for studying invasion and metastasis 
are mouse models. In this study mutant p53 expressing cells were also engineered to 
express a fluorescent protein, mCherry (when attempting to achieve a stable 
knock-down of mutant p53, the vectors encoding the p53 and scrambled short 
hairpins also encoded mCherry - see section 2.4.10). These cells could either be used 
in mouse xenograft models or could be surgically implanted into murine laryngeal 
tissues. Due to fluorescent labelling of these cells, tumour development and 
metastasis formation could be monitored using fluorescence in vivo imaging systems, 
without the need to sacrifice animals prematurely (hence reducing the number of 
animals needed). Additionally, the use of fluorescent cells would make identifying 
micrometastases following dissection much easier.
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5. Conclusion
Gain-of-function p53 mutants are associated with poor prognosis and therapeutic 
response in head and neck cancer (101, 513, 541). GOF p53 mutants likely act 
through altered transcriptional activity and/or novel protein-protein interactions but 
the molecular details of the mechanisms involved are still not entirely understood. 
Therefore, the aim of this project was to characterise the mechanisms of mutant p53 
GOF in laryngeal cancer by studying protein interactions of p53 mutants and gene 
expression profiles of cells expressing either of two GOF mutants representing two 
distinct mutational classes: structural (R175H) and contact (R273H).
Cell clones of a functionally p53-null (truncated) LSCC cell line with stable 
expression of either TAP-tagged R175H or R273H mutant of p53 have been 
generated. A number of proteins have been purified and identified in the mutant p53 
containing protein complexes in LSCC cells. One of these, HSP70 has been 
confirmed by immunoprecipitation to selectively interact with the p53-175H mutant, 
which may play a role in its stabilisation. It will be important to determine whether 
the remaining identified proteins selectively and/or specifically interact with mutant 
p53 and what the functional consequences of these interactions are.
Motility analysis of the generated cell clones revealed that p53-273H-expressing 
cells and to a smaller extent p53-175H-expressing cells display increased motility, 
which could explain the increased tumorigenic and metastatic potential of tumours 
harbouring p53 GOF mutants. A stable knock-down of the mutant p53 in 12-273H-39 
cells has been shown to reduce the motility of cells suggesting that p53-273H 
contributes to increased migratory potential of these cells and that this is not 
a consequence of clonal selection and variation. Interestingly however, those cells did
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not exhibit increased invasiveness in vitro although the assays used for this latter were 
based upon Boyden chambers and these may not be appropriate for the squamous cell 
lines studied here as analysis of cell motility in Boyden chambers suggests (see 
section 3.9.1).
Analysis of gene expression in p53-273H-expressing vs. p53-null laryngeal cancer 
cells revealed multiple genes that are differentially regulated in cells expressing the 
R273H mutant of p53. Importantly, the most significantly affected pathways included 
cell adhesion and ECM remodelling. Given the increased motility of these cells 
altered expression of cell adhesion and ECM remodelling regulating genes provides 
a plausible mechanism for the gain of function of this p53 mutant. In the light of 
recent studies suggesting that mutant p53 GOF may be achieved, at least in part, 
through inhibition of the tumour-suppressive effects of TAp63, it is important to note 
that the laryngeal cancer cells studied in this project appear' to express predominantly 
the ANp63 isoform (suggested to have oncogenic functions) (525). This suggests that 
p63 inhibition by the p53-273H mutant is not central to its gain of oncogenic function 
in LSCC cells. Analysis of the transcriptional networks generated on the basis of the 
expression data also suggests that this p53 mutant might modulate transcription 
through other transcription factors, such as Spl and NF-kB.
Unexpectedly, mutant p53 expression seemed to sensitise laryngeal cancer cells to 
ionising radiation. The fact that tumour-derived mutant p5 3-expressing laryngeal 
cancer cells studied in our laboratory also exhibited increased radiosensitivity, 
suggests that the results presented here are not an artefact and require further study to 
gain insight into the mechanism of radiosensitivity of mutant p53-expressing LSCC 
cells.
286
Conclusion
In conclusion, the studies described here have identified several new lines of 
investigation connecting mutant p53 with critical pathways involved in the regulation 
of cell survival (HSP70) and in cell motility (FN1, TIMP2 and others), one of the key 
determinants of metastatic potential. These results together with increased 
radiosensitivity of mutant p53-expressing cells also suggest that in LSCC cells p53 
GOF mutants may act via different pathways than those previously identified in other 
cancers and moreover it appears there may be differences in the modes of action of 
structural and DNA-contact mutants. Functional analysis of these pathways should 
provide insights into the mechanisms of action of two classes of p53 GOF mutants in 
LSCC and may lead also to the identification of novel therapeutic targets.
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Table 6.1: The list of genes differentially regulated in UM-SCC-12/high p53-273H, 
which were selected for qRT-PCR validation. Histone H3 was chosen as a housekeeping 
reference. The conditions used for amplification of the indicated targets for standard 
preparation and for qRT-PCR are indicated. (Primer design and optimisation of reaction 
conditions were performed by Dr Bryony Lloyd.)
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Appendix 2
The results of sequencing of p53 in pCMV-Script. The following primers were used 
for sequencing:
• CMVfor (5’-CGC AAA TGG GCG GTA GGC GTG-3’) - available from 
Eurofins MWG Operon,
• P53.601-620 (5’-TTG CGT GTG GAG TAT TTG GA-3’) - designed specifically 
for sequencing.
The obtained sequences were aligned to the reference sequence of p53 (accession 
number: NM 000546) using the AlignX® Module of Vector NTI Advance™ 11 
(Invitrogen).
p53 cDNA 
CMVfor 
p53.601-620
p53 cDNA 
CMVfor 
p53.601-620
1 65
(1) .............. ......................................................... ............................
(1) TTAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGATTACGCCAAGCTCGAAATTAACCC
(1) ...........................................................................................
66 130
(1) ..................................................................... A
(66) TCACTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCGCTCTAGCCCGGGCGGATCCA
(1) ......................................................................  -.........................
p53 CDNA 
CMVfor 
p53.601-620
(2)
(131)
(1)
131 195 
TGGAGGAGCCGCAGTCAGATCCTAGCGTCGAGCCCCCTCTGAGTCAGGAAACATTTTCAGACCTA 
TGGAGGAGCCGCAGTCAGATCCTAGCGTCGAGCCCCCTCTGAGTCAGGAAACATTTTCAGACCTA
p53 CDNA 
CMVfor 
p53.601-620
(67)
(196)
(1)
196 260 
TGGAAACTACTTCCTGAAAACAACGTTCTGTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGAT 
TGGAAACTACTTCCTGAAAACAACGTTCTGTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGAT
p53 CDNA 
CMVfor 
p53.601-620
p53 cDNA 
CMVfor 
p53.601-620
261 325
(132) GCTGTCCCCGGACGATATTGAACAATGGTTCACTGAAGACCCAGGTCCAGATGAAGCTCCCAGAA 
(261) GCTGTCCCCGGACGATATTGAACAATGGTTCACTGAAGACCCAGGTCCAGATGAAGCTCCCAGAA
(1) ...................... -....... -................................. ................................
SNP
326 72R 390
(197) TGCCAGAGGCTGCTCCCMfcTGGCCCCTGCACCAGCAGCTCCTACACCGGCGGCCCCTGCACCA 
(326) tgccagaggctgctcccBBgtggcccctgcaccagcagctcctacaccggcggcccctgcacca 
(1) .............. -...................................................................................
p53 CDNA 
CMVfor 
p53.601-620
(262)
(391)
(1)
391 455 
GCCCCCTCCTGGCCCCTGTCATCTTCTGTCCCTTCCCAGAAAACCTACCAGGGCAGCTACGGTTT 
GCCCCCTCCTGGCCCCTGTCATCTTCTGTCCCTTCCCAGAAAACCTACCAGGGCAGCTACGGTTT
p53 cDNA 
CMVfor 
p53.601-620
(327)
(456)
(1)
456 520 
CCGTCTGGGCTTCTTGCATTCTGGGACAGCCAAGTCTGTGACTTGCACGTACTCCCCTGCCCTCA 
CCGTCTGGGCTTCTTGCATTCTGGGACAGCCAAGTCTGTGACTTGCACGTACTCCCCTGCCCTCA
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p53 cDNA (392)
CMVfor (521)
p53.601-620 (1)
p53 CDNA (457
CMVfor (586
p53.601-620 (1
p53 CDNA (522)
CMVfor (651)
p53.601-620 (1)
p53 CDNA (587)
CMVfor (716)
p53.601-620 (1)
p53 cDNA (652)
CMVfor (781)
p53.601-620 (15)
p53 CDNA (717)
CMVfor (846)
p53.601-620 (80)
p53 CDNA (782)
CMVfor (911)
p53.601-620 (145)
p53 cDNA (847)
CMVfor (976)
p53.601-620 (210)
p53 CDNA 
CMVfor 
p53.601-620
(912)
(1041)
(275)
p53 CDNA 
CMVfor 
p53.601-620
(977)
(1058)
(340)
p53 CDNA 
CMVfor 
p53.601-620
(1042)
(1058)
(405)
p53 CDNA 
CMVfor 
p53.601-620
(1107)
(1058)
(470)
p53 CDNA 
CMVfor 
p53.601-620
(1172)
(1058)
(535)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(1058)
(600)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(1058)
(665)
silent
521 mutation 585 
acaagatgttttgccaactggccaagacctgccctgtgcagctgtgggttgatBBacacccccg 
acaagatgttttgccaactggccaagacctgccctgtgcagctgtgggttgat^Bacacccccg
586 650 
CCCGGCACCCGCGTCCGCGCCATGGCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAG 
CCCGGCACCCGCGTCCGCGCCATGGCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAG
651 715 
GCGCTGCCCCCACCATGAGCGCTGCTCAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCC 
GCGCTGCCCCCACCATGAGCGCTGCTCAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCC
716 780 
GAGTGGAAGGAAATTTGCGTGTGGAGTATTTGGATGACAGAAACACTTTTCGACATAGTGTGGTG 
GAGTGGAAGGAAATTTGCGTGTGGAGTATTTGGATGACAGAAACACTTTTCGACATAGTGTGGTG 
.................................................. TCG--ATAGTGTGGTG
781 845 
GTGCCCTATGAGCCGCCTGAGGTTGGCTCTGACTGTACCACCATCCACTACAACTACATGTGTAA 
GTGCCCTATGAGCCGCCTGAGGTTGGCTCTGACTGTACCACCATCCACTACAACTACATGTGTAA 
GTGCCCTATGAGCCGCCTGAGGTTGGCTCTGACTGTACCACCATCCACTACAACTACATGTGTAA
846 910 
CAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCA 
CAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCA 
CAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCA
911 975 
GTGGTAATCTACTGGGACGGAACAGCTTTGAGGTGCGTGTTTGTGCCTGTCCTGGGAGAGACCGG 
GTGGTAATCTACTGGGACGGAACAGCTTTGAGGTGCGTGTTTGTGCCTGTCCTGGGAGAGACCGG 
GTGGTAATCTACTGGGACGGAACAGCTTTGAGGTGCGTGTTTGTGCCTGTCCTGGGAGAGACCGG
976 1040 
CGCACAGAGGAAGAGAATCTCCGCAAGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCAC 
CGCACAGAGGAAGAGAATCTCCGCAAGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCAC 
CGCACAGAGGAAGAGAATCTCCGCAAGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCAC
1041 1105 
TAAGCGAGCACTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAG
TAAGCGAGCACTGCCCA-.................................. -............
TAAGCGAGCACTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAG
1106 1170 
AATATTTCACCCTTCAGATCCGTGGGCGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCC
AATATTTCACCCTTCAGATCCGTGGGCGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCC
1171 1235
TTGGAACTCAAGGATGCCCAGGCTGGGAAGGAGCCAGGGGGGAGCAGGGCTCACTCCAGCCACCT
TTGGAACTCAAGGATGCCCAGGCTGGGAAGGAGCCAGGGGGGAGCAGGGCTCACTCCAGCCACCT
1236 1300
GAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTG
GAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTG
1301 1365
ACTCAGACTGA........... ....................... ...................
ACTCAGACTGAGAATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACC 
1366 1430
AGGTAAGTGTACCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTCGATCGCCCTTCCCAA 
1431 1495
CAGTTGCGCAGCCTGAATGGCGAATGGAGATCCAATTTTTAAGTGTATAATGTGTTAAACTACTG
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p53 CDNA 
CMVfor 
p53.601-620
1496 1560
(1183) -----------------------------------------------------------------
(1058) ------------------------------------------------------------------
(730) ATTCTAATTGTTTGTGTATTTTAGATTCACAGTCCCAAGGCTCATTTCAGGCCCCTCAGTCCTCA
p53 CDNA 
CMVfor 
p53.601-620
1561 1625
(1183) ------------------------------------------------------------------
(1058) ------------------------------------------------------------------
(795) CAGTCTGTTCATGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACC
p53 CDNA 
CMVfor 
p53.601-620
1626 1690
(1183) ---- ----------- ------------ -----------------------------------
(1058) --------------------------------------------------- ---------------
(860) TCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATT
p53 CDNA 
CMVfor 
p53.601-620
1691 1755
(1058) --- --------------------- -----------------------------------------
(925) GCAGCTTATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTC
p53 CDNA 
CMVfor 
p53.601-620
1756 1792
(1183) .............................. .......
(1058) -------------------------------------
(990) ACTGCATTCTAGTTGTGGTTTGTCCAAACTCATCAAT
292
Appendices
Appendix 3
The results of sequencing of p53 in pNTAP-B. The following primers were used for 
sequencing:
• CMVfor (5*-CGC AAA TGG GCG GTA GGC GTG-3’) - available from 
Eurofins MWG Operon,
• p53.601-62Q (5’-TTG CGT GTG GAG TAT TTG GA-3’) - designed specifically 
for sequencing.
The obtained sequences were aligned to the reference sequence of p53 (accession 
number: NM_000546) using the AlignX® Module of Vector NTI Advance™ 11 
(Invitrogen).
p53 CDNA (1)
CMVfor (1)
p53.601-620 (1)
p53 cDNA (1)
CMVfor (66)
p53.601-620 (1)
p53 CDNA (1)
CMVfor (131)
p53.601-620 (1)
p53 CDNA (1)
CMVfor (196)
p53.601-620 (1)
p53 CDNA (1)
CMVfor (261)
p53.601-620 (1)
p53 CDNA (1)
CMVfor (326)
p53.601-620 (1)
p53 cDNA (26)
CMVfor (391)
p53.601-620 (1)
p53 cDNA (91)
CMVfor (456)
p53.601-620 (1)
1 65
TATAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGATTACGCCAAGCTCGAAATTAA.CC
66 130
CTCACTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCGCCACCATGAAGCGACGATG
131 CBP 195
GAAAAAGAATTTCATAGCCGTCTCAGCAGCCAACCGCTTTAAGAAAATCTCATCCTCCGGGGCAC
196 260
TTGGAAGCGGTAGCGGTACCATGGACGAGAAGACCACCGGCTGGCGGGGCGGCCACGTGGTGGAG
261 SBP 325
GGCCTGGCCGGCGAGCTGGAGCAGCTGCGGGCCAGGCTGGAGCACCACCCTCAGGGCCAGCGGGA
326 390
-----------------------------------------ATGGAGGAGCCGCAGTCAGATCCTA
GCCCTCCGGCGGCTGCAAGCTGGGCTGCCCGGGCGGATCCATGGAGGAGCCGCAGTCAGATCCTA
391 455 
GCGTCGAGCCCCCTCTGAGTCAGGAAACATTTTCAGACCTATGGAAACTACTTCCTGAAAACAAC 
GCGTCGAGCCCCCTCTGAGTCAGGAAACATTTTCAGACCTATGGAAACTACTTCCTGAAAACAAC
456 520 
GTTCTGTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGATGCTGTCCCCGGACGATATTGAACA 
GTTCTGTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGATGCTGTCCCCGGACGATATTGAACA
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p53 cDNA (156)
CMVfor (521)
p53.601-620 (1)
p53 CDNA (221)
CMVfor (586)
p53.601-620 (1)
p53 CDNA (286)
CMVfor (651)
p53.601-620 (1)
p53 CDNA (351)
CMVfor (716)
p53.601-620 (1)
p53 CDNA (416)
CMVfor (781)
p53.601-620 (1)
p53 CDNA (481)
CMVfor (846)
p53.601-620 (1)
p53 CDNA (546)
CMVfor (911)
p53.601-620 (1)
p53 CDNA (611)
CMVfor (976)
p53.601-620 (1)
p53 CDNA (676)
CMVfor (1013)
p53.601-620 (39)
p53 CDNA (741)
CMVfor (1013)
p53.601-620 (104)
p53 CDNA (806)
CMVfor (1013)
p53.601-620 (169)
p53 CDNA (871)
CMVfor (1013)
p53.601-620 (234)
p53 CDNA (936)
CMVfor (1013)
p53.601-620 (299)
p53 CDNA (1001)
CMVfor (1013)
p53.601-620 (364)
p53 CDNA (1066)
CMVfor (1013)
p53.601-620 (429)
SNP
521 72R 585
ATGGTTCACTGAAGACCCAGGTCCAGATGAAGCTCCCAGAATGCCAGAGGCTGCTCCCjHfcTGG
atggttcactgaagacccaggtccagatgaagctcccagaatgccagaggctgctcccBBgtgg
586 650 
CCCCTGCACCAGCAGCTCCTACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCT 
CCCCTGCACCAGCAGCTCCTACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCT
651 715 
TCTGTCCCTTCCCAGAAAACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGG 
TCTGTCCCTTCCCAGAAAACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGG
716 780 
GACAGCCAAGTCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCA 
GACAGCCAAGTCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCA
silent
781 mutation 845
AGACCTGCCCTGTGCAGCTGTGGGTTGATTCCjACACCCCCGCCCGGCACCCGCGTCCGCGCCATG
agacctgccctgtgcagctgtgggttgatHUcacccccgcccggcacccgcgtccgcgccatg
846 910 
GCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGCGCTG 
GCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGCGCTG
911 975 
CTCAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATTTGCGTGTGG 
CTCAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATTTGCGTGTGG
976 1040
AGTATTTGGATGACAGAAACACTTTTCGACATAGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTT
AGTATTTGGATGACAGAAACACTTTTCGACATAGTGT-...........................
........................ -TCG--CTAGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTT
1041 1105
GGCTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAA
GGCTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAA
1106 1170
CCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACA
CCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACA
1171 1235
GCTTTGAGGTGCGTGTTTGTGCCTGTCCTGGGAGAGACCGGCGCACAGAGGAAGAGAATCTCCGC
GCTTTGAGGTGCGTGTTTGTGCCTGTCCTGGGAGAGACCGGCGCACAGAGGAAGAGAATCTCCGC
1236 1300
AAGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCACTGCCCAACAACAC
AAGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCACTGCCCAACAACAC
1301 1365
CAGCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTG
CAGCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTG
1366 1430
GGCGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCT
GGCGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCT
1431 1495
GGGAAGGAGCCAGGGGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTAC
GGGAAGGAGCCAGGGGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTAC
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p53 cDNA 
CMVfor 
P53.601-620
(1131)
{1013)
(494)
p53 CDNA 
CMVfor 
p53.601-620
{1183)
{1013)
(559)
p53 cDNA 
CMVfor 
p53.601-620
(1183)
(1013)
(624)
p53 CDNA 
CMVfor 
p53.601-620
{1183)
{1013)
(689)
p53 CDNA 
CMVfor 
p53.601-620
{1183)
{1013)
(754)
p53 CDNA 
CMVfor 
p53.601-620
{1183)
{1013)
{819)
p53 CDNA 
CMVfor 
p53.601-620
{1183)
(1013)
(884)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(1013)
(949)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(1013)
(1014)
1496 1560
CTCCCGCCATAAAftAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGA-------------
CTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGAGAATTCGATATCA
1561 1625
AGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCTTAATTAATTAAGGTACCAGGTAA 
1626 1690
GTGTACCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTCGATCGCCCTTCCCAACAGTTG 
1691 1755
CGCAGCCTGAATGGCGAATGGAGATCCAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTA 
1756 1820
ATTGTTTGTGTATTTTAGATTCACAGTCCCAAGGCTCATTTCAGGCCCCTCAGTCCTCACAGTCT 
1821 1885
GTTCATGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCAC 
1886 1950
ACCTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCT 
1951 2015
TATAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTCACTGCAT 
2016 2051
TCTAGTTGTGGTTTGTCCAAACTCATCATGTATCTA
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Appendix 4
The results of sequencing of p53-175H in pCB6+. The following primers were used 
for sequencing:
• CMVfor (5’-CGC AAA TGG GCG GTA GGC GTG-3’) - available from 
Eurofins MWG Operon,
• p53.601-620 (5’-TTG CGT GTG GAG TAT TTG GA-3’) - designed specifically 
for sequencing.
The obtained sequences were aligned to the reference sequence of p53 (accession 
number: NM 000546) using the AlignX® Module of Vector NTI Advance™ 11 
(Invitrogen).
1 65
p53 CDNA (1) -------------------------------------------------------------------
CMVfor (1) ATAGCAGAGCTCGTTTAGTGAACCGTCAGAATTAATTCAGATCTGAATTCGAGCTCGCCCGGGGA
p53.601-620 (1) ------------------------------------------------------- ---------
66 130
p53 CDNA (1) -------------------------------------------------------------------
CMVfor (66) TCCCGCTAGAGCCACCGTCCAGGGAGCAGGTAGCTGCTGGGCTCCGGGGACACTTTGCGTTCGGG
p53.601-620 (1) ------------------------------------------------------------------
131 195
p53 CDNA (1) ------------------------------------------------------------------
CMVfor (131) CTGGGAGCGTGCTTTCCACGACGGTGACACGCTTCCCTGGATTGGCAGCCAGACTGCCTTCCGGG
p53.601-620 (!) ------------------------------ ------------------ -----------------
196 260
p53 CDNA (1) ATGGAGGAGCCGCAGTCAGATCCTAGCGTCGAGCCCCCTCTGAGTCAGGAAACATTT
CMVfor (196) TCACTGCCATGGAGGAGCCGCAGTCAGATCCTAGCGTCGAGCCCCCTCTGAGTCAGGAAACATTT
p53.601-620 (1) ------------------------------------------------- -----------------
261 325
p53 CDNA (58) TCAGACCTATGGAAACTACTTCCTGAAAACAACGTTCTGTCCCCCTTGCCGTCCCAAGCAATGGA
CMVfor (261) TCAGACCTATGGAAACTACTTCCTGAAAACAACGTTCTGTCCCCCTTGCCGTCCCAAGCAATGGA
p53.601-620 (1) ------------------------------------------------------------------
326 390
p53 CDNA (123) TGATTTGATGCTGTCCCCGGACGATATTGAACAATGGTTCACTGAAGACCCAGGTCCAGATGAAG
CMVfor (326) TGATTTGATGCTGTCCCCGGACGATATTGAACAATGGTTCACTGAAGACCCAGGTCCAGATGAAG
p53.601-620 (1) ------------------------------------------------- ----------------
SNP
391 72P 455
p53 cdna (188) ctcccagaatgccagaggctgctcccCcCgtggcccctgcaccagcagctcctacaccggcggcc
CMVfor (391) CTCCCAGAATGCCAGAGGCTGCTCCCpeCSGTGGCCCCTGCACCAGCAGCTCCTACACCGGCGGCC
p53.601-620 (1) ---------------------------- --------------------------------------
456 520
p53 CDNA (253) CCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTTCTGTCCCTTCCCAGAAAACCTACCAGGGCAG
CMVfor (456) CCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTTCTGTCCCTTCCCAGAAAACCTACCAGGGCAG
p53.601-620 (1) ----
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p53 cDNA 
CMVfor 
p53.601-620
p53 cDNA 
CMVfor 
p53.601-620
521 585
(318) CTACGGTTTCCGTCTGGGCTTCTTGCATTCTGGGACAGCCAAGTCTGTGACTTGCACGTACTCCC 
(521) CTACGGTTTCCGTCTGGGCTTCTTGCATTCTGGGACAGCCAAGTCTGTGACTTGCACGTACTCCC 
(1) ............. .......... ............................... ...............-...... .........
586 650
(383) CTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAGACCTGCCCTGTGCAGCTGTGGGTTGATTCC 
(586) CTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAGACCTGCCCTGTGCAGCTGTGGGTTGATTCC
(1)
651 715
p53 cDNA (448) ACACCCCCGCCCGGCACCCGCGTCCGCGCCATGGCCATCTACAAGCAGTCACAGCACATGACGGA
CMVfor (651) ACACCCCCGCCCGGCACCCGCGTCCGCGCCATGGCCATCTACAAGCAGTCACAGCACATGACGGA
p53.601-620 (1) ... ............. -.............. ....................... -........
p53 cDNA 
CMVfor 
p53.601-620
716 R175H 780
(513) ggttgtgaggM|tgcccccaccatgagcgctgctcagatagcgatggtctggcccctcctcagc 
(716) ggttgtgaggHItgcccccaccatgagcgctgctcagatagcgatggtctggcccctcctcagc 
(1) ....................... ....................... .......... .................................---........—
781 845
p53 CDNA (578) ATCTTATCCGAGTGGAAGGAAATTTGCGTGTGGAGTATTTGGATGACAGAAACACTTTTCGACAT
CMVfor (781) ATCTTATCCGAGTGGAAGGAAATTTGCGTGTGGAGTATTTGGATGACAGAAACACTTTTCGACAT
p53.601-620 (1) -................................... -........................ - AAT
846 910
p53 CDNA (643) AGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTTGGCTCTGACTGTACCACCATCCACTACAACTA
CMVfor (846) AGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTTGGCTCTGACTGTACCACCATCCACTACAACTA
p53.601-620 (4) AGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTTGGCTCTGACTGTACCACCATCCACTACAACTA
911 975
p53 CDNA (708) CATGTGTAACAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCATCACACTGG
CMVfor (911) CATGTGTAACAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCATCACACTGG
p53.601-620 (69) CATGTGTAACAGTTCCTGCATGGGCGGCATGAACCGGAGGCCCATCCTCACCATCATCACACTGG
976 1040
p53 CDNA (773) AAGACTCCAGTGGTAATCTACTGGGACGGAACAGCTTTGAGGTGCGTGTTTGTGCCTGTCCTGGG
CMVfor (976) A - GACTCCAGTGGTA- TCTACTGGA......... ........... ....................
p53.601-620 (134) AAGACTCCAGTGGTAATCTACTGGGACGGAACAGCTTTGAGGTGCGTGTTTGTGCCTGTCCTGGG
1041 1105
p53 CDNA (838) AGAGACCGGCGCACAGAGGAAGAGAATCTCCGCAAGAAAGGGGAGCCTCACCACGAGCTGCCCCC
CMVfor (999) ........ -........... -............................................
p53.601-620 (199) AGAGACCGGCGCACAGAGGAAGAGAATCTCCGCAAGAAAGGGGAGCCTCACCACGAGCTGCCCCC
1106 1170
p53 CDNA (903) AGGGAGCACTAAGCGAGCACTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAGAAACCAC
CMVfor (999) ......... ........................ .................. .............
p53.601-620 (264) AGGGAGCACTAAGCGAGCACTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAGAAACCAC
1171 1235
p53 cDNA (968) TGGATGGAGAATATTTCACCCTTCAGATCCGTGGGCGTGAGCGCTTCGAGATGTTCCGAGAGCTG
CMVfor (999) ........ ............ ....................... -.............-......
p53.601-620 (329) TGGATGGAGAATATTTCACCCTTCAGATCCGTGGGCGTGAGCGCTTCGAGATGTTCCGAGAGCTG
1236 1300
p53 CDNA (1033) AATGAGGCCTTGGAACTCAAGGATGCCCAGGCTGGGAAGGAGCCAGGGGGGAGCAGGGCTCACTC
CMVfor (999) .............-.............. --------------------- --------........
p53.601-620 (394) AATGAGGCCTTGGAACTCAAGGATGCCCAGGCTGGGAAGGAGCCAGGGGGGAGCAGGGCTCACTC
1301 1365
p53 CDNA (1098) CAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAACTCATGTTCAAGACAG
CMVfor (999) ............................ -................. .................. -
p53.601-620 (459) CAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAACTCATGTTCAAGACAG
p53 cDNA 
CMVfor 
p53.601-620
1366 1430
(1163) AAGGGCCTGACTCAGACTGA..............-............. -................
(999) ..... ........... .................... .............. ......... .....
(524) AAGGGCCTGACTCAGACTGACATTCTCCACTTCTTGTTCCCCACTGACAGCCTCCCACCCCCATC
p53 CDNA 
CMVfor 
p53.601-620
1431 1495
(1183) ..............-......-............. ................... ..........
(999) ...............-.................. -...............................
(589) TCTCCCTCCCCTGCCATTTTGGGTTTTGGGTCTTTGAACCCTTGCTTGCAATAGGTGTGCGTCAG
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p53 CDNA 
CMVfor 
p53.601-620
1496 1560
(1183) ------------------------------------------------------------------
(999) -------------------------------------------------------- ----------
(654) AAGCACCCAGGACTTCCATTTGCTTTGTCCCGGGGCTCCACTGAACAAGTTGGCCTGCACTGGTG
p53 CDNA 
CMVfor 
p53.601-620
1561 1625
(1183) ------------------------------------------------------------------
(999)------------------------------------------------------------ -----
(719) TTTTGTTGTGGGGAGGAGGATGGGGAGTAGGACATACCAGCTTAGATTTTAAGGTTTTTACTGTG
p53 CDNA 
CMVfor 
p53.601-620
1626 1690
(1183) ------------------------------------------------------------------
(999) ------------------------------------------------------------------
(784) AGGGATGTTTGGGAGATGTAAGAAATGTTCTTGCAGTTAAGGGTTAGTTTACAATCAGCCACATT
p53 CDNA 
CMVfor 
p53.601-620
1691
(1183) -------
(999) -------
(849) CTACGTAG
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Appendix 5
The results of sequencing of p53-175H in pCR2.1. The following primers were used 
for sequencing:
• Ml3 uni t-2n (5’-TGT AAA ACG ACG GCC AGT-3’) - available from Eurofins 
MWG Operon,
• Ml3 rev (-29) (5’-CAG GAA ACA GCT ATG ACC-3’) - available from Eurofins 
MWG Operon.
The obtained sequences were aligned to the reference sequence of p53 (accession 
number: NM_000546) for Ml3 uni (-21) or to the reverse complement (re) of this 
sequence for Ml3 rev (-29) using the AlignX® Module of Vector NTI Advance™ 11
(Invitrogen).
p53 CDNA 
M13 uni (-20)
1 64
(1) ................ .............. -.......................................................... ............---
(1) TAGGGCGATTGGGCCCTCTAGATGCATGCTCGAGCGGCCGCCAGTGTGATGGATATCTGCAGAA
65 128
p53 CDNA (1) ....... .........-ATGGAGGAGCCGCAGTCAGATCCTAGCGTCGAGCCCCCTCTGAGTC
Ml3 uni (-20) (65) TTCGGCTTGAGAGGATCCATGGAGGAGCCGCAGTCAGATCCTAGCGTCGAGCCCCCTCTGAGTC
129 192
p53 CDNA (47) AGGAAACATTTTCAGACCTATGGAAACTACTTCCTGAAAACAACGTTCTGTCCCCCTTGCCGTC
M13 uni (-20) (129) AGGAAACATTTTCAGACCTATGGAAACTACTTCCTGAAAACAACGTTCTGTCCCCCTTGCCGTC
p53 cDNA 
M13 uni (-20)
p53 CDNA 
M13 uni (-20)
193 256
(111) CCAAGCAATGGATGATTTGATGCTGTCCCCGGACGATATTGAACAATGGTTCACTGAAGACCCA 
(193) CCAAGCAATGGATGATTTGATGCTGTCCCCGGACGATATTGAACAATGGTTCACTGAAGACCCA
SNP
257 72P 320
(175) GGTCCAGATGAAGCTCCCAGAATGCCAGAGGCTGCTCCCBfcTGGCCCCTGCACCAGCAGCTC
(257) ggtccagatgaagctcccagaatgccagaggctgctccc^Bgtggcccctgcaccagcagctc
321 384
p53 cDNA (239) CTACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTTCTGTCCCTTCCCAGAA
Ml3 uni (-20) (321) CTACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTTCTGTCCCTTCCCAGAA
385 448
p53 cDNA (303) AACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGGGACAGCCAAGTCTGTG
M13 uni (-20) (385) AACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGGGACAGCCAAGTCTGTG
449 512
p53 cDNA (367) ACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAGACCTGCCCTGTGC
M13 uni (-20) (449) ACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAGACCTGCCCTGTGC
p53 CDNA 
M13 vmi (-20)
p53 CDNA 
M13 uni (-20)
513 576
(431) AGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATGGCCATCTACAAGCA 
(513) AGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATGGCCATCTACAAGCA
SNP
577 R175H 640
(495) gtcacagcacatgacggaggttgtgaggB||tgcccccaccatgagcgctgctcagatagcgat (577) gtcacagcacatgacggaggttgtgaggH|tgcccccaccatgagcgctgctcagatagcgat
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p53 cDNA 
M13 uni (-20)
p53 cDNA 
M13 uni (-20)
p53 cDNA 
M13 uni (-20)
p53 cDNA 
M13 uni (-20)
p53 CDNA 
M13 uni (-20)
p53 CDNA 
M13 uni (-20)
p53 CDNA 
M13 uni (-20)
p53 cDNA 
M13 uni (-20)
p53 cDNA 
M13 uni (-20)
p53 CDNA 
M13 uni (-20)
p53 cDNA rc 
M13 rev (-29)
p53 CDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
Ml3 rev (-29)
641 704 
(559) GGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATTTGCGTGTGGAGTATTTGGATG 
(641) GGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATTTGCGTGTGGAGTATTTGGATG
705 768 
(623) ACAGAAACACTTTTCGACATAGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTTGGCTCTGACTG 
(705) ACAGAAACACTTTTCGACATAGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTTGGCTCTGACTG
769 832 
(687) TACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAACCGGAGGCCC 
(769) TACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAACCGGAGGCCC
833 896 
(751) ATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACAGCTTTGAGG 
(833) ATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACAGCTTTGAGG
897 960
(815) TGCGTGTTTGTGCCTGTCCTGGGAGAGACCGGCGCACAGAGGAAGAGAATCTCCGCAAGAAAGG 
(897) TGCGTGTTTGTGCCTGTCCTGGGAGAGACCGGCGCACAGAGGAAGAGAATCTCCGCAAGAAAGG
961 1024
(879) GGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCACTGCCCAACAACACCAGCTCC 
(961) G-AGCCTOACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCACTGCCCAACA-CACCAGCTCC
1025 ’ 1088
(943) TCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTGGGCGTG 
(1023) TCTCCC-AGCCAAAGA-GAAACCACTG-------------------------------------
1089 1152
(1007) AGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCTGGGAA 
(1048) -----------------------------------------------------------------
1153 1216
(1071) GGAGCCAGGGGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCC 
(1048) -----------------------------------------------------------------
1217 1264
(1135) CGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGA 
(1048) ------------------------------------------------
1 64
(1) ----------------------------------------------------- TCAGTCTGAGTC
(1) cggatcactagtaacggccgccagtgtgctggaattcggcttgagagaattctcagtctgagtc
65 128
(13) aggcccttctgtcttgaacatgagttttttatggcgggaggtagactgaccctttttggacttc
(65) AGGCCCTTCTGTCTTGAACATGAGTTTTTTATGGCGGGAGGTAGACTGACCCTTTTTGGACTTC
129 192
(77) AGGTGGCTGGAGTGAGCCCTGCTCCCCCCTGGCTCCTTCCCAGCCTGGGCATCCTTGAGTTCCA 
(129) AGGTGGCTGGAGTGAGCCCTGCTCCCCCCTGGCTCCTTCCCAGCCTGGGCATCCTTGAGTTCCA
193 256
(141) AGGCCTCATTCAGCTCTCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGAAGGGTGAAATA 
(193) AGGCCTCATTCAGCTCTCGGAACATCTCGAAGCGCTCACGCCCACGGATCTGAAGGGTGAAATA
257 320
(205) TTCTCCATCCAGTGGTTTCTTCTTTGGCTGGGGAGAGGAGCTGGTGTTGTTGGGCAGTGCTCGC 
(257) TTCTCCATCCAGTGGTTTCTTGTTTGGCTGGGGAGAGGAGCTGGTGTTGTTGGGCAGTGCTCGC
321 384
(269) TTAGTGCTCCCTGGGGGCAGCTCGTGGTGAGGCTCCCCTTTCTTGCGGAGATTCTCTTCCTCTG 
(321) TTAGTGCTCCCTGGGGGCAGCTCGTGGTGAGGCTCCCCTTTCTTGCGGAGATTCTCTTCCTCTG
385
(333)
(385)
448
TGCGCCGGTCTCTCCCAGGACAGGCACAAACACGCACCTCAAAGCTGTTCCGTCCCAGTAGATT
TGCGCCGGTCTCTCCCAGGACAGGCACAAACACGCACCTCAAAGCTGTTCCGTCCCAGTAGATT
449 512 
(397) ACCACTGGAGTCTTCCAGTGTGATGATGGTGAGGATGGGCCTCCGGTTCATGCCGCCCATGCAG 
(449) ACCACTGGAGTCTTCCAGTGTGATGATGGTGAGGATGGGCCTCCGGTTCATGCCGCCCATGCAG
513 576 
(461) GAACTGTTACACATGTAGTTGTAGTGGATGGTGGTACAGTCAGAGCCAACCTCAGGCGGCTCAT 
(513) GAACTGTTACACATGTAGTTGTAGTGGATGGTGGTACAGTCAGAGCCAACCTCAGGCGGCTCAT
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p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
p53 cDNA rc 
M13 rev (-29)
577 640
(525) AGGGCACCACCACACTATGTCGAAAAGTGTTTCTGTCATCCAAATACTCCACACGCAAATTTCC 
(577) AGGGCACCACCACACTATGTCGAAAAGTGTTTCTGTCATCCAAATACTCCACACGCAAATTTCC
641 704
(589) TTCCACTCGGATAAGATGCTGAGGAGGGGCCAGACCATCGCTATCTGAGCAGCGCTCATGGTGG 
(641) TTCCACTCGGATAAGATGCTGAGGAGGGGCCAGACCATCGCTATCTGAGCAGCGCTCATGGTGG
705 R175H 768
(653) gggcaIMcctcacaacctccgtcatgtgctgtgactgcttgtagatggccatggcgcggacgc (705) gggcaBBcctcacaacctccgtcatgtgctgtgactgcttgtagatggccatggcgcggacgc
769 832
(717) GGGTGCCGGGCGGGGGTGTGGAATCAACCCACAGCTGCACAGGGCAGGTCTTGGCCAGTTGGCA 
(769) GGGTGCCGGGCGGGGGTGTGGAATCAACCCACAGCTGCACAGGGCAGGTCTTGGCCAGTTGGCA
833 896
(781) AAACATCTTGTTGAGGGCAGGGGAGTACGTGCAAGTCACAGACTTGGCTGTCCCAGAATGCAAG 
(833) AAACATCTTGTTGAGGGCAGGGGAGTACGTGCAAGTCACAGACTTGGCTGTCCCAGAATGCAAG
897 960
(845) AAGCCCAGACGGAAACCGTAGCTGCCCTGGTAGGTTTTCTGGGAAGGGACAGAAGATGACAGGG 
(897) AAGCCCAGACGGAAACCGTAGCTGCCCTGGTAG -..... -.......................
961 1024
(909) GCCAGGAGGGGGCTGGTGCAGGGGCCGCCGGTGTAGGAGCTGCTGGTGCAGGGGCCACGGGGGG 
(930) ............................. .........-............. -...........
1025 1088
(973) AGCAGCCTCTGGCATTCTGGGAGCTTCATCTGGACCTGGGTCTTCAGTGAACCATTGTTCAATA  
(930) .................................................................
1089 1152
(1037) TCGTCCGGGGACAGCATCAAATCATCCATTGCTTGGGACGGCAAGGGGGACAGAACGTTGTTTT 
(930) -----------------------............ -.....-----------------------
1153 1216
(1101) CAGGAAGTAGTTTCCATAGGTCTGAAAATGTTTCCTGACTCAGAGGGGGCTCGACGCTAGGATC 
(930) ........ ............. .................. ........................
1217 1234
(1165) TGACTGCGGCTCCTCCAT 
(930) ...... ---........
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Appendix 6
The results of sequencing of p53-175H in pNTAP-B. The following primers were 
used for sequencing:
• CMVfor (S’-CGC AAA TGG GCG GTA GGC GTG-3’) - available from 
Eurofms MWG Operon,
• n53.601-620 (S’-TTG CGT GTG GAG TAT TTG GA-3’) - designed specifically 
for sequencing.
The obtained sequences were aligned to the reference sequence of p53 (accession 
number: NM_000546) using the AlignX® Module of Vector NTI Advance™ 11 
(Invitrogen).
p53 cDNA (1)
CMVfor (1)
p53.601-620 (1)
p53 CDNA (1)
CMVfor (66)
p53.601-620 (1)
p53 CDNA (1)
CMVfor (131)
p53.601-620 (1)
p53 CDNA (1)
CMVfor (196)
p53.601-620 (1)
p53 CDNA (1)
CMVfor (261)
p53.601-620 (1)
p53 CDNA (1)
CMVfor (326)
p53.601-620 (1)
p53 CDNA (28)
CMVfor (391)
p53.601-620 (1)
p53 CDNA (93)
CMVfor (456)
p53.601-620 (1)
1 65
ATAGCAGAGCTGGTTTAGTGACCGTCAGATCCGCTAGCGATTACGCCAAGCTCGAAATTAACCCT
66 130
CACTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCGCCACCATGAAGCGACGATOGA
131 CBP 195
A^AAGAATTTCATAGCCGTCTCAGCAGCCAACCGCTTTAAGAAAATCTCATCCTCCGGGGGAC-TT
196 260
GGAAGCGGTAGCGGTACCATGGACGAGAAGACCACCGGCTGGCGGGGCGGCCACGTGGTGGAGGG
261 SBP 325
CCTGGCCGGCGAGCTGGAGCAGCTGCGGGCCAGGCTGGAGCACCACCCTCAGGGCCAGCGGGAGC
326 390
-------------------------------------- ATGGAGGAGCCGCAGTCAGATCCTAGC
CCTCCGGCGGCTGCAAGCTGGGCTGCCCGGGCGGATCCATGGAGGAGCCGCAGTCAGATCCTAGC
391 455 
GTCGAGCCCCCTCTGAGTCAGGAAACATTTTCAGACCTATGGAAACTACTTCCTGAAAACAACGT  
GTCGAGCCCCCTCTGAGTCAGGAAACATTTTCAGACCTATGGAAACTACTTCCTGAAAACAACGT
456 520 
TCTGTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGATGCTGTCCCCGGACGATATTGAACAAT 
TCTGTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGATGCTGTCCCCGGACGATATTGAACAAT
302
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p53 cDNA (158)
CMVfor (521)
p53.601-620 (1)
p53 CDNA (223)
CMVfor (586)
p53.601-620 (1)
p53 CDNA (288)
CMVfor (651)
p53.601-620 (1)
p53 CDNA (353)
CMVfor (716)
p53.601-620 (1)
p53 CDNA (418)
CMVfor (781)
p53.601-620 (1)
p53 CDNA (483)
CMVfor (846)
p53.601-620 (1)
p53 CDNA (548)
CMVfor (911)
p53.601-620 (1)
p53 cDNA (613)
CMVfor (960)
p53.601-620 (1)
p53 CDNA (678)
CMVfor (960)
p53.601-620 (41)
p53 cDNA (743)
CMVfor (960)
p53.601-620 (106)
p53 CDNA (808)
CMVfor (960)
p53.601-620 (171)
p53 cDNA (873)
CMVfor (960)
p53.601-620 (236)
p53 cDNA (938)
CMVfor (960)
p53.601-620 (301)
p53 CDNA (1003)
CMVfor (960)
p53.601-620 (366)
p53 CDNA (1068)
CMVfor (960)
p53.601-620 (431)
SNP
521 72P 585
GGTTCACTGAAGACCCAGGTCCAGATGAAGCTCCCAGAATGCCAGAGGCTGCTCCCCCCGTGGCC
ggttcactgaagacccaggtccagatgaagctcccagaatgccagaggctgctcccBBgtggcc
586 650 
CCTGCACCAGCAGCTCCTACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTTC 
CCTGCACCAGCAGCTCCTACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTTC
651 715 
TGTCCCTTCCCAGAAAACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGGGA 
TGTCCCTTCCCAGAAAACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGGGA
716 780 
CAGCCAAGTCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAG 
CAGCCAAGTCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAAG
781 845 
ACCTGCCCTGTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATGGC 
ACCTGCCCTGTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATGGC
846 R175H 910 
catctacaagcagtcacagcacatgacggaggttgtgaggBBtgcccccaccatgagcgctgct 
catctacaagcagtcacagcacatgacggaggttgtgaggHItgcccccaccatgagcgctgct
911 975 
CAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATTTGCGTGTGGAG 
CAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGG...............-
976 1040
TATTTGGATGACAGAAACACTTTTCGACATAGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTTGG
.......................TCGC--TAGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTTGG
1041 1105
CTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAACC
CTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAACC
1106 1170
GGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACAGC
GGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACAGC
1171 1235
TTTGAGGTGCGTGTTTGTGCCTGTCCTGGGAGAGACCGGCGCACAGAGGAAGAGAATCTCCGCAA
TTTGAGGTGCGTGTTTGTGCCTGTCCTGGGAGAGACCGGCGCACAGAGGAAGAGAATCTCCGCAA
1236 1300
GAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCACTGCCCAACAACACCA
GAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCACTGCCCAACAACACCA
1301 1365
GCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTGGG
GCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTGGG
1366 1430
CGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCTGG
CGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCTGG
1431 1495
GAAGGAGCCAGGGGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACCT
GAAGGAGCCAGGGGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACCT
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p53 CDNA 
CMVfor 
p53.601-620
(1133)
(960)
(496)
p53 cDNA 
CMVfor 
p53.601-620
(1183)
(960)
(561)
p53 cDNA 
CMVfor 
p53.601-620
(1183)
(960)
(626)
p53 cDNA 
CMVfor 
p53.601-620
(1183)
(960)
(691)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(960)
(756)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(960)
(821)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(960)
(886)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(960)
(951)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(960)
(1016)
1496 1560
CCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGA---------------
CCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGAGAATTCGATATCAAG
1561 1625
CTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCTTAATTAATTAAGGTACCAGGTAAGT 
1626 1690
GTACCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTCGATCGCCCTTCCCAACAGTTGCG 
1691 1755
CAGCCTGAATGGCGAATGGAGATCCAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAAT 
1756 1820
TGTTTGTGTATTTTAGATTCACAGTCCCAAGGCTCATTTCAGGCCCCTCAGTCCTCACAGTCTGT 
1821 1885
TCATGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACAC 
1886 1950
CTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTA 
1951 2015
TAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCAGTGCATT 
2016 2050
CTAGTTGTGGTTTGTCCAAACTCATCAATGTATCT
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Appendix 7
The results of sequencing of p53-273H in pET24a(+).The following primers were 
used for sequencing:
• 17 (5’-TAA TAG GAG TCA CTA TAG GG-3’) - available from Eurofins MWG 
Operon,
• p53.601-620 (5’-TTG CGT GTG GAG TAT TTG GA-3’) - designed specifically 
for sequencing.
The obtained sequences were aligned to the reference sequence of p53 (accession 
number: NM 000546) using the AlignX® Module of Vector NTI Advance™ 11 
(Invitrogen).
p53 cDNA (1)
T7 (1)
p53.601-620 (1)
p53 cDNA (27)
T7 (66)
p53.601-620 (1)
p53 cDNA (92)
T7 (131)
p53.601-620 (1)
p53 CDNA (157)
T7 (196)
p53.601-620 (1)
p53 CDNA (222)
T7 (261)
p53.601-620 (1)
p53 CDNA (287)
T7 (326)
p53.601-620 (1)
p53 CDNA (352)
T7 (391)
p53.601-620 (1)
p53 CDNA (417)
T7 (456)
p53.601-620 (1)
1 65
............................. ..........ATGGAGGAGCCGCAGTCAGATCCTAG
TAGAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATGGAGGAGCCGCAGTCAGATCCTAG
66 130 
CGTCGAGCCCCCTCTGAGTCAGGAAACATTTTCAGACCTATGGAAACTACTTCCTGAAAACAACG 
CGTCGAGCCCCCTCTGAGTCAGGAAACATTTTCAGACCTATGGAAACTACTTCCTGAAAACAACG
131 195 
TTCTGTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGATGCTGTCCCCGGACGATATTGAACAA 
TTCTGTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGATGCTGTCCCCGGACGATATTGAACAA
SNP
196 72P 260
TGGTTCACTGAAGACCCAGGTCCAGATGAAGCTCCCAGAATGCCAGAGGCTGCTCCCBfcTGGC
tggttcactgaagacccaggtccagatgaagctcccagaatgccagaggctgctcccBBgtggc
261 325 
CCCTGCACCAGCAGCTCCTACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTT 
CCCTGCACCAGCAGCTCCTACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCTT
326 390 
CTGTCCCTTCCCAGAAAACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGGG 
CTGTCCCTTCCCAGAAAACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGGG
391 455 
ACAGCCAAGTCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAA 
ACAGCCAAGTCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCAA
456 520 
GACCTGCCCTGTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATGG 
GACCTGCCCTGTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATGG
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p53 cDNA 
T7
p53.601-620
521 585
(482) CCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGCGCTGC 
(521) CCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGCGCTGC 
(1) ...................-......................... ..............-.............................
p53 cDNA 
T7
p53.601-620
586 650
(547) TCAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATTTGCGTGTGGA  
(586) TCAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATTTGCGTGTGGA  
(1) ............................................... ..... ......................................
p53 CDNA 
T7
p53.601-620
651 715
(612) GTATTTGGATGACAGAAACACTTTTCGACATAGTGTGGTGGTG C C CTATGAG C CGCCTGAGGTTG 
(651) GTATTTGGATGACAGAAACACTTTTCGACATAGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTTG 
(1) -................... ...... CGAC - TAGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTTG
p53 CDNA 
T7
p53.601-620
716 780
(677) GCTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAAC 
(716) GCTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAAC 
(40) GCTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAAC
781 845
p53 CDNA (742) CGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACAG
T7 (781) CGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACAG
p53.601-620 (105) CGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACAG
p53 cDNA 
T7
p53.601-620
846 R273H 910 
(807) ctttgaggtgBBgtttgtgcctgtcctgggagagaccggcgcacagaggaagagaatctccgca 
(846) ctttgaggtg^Bgtttgtgcctgtcctgggagagaccggcgcacagaggaagagaatctccgca 
(170) ctttgaggtgBBgtttgtgcctgtcctgggagagaccggcgcacagaggaagagaatctccgca
p53 cDNA 
T7
p53.601-620
911 975 
(872) AGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCACTGCCCAACAACACC 
(911) AGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCACTGCCCAACAACACC 
(235) AGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCACTGCCCAACAACACC
p53 CDNA 
T7
p53.601-620
976 1040
(937) AGCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTGG
(976) AGCTCCTCTCCC - AGCCAAAGAAGAAACCACTG.............. .............. .....
(300) AGCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTGG
1041 1105
p53 cDNA (1002) GCGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCTG
T7 (1008) ...................... ................. ------ ----------------- ------
p53.601-620 (365) GCGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCTG
1106 1170
p53 CDNA (1067) GGAAGGAGCCAGGGGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACC
T7 (1008) ......... ......................................... .............. .....
p53.601-620 (430) GGAAGGAGCCAGGGGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTACC
p53 CDNA 
T7
p53.601-620
1171 1235
(1132) TCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGA...............
(1008) .................. ......... ..................................... .....
(495) TCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGAATTCGAGCTCCGTC
p53 CDNA 
T7
p53.601-620
1236 1300
(1183) ........................-............-.................................
(1008) ...................................-...................................
(560) GACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGC
p53 CDNA 
T7
p53.601-620
1301 1365
(1183) ...............-......................-............. -........ -...... -
(1008) ...................................................... ................
(625) CCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCT
p53 CDNA 
T7
p53.601-620
1366 1430
(1183) ........... ......... -........ ................ ....... ..... -........
(1008) ...............-..... ......................... ............... ........
(690) CTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATTGGCGAATGGGACG
p53 cDNA 
T7
p53.601-620
1431 1495
(1183) -.................. ......... ...................................... .
(1008) --------- --------- -..... ............. ...............................
(755) CGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTT
306
Appendices
p53 CDNA 
T7
P53.601-620
1496 1560
(1183) ------------------------------------------------------- -----------
(1008) .............................. ...................................-
(820) GGCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTT
p53 CDNA 
T7
p53.601-620
1561 1625
(1183) ------------------------------------------------------------ ------
(1008) ------------------------------------------------------------------
(885) TCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCG
p53 cDNA 
T7
p53.601-620
1626 1683
(1183) ------------------------------------- ---------------------
(1008) -----------------------------------------------------------
(950) ACCCCAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACG
307
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Appendix 8
The results of sequencing of p53-273H in pNTAP-B. The following primers were 
used for sequencing:
• CMVfor (S’-CGC AAA TGG GCG GTA GGC GTG-3’) - available from 
Eurofms MWG Operon,
• P53.6Q1-62Q (S’-TTG CGT GTG GAG TAT TTG GA-3’) - designed specifically 
for sequencing.
The obtained sequences were aligned to the reference sequence of p53 (accession 
number: NM_000546) using the AlignX® Module of Vector NTI Advance™ 11 
(Invitrogen).
p53 cDNA (1)
CMVfor (1)
p53.601-620 (1)
p53 cDNA (1)
CMVfor (66)
p53.601-620 (1)
p53 CDNA (1)
CMVfor (131)
p53.601-620 (1)
p53 cDNA (1)
CMVfor (196)
p53.601-620 (1)
p53 cDNA (1)
CMVfor (261)
p53.601-620 (1)
p53 cDNA (1)
CMVfor (326)
p53.601-620 (1)
p53 CDNA (26)
CMVfor (391)
p53.601-620 (1)
p53 CDNA (31)
CMVfor (456)
p53.601-620 (1)
1 65
TATAGCAGAGCTGGTTTAGTGAACCGTCAGATCCGCTAGCGATTACGCCAAGCTCGAAATTAACC
66 130
CTCACTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCGCCACCATOAAGCGACGATG
131 CBP 195
GAAAAAGAATTTCATAGCCGTCTCAGCAGCCAACCGCTTTAAGAAAATCTCATCCTCCGGGGGAC
196 260
TTGGAAGCGGTAGCGGTACCATGGACGAGAAGACCACCGGCTGGCGGGGCGGCCACGTGGTGGAG
261 SBP 325
GGCCTGGCCGGCGAGCTGGAGCAGCTGCGGGCCAGGCTGGAGCACCACCCTCAGGGCCAGCGGGA
326 390
--------- ------------------------------ atggaggag c cg cagtc AG atc c ta
gccctccggcggctgcaagctgggctgcccgggcggatctatggaggagccgcagtcagatccta
391 455
gcgtcgagccccctctgagtcaggaaacattttcagacctatggaaactacttcctgaaaacaac
GCGTCGAGCCCCCTCTGAGTCAGGAAACATTTTCAGACCTATGGAAACTACTTCCTGAAAACAAC
456 520 
GTTCTGTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGATGCTGTCCCCGGACGATATTGAACA 
GTTCTGTCCCCCTTGCCGTCCCAAGCAATGGATGATTTGATGCTGTCCCCGGACGATATTGAACA
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p53 cDNA (156)
CMVfor (521)
p53.601-620 (1)
p53 CDNA (221)
CMVfor (586)
p53.601-620 (1)
p53 CDNA (286)
CMVfor (651)
p53.601-620 (1)
p53 CDNA (351)
CMVfor (716)
p53.601-620 (1)
p53 CDNA (416)
CMVfor (781)
p53.601-620 (1)
p53 CDNA (481)
CMVfor (846)
p53.601-620 (1)
p53 CDNA (546)
CMVfor (911)
p53.601-620 (1)
p53 CDNA (611)
CMVfor (976)
p53.601-620 (1)
p53 CDNA (676)
CMVfor (978)
p53.601-620 (36)
p53 CDNA (741)
CMVfor (978)
p53.601-620 (101)
p53 CDNA (806)
CMVfor (978)
p53.601-620 (166)
p53 cDNA (871)
CMVfor (978)
p53.601-620 (231)
p53 CDNA (936)
CMVfor (978)
p53.601-620 (296)
p53 CDNA (1001)
CMVfor (978)
p53.601-620 (361)
p53 cDNA (1066)
CMVfor (978)
p53.601-620 (426)
SNP
521 72P 585
atggttcactgaagacccaggtccagatgaagctcccagaatgccagaggctgctcccBBgtgg
ATGGTTCACTGAAGACCCAGGTCCAGATGAAGCTCCCAGAATGCCAGAGGCTGCTCCCCCC
586 650 
CCCCTGCACCAGCAGCTCCTACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCT 
CCCCTGCACCAGCAGCTCCTACACCGGCGGCCCCTGCACCAGCCCCCTCCTGGCCCCTGTCATCT
651 715 
TCTGTCCCTTCCCAGAAAACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGG 
TCTGTCCCTTCCCAGAAAACCTACCAGGGCAGCTACGGTTTCCGTCTGGGCTTCTTGCATTCTGG
716 780 
GACAGCCAAGTCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCA 
GACAGCCAAGTCTGTGACTTGCACGTACTCCCCTGCCCTCAACAAGATGTTTTGCCAACTGGCCA
781 845 
AGACCTGCCCTGTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATG 
AGACCTGCCCTGTGCAGCTGTGGGTTGATTCCACACCCCCGCCCGGCACCCGCGTCCGCGCCATG
846 910 
GCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGCGCTG 
GCCATCTACAAGCAGTCACAGCACATGACGGAGGTTGTGAGGCGCTGCCCCCACCATGAGCGCTG
911 975 
CTCAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATTTGCGTGTGG 
CTCAGATAGCGATGGTCTGGCCCCTCCTCAGCATCTTATCCGAGTGGAAGGAAATTTGCGTGTGG
976 1040
AGTATTTGGATGACAGAAACACTTTTCGACATAGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTT
AG................................................................
------------------------------------------------------------------- -CTAGTGTGGTGGTGCCCTATGAGCCGCCTGAGGTT
1041 1105
GGCTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAA
GGCTCTGACTGTACCACCATCCACTACAACTACATGTGTAACAGTTCCTGCATGGGCGGCATGAA
1106 1170
CCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACA
CCGGAGGCCCATCCTCACCATCATCACACTGGAAGACTCCAGTGGTAATCTACTGGGACGGAACA 
1171 R273H 1235
gctttgaggtgBBgtttgtgcctgtcctgggagagaccggcgcacagaggaagagaatctccgc
GCTTTGAGGTGBfGTTTGTGCCTGTCCTGGGAGAGACCGGCGCACAGAGGAAGAGAATCTCCGC
1236 1300
AAGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCACTGCCCAACAACAC
AAGAAAGGGGAGCCTCACCACGAGCTGCCCCCAGGGAGCACTAAGCGAGCACTGCCCAACAACAC
1301 1365
CAGCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTG
CAGCTCCTCTCCCCAGCCAAAGAAGAAACCACTGGATGGAGAATATTTCACCCTTCAGATCCGTG
1366 1430
GGCGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCT
GGCGTGAGCGCTTCGAGATGTTCCGAGAGCTGAATGAGGCCTTGGAACTCAAGGATGCCCAGGCT
1431 1495
GGGAAGGAGCCAGGGGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTAC
GGGAAGGAGCCAGGGGGGAGCAGGGCTCACTCCAGCCACCTGAAGTCCAAAAAGGGTCAGTCTAC
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p53 cDNA 
CMVfor 
p53.601-620
(1131)
(978)
(491)
p53 cDNA 
CMVfor 
p53.601-620
(1183)
(978)
(556)
p53 cDNA 
CMVfor 
p53.601-620
(1183)
(978)
(621)
p53 cDNA 
CMVfor 
p53.601-620
(1183)
(978)
(686)
p53 cDNA 
CMVfor 
p53.601-620
(1183)
(978)
(751)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(978)
(816)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(978)
(881)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(978)
(946)
p53 CDNA 
CMVfor 
p53.601-620
(1183)
(978)
(1011)
1496 1S60
CTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGA...... ......
CTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGAATTCGATATCAAG
1561 1625
CTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCTTAATTAATTAAGGTACCAGGTAAGT 
1626 1690
GTACCCAATTCGCCCTATAGTGAGTCGTATTACAATTCACTCGATCGCCCTTCCCAACAGTTGCG 
1691 1755
CAGCCTGAATGGCGAATGGAGATCCAATTTTTAAGTGTATAATGTGTTAAACTACTGATTCTAAT 
1756 1820
TGTTTGTGTATTTTAGATTCACAGTCCCAAGGCTCATTTCAGGCCCCTCAGTCCTCACAGTCTGT 
1821 1885
tcatgatcataatcagccataccacatttgtagaggttttacttgctttaaaaaacctcccacac 
1886 1950
CTCCCCCTGAACCTGAAACATAAAATGAATGCAATTGTTGTTGTTAACTTGTTTATTGCAGCTTA 
1951 2015
TAATGGTTACAAATAAAGCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATT 
2016 2039
CTAGTTGTGGTTTGTCCAAACTCA
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Appendix 9
Table 6.2: The list of proteins identified in the streptavidin eluate fraction purified from 
UM-SCC-12 cells.
Symbol Full name No. of peptides Coverage
MYH9 Myosin-9 69 32.30%
ACTG Actin, cytoplasmic 2 45 54.93%
ACTB Actin, cytoplasmic 1 43 54.93%
MYOIC Myosin-1C 23 25.39%
CLH1 Clathrin heavy chain 1 15 13.07%
MYOIB Myosin-IB 17 13.38%
LIMA1 LIM domain and actin-binding protein 1 8 14.76%
TBA1B Tubulin alpha-IB chain 8 28.82%
TBA1C Tubulin alpha-lC chain 8 28.95%
BASP1 Brain acid soluble protein 1 10 46.26%
CALM Calmodulin 10 39.60%
PYC Pyruvate carboxylase, mitochondrial 7 11.04%
ANXA2 Annexin A2 10 28.61%
TPM4 Tropomyosin alpha-4 chain 8 27.82%
DREB Drebrin 9 15.87%
MYL6 Myosin light polypeptide 6 6 45.70%
TBB5 Tubulin beta chain 6 18.02%
TBB2C Tubulin beta-2C chain 6 17.98%
TBB2B Tubulin beta-2B chain 5 15.28%
TBB2A Tubulin beta-2 A chain 5 15.28%
TBB3 Tubulin beta-3 chain 5 12.00%
TBB4 Tubulin beta-4 chain 4 13.96%
TPM3 Tropomyosin alpha-3 chain 5 16.55%
HSP7C Heat shock cognate 71 kDa protein 3 6.97%
EF1A3 Putative elongation factor 1-alpha-like 3 3 11.04%
EF1A1 Elongation factor 1-alpha-1 3 11.04%
EF1A2 Elongation factor 1-alpha-2 2 5.83%
RLA2 60S acidic ribosomal protein P2 3 59.13%
NPM Nucleophosmin 3 16.33%
CALL3 Calmodulin-like protein 3 2 18.79%
HSPB1 Heat shock protein beta-1 2 16.10%
MRLC3 Myosin regulatory light chain MRLC3 2 18.13%
MRLC2 Myosin regulatory light chain MRLC2 2 18.02%
PEAK Junction plakoglobin 2 5.10%
TPM3L Putative tropomyosin alpha-3 chain-like protein 4 6.73%
GNAI2 Guanine nucleotide-binding protein G(i) alpha-2 subunit 2 7.32%
GNAI1 Guanine nucleotide-binding protein G(i) alpha-1 subunit 1 3.67%
GNAI3 Guanine nucleotide-binding protein G(k) subunit alpha 1 3.67%
CAPZB F-actin-capping protein subunit beta 2 14.08%
G3P Glyceraldehyde-3-phosphate dehydrogenase 2 8.36%
GBB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 1 5.59%
ACTBL Beta-actin-like protein 2 6 19.15%
AHNK Neuroblast differentiation-associated protein AHNAK 1 0.54%
PP1G Serine/threonine-protein phosphatase PP1-gamma catalytic subunit 1 5.26%
PP1B Serine/threonine-protein phosphatase PPl-beta catalytic subunit 1 5.20%
PP1A Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 1 5.15%
COF1 Cofilin-1 1 10.24%
COF2 Cofilin-2 1 10.24%
RLA1 60S acidic ribosomal protein PI 1 14.04%
MYH10 Myosin-10 10 6.5 8° o
ANXA1 Annexin A1 1 4.62%
YBOX1 Nuclease-sensitive element-binding protein 1 1 5.86%
CAV1 Caveolin-1 1 11.80%
RL12 60S ribosomal protein L12 1 9.09%
RL7A 60S ribosomal protein L7a 1 9.02%
R1 32 60S ribosomal protein L32 1 9.63%
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Table 6.2 (cont.): The list of proteins identified in the streptavidin eluate fraction purified 
from UM-SCC-12 cells.
Symbol Full name No. of peptides Coverage
RS5 40S ribosomal protein S5 1 7.35%
RL7 60S ribosomal protein L7 1 7.66%
COR 1C Coronin-lC 1 3.38%
GBG12 Guanine nucleotide-binding protein G(I)/G(S)/G(0) subunit gamma-12 1 22.22%
RL6 60S ribosomal protein L6 1 5.21%
RL21 60S ribosomal protein L21 1 9.38%
PRP19 Pre-mRNA-processing factor 19 1 2.38%
RL8 60S ribosomal protein L8 1 6.23%
CAZA1 F-actin-capping protein subunit alpha-1 1 5.59%
ACTC Actin. alpha cardiac muscle 1 11 17.77%
ACTS Actin. alpha skeletal muscle 11 17.77%
ACTA Actin, aortic smooth muscle 7 14.85%
ACTH Actin, gamma-enteric smooth muscle 7 14.89%
ATPB ATP synthase subunit beta, mitochondrial 1 3.02%
UBIQ Ubiquitin 1 21.05%
Note: Not all the identified peptides could be unequivocally assigned to one protein 
due to high sequence similarity of many proteins. Those ambiguous cases are shaded
with the same colour.
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Table 6.3: The list of proteins identified in the streptavidin eluate fraction purified from 
12-175H-20 cells.
Symbol Full name No. of peptides Coverage
MYH9 Myosin-9 118 41.12%
HSP71 Heat shock 70 kDa protein 1 38 51.79%
HSP7C Heat shock cognate 71 kDa protein 43 46.13%
ACTB Actin, cytoplasmic 1 45 55.20%
MYOIC Myosin-1C 22 26.17%
TBB5 Tubulin beta chain 18 41.89%
P53 Cellular tumour antigen p53 21 41.48%
TBA1B Tubulin alpha-1 B chain 17 42.57%
CALM Calmodulin 15 79.19%
MYOIB Myosin-IB 21 13.64%
BASP1 Brain acid soluble protein 1 12 46.26%
MYL6 Myosin light polypeptide 6 13 45.70%
MYH10 Myosin-10 16 10.68%
BAG2 BAG family molecular chaperone regulator 2 7 30.33%
CLH1 Clathrin heavy chain 1 8 6.39%
TPM3 Tropomyosin alpha-3 chain 5 16.55%
MRLC3 Myosin regulatory light chain MRLC3 8 35.09%
MRLC2 Myosin regulatory light chain MRLC2 8 34.88%
ANXA2 Annexin A2 7 14.45%
DRF.B Drebrin 4 10.63%
LIMA1 LIM domain and actin-binding protein 1 3 6.46%
TPM4 Tropomyosin alpha-4 chain 7 15.32%
HSPB1 Heat shock protein beta-1 3 26.34%
TPM3L Putative tropomyosin alpha-3 chain-like protein 4 6.73%
TMOD3 Tropomodulin-3 2 12.22%
COF1 Cofilin-1 2 18.67%
COF2 Cofilin-2 1 10.24%
TBB2C Tubulin beta-2C chain 17 35.73%
ACTG Actin, cytoplasmic 2 44 55.20%
MYLK2 Myosin light chain kinase 2, skeletal/cardiac muscle 1 1.85%
ACTC Actin, alpha cardiac muscle 1 9 17.77%
ACTS Actin, alpha skeletal muscle 9 17.77%
ACTA Actin, aortic smooth muscle 6 14.85%
ACTH Actin, gamma-enteric smooth muscle 6 14.89%
PYC Pyruvate carboxylase, mitochondrial 1 1.87%
Myosin-Vl 1 1.16%
YBOX1 Nuclease-sensitive element-binding protein 1 1 5.86%
Note: Not all the identified peptides could be unequivocally assigned to one protein 
due to high sequence similarity of many proteins. Those ambiguous cases are shaded 
with the same colour. The proteins present only in the test sample and not in the 
control are shown in red.
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Table 6.4: The list of proteins identified in the streptavidin eluate fraction purified from 
12-273H-39 cells.
Symbol Full name No. of peptides Coverage
MYH9 Myosin-9 163 45.51%
MYH10 Myosin-10 51 26.01%
ACTB Actin, cytoplasmic 1 52 47.47%
! P53 Cellular tumour antigen p53 37 57.51%
MY01C Myosin-1C 20 21.07%
MY01B Myosin-IB 14 12.85%
CALM Calmodulin 18 45.64%
MYL6 Myosin light polypeptide 6 15 52.98%
DREB Drebrin 11 I6.02°o
LIMA1 LIM domain and actin-binding protein 1 7 11.73%
TPM4 Tropomyosin alpha-4 chain 8 23.79%
TBA3E Tubulin alpha-3E chain 5 13.56%
TBA3C Tubulin alpha-3C/D chain 5 13.56%
TBA1B Tubulin alpha-IB chain 4 10.20%
TBA1A Tubulin alpha-1A chain 4 10.20%
TPM3 Tropomyosin alpha-3 chain 7 22.54%
ML12B Myosin regulatory light chain 12B 9 33.72%
ML12A Myosin regulatory light chain 12A 9 33.92%
BASP1 Brain acid soluble protein 1 6 35.68%
K2C1 Keratin, type 11 cytoskeletal 1 4 7.14%
ANXA2 Annexin A2 4 14.75%
AXA2L Putative annexin A2-like protein 3 10.62%
ALBU Serum albumin 3 7.88%
TBB5 Tubulin beta chain 4 9.46%
TBB2C Tubulin beta-2C chain 4 9.44%
TBB2B Tubulin beta-2B chain 4 9.44%
TBB2A Tubulin beta-2 A chain 4 9.44%
TBB3 Tubulin beta-3 chain 4 9.33%
MY 06 Myosin-VI 2 2.01%
NPM Nucleophosmin 2 11.56%
TPM3L Putative tropomyosin alpha-3 chain-like protein 5 13.90%
KICK) Keratin, type 1 cytoskeletal 10 2 3.94%
COR 1C Coronin-lC 2 8.65%
CD59 CD59 glycoprotein 2 20.31%
MYLK2 Myosin light chain kinase 2, skeletal/cardiac muscle 2 1.85%
K22E Keratin, type 11 cytoskeletal 2 epidermal 3 5.63%
Keratin, type 11 cytoskeletal 6A 2 3.90%
K2C75 Keratin, type 11 cytoskeletal 75 1 2.18%
Keratin, type 11 cytoskeletal 5 2 3.73%
Keratin, type 11 cytoskeletal 6C 2 3.90%
K2C6B Keratin, type 11 cytoskeletal 6B 2 3.90%
K2C79 Keratin, type II cytoskeletal 79 1 2.24%
TM0D3 Tropomodulin-3 1 3.41%
ACTG Actin, cytoplasmic 2 49 47.20%
H12 Histone H 1.2 1 7.51%
ACTC Actin, alpha cardiac muscle 1 13 14.32%
ACTS Actin, alpha skeletal muscle 13 14.32%
ACTA Actin, aortic smooth muscle 9 11.41%
ACTH Actin, gamma-enteric smooth muscle 9 11.44%
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Note: Not all the identified peptides could be unequivocally assigned to one protein 
due to high sequence similarity of many proteins. Those ambiguous cases are shaded 
with the same colour. The proteins present only in the test sample and not in the 
control are shown in red.
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Appendix 10
Live cell imaging was performed on UM-SCC-12, 12-175H-20, 12-273H-39, 
12-273H-41 and 12-273H-null cells. The cells were imaged for 14.4 hours with 
a time-lapse of 3 min. Movies were generated from the recorded images at 
15 frames/sec. See the attached CD for representative movies.
Appendix 11
12-273H-39 cells were transfected with scrambled siRNA, siRNA for p53, 
Lipofectamine alone or left untreated. The cells were imaged for 12 hours 
(24-36 hours post treatment and 36-48 hours post treatment) with a time lapse of 
3 min. Movies were generated from the recorded images at 15 frames/sec. See the 
attached CD for representative movies.
Appendix 12
Live cell imaging was performed on UM-SCC-12, 12-273H-39, 12-273H-39-lowi and 
12-273H-39-1ow3 cells. The cells were imaged for 12 horns with a time-lapse of 
3 min. Movies were generated from the recorded images at 15 frames/sec. See the 
attached CD for representative movies.
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Appendix 13
Table 6.5: The list of genes, which were found to be up-regulated in 12-273H-39 cells 
compared to UM-SCC-12 cells. Statistical analysis was performed using Student’s t-Test. 
(Data analysis perfonned by Dr Bryony Lloyd.)
Gene Full name Relative p valuesymbol expression
TPS 3 tumour protein p53 65.4 0.000006
SPRR2A small proline-rich protein 2A 23.1 0.0013
TLR4 toll-like receptor 4 14.6 0.00019
MFAP5 microfibrillar associated protein 5 12.0 0.0051
C3 complement component 3 11.6 0.00049
CLDN4 claudin 4 10.5 0.007
S100A8 SI00 calcium binding protein A8 10.3 0.00012
C8orf4 chromosome 8 open reading frame 4 10.2 0.000026
FN1 fibronectin 1 8.4 0.017
PTGES prostaglandin E synthase 8.1 0.000005
TIMP2 TIMP metallopeptidase inhibitor 2 7.9 0.0058
EVI2B ecotropic viral integration site 2B 7.6 0.00046
TGM3 transglutaminase 3 7.4 0.0243
NCF2 neutrophil cytosolic factor 2 7.3 0.00076
GDF15 growth differentiation factor 15 7.2 0.0018
IL24 interleukin 24 7.1 0.026
KLRC3 killer cell lectin-like receptor subfamily C, member 3 6.9 0.000098
SDR16C5 short chain dehydrogenase/reductase family 16C, member 5 6.6 0.000075
LCN2 lipocalin 2 6.5 0.0025
RAET1L retinoic acid early transcript 1L 6.0 0.0028
SAA1 serum amyloid A1 6.0 0.0024
ULBP1 UL16 binding protein 1 5.9 0.0032
TSPAN1 tetraspanin 1 5.8 0.00073
SLC16A3 solute carrier family 16, member 3 (monocarboxylic acid transporter 4) 5.6 0.00068
CLDN1 claudin 1 5.6 0.041
SCEL sciellin 5.5 0.000067
TSPAN8 tetraspanin 8 5.5 0.0066
PLA2G16 phospholipase A2, group XVI 5.5 0.0028
SLC2A3 solute carrier family 2 (facilitated glucose transporter) 5.3 0.0061
GFPT2 glutamine-fructose-6-phosphate transaminase 2 5.0 0.0035
TNFRSF9 tumour necrosis factor receptor superfamily, member 9 4.9 0.015
BIRC3 baculoviral IAP repeat-containing 3 4.8 0.016
IFIT2 interferon-induced protein with tetratricopeptide repeats 2 4.8 0.00093
TSPAN18 tetraspanin 18 4.7 0.00018
CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 4.7 0.0073
TFP1 tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 4.6 0.0051
ACAA2 acetyl-Coenzyme A acyltransferase 2 4.5 0.013
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 4.4 0.0056
STEAP1 six transmembrane epithelial antigen of the prostate 1 4.4 0.0015
SLPI secretory leukocyte peptidase inhibitor 4.4 0.010
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 4.3 0.00052
SPRY2 sprouty homolog 2 (Drosophila) 4.1 0.0018
ZNF114 zinc finger protein 114 4.0 0.000005
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Table 6.5 (cont.): The list of genes, which were found to be up-regulated in 12-273H-39 
cells compared to UM-SCC-12 cells. Statistical analysis was performed using Student’s 
t-Test. (Data analysis performed by Dr Bryony Lloyd.)
Gene Full name Relative p valuesymbol expression
LOX lysyl oxidase 4.0 0.0022
IL8 interleukin 8 4.0 0.0066
PROS1 protein S (alpha) 3.9 0.0028
GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin type 3.9 0.0039
PLAU plasminogen activator, urokinase 3.9 0.011
SPRR2D small proline-rich protein 2D 3.9 0.0022
DNER delta/notch-like EGF repeat containing 3.9 0.011
RGS2 regulator of G-protein signalling 2, 24kDa 3.8 0.00061
CLDN7 claudin 7 3.8 0.027
GPR110 G protein-coupled receptor 110 3.7 0.017
DLX5 distal-less homeobox 5 3.7 0.0046
LIPH lipase, member H 3.7 0.00017
LAPTM5 lysosomal protein transmembrane 5 3.7 0.000030
EPAS1 endothelial PAS domain protein 1 3.6 0.013
SPRR3 small proline-rich protein 3 3.5 0.0020
PI3 peptidase inhibitor 3, skin-derived 3.5 0.0022
GNG2 guanine nucleotide binding protein (G protein), gamma 2 3.5 0.00041
IGFBP7 insulin-like growth factor binding protein 7 3.5 0.000017
ANKRD22 ankyrin repeat domain 22 3.5 0.011
EHF ets homologous factor 3.4 0.0067
PAG1 phosphoprotein associated with glycosphingolipid microdomains 1 3.4 0.010
PDZD2 PDZ domain containing 2 3.4 0.00034
ABCA12 ATP-binding cassette, sub-family A (ABC1), member 12 3.4 0.000029
IGFL1 IGF-like family member 1 3.4 0.0014
SAMD9L sterile alpha motif domain containing 9-like 3.3 0.0041
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 0.0044
IL1F9 interleukin 1 family, member 9 J.J 0.0014
MAP3K5 mitogen-activated protein kinase kinase kinase 5 0.00025
RBM47 RNA binding motif protein 47 3.2 0.0050
DNAH6 dynein, axonemal, heavy chain 6 3.2 0.0025
GPR126 G protein-coupled receptor 126 3.1 0.021
FAM49A family with sequence similarity 49, member A 3.1 0.0014
DUSP10 dual specificity phosphatase 10 3.1 0.0017
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 3.0 0.0042
NRP2 neuropil in 2 3.0 0.0031
RBKS ribokinase 3.0 0.00065
IRAK2 interleukin-1 receptor-associated kinase 2 3.0 0.0013
ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, VO subunit d2 3.0 0.00015
RASSF5 Ras association (RalGDS/AF-6) domain family member 5 3.0 0.000619
MMP2 matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) 2.9 0.00050
GPR1 G protein-coupled receptor 1 2.9 0.020
TXNIP thioredoxin interacting protein 2.9 0.0085
SPRR1B small proline-rich protein 1B (comifin) 2.9 0.0040
ABLIM3 actin binding L1M protein family, member 3 2.9 0.0040
TIMP3 T1MP metallopeptidase inhibitor 3 2.9 0.0011
SLFN5 schlafen family member 5 2.9 0.00095
CXCL2 chemokine (C-X-C motif) ligand 2 2.8 0.020
RNF146 ring finger protein 146 2.8 0.0030
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Table 6.5 (cont.): The list of genes, which were found to be up-regulated in 12-273H-39 
cells compared to UM-SCC-12 cells. Statistical analysis was performed using Student’s 
t-Test. (Data analysis performed by Dr Bryony Lloyd.)
Gene Full name Relative p valuesymbol expression
LY96 lymphocyte antigen 96 2.8 0.0087
ECM1 extracellular matrix protein 1 2.8 0.0010
C5orf41 chromosome 5 open reading frame 41 2.8 0.0067
GPR110 G protein-coupled receptor 110 2.8 0.0091
CCL20 chemokine (C-C motif) ligand 20 2.8 0.000032
GJB4 gap junction protein, beta 4, 30.3kDa 2.8 0.0073
RASA4 RAS p21 protein activator 4 2.8 0.00050
TMEM159 transmembrane protein 159 2.7 0.0052
TSPAN2 tetraspanin 2 2.7 0.0054
SAT1 spermidine/spermine N1-acetyltransferase 1 2.7 0.0012
PTAFR platelet-activating factor receptor 2.7 0.035
LGALS3 lectin, galactoside-binding, soluble, 3 2.7 0.00044
SLC1A1 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 2.7 0.0057
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 2.7 0.023
FRK. fyn-related kinase 2.7 0.023
PLXNA2 plexin A2 2.6 0.017
MR1 major histocompatibility complex, class 1-related 2.6 0.00067
CYP39A1 cytochrome P450, family 39, subfamily A, polypeptide 1 2.6 0.0015
MMP28 matrix metallopeptidase 28 2.6 0.00018
TMEM47 transmembrane protein 47 2.6 0.0033
SERP1NB1 serpin peptidase inhibitor, clade B (ovalbumin), member 1 2.5 0.019
MARCH3 membrane-associated ring finger (C3HC4) 3 2.5 0.0061
HEY1 hairy/enhancer-of-split related with YRPW motif 1 2.5 0.0014
VEGFA vascular endothelial growth factor A 2.5 0.0037
NPL N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase) 2.5 0.012
EV12A ecotropic viral integration site 2A 2.5 0.0028
MT1X metallothionein IX 2.5 0.0032
ANKRD42 ankyrin repeat domain 42 2.5 0.0016
KRT86 keratin 86 2.5 0.0026
ERRFI1 ERBB receptor feedback inhibitor 1 2.4 0.0030
CBWD3 COBW domain containing 3 2.4 0.051
ID2 inhibitor of DNA binding 2, dominant negative helix-loop- helix protein 2.4 0.013
MMP1 matrix metallopeptidase 1 (interstitial collagenase) 2.4 0.0027
CITED2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 2.4 0.0014
AG API 1 ankyrin repeat and GTPase domain Arf GTPase activating 
protein 11
2.4 0.0022
DAB2 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 2.4 0.019
MERTK c-mer proto-oncogene tyrosine kinase 2.4 0.025
GSDMC gasdermin C 2.4 0.00033
TRIB2 tribbles homolog 2 (Drosophila) 2.4 0.0016
GPNMB glycoprotein (transmembrane) nmb 2.4 0.030
MYEOV myeloma overexpressed (in a subset of t(l 1;14) positive multiple myelomas) 2.4 0.0066
IFIT1 interferon-induced protein with tetratricopeptide repeats 2.4 0.030
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Table 6.5 (cont.): The list of genes, which were found to be up-regulated in 12-273H-39 
cells compared to UM-SCC-12 cells. Statistical analysis was performed using Student’s 
t-Test. (Data analysis perfonned by Dr Bryony Lloyd.)
Gene Full name Relative p valuesymbol expression
C9orf70 chromosome 9 open reading frame 70 2.4 0.00039
RHBDL2 rhomboid, veinlet-like 2 (Drosophila) 2.4 0.000067
DOCK4 dedicator of cytokinesis 4 2.4 0.0026
SAA1 serum amyloid A1 2.4 0.041
MCTP1 multiple C2 domains, transmembrane 1 2.4 0.0010
RWDD2A RWD domain containing 2A 2.4 0.0048
RPL41 ribosomal protein L41 2.4 0.012
CA13 carbonic anhydrase XIII 2.3 0.0026
SEMA3B sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B 2.3 0.00022
LPAR3 lysophosphatidic acid receptor 3 2.3 0.0018
DUSP1 dual specificity phosphatase 1 2.3 0.0015
HLA-B major histocompatibility complex, class I, B 2.3 0.0045
C15orf52 chromosome 15 open reading frame 52 2.3 0.0010
ENC1 ectodermal-neural cortex (with BTB-like domain) 2.3 0.038
CAPG capping protein (actin filament), gelsolin-like 2.3 0.00031
STK10 serine/threonine kinase 10 2.3 0.0023
LIE leukaemia inhibitory factor (cholinergic differentiation factor) 2.3 0.026
NOV nephroblastoma overexpressed gene 2.3 0.00028
TLN2 talin 2 2.3 0.00092
SOD2 superoxide dismutase 2, mitochondrial 2.3 0.0087
ZNF718 zinc finger protein 718 2.3 0.0035
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Table 6.6: The list of genes, which were found to be down-regulated in 12-273H-39 cells 
compared to UM-SCC-12 cells. Statistical analysis was performed using Student’s t-Test. 
(Data analysis performed by Dr Bryony Lloyd.)
Gene Full name Relative p valuesymbol expression
LPAR1 lysophosphatidic acid receptor 1 -2.3 0.0011
NOS1 nitric oxide synthase 1 (neuronal) -2.3 0.0021
PRR5L proline rich 5 like -2.3 0.010
CABLES 1 Cdk5 and Abl enzyme substrate 1 -2.4 0.041
LEF1 lymphoid enhancer-binding factor 1 -2.4 0.030
PPP4R4 protein phosphatase 4, regulatory subunit 4 -2.5 0.0039
MTMR10 myotubularin related protein 10 -2.5 0.00035
OBP2B odorant binding protein 2B -2.6 0.038
NMT2 N-myristoyltransferase 2 -2.6 0.0046
CCDC3 coiled-coil domain containing 3 -2.6 0.0055
FLRT2 fibronectin leucine rich transmembrane protein 2 -2.6 0.00085
ACSM2B acyl-CoA synthetase medium-chain family member 2B -2.6 0.022
FBN2 fibrillin 2 -2.6 0.0060
SIRPA signal-regulatory protein alpha -2.6 0.000030
CNTN1 contactin 1 -2.7 0.0029
HTRA3 HtrA serine peptidase 3 -2.7 0.00047
TAFIA TATA box binding protein (TBP)-associated factor, RNA polymerase I, A, 48kDa -2.8 0.0069
RFX7 regulatory factor X, 7 -2.8 0.0045
SLC1A4 solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 -2.8 0.037
LAMA1 laminin, alpha 1 -2.8 0.000045
KMO kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) -2.8 0.0066
WNT7B wingless-type MMTV integration site family, member 7B -3.0 0.00027
FECH ferrochelatase (protoporphyria) -3.0 0.0036
CCBE1 collagen and calcium binding EGF domains 1 -3.0 0.0017
WNT5A wingless-type MMTV integration site family, member 5A -3.0 0.0026
FGFR2 fibroblast growth factor receptor 2 -3.1 0.0039
FST follistatin -3.2 0.0025
SLC2A5 solute carrier family 2 (facilitated glucose/ffuctose transporter), member 5 -3.2 0.023
COL12A1 collagen, type XII, alpha 1 -3.4 0.0070
RBMS3 RNA binding motif, single stranded interacting protein 3 -3.8 0.0018
RARB retinoic acid receptor, beta -3.9 0.0085
KRT14 keratin 14 -4.1 0.0086
CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1 -5.1 0.014
SERPINF1 serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 -5.2 0.0026
OLR1 oxidized low density lipoprotein (lectin-like) receptor 1 -5.8 0.017
PARTI prostate androgen-regulated transcript 1 -6.0 0.0080
NPNT nephronectin -6.9 0.0034
OGN osteoglycin -8.5 0.000010
CCND2 cyclin D2 -10.9 0.000028
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Appendix 14
/
Z / //f|
ilW \
b * ~x
0) 0) mc/> 0) JZro V) E CL0) ro >, (/>
o 0)o NC ox:Q. 0) CL
O Q.O o O
o3 3 o3 a>c c c0) 0) (U 0)
O O O
7 t V yl
■O
0)
0)
CO
3 CO
CO O)
3 a> o
a> i TO
a> c 3E. $ O)
CL o (U
3 o o:
>
Figure 6.1: A model of network of transcriptional regulation by p53-273H via Spl
(p = 7.86x 10158). p value was calculated using a formula for hypergeometric distribution. 
(Data analysis perfonned by Dr Bryony Lloyd.)
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Figure 6.2: A model of network of transcriptional regulation by p53-273H via NF-kB
(p = 2.36x 10“~18). p value was calculated using a formula for hypergeometric distribution. 
(Data analysis performed by Dr Bryony Lloyd.)
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Figure 6.3: A model of network of transcriptional regulation by p53-273H
(p = 8.17x 10“75). p value was calculated using a formula for hypergeometric distribution. 
(Data analysis performed by Dr Bryony Lloyd.)
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Appendix 15
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Figure 6.4: Expression levels of the indicated genes in the individual transfections of 
UM-SCC-12 cells. qRT-PCR was performed on RNA extracted from UM-SCC-12 cells 
transiently transfected in triplicate with the indicated vectors. The histograms show mean of 
the average expression levels (normalised to histone H3 expression) from two reverse 
transcription reactions performed from RNA samples for each transfection (see Figure 2.2), 
the error bars represent standard deviation. (Data provided by Dr Bryony Lloyd.)
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Figure 6.4 (cont.): Expression levels of the indicated genes in the individual transfections 
of UM-SCC-12 cells. qRT-PCR was performed on RNA extracted from UM-SCC-12 cells 
transiently transfected in triplicate with the indicated vectors. The histograms show mean of 
the average expression levels (normalised to histone H3 expression) from two reverse 
transcription reactions performed from RNA samples for each transfection (see Figure 2.2), 
the error bars represent standard deviation. (Data provided by Dr Bryony Lloyd.)
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Figure 6.4 (cont.): Expression levels of the indicated genes in the individual transfections 
of UM-SCC-12 cells. qRT-PCR was performed on RNA extracted from UM-SCC-12 cells 
transiently transfected in triplicate with the indicated vectors. The histograms show mean of 
the average expression levels (normalised to histone H3 expression) from two reverse 
transcription reactions perfonned from RNA samples for each transfection (see Figure 2.2), 
the error bars represent standard deviation. (Data provided by Dr Bryony Lloyd.)
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Figure 6.4 (cont.): Expression levels of the indicated genes in the individual transfections 
of UM-SCC-12 cells. qRT-PCR was performed on RNA extracted from UM-SCC-12 cells 
transiently transfected in triplicate with the indicated vectors. The histograms show mean of 
the average expression levels (normalised to histone H3 expression) from two reverse 
transcription reactions performed from RNA samples for each transfection (see Figure 2.2), 
the error bars represent standard deviation. (Data provided by Dr Bryony Lloyd.)
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Figure 6.5: Expression levels of the indicated genes in the individual transfections of 
H1299 cells. qRT-PCR was performed on RNA extracted from HI299 cells transiently 
transfected in triplicate with the indicated vectors. The histograms show mean of the average 
expression levels (normalised to histone H3 expression) from two reverse transcription 
reactions performed from RNA samples for each transfection (see Figure 2.2), the error bars 
represent standard deviation. (Data provided by Dr Bryony Lloyd.)
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Figure 6.5 (cont.): Expression levels of the indicated genes in the individual transfections 
of H1299 cells. qRT-PCR was performed on RNA extracted from H1299 cells transiently 
transfected in triplicate with the indicated vectors. The histograms show mean of the average 
expression levels (normalised to histone H3 expression) from two reverse transcription 
reactions performed from RNA samples for each transfection (see Figure 2.2), the error bars 
represent standard deviation. (Data provided by Dr Bryony Lloyd.)
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Figure 6.5 (cont.): Expression levels of the indicated genes in the individual transfections 
of H1299 cells. qRT-PCR was performed on RNA extracted from HI299 cells transiently 
transfected in triplicate with the indicated vectors. The histograms show mean of the average 
expression levels (normalised to histone H3 expression) from two reverse transcription 
reactions performed from RNA samples for each transfection (see Figure 2.2), the error bars 
represent standard deviation. (Data provided by Dr Bryony Lloyd.)
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Figure 6.5 (cont.): Expression levels of the indicated genes in the individual transfections 
of H1299 cells. qRT-PCR was performed on RNA extracted from HI299 cells transiently 
transfected in triplicate with the indicated vectors. The histograms show mean of the average 
expression levels (normalised to histone H3 expression) from two reverse transcription 
reactions performed from RNA samples for each transfection (see Figure 2.2), the error bars 
represent standard deviation. (Data provided by Dr Bryony Lloyd.)
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